Array ( [0] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF YKL-40 AS A BIOMARKER FOR ASSESSING FUNCTIONAL OUTCOME IN ACUTE ISCHEMIC STROKE PATIENTS TREATED WITH ENDOVASCULAR THERAPY [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-ykl-40-as-a-biomarker-for-assessing-functional-outcome-in-acute-ischemic-stroke-patients-treated-with-endovascular-therapy/ [post_content] => Today, more than 40% of acute ischemic stroke (AIS) patients treated with endovascular therapy (EVT) will remain severely disabled at 3 months. The inventors hypothesized that acute microglial inflammation plays a pivotal role in post-AIS brain changes leading to poor functional outcome. Glycoprotein YKL-40 is a biomarker of astrocytic and microglial activation. The inventors thus conducted a monocentric prospective study including 120 patients treated with EVT, for whom 3 blood samples (before, within 1-h, 24-h post-EVT) were drawn to measure plasma YKL-40 concentrations. The inventors found that 3-month functional outcome was significantly and independently associated with acute plasma YKL-40 levels. the present invention relates to the use of YKL-40 as a biomarker for assessing functional outcome in AIS patients treated with EVT. [post_date] => 2024-10-24 17:10:02 [post_modified] => 2024-10-24 17:10:02 [ID] => 8130 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5e0d9f3a-9228-11ef-800b-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-10-17 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22401-D1 [keywords] => acute ischemic stroke (AIS), YKL-40, Prognosis, ELISA [pub_scient_inv_dispo] => Eur Stroke J, 2024 Jun 6:23969873241256813., Boutelier et al., Acute astrocytic reaction is associated with 3-month functional outcome after stroke treated with endovascular therapy, doi: 10.1177/23969873241256813. Online ahead of print. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => MAIER Benjamin; DESILLES Jean-Philippe; PAQUET Claire; DELVOYE François; MAZIGHI Mikhael; BOUTELIER Ada [number_application] => EP23 306 815.4 on 17/10/23 and PCT/EP2024/079157on 16/10/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Central Nervous SystemTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 0 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Acute ischemic stroke, Biomarker, Central Nervous System, Immunoassay, Pre-Analytic Validation [taxonomieurl] => Acute ischemic stroke, Biomarker, Central Nervous System, Immunoassay, Pre-Analytic Validation ) [1] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF PROGNOSIS AND TREATMENT OF PATIENTS SUFFERING FROM CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-prognosis-and-treatment-of-patients-suffering-from-cancer/ [post_content] => Lung fibroblast play an important role in lung cancer tumor microenvironment (TME). Senescence is involved in the pathophysiology of tumorogenesis. analyze how sPLA2 influenced lung cancer cell malignant properties. The inventors show that secreted PLA2 XIIA (sPLA2 XIIA) play a key role in lung cancer cell malignant properties. They demonstrate that sPLA2 XIIA increases the proliferation, the migration and organoid growth of both lung cancer cell lines (NCI and A549). Indeed, they shows that sPLA2 XIIA induces notably the epithelial mesenchymal transition (EMT), which is involved in the invasion of cancer cells and in the formation of metastasis. They also demonstrate that the effect of sPLA2 XIIA is mediated in particular by syndecan 1 and 4. Taken altogether, these data define sPLA2 XIIA as a circulating biomarker of poor prognosis in lung cancer and establish a requirement for sPLA2 XIIA inhibition for the treatment or prevention of cancer, especially lung cancer in the COPD patients. [post_date] => 2024-10-24 16:55:01 [post_modified] => 2024-10-24 16:55:01 [ID] => 8129 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 95203afc-9226-11ef-b722-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-10-12 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19258-D1 [keywords] => Lung Cancer, COPD, Prognosis, Treatment response prediction, sPLA2, Q-PCR [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => HERATH Danushki; BOCZKOWSKI Jorge Bernardo; ORANGER Mathilde [number_application] => EP23 306 700.8 on 03/10/23 and PCT/EP2024/077748 on 02/10/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Lung cancerTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 1 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, In vitro poc, Lung cancer, Method, Oncology, Target, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, In vitro poc, Lung cancer, Method, Oncology, Target, Transcriptomics ) [2] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS, TREATMENT AND ANALYSIS OFNLRP3-ASSOCIATED AUTOINFLAMMATORY DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-treatment-and-analysis-ofnlrp3-associated-autoinflammatory-diseases-2/ [post_content] => Using NLRP3-deficient U937 cells reconstituted with doxycycline-inducible NLRP3 variants in response to NLRP3 induction, the present inventors have developed a novel functional cell-based assay to screen for NLRP3 variants that uncouples NLRP3 induction, priming and activation. The inventors studied and characterized 38 NLRP3 variants by assessing pyroptosis and IL-1u03b2/18 secretion in, priming and/or activation. The results were confirmed in primary monocytes from patients carrying different variants. The present invention pertains to a method for characterizing NLRP3 mutations that allows discriminating gain-of-function mutants from polymorphism without any impact on NLRP3 activity. The invention also relates to methods for the diagnosis of NLRP3-associated autoinflammatory diseases and for predicting a response to NLRP3 inhibitors based on the detection of specific NLRP3 mutations in a sample obtained from a patient. The invention also relates to new NLRP3 inhibitors. [post_date] => 2024-10-24 16:05:01 [post_modified] => 2024-10-24 18:10:02 [ID] => 8128 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4551d172-921f-11ef-b929-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-09-04 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23231-D1 [keywords] => NLRP3, mutation, Autoinflammatory diseases, Cryopyrin-associated autoinflammatory syndromes (CAPS), prognosis, sequencing [pub_scient_inv_dispo] => J Exp Med, 2024 May 6;221(5):e20231200., Cosson et al., Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation; doi: 10.1084/jem.20231200. Epub 2024 Mar 26. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => PY Bénédicte [number_application] => EP23 306 463.3 on 04/09/23 and PCT/EP2024/074525 on 03/09/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => sequencing [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Other Immunological DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 2 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunology, Method, Other Immunological Disorders, Sequencing [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunology, Method, Other Immunological Disorders, Sequencing ) [3] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND KITS FOR DIAGNOSING CAUSE OF NEPHROTIC SYNDROME AND GUIDING THERAPY [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-kits-for-diagnosing-cause-of-nephrotic-syndrome-and-guiding-therapy/ [post_content] => The present invention describes the identification of a soluble glomerular permeability factor, anti-Vasorin (or anti-VASN) autoantibodies synthesized by immune system cells, which opens up new perspectives for pathophysiological understanding, monitoring, and therapy of nephrotic syndrome. Clinical applications can include strategies for preventing the action of autoantibodies against said podocyte protein, inhibiting the production of antibodies against this protein, or eliminating these autoantibodies. Although the exact role of anti-VASN autoantibodies and VASN in nephrotic syndrome is still not well understood, the presence of circulating autoantibodies against VASN is highly specific to nephrotic syndrome. Up to now, no anti-VASN autoantibodies have been described in healthy individuals.Thus, the present invention relates to methods and kits for determining whether a subject has or is at risk of having a nephrotic syndrome associated with anti-VASN auto-antibodies or not. [post_date] => 2024-10-24 15:10:01 [post_modified] => 2024-10-24 15:10:01 [ID] => 8127 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 09dc850e-9217-11ef-a18e-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-07-24 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23308-D1 [keywords] => anti-VASN autoantibodies, nephrotic syndrome, Diagnosis, Prognosis, Prevention, Treatment response prediction, ELISA [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => GHIGGERI Gian Marco; BRUSCHI Maurizio; LENOIR Olivia; D/’IZARNY-GARGAS Thibaut; THARAUX Pierre-Louis [number_application] => EP23 306 270.2 on 24/07/23 and PCT/EP2024/073960 on 27/08/2024
[technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Genito Urinary SystemTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 3 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Immunoassay, Method, Pre-Analytic Validation [taxonomieurl] => Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Immunoassay, Method, Pre-Analytic Validation ) [4] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR PREDICTING COGNITIVE DECLINE IN A SUBJECT [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-predicting-cognitive-decline-in-a-subject/ [post_content] => Alzheimer/’s disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1/C26:0 in a biological sample obtained from the subject. [post_date] => 2024-10-24 14:25:01 [post_modified] => 2024-10-24 14:25:01 [ID] => 8126 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 800c0e8a-9211-11ef-ba87-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-08-18 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23195-D1 [keywords] => Alzheimer, Prognosis, Metabolite Signature, Mass Spectrometry [pub_scient_inv_dispo] => J Gerontol A Biol Sci Med Sci, 2024 May 1;79(5):glae077., Tremblay-Franco et al., Integrative Multimodal Metabolomics to Early Predict Cognitive Decline Among Amyloid Positive Community-Dwelling Older Adults, doi: 10.1093/gerona/glae077. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => ADER-PERARNAU Isabelle; VELLAS Bruno; TREMBLAY-FRANCO Marie [number_application] => EP23 306 392.4 on 18/08/23 and PCT/EP2024/073060 on 16/08/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => mass_spectrometry [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Central Nervous SystemTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 4 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Central Nervous System, Human POC, Mass spectrometry, Method [taxonomieurl] => Biomarker, Biomarker, Central Nervous System, Human POC, Mass spectrometry, Method ) [5] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEW PROGNOSTIC METHOD OF KIDNEY FAILURE [guid] => https://technology-offers.inserm-transfert.com/offer/new-prognostic-method-of-kidney-failure/ [post_content] => The present invention relates to the prediction of kidney injury. In this study, the inventors studied the transcriptomic landscape in AAV-GN to find biomarkers for refining diagnosis and/or prognosis, which would help stratify patient risk and tailor therapeutic management. The objectives of this study were to investigate the potential prognostic value and/or pathogenic role of the most relevant genes associated with kidney survival. They identified a 4-gene signature (XRCC6, PRKCD, TEK, and CLU) that predicted kidney survival better than histological-based classifications. Thus, the invention relates to a method for predicting the development of a kidney failure in a patient suffering from an ANCA-associated vasculitis-associated GN (AAV-GN). [post_date] => 2024-10-24 13:55:02 [post_modified] => 2024-10-24 13:55:02 [ID] => 8125 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 77b5e656-920d-11ef-aceb-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-08-02 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22461-D1 [keywords] => Kidney Failure, Prognosis, XRCC6, PRKCD, TEK, CLU, Q-PCR, RNA-Seq [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => DELNESTE Yves; COPIN Marie-christine; AUGUSTO Jean-François [number_application] => EP23 306 324.7 on 02/08/23 and PCT/EP2024/071795 on 01/08/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Genito Urinary SystemTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 5 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Analytic validation, Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Transcriptomics [taxonomieurl] => Analytic validation, Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Transcriptomics ) [6] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF DETERMINING WHETHER A SUBJECT SUFFERING FROM LUPUS NEPHRITIS (LN) WILL ACHIEVE A RESPONSE WITH AN INDUCTION THERAPY [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-determining-whether-a-subject-suffering-from-lupus-nephritis-ln-will-achieve-a-response-with-an-induction-therapy/ [post_content] => Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, according to immune deposits and to the type of glomerular cell injury. Proliferative lesions represent the most severe form of lupus nephritis (LN) and often lead to kidney failure and death. Mucosal-associated invariant T (MAIT) are a subset of innate-like T cells that recognize microbial-derived ligands from the riboflavin synthesis pathway. Now the inventors analyzed the phenotype and function of peripheral blood MAIT cells by flow cytometry in 26 patients with LN and in a control group of 16 healthy volunteers. The inventors found that MAIT cell frequencies are markedly reduced in blood of LN patients. More particularly, among LN patients, baseline MAIT cell frequency, Ki-67 expression evaluating proliferative activity and granzyme B production measuring cytotoxicity represent promising prognostic factors of renal response one year after induction therapy. In conclusion, the inventors showed that baseline frequency and cytotoxic profile of MAIT cells may represent a promising prognostic factor of renal remission one year after induction therapy. [post_date] => 2024-10-24 13:20:02 [post_modified] => 2024-10-24 13:20:02 [ID] => 8124 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6a31e3fe-9208-11ef-bb62-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-07-24 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23304-D1 [keywords] => Lupus Nephritis, Systemic lupus erythematosus, MAIT Cells, Flow Cytometry, Diagnosis, Treatment response prediction [pub_scient_inv_dispo] => Front Immunol, 2023 Oct 10:14:1205405, Litvinova et al., MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcome, . doi: 10.3389/fimmu.2023.1205405. eCollection 2023. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => FLAMENT Héloïse; MONTEIRO Renato; LEHUEN-MONTEIRO Agnès [number_application] => EP23 306 270.2 on 24/07/23 and PCT/EP2024/070803 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Systemic Lupus ErythematosusTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 6 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Human POC, Immunoassay, Immunology, Method, Systemic Lupus Erythematosus [taxonomieurl] => Biomarker, Human POC, Immunoassay, Immunology, Method, Systemic Lupus Erythematosus ) [7] => stdClass Object ( [post] => stdClass Object ( [post_title] => CD1A AS A BIOMARKER AND BIOTARGET IN CUTANEOUS T-CELL LYMPHOMAS [guid] => https://technology-offers.inserm-transfert.com/offer/cd1a-as-a-biomarker-and-biotarget-in-cutaneous-t-cell-lymphomas/ [post_content] => The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of CD1a by Sézary cells. CD1a therefore appears as a diagnostic marker for monitoring Sézary syndrome and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of cutaneous T cell-lymphomas. [post_date] => 2024-10-24 10:05:02 [post_modified] => 2024-10-24 10:05:02 [ID] => 8123 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 40a9931c-91ed-11ef-81de-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-07-17 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23255-D1 [keywords] => Sézary Syndrome, cutaneous T cell lymphomas, Diagnosis, Treatment response Prediction, CD1a, ELISA [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => BENSUSSAN Armand; GIUSTINIANI Jérôme; DE MASSON Adele [number_application] => EP23 306 229.8 on 17/07/23 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 7 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Oncology, Sezary syndrome, Target [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Oncology, Sezary syndrome, Target ) [8] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR DISCRIMINATING AND TREATING STROKE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-discriminating-and-treating-stroke/ [post_content] => Stroke is the second cause of death and the first cause of adult disability in industrialized countries. The goal of emergency therapy for acute ischemic stroke is prompt restoration of blood flow to regions of brain that are ischemic but not yet infarcted. Based on this, the inventors compare the plasma concentration of total tPA (antigenic: active + PAI-1 bound) in patients with acute ischemic stroke before any treatment with those in a healthy control group, to evaluate the interest of tPA as a potential diagnostic biomarker in the acute phase of ischemic stroke.In particular, the present invention relates to method for discriminating at early stage an hemorrhagic stroke from an ischemic stroke or a mimic stroke in a subject in need thereof, comprising the steps of i) determining in a blood sample obtained from the said subject the level of tissue-type plasminogen activator (tPA), ii) comparing the level determined in step i) with a reference value and iii) concluding when the level of tissue-type plasminogen activator (tPA) determined at step i) is higher than the reference value is predictive of a risk of having or developing an ischemic stroke or a mimic stroke or concluding when the level of tissue-type plasminogen activator (tPA) determined at step i) is lower than the reference value is predictive of a risk of having or developing a hemorrhagic stroke [post_date] => 2024-10-24 09:50:02 [post_modified] => 2024-10-24 09:50:02 [ID] => 8122 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ce0955ce-91ea-11ef-99ee-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-05-23 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23212-D1 [keywords] => Stroke, Differential diagnostic, Ischemic stroke, Hemorrhagic stroke, tPA, ELISA [pub_scient_inv_dispo] => Ann Clin Transl Neurol, 2024 Sep 10, Jauquet et al., Endogenous tPA levels: A biomarker for discriminating hemorrhagic stroke from ischemic stroke and stroke mimics, doi: 10.1002/acn3.52197. Online ahead of print. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => ROUSSEL Benoît; VIVIEN Denis [number_application] => European Procedure (Patents) (EPA) - 23 Mai 2023 - 23 305 817.1 and PCT/EP2024/064107 on 22/05/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• StrokeTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 8 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Central Nervous System, Immunoassay, Method, Pre-Analytic Validation, Stroke [taxonomieurl] => Biomarker, Central Nervous System, Immunoassay, Method, Pre-Analytic Validation, Stroke ) [9] => stdClass Object ( [post] => stdClass Object ( [post_title] => STRATIFICATE AND METHOD TO TREAT A PATIENT SUFFERING FROM A CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/stratificate-and-method-to-treat-a-patient-suffering-from-a-cancer/ [post_content] => The present invention relates the stratification and treatment of patient suffering from a cancer. In this study, the inventors analyzed the adenosine methylation level of miR-125a-5p (m6A-miR-125a-5p) using RNA immunoprecipitation with an anti-methyl-base-antibody followed by qPCR. CLIP and ELISA were used to study the effect of m6A-miR-125a-5p on its ability to be recruited on GW182 and impact PD-1 expression, respectively. They showed that the METTL3-mediated m6A-miR-125a-5p regulates the expression of IGSF11/VSIG3 which acts as a molecular determinant of the immunogenicity of tumor cells. Observations in two lung cancer patients treated with anti-PD-1 therapy show that the m6A-miR-125a-5p level is analyzable from EVs/exosomes from longitudinal blood samples. These data provide that m6A-miR-125a-5p level can be used as a biomarker and therapeutic solutions (anti-IGSF11 antibody and METTL3 inhibitor) could potentially address the anti-PD1 therapy failure in a context of precision and personalized medicine intended for the right patient, at the right time, with the right therapy. Thus the invention relates to a method of identifying a patient having or at risk of having or developing a resistance to anti-PD-1 therapy based on the expression level of the extracellular vesicles adenosine methylated miR-125a-5p (m6A-miR-125a-5p). [post_date] => 2024-10-23 16:10:02 [post_modified] => 2024-10-23 16:10:02 [ID] => 8121 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d6523172-9156-11ef-924d-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-05-17 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21448-D1 [keywords] => Lung Cancer, miRNA, treatment response prediction, immunotherapy [pub_scient_inv_dispo] => Cancers (Basel). 2023 Jun 14;15(12):3188., Bougras-Cartion et al., Adenosine Methylation Level of miR-125a-5p Promotes Anti-PD-1 Therapy Escape through the Regulation of IGSF11/VSIG3 Expression, doi: 10.3390/cancers15123188. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => CARTRON Pierre-François; NADARADJANE Arulraj; BOUGRAS-CARTRON Gwenola [number_application] => European Procedure (Patents) (EPA) - 17 Mai 2023 - 23 305 796.7 and PCT/EP2024/063568 on 16/05/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Lung cancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 9 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Human POC, Lung cancer, Method, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Human POC, Lung cancer, Method, Oncology, Transcriptomics ) [10] => stdClass Object ( [post] => stdClass Object ( [post_title] => BIALLELIC GENE MUTATIONS FOR THE DIAGNOSIS OF NEONATAL SYSTEMIC HYPERTENSION [guid] => https://technology-offers.inserm-transfert.com/offer/biallelic-gene-mutations-for-the-diagnosis-of-neonatal-systemic-hypertension/ [post_content] => The present invention relates to a method and kit for identifying a subject having or at risk of having or developing an isolated neonatal systemic hypertension (NSH) and/or NSH associated cardiogenic shock, comprising determining, in a sample obtained from said subject, the presence or absence of bi-allelic nucleotide variants (NV) located in NPR1 gene, said NV predicted to be pathogenic and being associated with NPR1 loss of function. The present inventors have established a statistical link between specific predicted pathogenic variants located in the NPR1 gene and neonatal systemic hypertension (NSH) in a cohort of NSH disease families. More precisely, the present inventors have established a link between specific predicted biallelic pathogenic variants contained in NPR1 in patients with NSH and/or cardiogenic shock (in multiplex and consanguineous families) associated sometime with increased Nuchal Translucency (NT). Another object of the invention relates to a method for treating neonatal systemic hypertension (NSH) and/or NSH associated cardiogenic shock. [post_date] => 2024-10-23 15:45:02 [post_modified] => 2024-10-23 17:50:02 [ID] => 8120 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 63651e02-9153-11ef-8699-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-04-24 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23100-D1 [keywords] => neonatal systemic hypertension (NSH), NPR1, Diagnosis, mutation, sequencing, transcriptomics [pub_scient_inv_dispo] => J Med Genet, 2023 Apr 20, Capri et al, Biallelic NPR1 loss of function variants are responsible for neonatal systemic hypertension, doi: 10.1136/jmg-2023-109176. Online ahead of print. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => MELKI Judith,CAPRI Yline [number_application] => European Procedure (Patents) (EPA) - 24 Avr. 2023 - 23 315 100.0 and PCT/EP2024/060551 on 18/04/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => sequencing,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Hypertension/Pulmonary Arterial HypertensionTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 10 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Cardiovascular Diseases, Human POC, Hypertension/Pulmonary Arterial Hypertension, Method, Sequencing, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Cardiovascular Diseases, Human POC, Hypertension/Pulmonary Arterial Hypertension, Method, Sequencing, Transcriptomics ) [11] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR DISCRIMINATING MONO-IMMUNOTHERAPY FROM COMBINED IMMUNOTHERAPY IN CANCERS [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-discriminating-mono-immunotherapy-from-combined-immunotherapy-in-cancers/ [post_content] => Combination therapy with anti-PD-1 and anti-CTLA-4 is now indicated in many cancers. It appears to be more effective than anti-PD-1 monotherapy, but more toxic. This work has shown that plasma levels of soluble CD27 are inversely correlated with survival in melanoma patients treated with anti-PD-1. This result was validated in 2 independent cohorts of patients representing 180 patients in total. Interestingly, this predicting role of sCD27 in anti-PD-1 treated melanoma patients was found both with an optimal cut-off defined by the Youden test, but also with the same cut-off previously defined in kidney cancer. This suggests some analytical robustness of this marker. Inventors have also shown that plasma sCD27 levels prior to anti-PD-1 treatment are inversely correlated with progression free survival (PFS). On the contrary, in patients with metastatic melanoma treated with anti-PD-1 and anti-CTLA-4, plasma sCD27 levels are not statistically significantly associated with patient survival or progression-free survival. They therefore find a discrepancy between the predictive impact of sCD27 on survival of patients treated with anti-PD-1 immunotherapy alone or with combined anti-PD-1 and anti-CTLA-4 immunotherapy. Plasma sCD27 concentrations represents a new type of biomarker to help in the management of these patients. [post_date] => 2024-10-23 15:15:02 [post_modified] => 2024-10-23 15:15:02 [ID] => 8119 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2fb0a8a0-914f-11ef-9ef7-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-03-28 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23133-D1 [keywords] => Melanoma, Kidney Cancer, Treatment response prediction, Prognosis, Combinatory treatment, sCD27 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => TARTOUR Eric,OUDARD Stephane,SAM Ikuan,LEBBÉ Céleste,BEN HAMOUDA Nadine [number_application] => European Procedure (Patents) (EPA) - 28 Mars 2023 - 23 305 423.8 and EP23 305 423.8 on 28/03/23 and PCT/EP2024/058363 on 27/03/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• MelanomaTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 11 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Analytic validation, Biomarker, Biomarker, Immunoassay, Melanoma, Oncology [taxonomieurl] => Analytic validation, Biomarker, Biomarker, Immunoassay, Melanoma, Oncology ) [12] => stdClass Object ( [post] => stdClass Object ( [post_title] => A GENE SIGNATURE FOR DIAGNOSING STIMULATOR OF INTERFERON GENES (STING)-ASSOCIATED VASCULOPATHY WITH ONSET IN INFANCY (SAVI) [guid] => https://technology-offers.inserm-transfert.com/offer/a-gene-signature-for-diagnosing-stimulator-of-interferon-genes-sting-associated-vasculopathy-with-onset-in-infancy-savi/ [post_content] => Gain-of-function mutations in STING1, that codes for the Stimulator of Interferon Gene (STING), result in a severe autoinflammatory disease termed STING-associated vasculopathy with onset in infancy (SAVI). Although elevated type I interferon (IFN) production is thought to be the leading cause of the symptoms observed in patients, STING can induce a set of pathways, and their role in the onset and severity of SAVI remains to be elucidated. To address this point, the inventors compared a single-cell RNA sequencing (scRNA-seq) dataset of peripheral blood mononuclear cells (PBMCs) from SAVI patients to a dataset of healthy PBMCs treated with recombinant IFN-u03b2. In particular, scRNA-seq clustering identified a patient-specific subset of monocytes, highly inflammatory and expressing a strong integrated stress response (ISR). Even more particularly, the inventors have identified at the transcriptomic level a STING-associated signature of 21 genes that is driven by STING activation, independently of type I IFN. This signature is therefore suitable to better distinguish SAVI from other type I interferonopathy. [post_date] => 2024-10-23 14:40:01 [post_modified] => 2024-10-23 16:50:02 [ID] => 8118 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a53b5eee-914a-11ef-9cd5-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-03-27 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23085-D1 [keywords] => STING-associated vasculopathy with onset in infancy (SAVI), RNA Signature, Diagnostic, Prognosis, Treatment response prediction [pub_scient_inv_dispo] => Cell Rep Med, 2023 Dec 19;4(12):101333., De Cevins et al. , Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response, doi: 10.1016/j.xcrm.2023.101333. [access_to_detailed_offer] => [rare_disease] => 1 [second_indication] => 0 [inventors] => MENAGER Mickaël; RIEUX-LAUCAT Frédéric [number_application] => International Procedure (PCT) - 27 Mars 2023 - PCT/IB2023/000159 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• VasculitisTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 12 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Cardiovascular Diseases, Human POC, Method, Transcriptomics, Vasculitis [taxonomieurl] => Biomarker, Biomarker, Cardiovascular Diseases, Human POC, Method, Transcriptomics, Vasculitis ) [13] => stdClass Object ( [post] => stdClass Object ( [post_title] => THE CIRCULAR RNA CIRCLTBP2 AS A BIOMARKER AND BIOTARGET IN INTRAHEPATIC CHOLANGIOCARCINOMAS [guid] => https://technology-offers.inserm-transfert.com/offer/the-circular-rna-circltbp2-as-a-biomarker-and-biotarget-in-intrahepatic-cholangiocarcinomas/ [post_content] => Intrahepatic cholangiocarcinoma (iCCA) is a deadly cancer worldwide with an increasing incidence and limited therapeutic options. Therefore, there is an urgent need to open the field to new concepts for identifying clinically relevant therapeutic targets and biomarkers. Here, the inventors explored the role and the clinical relevance of circular RNA circLTBP2 in iCCA. In particular, CircLTBP2 (hsa_circ_0032603) was identified as a novel TGFu03b2-induced circRNA in several CCA cell lines. CircLTBP2 promotes tumor cell proliferation, migration and resistance to gemcitabine-induced apoptosis in vitro and tumor growth in vivo. Mechanistically, circLTBP2 acts as a competitive RNA regulating notably the activity of the tumor suppressor microRNA miR-338-3p, leading to the overexpression of its pro-metastatic targets. The restoration of miR-338-3p levels in iCCA cells reversed the pro-tumorigenic effects driven by circLTBP2, including the resistance to gemcitabine-induced apoptosis. In addition, circLTBP2 expression predicted a reduced survival, as detected in tumor tissues but also in serum exosomes isolated from patients with iCCA. In conclusion, CircLTBP2 is a novel effector of the pro-tumorigenic arm of TGFu03b2 and a clinically relevant biomarker easily detected from liquid biopsies in iCCA. Thus, the present invention relates to the circulating RNA circLTBP2 as a biomarker and biotarget in intrahepatic cholangiocarcinomas. [post_date] => 2024-10-23 10:10:01 [post_modified] => 2024-10-23 10:10:01 [ID] => 8117 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d7ee2b76-9124-11ef-886f-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-03-14 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21460-D1 [keywords] => Intrahepatic cholangiocarcinoma (iCCA), dignosis, prognosis, treatment response prediction, CircLTBP2, transcriptomic [pub_scient_inv_dispo] => JHEP Rep, 2023 Sep 5;5(12):100900., Louis C et al., TGFu03b2-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p, doi: 10.1016/j.jhepr.2023.100900. eCollection 2023 Dec. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => COULOUARN Cédric,EDELINE Julien,LOUIS Corentin,DESOTEUX Matthis [number_application] => European Procedure (Patents) (EPA) - 14 Mars 2023 - 23 305 343.8 and PCT/EP2024/056634 on 13/03/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Liver CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 13 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Liver Cancer, Method, Oncology, Pre-Analytic Validation, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Liver Cancer, Method, Oncology, Pre-Analytic Validation, Transcriptomics ) [14] => stdClass Object ( [post] => stdClass Object ( [post_title] => INDOLE-3-PROPIONIC ACID AS AN IMPORTANT CONTRIBUTOR TO VIRAL INFECTION OUTCOMES AND A BIOMARKER OF VIRAL INFECTION SEVERITY [guid] => https://technology-offers.inserm-transfert.com/offer/indole-3-propionic-acid-as-an-important-contributor-to-viral-infection-outcomes-and-a-biomarker-of-viral-infection-severity/ [post_content] => The gut-to-lung axis is critical during respiratory infections, including influenza A virus (IAV) infection. In the present study, the inventors used high-resolution shotgun metagenomics and targeted metabolomics analyses to characterize influenza-associated changes in the mouse gut microbiota/’s composition and metabolism. Quantitative targeted metabolomics analysis of serum revealed changes in specific classes of gut microbiota metabolites, including SCFAs, indole-containing tryptophan metabolites, trimethylamine, and polyamines. The changes in microbiota-associated metabolites were correlated with changes in taxon abundances and levels of disease markers. For instance, the tryptophan metabolite indole-3-propionic acid (IPA) was correlated positively with some Bacillota species but negatively with Bacteroidales bacteria M7, the viral load, and inflammation markers. Given its marked fall during infection, the inventors tested the effects of IPA supplementation in diseased animals. This supplementation was associated with a lower viral load and lower levels of local (lung) and systemic inflammation during influenza. Taken as a whole, the results highlighted IPA as both an important metabolic modulator to disease severity and a potential biomarker of influenza outcomes. [post_date] => 2024-10-23 09:35:05 [post_modified] => 2024-10-23 09:35:05 [ID] => 8116 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d56b2994-911f-11ef-9faf-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-02-24 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO23038-D1 [keywords] => Influenza, prognosis, Mass spectrometry, metabolite, indole-3-propionic acid (IPA) [pub_scient_inv_dispo] => Gut Microbes, 2024 Jan-Dec;16(1):2325067., Heumel et al., Shotgun metagenomics and systemic targeted metabolomics highlight indole-3-propionic acid as a protective gut microbial metabolite against influenza infection, doi: 10.1080/19490976.2024.2325067. Epub 2024 Mar 6. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => TROTTEIN François,VINOLO Marco Aurélio Ramirez,SENCIO Valentin,RODRIGUEZ Patricia Brio,RODOVALHO Vinicius de Rezende,HEUMEL Séverine [number_application] => European Procedure (Patents) (EPA) - 24 Févr. 2023 - 23 305 245.5 and PCT/EP2024/054616 on 23/02/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => mass_spectrometry [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• InfluenzaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 14 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Animal POC, Biomarker, Biomarker, Infectious Diseases, Influenza, Mass spectrometry, Target [taxonomieurl] => Animal POC, Biomarker, Biomarker, Infectious Diseases, Influenza, Mass spectrometry, Target ) [15] => stdClass Object ( [post] => stdClass Object ( [post_title] => VASORIN AS A BIOMARKER AND BIOTARGET IN NEPHROLOGY [guid] => https://technology-offers.inserm-transfert.com/offer/vasorin-as-a-biomarker-and-biotarget-in-nephrology/ [post_content] => Aiming to identify factors underlying podocytes loss, the inventors revealed a markedly decreased expression of Vasorin (VASN) using comparative deep RNA sequencing of microdissected glomeruli from controls and patients diagnosed with FSGS or crescentic glomerulonephritis (CGN), that they further confirmed by in situ hybridization and immunohistochemistry. In particular, the inventors found that VASN is mainly expressed in podocytes during health. Furthermore, the inventors found that the level of glomerular or podocyte expression of the VASN gene depends on the kind of glomerular disease considered, suggesting this could be a helpful biomarker for differential diagnosis or outcome prediction.Of specific interest, 1/ the expression of VASN is significantly less in kidneys from patients suffering from secondary FSGS or anti-neutrophil cytoplasmic antibodies (ANCA) associated crescentic glomerulonephritis than in control normal kidneys or minimal change disease (MN), suggesting that low VASN abundance would predict poor outcome. 2/ Podocyte expression of the VASN gene is significantly less in secondary FSGS than in primary FSGS. 3/ Podocyte expression of the VASN gene is significantly less in FSGS (primary and secondary) than in MCD cases. 4/ Podocyte or glomerular expression of the VASN gene is increased substantially in kidneys biopsies diagnosed with membranous nephropathy (MN), minimal change disease (MCD), and lupus nephritis (LN) as compared with controls and FSGS, suggesting that this could be used to discriminate disease types, causes, outcome, or response to therapy.Accordingly, the present invention relates to the use of VASN as a biomarker and a biotarget for kidney diseases. [post_date] => 2024-10-22 17:30:01 [post_modified] => 2024-10-22 17:30:01 [ID] => 8115 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2d1b6104-9099-11ef-8948-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2023-01-17 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22440-D1 [keywords] => Chronic Kidney Disease, Differential diagnostic, primary focal segmental glomerulosclerosis, secondary focal segmental glomerulosclerosis, Vasorin [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => KRAUTZBERGER Anja Michaela; MAHTAL Nassim; SCHREWE Heinrich; SIEGERIST Florian; ENDLICH Nicole; THARAUX Pierre-Louis [number_application] => European Procedure (Patents) (EPA) - 17 Janv. 2023 - 23 305 057.4 and PCT/EP2024/050919 on 16/01/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => imaging,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Genito Urinary SystemTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 15 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Human POC, Imaging, Target, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Human POC, Imaging, Target, Transcriptomics ) [16] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR PROGNOSIS AND MONITORING PULMONARYHYPERTENSION [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-prognosis-and-monitoring-pulmonaryhypertension/ [post_content] => In the present invention, in Pulmonary Arterial Hypertension (PAH) patient/’s blood samples (EFFORT cohort), inventors results indicate that activinu2013Smad2/3 signaling is overactive, as reflected by the overabundance of inhibin-u03b2A, inhibin-u03b2B, activin type-I and type-II receptors, and phospho-Smad2/3 in PAH vascular endothelial and smooth muscle cells and by the fact that elevated levels of activin A and follistatin-like 3 (FSTL3) level in serum predict adverse outcome. With an independent external PAH cohort, inventors confirmed that both activin A and FSTL3 are prognostic biomarkers in PAH. Thereafter, this approach allows to identify a BMP/TGF ligands combinations that represent a reliable biomarker of PAH severity and/or mortality, validated in a second independent cohorts of PAH patient (Imperial College of London, UK study) 2-biomarker panel composed of activin A and follistatin-like 3 (FSTL3) that was independently associated with prognosis both at the time of PAH diagnosis and at the first follow-up after PAH therapy initiation. More specifically present invention relates to methods for prognosis and/or monitoring of the severe form of Pulmonary Hypertension (PH) and PAH through comparison of specific markers combinations in PH or PAH patient. [post_date] => 2024-10-22 17:00:01 [post_modified] => 2024-10-22 17:00:01 [ID] => 8114 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0ecbb0d6-9095-11ef-818c-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2022-12-21 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22307-D1 [keywords] => Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH), Prognosis, ELISA, Biomarker, follistatin-like 3 (FSTL3) [pub_scient_inv_dispo] => Circulation, 2023 Jun 13;147(24):1809-1822., Guignabert et al, Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension, doi: 10.1161/CIRCULATIONAHA.122.061501. Epub 2023 Apr 25. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => GUIGNABERT Christophe,SITBON Olivier,BOUCLY Athénaïs,TU Ly,HUMBERT Marc,SAVALE Laurent [number_application] => European Procedure (Patents) (EPA) - 21 Déc. 2022 - 22 306 977.4 and EP22 306 977.4 on 21/12/22 and PCT/EP2023/086809 on 20/12/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Hypertension/Pulmonary Arterial HypertensionTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 16 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Cardiovascular Diseases, Human POC, Hypertension/Pulmonary Arterial Hypertension, Immunoassay, Method [taxonomieurl] => Biomarker, Biomarker, Cardiovascular Diseases, Human POC, Hypertension/Pulmonary Arterial Hypertension, Immunoassay, Method ) [17] => stdClass Object ( [post] => stdClass Object ( [post_title] => Non-invasive diagnosis of steatohepatitis based on cytokeratin 18 in asymptomatic patients hospitalized for alcohol withdrawal [guid] => https://technology-offers.inserm-transfert.com/offer/non-invasive-diagnosis-of-steatohepatitis-based-on-cytokeratin-18-in-asymptomatic-patients-hospitalized-for-alcohol-withdrawal/ [post_content] => The invention relates to the field of diagnosing steatohepatitis, in particular alcoholic steatohepatitis. By following studies on a cohort of nearly 200 patients, the inventors showed that four or five specific, readily available markers, when combined in a function, make it possible, by themselves, to highly accurately diagnose steatohepatitis at the early stages of the disease, when the subject is still asymptomatic. In particular, the invention relates to a non-invasive, highly performant method of diagnosing steatohepatitis in a subject, which combines in a function the values of the age, the blood concentration of cytokeratin 18 and at least two of: the body mass index, the blood concentration of a-2-macroglobulin and a data representative of liver stiffness as obtained by an ex vivo imaging technique. The method of the invention makes it possible to identify asymptomatic patients that may then benefit from potential therapeutics and/or be motivated to reduce alcohol consumption. [post_date] => 2024-10-22 16:30:02 [post_modified] => 2024-10-22 16:30:02 [ID] => 8113 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f5de2b5c-9090-11ef-b93e-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2022-11-17 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21437-D1 [keywords] => Steatohepatitis, CK18, signature, biomarqueur, prevention, diagnosis, prognosisi, treatment response prediction, biomarker [pub_scient_inv_dispo] => Aliment Pharmacol Ther. 2023 Jul;58(1):80-88. doi: 10.1111/apt.17515. Epub 2023 Apr 20. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => SAMSON Michel,MOIRAND Romain,CHALIN Arnaud [number_application] => European Procedure (Patents) (EPA) - 17 Nov. 2022 - 22 306 690.3 and PCT/EP2023/082033 on 16/11/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 17 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Gastrointestinal Diseases, Immunoassay, Liver Disease, Non-Alcoholic Steatohepatitis, Pre-Analytic Validation [taxonomieurl] => Biomarker, Gastrointestinal Diseases, Immunoassay, Liver Disease, Non-Alcoholic Steatohepatitis, Pre-Analytic Validation ) [18] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF THE POPULATION OF SLAMF4+ CCR5+ EFFECTOR MEMORY CD4+ T CELLS AS A BIOMARKER IN RHEUMATOID ARTHRITIS [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-the-population-of-slamf4-ccr5-effector-memory-cd4-t-cells-as-a-biomarker-in-rheumatoid-arthritis/ [post_content] => CD4+ Foxp3- conventional T cells (Tconv) play a key role in the inflammatory process involved in rheumatoid arthritis (RA). It is now becoming increasingly clear that in RA, chronic Tconv stimulation does not induce a sufficient level of exhaustion to inhibit their pathological response. The inventors/’ objectives were to determine whether SLAMF receptors are involved in the establishment of the Tconv pro-inflammatory response and whether these receptors represent a protection against Tconv exhaustion. Thus the inventors immunophenotyped blood T cells from RA patients (n=64) and from healthy donors (HD) (n=14) using a 13-marker flow cytometry panel. The expression of SLAMF receptors was determine among four Tconv subpopulations with different activation status (naive, central memory, effector memory and terminally differentiated effector CD4+ T cells). To assess the inflammatory tropism and functionality of different Tconv subpopulations, CCR5 expression was studied. Only the frequency of SLAMF4+ cells among effector memory T cells (Tem; CCR7-, CD45RA-) was correlated with disease activity. More particularly, the inventors showed that only SLAMF4+ Tem expressing CCR5 were linked to RA activity. The inventors revealed that SLAMF4+ CCR5+ Tem represent a distinct Tconv subpopulation resistant to PD-1 mediated inhibition and strongly linked to RA activity. [post_date] => 2024-10-22 14:45:01 [post_modified] => 2024-10-22 16:45:05 [ID] => 8112 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b82a1e06-9081-11ef-8e81-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2022-11-14 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22284-D1 [keywords] => rheumatoid arthritis (RA), Biomarker, Prognosis, Flow Cytometry, SLAMF4 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => BITON Jérôme,BOUZIDI Houda Ghozlane,BESSIS Natacha,LACAUD Mégane,BOISSIER Marie-Christophe [number_application] => International Procedure (PCT) - 14 Nov. 2022 - PCT/EP2022/081802 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Rheumatoid ArthritisTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 18 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Method, Rheumatoid Arthritis [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Method, Rheumatoid Arthritis ) [19] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR DETERMINING THE RELATIVE AGE OF RED BLOOD CELLS [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-determining-the-relative-age-of-red-blood-cells/ [post_content] => Glycated Hb was measured and compared between five healthy donors (AA), seven non-diabetic and non-transfused homozygous SCD patients (SS) and five non-diabetic, transfused SS patients. The single cell glycation was assessed by flow cytometry using mouse anti-human HbA1c antibody. The inventors demonstrated that glycated Hb was significantly lower in SS patients than in healthy donors (glycated HbS =3.7%, glycated HbA =5.3%, p=0.0025 by DCA and HPLC respectively, and by flow cytometry p=0.0061). In transfused SS patients, results showed that glycated Hb was lower in autologous SS-RBCs than in AA-RBCs by a factor of four (P= 0.008), thus confirming the characterized reduced lifespan of SS RBCs. Glycated Hb levels were measured in RBC sub-populations based on their HbF level (high HbF or low HbF subfractions) in non-transfused SS patients. Single cell glycated Hb assessed by flow cytometry allows to simultaneously estimate the relative age of different RBC sub-populations. This new tool is noninvasive and requires only one single time point measurement.The present invention relates to a method for in vitro determination of the relative age evaluation of subpopulation of red blood cells by using intracellular glycated hemoglobin measurement by flow cytometry. [post_date] => 2024-10-22 14:20:02 [post_modified] => 2024-10-22 14:20:02 [ID] => 8111 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 70925dc2-907e-11ef-afb9-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2022-11-22 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22218-D1 [keywords] => Diagnostic, Biomarker, Glycated Hb, sickle cell disease (SCD), Flow Cytometry [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => BARTOLUCCI Pablo,DJOUDER Nassima,HEBERT Nicolas [number_application] => European Procedure (Patents) (EPA) - 03 Nov. 2022 - 22 306 656.4 and PCT/EP2023/080678 on 03/11/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Hematological DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 19 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Anemia, Biomarker, Biomarker, Hematological Disorders, Human POC, Immunoassay, Method, Sickle Cell Disease [taxonomieurl] => Anemia, Biomarker, Biomarker, Hematological Disorders, Human POC, Immunoassay, Method, Sickle Cell Disease ) [20] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD AND COMPOSITION FOR DETERMINING THE LEVEL OF OGLCNACYLATION IN HORSES [guid] => https://technology-offers.inserm-transfert.com/offer/method-and-composition-for-determining-the-level-of-oglcnacylation-in-horses/ [post_content] => Inventors have used three cohorts of horses: a cohort consisting of healthy horses (n=20), a cohort consisting of horses hospitalized for colic without signs of sepsis until discharge (n=17) and horses hospitalized for colic with signs of sepsis (n=20). They performed western blot analysis and confirmed the presence of O-GlcNAc in the blood of the horses and showed that, that the O-GlcNAc levels in septic horses tended to decrease between admission and the first day (D1) after admission. This decrease became significant from the second day (D2) of hospitalization. Accordingly, the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps:i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; andiii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value. [post_date] => 2024-10-22 13:55:01 [post_modified] => 2024-10-22 13:55:01 [ID] => 8110 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f339d6b4-907a-11ef-9757-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2022-10-18 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22254-R1 [keywords] => Sepsis, O-GlcNacylation, biomarker, Horse, veterinary [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => LAUZIER Benjamin,LEROUX Aurélia,BLANGY-LETHEULE Angélique,DUPAS Thomas [number_application] => European Procedure (Patents) (EPA) - 18 Oct. 2022 - 22 306 576.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• Research toolField of development:
• Sepsis / Septic ShockTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 20 [terms] => Array ( [0] => Research ) [taxonomie] => Infectious Diseases, Research tool, Sepsis / Septic Shock [taxonomieurl] => Infectious Diseases, Research tool, Sepsis / Septic Shock ) [21] => stdClass Object ( [post] => stdClass Object ( [post_title] => CD81 AS A BIOMARKER AND BIOTARGET IN T-CELL MALIGNANCIES [guid] => https://technology-offers.inserm-transfert.com/offer/cd81-as-a-biomarker-and-biotarget-in-t-cell-malignancies/ [post_content] => The present study of the regulatory T phenotype of Sézary cells led to the discovery of the overexpression of CD81 by Sézary cells. CD81 has also been shown to be a relevant therapeutic target in the treatment of Sézary syndrome, NK/T lymphoma, hepatosplenic T-cell lymphoma and acute T cell leukemia. CD81 therefore appears as a diagnostic marker and as a therapeutic target in T-cell malignancies. Accordingly, the present invention relates CD81 as a biomarker and biotarget in T-cell malignancies. [post_date] => 2024-10-22 13:35:02 [post_modified] => 2024-10-22 13:35:02 [ID] => 8109 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 97885af4-9078-11ef-ae6c-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2022-10-12 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22403-D1 [keywords] => CD81, Flow Cytometry, Sezary syndrome, Cutaneous T cell Lymphoma [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => BENSUSSAN Armand,ORTONNE Nicolas,GIUSTINIANI Jérôme,DE MASSON Adele [number_application] => European Procedure (Patents) (EPA) - 12 Oct. 2022 - 22 306 545.9 and PCT/EP2023/078198 11/11/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 21 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, In vitro poc, Lymphoma, Method, Oncology, Sezary syndrome, Target [taxonomieurl] => Biomarker, Biomarker, Immunoassay, In vitro poc, Lymphoma, Method, Oncology, Sezary syndrome, Target ) [22] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF ALBUMIN ISOFORMS PROFILES FOR THE CHARACTERIZATION OF THE ETIOLOGY AND SEVERITY OF LIVER INJURIES [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-albumin-isoforms-profiles-for-the-characterization-of-the-etiology-and-severity-of-liver-injuries/ [post_content] => The inventors hypothesized that each type of liver injury can be revealed by a specific profile of HSA posttranslational modifications. Therefore, the aim of inventors was to study the pattern of albumin isoforms in rats intoxicated with acetaminophen (APAP), ethanol, and CCl4. The second objective was to explore the potential of these isoforms as biomarkers of liver specific injuries. The results demonstrate that albumin posttranslational modifications (Alb-PTM) occur very early during the course of liver injuries induced by hepatotoxic substances. In 3 animal models, native albumin started to decrease in favor of other isoforms 24 hours after the administration of APAP, ethanol or CCl4. Interestingly, the nature and the intensity of isoforms were different depending on the hepatotoxic substance. In a cohort of cirrhotic patients, the inventors were able to identify up to 14 albumin isoforms, all of which were also present in control patients. However, the inventors observed that the increase in the HSA-DA isoform was specific to patients with cirrhosis due to alcohol abuse, HSA+SGGS and HSA+2Glyc were increased specifically in NASH patients, and HSA-DA+Cys with HSA+SO2H were increased only in patients with the mixed form. In addition, we did not observe a specific isoform able to clearly discriminate the different stages of liver disease, but principal component analysis of the MS dataset perfectly separated cirrhosis patients with different Child-Pugh scores and control patients. The present invention thus relates to the use of albumin isoforms profiles for the characterization of the etiology and severity of liver injuries. [post_date] => 2024-10-22 10:15:02 [post_modified] => 2024-10-22 10:15:02 [ID] => 8108 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1e15b7aa-905c-11ef-b885-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 2022-10-07 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22116-D1 [keywords] => Liver Injuries, Liver Transplant, NASH, MASH, Mass spectrometry [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => EL BALKHI Souleiman,SAINT-MARCOUX Franck,SAUVAGE François-Ludovic,RAHALI Mohamed-Ali,MARQUET Pierre [number_application] => European Procedure (Patents) (EPA) - 07 Oct. 2022 - 22 306 513.7
PCT/EP2023/077721 on 06/10/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => mass_spectrometry [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 22 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Gastrointestinal Diseases, Human POC, Liver Disease, Mass spectrometry, Method [taxonomieurl] => Biomarker, Biomarker, Gastrointestinal Diseases, Human POC, Liver Disease, Mass spectrometry, Method ) [23] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-an-agent-capable-of-inhibiting-the-activation-of-mait-cells-for-the-treatment-of-rheumatoid-arthritis/ [post_content] => Rheumatoid arthritis (RA) is the most common form of inflammatory rheumatism involving small joints which are the seat for swelling and pain with structural damage, responsible for functional disabilities if no treatment is proposed. The inventors show that circulating MAIT cells were reduced and exhibited an activated and anti-apoptotic phenotype in RA patients compared to healthy controls. MAIT cell levels were also found to be increased in the synovial fluid as compared with the peripheral blood, suggesting that circulating MAIT cell deficiency is due to the migration of MAIT cells into the joint. Severity of arthritis induced by mBSA was reduced in mice depleted in MAIT cells. This data suggest that MAIT cells contribute to exacerbation of arthritis. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of rheumatoid arthritis. [post_date] => 2024-10-09 07:45:01 [post_modified] => 2024-10-09 07:45:01 [ID] => 8102 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f3b78c0a-860f-11ef-a34f-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO22036-T1 [keywords] => MAIT cells, rheumatoid arthritis [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO22036-T1_Avouac.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => AVOUAC Jérôme,LESTURGIE Manon,LEHUEN-MONTEIRO Agnès,GONZALEZ Virginie [number_application] => European Procedure (Patents) (EPA) - 02 Sept. 2022 - 22 306 303.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 23 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => [taxonomieurl] => ) [24] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE TREATMENT OF TH2-MEDIATED DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-treatment-of-th2-mediated-diseases/ [post_content] => Voltage-dependent calcium channels (Cav1) contribute to T-cell activation. The inventors previously showed that Th2 cells co-express Cav1.2 and Cav1.3 calcium channels acting in a non-redundant and concerted way to initiate early TCR-driven calcium influx required for cytokine production and Th2-cell functions. While they have demonstrated that both channels have to be present on the same T-cell to induce allergic asthma, how these channels are regulated under TCR engagement is yet unknown. They investigated the relationship between PKCu03b1 and the Cav1.2/Cav1.3 duo channels in Th2 cells. They showed that PKC activation was sufficient to trigger Cav1-dependent calcium response and Th2 cytokine production. Cav1 channels, and especially Cav1.3, expression increased at the cell membrane of Th2 cells upon TCR stimulation and PKCu03b1 selectively associated with Cav1.3 upon activation. They showed that PKCu03b1 antisense oligonucleotides (PKCu03b1-AS) decreased Th2-cell functions and were beneficial in active and passive models of Th2-mediated airway inflammation induced by OVA. Altogether these results show that PKCu03b1 by interacting selectively with Cav1.3 after TCR engagement regulates Cav1.2/Cav1.3 duo-dependent calcium signaling and probably by this way impairs Th2-cell functions and their potential to mediate inflammation. [post_date] => 2024-10-08 16:55:02 [post_modified] => 2024-10-08 16:55:02 [ID] => 8099 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 22b78b02-774e-11ef-a1f1-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO22179-T1 [keywords] => TH2-MEDIATED DISEASES, Voltage-dependent calcium channels, Cav, PKCu03b1 [pub_scient_inv_dispo] => Giang, Nicolas et al. /u201cPKCu03b1 interacts with Cav 1.3 calcium channels to promote the Cav 1.2/Cav 1.3 duo tuning Th2 functions./u201d Allergy vol. 78,3 (2023): 879-882. doi:10.1111/all.15611 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO22179-T1_Savignac.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => SAVIGNAC Magali,PELLETIER Lucette [number_application] => European Procedure (Patents) (EPA) - 05 Août 2022 - 22 306 190.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 24 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Allergies, Basic research, Drug, Immunology [taxonomieurl] => Allergies, Basic research, Drug, Immunology ) [25] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF HIF-1¿ STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-hif-1-stabilizing-agents-for-the-treatment-of-type-i-interferonopathies/ [post_content] => Type I interferonopathies represent a subgroup of autoinflammatory diseases caused by mutations in genes associated with proteasome degradation or cytoplasmic RNA- and DNA- sensing pathways. Among them, Aicardi-Goutières syndrome (AGS) ischaracterised by both neurological and extra-neurological involvement with onset in childhood. Chronic inflammation in response to uncontrolled type I IFN production is, among other things, associated with IP-10 secretion. The inventors analysed, at the single-cell transcriptomic levels, peripheral blood samples from patients bearing mutations in three AGS-causing genes, i.e., SAMHD1, RNASEH2B or ADAR1 genes. Using machine-learning approaches and differential gene expression performed on these single-cell data, they identified a drastic loss of transcription factor hypoxia induced factor 1 u03b1 (HIF-1u03b1) expression associated with features of a metabolic switch and mitochondrial stress in monocytes/dendritic cells of patients. Chemical stabilization of HIF-1u03b1, with a synthetic drug (DMOG) in an in vitro model of AGS, allowed the inventors to reverse the energy metabolic switch, attenuate mitochondrial stress and markedly reduce IP-10 production. The inventors therefore propose that inappropriate energy metabolic switch contributes to exacerbated chronic inflammation in AGS, and that targeting this pathway might represent a promising therapeutic approach. [post_date] => 2024-10-03 16:10:01 [post_modified] => 2024-10-03 16:10:01 [ID] => 8095 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d486ca54-819f-11ef-8dcd-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO23003-T1 [keywords] => Type I interferonopathy, Aicardi-Goutières syndrome,HIF-1u03b1 [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO23003-T1_Menager.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => MENAGER Mickaël,BATIGNES Maxime [number_application] => European Procedure (Patents) (EPA) - 06 Févr. 2023 - 23 305 153.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 25 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Immunology, Inflammation, Target [taxonomieurl] => Immunology, Inflammation, Target ) [26] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE TREATMENT OF FOOD ALLERGY [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-treatment-of-food-allergy/ [post_content] => The incidence of food allergy has dramatically increased over the last three decades in industrialized countries, now affecting more than 200 million people worldwide. Treatment options for food allergy are still limited: lifelong avoidance of the allergen is the main approach, followed by allergen-specific oral immunotherapy, which carries inherent risks. Food allergy occurs when type 2 immune responses are dysregulated, leading to production of allergen- specific IgE, and IgE-mediated mast cell degranulation upon re-exposure to the same allergen. Here, the Inventors demonstrate that dietary fructo-oligosaccharides, which are a major class of FODMAPs, can aggravate food allergic reactions through a mechanism involving formation of AGEs and activation of the receptor RAGE, implying that inhibition of the AGE/AGE pathway represents a potential therapeutic strategy in food allergy. [post_date] => 2024-10-03 15:25:02 [post_modified] => 2024-10-03 15:25:02 [ID] => 8093 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8f4285ec-8199-11ef-9473-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO22178-T1 [keywords] => RAGE, AGE, food allergy, FODMAPs [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO22178-T1_Reber.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => REBER Laurent,KAMPHUIS Jasper [number_application] => European Procedure (Patents) (EPA) - 08 Mars 2023 - 23 305 306.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 26 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Allergies, Drug, Immunology, Product, Target [taxonomieurl] => Allergies, Drug, Immunology, Product, Target ) [27] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR REPARING AIRWAY EPITHELIAL CELL IN FIBROSIS CYSTIC PATIENT [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-reparing-airway-epithelial-cell-in-fibrosis-cystic-patient/ [post_content] => The present invention relates to the treatment of fibrosis cystic. The inventors have demonstrated that specialised pro-resolution lipid mediators (SPMs) regulate tight junction formation and prevent its disruption during Aspergillus fumigatus infection of CF airway epithelial cells. Moreover, they have demonstrated that these SPMs repair the CF airway epithelial cells. Thus, the invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. The present invention also relates to methods and pharmaceutical compositions for treating or preventing Aspergillus fumigatus infection in patient suffering from cystic fibrosis.In cystic fibrosis (CF), impaired mucociliary clearance leads to chronic infection and inflammation. However, cilia beating features in a CF altered environment, consisting of dehydrated airway surface liquid layer and abnormal mucus, have not been fully characterized. Furthermore, acute inflammation is normally followed by an active resolution phase requiring specialized proresolving lipid mediators (SPMs) and allowing return to homeostasis. However, altered SPMs biosynthesis has been reported in CF. Here, we explored cilia beating dynamics in CF airways primary cultures and its response to the SPMs, resolvin E1 (RvE1) and lipoxin B4 (LXB4). Human nasal epithelial cells (hNECs) from CF and non-CF donors were grown at air-liquid interface. The ciliary beat frequency, synchronization, orientation, and density were analyzed from high-speed video microscopy using a multiscale Differential Dynamic Microscopy algorithm and an in-house developed method. Mucins and ASL layer height were studied by qRT-PCR and confocal microscopy. Principal component analysis showed that CF and non-CF hNEC had distinct cilia beating phenotypes, which was mostly explained by differences in cilia beat organization rather than frequency. Exposure to RvE1 (10 nM) and to LXB4 (10 nM) restored a non-CF-like cilia beating phenotype. Furthermore, RvE1 increased the airway surface liquid (ASL) layer height and reduced the mucin MUC5AC thickness. The calcium-activated chloride channel, TMEM16A, was involved in the RvE1 effect on cilia beating, hydration, and mucus. Altogether, our results provide evidence for defective cilia beating in CF airway epithelium and a role of RvE1 and LXB4 to restore the main epithelial functions involved in the mucociliary clearance. [post_date] => 2024-10-01 16:25:01 [post_modified] => 2024-10-01 16:25:01 [ID] => 8090 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c8b8f6de-800f-11ef-8d0c-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO22248-T1 [keywords] => Cystic fibrosis, SPMs, RvE1, LXB4, Aspergillus fumigatus [pub_scient_inv_dispo] => Briottet, Maëlle et al. /u201cSpecialized proresolving mediator resolvin E1 corrects the altered cystic fibrosis nasal epithelium cilia beating dynamics./u201d Proceedings of the National Academy of Sciences of the United States of America vol. 121,5 (2024): e2313089121. [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO22248-T1_Urbach.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => URBACH Valerie,SY Khadeeja Adam,BOTTEREL Françoise [number_application] => European Procedure (Patents) (EPA) - 07 Juin 2022 - 22 305 824.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 27 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cystic Fibrosis, Drug, Respiratory Disease, Target [taxonomieurl] => Cystic Fibrosis, Drug, Respiratory Disease, Target ) [28] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF RAC2 MONOGENIC DISORDERS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treatment-of-rac2-monogenic-disorders/ [post_content] => A growing number of patients presenting severe combined immunodeficiencies attributed to monoallelic RAC2 variants have been identified. The expression of the RHO GTPase RAC2 is restricted to the hematopoietic lineage. RAC2 variants have been described to cause immunodeficiencies associated with high frequency of infection, leukopenia, and autoinflammatory features. Here, we show that specific RAC2 activating mutations induce the NLRP3 inflammasome activation leading to the secretion of IL-1u03b2 and IL-18 from macrophages. This activation depends on the activation state of the RAC2 variant and is mediated by the downstream kinase PAK1. Inhibiting the RAC2-PAK1-NLRP3 inflammasome pathway might be considered as a potential treatment for these patients. [post_date] => 2024-10-01 15:15:02 [post_modified] => 2024-10-01 17:15:03 [ID] => 8088 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b631af7e-8005-11ef-b70d-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO22092-T1 [keywords] => Rac2, NLRP3, inflammation, inflammasome [pub_scient_inv_dispo] => Doye, Anne et al. /u201cRAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation./u201d The Journal of experimental medicine vol. 221,10 (2024): e20231562. doi:10.1084/jem.20231562 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO22092-T1_Boyer.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => BOYER (NICE) Laurent [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 28 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Immunology, Target [taxonomieurl] => Immunology, Target ) [29] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF LET-7B OR MIR-21 INHIBITORS FOR THE TREATMENT INFLAMMATORY BOWEL DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-let-7b-or-mir-21-inhibitors-for-the-treatment-inflammatory-bowel-diseases/ [post_content] => Inflammatory bowel diseases (IBD) etiology is multifactorial. Luminal microRNAs (miRNAs) have been suspected to play a role in the promotion of chronic inflammation, but the extent to which fecal miRNAs are interacting with the intestinal ecosystem in a way that contribute to diseases, including IBD, remains unknown. Here, fecal let-7b and miR-21 were found elevated, associated with inflammation, and correlating with multiple bacteria in IBD patients and IL-10-/- mice, model of spontaneous colitis. Using an in vitro microbiota modeling system, we revealed that these two miRNAs can directly modify the composition and function of complex human microbiota, increasing their proinflammatory potential. In vivo investigations revealed that luminal increase of let-7b drastically alters the intestinal microbiota and enhances macrophages’ associated proinflammatory cytokines (TNF, IL-6, and IL-1u03b2). Such proinflammatory effects are resilient and dependent on the bacterial presence. Moreover, we identified that besides impairing the intestinal barrier function, miR-21 increases myeloperoxidase and antimicrobial peptides secretion, causing intestinal dysbiosis. More importantly, in vivo inhibition of let-7b and miR-21 with anti-miRNAs significantly improved the intestinal mucosal barrier function and promoted a healthier host-microbiota interaction in the intestinal lining, which altogether conferred protection against colitis. In summary, we provide evidence of the functional significance of fecal miRNAs in host-microbiota communication, highlighting their therapeutic potential in intestinal inflammation and dysbiosis-related conditions, such as IBD. [post_date] => 2024-09-25 16:00:02 [post_modified] => 2024-09-25 16:00:02 [ID] => 8085 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bc758758-7b54-11ef-a6b2-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO22444-T1 [keywords] => Inflammatory bowel disease, IBD, let-7b, miR-21, miRNA [pub_scient_inv_dispo] => Casado-Bedmar M, Roy M, Berthet L, Hugot JP, Yang C, Manceau H, Peoc’h K, Chassaing B, Merlin D, Viennois E. Fecal let-7b and miR-21 directly modulate the intestinal microbiota, driving chronic inflammation. Gut Microbes. 2024 Jan-Dec;16(1):2394249. doi: 10.1080/19490976.2024.2394249. [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO22444-T1_Viennois.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => CASADO BEDMAR Maria Teresa; VIENNOIS Emilie [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 29 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target [taxonomieurl] => Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target ) [30] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS, TREATMENT AND ANALYSIS OFNLRP3-ASSOCIATED AUTOINFLAMMATORY DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-treatment-and-analysis-ofnlrp3-associated-autoinflammatory-diseases/ [post_content] => NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development. [post_date] => 2024-09-25 11:55:01 [post_modified] => 2024-09-25 13:55:03 [ID] => 8083 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d3139418-7b32-11ef-80b1-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO23231-T1 [keywords] => NLRP3, inflammasome, NLRP3-AID [pub_scient_inv_dispo] => Cosson, Camille et al. /u201cFunctional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation./u201d The Journal of experimental medicine vol. 221,5 (2024): e20231200. doi:10.1084/jem.20231200 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO23231-T1_PY.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => PY Bénédicte [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 30 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Basic research, Biomarker, Drug, Immunology, Target [taxonomieurl] => Basic research, Biomarker, Drug, Immunology, Target ) [31] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF BRANCHED CHAIN FATTY ACIDS (BCFAS) FOR THETREATMENT OF INFLAMMATORY BOWEL DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-branched-chain-fatty-acids-bcfas-for-thetreatment-of-inflammatory-bowel-diseases/ [post_content] => The gut microbiota produces a wide variety of metabolites, which interact with intestinal cells by modulating either gene transcription or post-translational modifications of gut proteins. The effect of gut commensal bacteria on SUMOylation, an essential ubiquitin-like modification in intestinal physiology, remains however unknown. Here, the inventors show that branched chain fatty acids (BCFAs) increase protein SUMOylation in different intestinal cell lines. They demonstrated that the hyperSUMOylation induced by BCFAs inhibits the activation of the NF-u03baB pathway by blocking the degradation of the inhibitory factor u0399u03baBu03b1 in response to TNFu03b1. This results in a decrease in pro-inflammatory cytokines expression as well as a decrease in intestinal epithelial permeability in response to TNFu03b1. Accordingly, the present invention relates to the use of Branched Chain Fatty Acids (BCFAs) for the treatment of diseases associated with intestinal inflammation such as Inflammatory Bowel Diseases and Irritable Bowel Syndrome. [post_date] => 2024-09-20 12:50:01 [post_modified] => 2024-09-20 12:50:01 [ID] => 8066 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e4143df6-774c-11ef-92f9-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO19110-T1 [keywords] => IBD, BCFA, inflammatory bowel disease [pub_scient_inv_dispo] => Ezzine, Chaima et al. /u201cFatty acids produced by the gut microbiota dampen host inflammatory responses by modulating intestinal SUMOylation./u201d Gut microbes vol. 14,1 (2022): 2108280. doi:10.1080/19490976.2022.2108280 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO19110-T1_Ribet.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => RIBET David,DECHELOTTE Pierre,EZZINE Chaima [number_application] => European Procedure (Patents) (EPA) - 31 Août 2021 - 21306182.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 31 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Basic research, Concept and/or application formulated, Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target [taxonomieurl] => Basic research, Concept and/or application formulated, Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target ) [32] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REPAIRING INTESTINAL MUCOSAL [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-repairing-intestinal-mucosal/ [post_content] => In the management of patients with inflammatory bowel diseases (IBD), there is a need to identify druggable biological pathways to improve mucosal repair and efficacy of TNF alpha biologics. Based on the VIVA transgenic model of Vnn1 overexpression on intestinal cells, the inventors show that the epithelial pantetheinase Vnn1 has a dual effect on colon: (1) its enzymatic products, cysteamine and pantothenic acid (vitamin B5) enhance coenzyme A regeneration and colon fitness through metabolic rewiring; (2) they favor microbiota-dependent accumulation of butyrate, previously shown to regulate mucosal energetics and to be reduced in IBD patients. Upon dextran sodium sulfate (DSS)-induced colitis, Vnn1 exerts a cytoprotective role on colonocytes and reinforces the mucosal barrier. Remarkably, this global pro-healing phenotype is recapitulated by treating control mice with the substrate (pantethine) or the products of pantetheinase activity prior to exposure to DSS. Therefore, enhancement of vitamin B5-driven metabolism should improve mucosal healing and maintain colon fitness and might enhance the efficacy of anti-inflammatory anti-TNF alpha therapy. [post_date] => 2024-09-19 14:45:02 [post_modified] => 2024-09-19 14:45:02 [ID] => 8063 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0854fa52-7694-11ef-be47-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO18084-T1 [keywords] => Inflammatory bowel disease, IBD, Vnn1, vitamin B5, anti-TNF alpha [pub_scient_inv_dispo] => Millet, Virginie et al. /u201cHarnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis./u201d Gut vol. 72,6 (2023): 1115-1128. doi:10.1136/gutjnl-2021-325792 [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => NAQUET Philippe,MILLET Virginie,GALLAND Franck [number_application] => European Procedure (Patents) (EPA) - 02 Nov. 2021 - 21 306 537.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 32 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Inflammation, Target [taxonomieurl] => Drug, Immunology, Inflammation, Target ) [33] => stdClass Object ( [post] => stdClass Object ( [post_title] => Nlrp6 supports diurnal oscillation of host-microbiota interactions through casein kinase 2 [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=7440 [post_content] => The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthetized or natural selective Csnk2 inhibitors such as flavones. [post_date] => 2024-09-11 13:44:23 [post_modified] => 2024-09-18 18:25:02 [ID] => 7440 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4c9f0ec6-8d37-4f71-b61c-6a4ff803dca9 [etat_fiche_online] => en_ligne [date_application] => 2016-05-20 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO16079-T1 [keywords] => Nlrp6; Csnk2 inhibitor, Microbiome [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => [number_application] => European Procedure (Patents) (EPA) - 20 Mai 2016 - 16 305 585.8 [technology_engineering] => [multidisciplinary_field] => microbiota [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 33 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Basic research, Drug, Immunology, Microbiota, Product, Small Molecule [taxonomieurl] => Basic research, Drug, Immunology, Microbiota, Product, Small Molecule ) [34] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-the-treatment-of-systemic-mastocytosis/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA u0394 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor. [post_date] => 2024-09-11 13:43:44 [post_modified] => 2024-09-26 15:35:02 [ID] => 7402 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a27d83b5-c5aa-15d9-8428-5ab8f08c26a2 [etat_fiche_online] => en_ligne [date_application] => 2016-09-16 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO16342-T1 [keywords] => Systemic mastocytosis, XPO1 inhibitor, exportin-1 [pub_scient_inv_dispo] => Guillem, Flavia et al. /u201cXPO1 regulates erythroid differentiation and is a new target for the treatment of u03b2-thalassemia./u201d Haematologica vol. 105,9 2240-2249. 1 Sep. 2020, doi:10.3324/haematol.2018.210054 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO16342-T1_HERMINE.pdf [rare_disease] => 1 [second_indication] => 0 [inventors] => HERMINE Olivier,DAMAJ Gandhi,LADRAA Sophia,GUILLEM Flavia [number_application] => European Procedure (Patents) (EPA) - 16 Sept. 2016 - 16 306 181.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 34 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Identification, Immunology, Method, Target [taxonomieurl] => Drug, Identification, Immunology, Method, Target ) [35] => stdClass Object ( [post] => stdClass Object ( [post_title] => Lymphotoxin alpha regulates the immunosuppressive functions of Regulatory T cells [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=7345 [post_content] => The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT?-/- Tregs or the adoptive transfer of Tregs previously incubated with soluble lymphotoxin-? receptor in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to a method of treating or preventing autoimmune disorders and inflammatory-associated cancers in a subject in need thereof comprising the step of administrating to the subject a therapeutically effective amount of regulatory T cells which have been previously incubated with effective amount of soluble lymphotoxin-? receptor. [post_date] => 2024-09-11 13:43:10 [post_modified] => 2024-09-24 11:15:04 [ID] => 7345 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 842191af-5f92-79b0-60f0-5f5f5e232adc [etat_fiche_online] => en_ligne [date_application] => 2019-05-14 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO19143-T1 [keywords] => IBD, Regulatory T Cells, Treg, Auto-immune diseases, CAR-T-Reg [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO19143-T1_Irla.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => IRLA Magali [number_application] => European Procedure (Patents) (EPA) - 14 Mai 2019 - 19 305 618.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 35 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Method, Protein, Target, Validation in vivo [taxonomieurl] => Biologic, Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Method, Protein, Target, Validation in vivo ) [36] => stdClass Object ( [post] => stdClass Object ( [post_title] => GSK3B AND USES THEREOF IN THE DIAGNOSTIC AND TREATMENT OF HYPOPIGMENTATION DISORDERS [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=7313 [post_content] => The present invention relates to the identification of the glycogen synthase kinase-3 beta (GSK3B or GSK-3P) as a therapeutic target of pigmentation disorder and as biomarker of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects. [post_date] => 2024-09-24 11:55:02 [post_modified] => 2024-09-24 11:55:04 [ID] => 7313 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 80120b7c-d88b-48a3-b202-5fe4c421351c [etat_fiche_online] => en_ligne [date_application] => 2014-12-18 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO15318-T1 [keywords] => GSK3B, hypopigmentation disorder [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO15318-T1_Passeron.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => JOLY Florence [number_application] => European Procedure (Patents) (EPA) - 18 Déc. 2014 - 14307090.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 36 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Drug, Target, Validation in vitro [taxonomieurl] => Dermatology, Drug, Target, Validation in vitro ) [37] => stdClass Object ( [post] => stdClass Object ( [post_title] => DIAGNOSIS, PROGNOSIS AND TREATMENT OF A DISEASE RELATED TO A DECREASE OF F. PRAUSNITZII [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=7242 [post_content] => The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4+ CD8u03b1u03b1low phenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of F. prau. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of F. prau-specific cells among CD4+ CD8u03b1u03b1low T lymphocytes, from a blood sample and without needing to assess their F. prauspecificity. T lymphocytes with a CD4+ CD8u03b1u03b1low CCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease of F. prauis particularly an inflammatory bowel disease (IBD), such as Crohn’s disease. [post_date] => 2024-09-24 11:35:05 [post_modified] => 2024-09-24 11:35:05 [ID] => 7242 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3ca7317b-9885-8635-22ea-5e85aacf4f7c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO17114-T1 [keywords] => IBD, inflammatory bowel disease, F. prausnitzii, CCR6 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => JOTEREAU Francine,GODEFROY Emmanuelle,SARRABAYROUSE Guillaume,SOKOL Harry,ALTARE Frédéric [number_application] => European Procedure (Patents) (EPA) - 01 Juin 2018 - 18305677.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 37 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gastrointestinal Diseases, Identification, Inflammatory Bowel Disease / Crohn's Disease, Target [taxonomieurl] => Drug, Gastrointestinal Diseases, Identification, Inflammatory Bowel Disease / Crohn's Disease, Target ) [38] => stdClass Object ( [post] => stdClass Object ( [post_title] => REGULATORY T CELLS GENETICALLY MODIFIED FOR THE LYMPHOTOXIN ALPHA GENE AND USES THEREOF [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=7232 [post_content] => The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LTu03b1, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LTu03b1/u2212//u2212 Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LTu03b1 expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha. [post_date] => 2024-09-24 11:20:01 [post_modified] => 2024-09-24 11:20:04 [ID] => 7232 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2ec4641d-ef4e-b04b-2bd5-5d80c5ad481e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO17326-T2 [keywords] => [pub_scient_inv_dispo] => Borelli, Alexia et al. /u201cLymphotoxin limits Foxp3+ regulatory T cell development from Foxp3lo precursors via IL-4 signaling./u201d Nature communications vol. 15,1 6976. 14 Aug. 2024, doi:10.1038/s41467-024-51164-5 [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => IRLA Magali [number_application] => European Procedure (Patents) (EPA) - 14 Nov. 2017 - 17 306 579.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• ImmunologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 38 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Immunology [taxonomieurl] => Immunology ) [39] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS CCR8 [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-and-treatment-of-t-cell-lymphomas-ccr8-2/ [post_content] => T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sézary cells and showed the expression of CCR8 (CD198) by Sézary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas. [post_date] => 2024-08-28 10:25:27 [post_modified] => 2024-09-11 15:45:45 [ID] => 6508 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e3a0059b-e72d-b32c-13f9-648819fa2c1b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21120-T1 [keywords] => CTCL; CCR8, Sézary Syndrome [pub_scient_inv_dispo] => Giustiniani J, Dobos G, Moins-Teisserenc H, Eustaquio T, Battistella M, Ortonne N, Ram-Wolff C, Bouaziz JD, Marie-Cardine A, Mourah S, Bagot M, Kupper TS, Clark RA, Bensussan A, de Masson A. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. Blood Adv. 2022 Jun 14;6(11):3507-3512. doi: 10.1182/bloodadvances.2021006512. PMID: 35201316; PMCID: PMC9198911. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BENSUSSAN Armand,DE MASSON Adele,BATTISTELLA Maxime,GIUSTINIANI Jérôme,BAGOT Martine,ORTONNE Nicolas,MARIE-CARDINE Anne [number_application] => European Procedure (Patents) (EPA) - 23 Mars 2021 - 21 305 356.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LymphomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 39 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Biomarker, Drug, Lymphoma, Method, Oncology, Protein, Sezary syndrome [taxonomieurl] => Antibody, Biologic, Biomarker, Drug, Lymphoma, Method, Oncology, Protein, Sezary syndrome ) [40] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF SPLICE SWITCHING OLIGONUCLEOTIDES FOR EXON SKIPPING-MEDIATED KNOCKDOWN OF PIM2 [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-splice-switching-oligonucleotides-for-exon-skipping-mediated-knockdown-of-pim2/ [post_content] => PIM2 kinase deregulation has been reported in several cancers. In particular, PIM2 isconsidered in multiple myeloma as part of the oncogenic process and several PIM kinaseinhibitors have been developed showing encouraging results in preclinical studies and clinical trials. Now the inventors have developed an antisense RNA strategy based on a splice-switching oligonucleotide (SSO) so as to induce efficient knockdown of PIM2 expression. This SSOmediated knockdown is a powerful approach to for cancer treatments. Accordingly, the present invention relates to the use of splice switching oligonucleotides for exon skipping-mediated knockdown of PIM2. [post_date] => 2024-08-28 10:25:10 [post_modified] => 2024-09-11 15:45:30 [ID] => 6506 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e35a7622-a903-2a05-e1a5-645d092dc336 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21121-T1 [keywords] => [pub_scient_inv_dispo] => Haas M, Caron G, Chatonnet F, Manenti S, Alaterre E, Devin J, Delaloy C, Bertolin G, Viel R, Pignarre A, Llamas-Gutierrez F, Marchalot A, Decaux O, Tarte K, Delpy L, Moreaux J, Fest T. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma. Blood. 2022 Apr 14;139(15):2316-2337. doi: 10.1182/blood.2021014011. PMID: 35108359. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => FEST Thierry,MOREAUX Jérôme,MARCHALOT Anne,LACOMBE Gersende,HAAS Marion,DELPY Laurent [number_application] => European Procedure (Patents) (EPA) - 19 Avr. 2021 - 21 305 513.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Multiple myelomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 40 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Multiple myeloma, Oligonucleotide, Oncology, Target [taxonomieurl] => Drug, Multiple myeloma, Oligonucleotide, Oncology, Target ) [41] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTI-ROBO4 HUMAN MONOCLONAL ANTIBODIES AND USESTHEREOF FOR THE TREATMENT OF CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/anti-robo4-human-monoclonal-antibodies-and-usesthereof-for-the-treatment-of-cancer/ [post_content] => There is an interest to develop anti-ROBO4 antibodies that can be suitable for the treatment of cancer. The inventors produced new human antibodies directed against ROBO4 were by aphage display strategy and the antibody selection was performed by using HEK and HEK stably expressing ROBO4 (HEK-ROBO4) cell lines. As a first step, a batch of 6 differentantibodies named D3, H3, H9, E11, H11 and G12 was tested for their binding properties. Theantibodies were then tested for their ability to inhibit the attachment of tumor cells toosteoblastic cells in monolayers. Finally the inventors showed that the anti-ROBO4 antibodies E11 and G12 inhibits significantly the formation of the tumor spheroid. The present invention thus relates to anti-ROBO4 human monoclonal antibodies and uses thereof for the treatment of cancer. [post_date] => 2024-08-28 10:25:07 [post_modified] => 2024-09-11 15:45:29 [ID] => 6504 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5f574197-c19c-48ef-0409-64467d3f382d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22052-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CLEZARDIN Philippe,ECKEL Bénédicte,DIAZ-LATOUD Chantal,CLEMENT-DEMANGE Lise,BERNARD Margaux,CHENTOUF Myriam,ROBERT Bruno,MARTINEAU Pierre [number_application] => European Procedure (Patents) (EPA) - 16 Févr. 2022 - 22305173.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 41 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Oncology, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Oncology, Product, Product, Protein ) [42] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR TREATING CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-treating-cancer/ [post_content] => The present invention relates to a method of treating HER2EU overexpressing cancers. The inventors discovered that the heme-mediated formation of dimers and in general oligomers of Trastuzumab is associated with an improved complement-mediated cytotoxicity on breast cancer cells. The present data highlight that the sensitivity to heme of Trastuzumab, may have major repercussion on its therapeutic activity. Thus the invention relates to the combination of an HER2eu antibody with a heme and/or of its oligomers and its therapeutic composition in the HER2EU characteristic cancer treatment. [post_date] => 2024-08-28 10:25:05 [post_modified] => 2024-09-11 15:45:13 [ID] => 6503 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c3430d7a-940c-2cb7-9f48-5f8016683278 [etat_fiche_online] => en_ligne [date_application] => 10-09-2018 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17187-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DIMITROV Jordan,MAREY JAROSSAY Annaelle,LACROIX-DESMAZES Sébastien [number_application] => European Procedure (Patents) (EPA) - 10 Sept. 2018 - 18 306 187.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 42 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Method, Oncology [taxonomieurl] => Method, Oncology ) [43] => stdClass Object ( [post] => stdClass Object ( [post_title] => TREATMENT OF LIVER CANCERS BY DISRUPTING THE BETA-CATENIN/TCF-4 BINDING SITE LOCATED UPSTREAM OF MEG3 IN THE DLK1/DIO3 LOCUS [guid] => https://technology-offers.inserm-transfert.com/offer/treatment-of-liver-cancers-by-disrupting-the-beta-catenin-tcf-4-binding-site-located-upstream-of-meg3-in-the-dlk1-dio3-locus/ [post_content] => Activating mutations in CTNNB1 gene encoding u03b2-catenin is encountered in approximately 30% of hepatocellular carcinoma (HCC) and in more than 80% of hepatoblastoma. In Apcu0394hep model, the inventors unravel the biggest cluster of non-coding RNAs identified called the DLK1/DIO3 locus as the most significantly induced region in response to u03b2-catenin activation regarding transcription of coding and non-coding elements. Using in vivo CRISPR-cas9 strategy, the inventors were able to demonstrate that u03b2-catenin and its cofactor TCF-4 directly bind on a WRE-containing site located upstream of Meg3 to create an active enhancer regulatory region engaged in chromatin remodeling in the direct vicinity of this binding site but also at distance by long range DNA-DNA contacts to promote transcription of the entire locus. TheseCRISPR-cas9 constructs have also proved to be a valuable strategy to impair the locus expression in the murine models mimicking HCC and hepatoblastoma (Apcu0394hep and u03b2-catenin Exon3 tumors) but also in two cell lines with activating mutations in u03b2-catenin encoding gene, the murine Hepa1-6 and human HuH6 cells. In transformed cells, it significantly impaired cell proliferation in vitro and HuH6 stemness capacities but also tumor progression in Hepa1-6 allografts. In mouse models, the locus editing during early steps of tumorigenesis decreased the proliferation of Apcu0394hep preneoplastic hepatocytes but also those of Apcu0394hep and u03b2-catenin Exon3 tumor cell resulting in impairment of tumor size. In conclusion, the results demonstrate that disrupting the-catenin/TCF-4 binding site located upstream of Meg3 in the DLK1/DIO3 locus represents a very interesting approach for the treatment of liver cancers. [post_date] => 2024-08-28 10:24:59 [post_modified] => 2024-09-11 15:45:32 [ID] => 6499 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7b599a09-3976-96ca-14b2-645d0be8e90b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22031-T1 [keywords] => [pub_scient_inv_dispo] => Sanceau J, Poupel L, Joubel C, Lagoutte I, Caruso S, Pinto S, Desbois-Mouthon C, Godard C, Hamimi A, Montmory E, Dulary C, Chantalat S, Roehrig A, Muret K, Saint-Pierre B, Deleuze JF, Mouillet-Richard S, Forné T, Grosset CF, Zucman-Rossi J, Colnot S, Gougelet A. DLK1/DIO3 locus upregulation by a u03b2-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis. Mol Ther. 2024 Apr 3;32(4):1125-1143. doi: 10.1016/j.ymthe.2024.01.036. Epub 2024 Feb 3. PMID: 38311851; PMCID: PMC11163201. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GOUGELET Angélique,POUPEL Lucie,SANCEAU Julie,COLNOT Sabine [number_application] => European Procedure (Patents) (EPA) - 14 Févr. 2022 - 22 305 162.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Liver CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 43 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Liver Cancer, Method, Oncology [taxonomieurl] => Drug, Liver Cancer, Method, Oncology ) [44] => stdClass Object ( [post] => stdClass Object ( [post_title] => COMBINATION TREATMENT OF PANCREATIC CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/combination-treatment-of-pancreatic-cancer/ [post_content] => PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. The inventors questioned this concept, by mapping differential isoformspecific downstream signalling in response to their constant selective inhibition in pancreatic cancer, a disease currently without therapy. They identified common and specific signals activated by each PI3K isoform. These data make the rational for the development of highly selective PI3K isoform drugs used in combination, instead of compounds inhibiting all PI3Ks. In particular, the inventors showed that combined p110? and p110? inhibition is the most efficient strategy for pancreatic cancer patients. [post_date] => 2024-08-28 10:24:56 [post_modified] => 2024-09-11 15:45:11 [ID] => 6493 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0dcabed8-3fa5-4369-83a4-83422c93fa7c [etat_fiche_online] => en_ligne [date_application] => 13-10-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17523-T1 [keywords] => PI3 Kinase [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GUILLERMET-GUIBERT Julie,CINTAS Célia,REICHERT Maximilian [number_application] => European Procedure (Patents) (EPA) - 13 Oct. 2017 - 17 306 391.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Pancreatic CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 44 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Method, Oncology, Pancreatic Cancer [taxonomieurl] => Drug, Method, Oncology, Pancreatic Cancer ) [45] => stdClass Object ( [post] => stdClass Object ( [post_title] => A XPO1 inhibitor for the treatment of Myelodysplastic syndromes [guid] => https://technology-offers.inserm-transfert.com/offer/a-xpo1-inhibitor-for-the-treatment-of-myelodysplastic-syndromes/ [post_content] => The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter. [post_date] => 2024-08-28 10:24:55 [post_modified] => 2024-09-11 15:45:11 [ID] => 6492 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b36091c5-4f61-4b74-8fd5-e3b179fb986d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14070-T1 [keywords] => Oncology - Myelodysplastic Syndromes - Small molecule - XPO1 inhibitor [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => FONTENAY Michaela,ARLET Jean-benoît,GUILLEM Flavia,COURTOIS Genevieve [number_application] => European Procedure (Patents) (EPA) - 10 Juin 2014 - 14 305 873.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 45 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Method, Oncology [taxonomieurl] => Method, Oncology ) [46] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF A L-ASPARAGINASE IN COMBINATION WITH A FERROPTOSIS INDUCER FOR THE TREATMENT OF EXTRANODAL NATURAL KILLER/TCELL LYMPHOMA [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-a-l-asparaginase-in-combination-with-a-ferroptosis-inducer-for-the-treatment-of-extranodal-natural-killer-tcell-lymphoma/ [post_content] => Extranodal natural killer/T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of the tumor. However the use of L-asparaginase-containing regimens obtained impressive outcomes as induction or salvage treatment for ENKTCL. Although more than 70% of early-stage patients can achievelong-term survival, patients with advanced-stage disease had extremely poor prognosis even after asparaginase-based chemotherapy regimens. There is thus a medical need for improving the treatment of ENKTCL with L-asparaginase. Now the inventors demonstrate the interest of the use of L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. In particular, combination of APR-246 and Erwinase® has synergistic effects in KHYG-1 cells. The present invention thus relates to the use of a L-asparaginase in combination with a ferroptosis inducer for the treatment of ENKTCL. [post_date] => 2024-08-28 10:24:54 [post_modified] => 2024-09-11 15:45:34 [ID] => 6491 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4a976a39-ae75-7ee0-1299-645d0d19dcc4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21432-T1 [keywords] => Combination treatment; ENKTCL; Ferroptosis [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HERMINE Olivier,COURONNE Lucile,SIMONIN Mathieu,ANDRIEU Guillaume,MAROUF Amira,ASNAFI Vahid [number_application] => European Procedure (Patents) (EPA) - 04 Juil. 2022 - 22 305 993.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LymphomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 46 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Lymphoma, Method, Oncology [taxonomieurl] => Drug, Lymphoma, Method, Oncology ) [47] => stdClass Object ( [post] => stdClass Object ( [post_title] => EXTRACELLULAR VESICLES FUNCTIONALIZED WITH AN ERV SYNCITIN AND USES THEREOF FOR CARGO DELIVERY [guid] => https://technology-offers.inserm-transfert.com/offer/extracellular-vesicles-functionalized-with-an-erv-syncitin-and-uses-thereof-for-cargo-delivery/ [post_content] => EVs are being recognized as vectors for drug delivery. In particular, EV loading with targeting and therapeutic agents brings along an interesting opportunity to translate EVs into a biomimetic selective delivery system. Indeed, EVs constitute a physiological carrier being potentially less immunogenic than artificial delivery vehicles. The inventors now developed a novel method to control the loading of a cargo into EVs on demand. These EVs are equipped, if necessary, with non-viral fusogen, therefore enhancing EV-cargo delivery into acceptor cells. To acutely measure this process, they follow the fate of a luciferase-tagged cargo. Cargo loading was enabled through a drug-reversible inducible dimerization system. Briefly, donor cells were transfected with plasmids encoding for FKBP-tagged CD63, a classical membrane EV marker, and FRB-Nanoluciferase (NLuc) that is normally cytosolic. Upon addition of the dimerizing drug, FRB-Nluc interacts with FKBP-CD63 and is recruited into secreted EVs. This is accompanied by an enhanced delivery into acceptor cells. This phenomenon can be further enhanced when EVs are equipped with syncitin1, a mammalian fusogenic protein that trigger fusion between EV membrane and the plasma membrane of acceptor cells. Using this novel process, the inventors further demonstrated that the catalytic domain of the Diphteria toxin (DTA), that is responsible for protein synthesis inhibition and ultimately cell death, can be delivered to acceptor cells via functionalized EVs. This led to protein synthesis inhibition and death of acceptor cells. This novel method and the derived applications promise to open new doors in precision care medicine, especially when EVs will be equipped with antibodies raised against cell specific antigens. [post_date] => 2024-08-28 10:24:52 [post_modified] => 2024-09-11 15:45:35 [ID] => 6488 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a7293b42-564c-11ef-ad06-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO22268-T1 [keywords] => [pub_scient_inv_dispo] => Bui S, Dancourt J, Lavieu G. Virus-Free Method to Control and Enhance Extracellular Vesicle Cargo Loading and Delivery. ACS Appl Bio Mater. 2023 Mar 20;6(3):1081-1091. doi: 10.1021/acsabm.2c00955. Epub 2023 Feb 13. PMID: 36781171; PMCID: PMC10031566. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => LAVIEU Grégory,BUI Shéryl,DANCOURT Julia [number_application] => European Procedure (Patents) (EPA) - 21 Juil. 2022 - 22 306 089.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 47 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Method, Oncology [taxonomieurl] => Biologic, Drug, Method, Oncology ) [48] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR CONTROLLING THE TUMOR CELL KILLING BY LIGHT [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-controlling-the-tumor-cell-killing-by-light/ [post_content] => The inventors have developed a new system of optogenetics-based recombinant system allowing to target tumor cells to control in space and time tumor cell lysis by cytotoxic T lymphocytes (CTLs) with light. To do so, they have coupled tumor-specific antigen antibody to a photoreceptor protein that can bind an optogenetic domain linked to a Fab fragment derived from an agonistic antibody targeting the TCR. They demonstrated that these new system allow the spatio-temporal control of the tumor cell killing by CTLs in vitro, in response to light. The present invention relates to methods of activating on demand an immune cell or a plurality of immune cells, and methods for treating cancer. [post_date] => 2024-08-28 10:24:50 [post_modified] => 2024-09-11 15:45:36 [ID] => 6485 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9c9ec06c-564b-11ef-92f2-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO22018-T1 [keywords] => [pub_scient_inv_dispo] => Jaeger M, Anastasio A, Chamy L, Brustlein S, Vincentelli R, Durbesson F, Gigan J, Thépaut M, Char R, Boussand M, Lechelon M, Argüello RJ, Marguet D, He HT, Lasserre R. Light-inducible T cell engagers trigger, tune, and shape the activation of primary T cells. Proc Natl Acad Sci U S A. 2023 Sep 26;120(39):e2302500120. doi: 10.1073/pnas.2302500120. Epub 2023 Sep 18. PMID: 37722050; PMCID: PMC10523538. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => LASSERRE Remi,JAEGER Morgane [number_application] => European Procedure (Patents) (EPA) - 14 Avr. 2022 - 22 305 545.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 48 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Method, Oncology [taxonomieurl] => Drug, Method, Oncology ) [49] => stdClass Object ( [post] => stdClass Object ( [post_title] => Methods and pharmaceutical composition for cancer immunotherapy [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-composition-for-cancer-immunotherapy/ [post_content] => The present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amountof a TNFalpha blocking agent to a subject in combination with the immune checkpoint inhibitor. [post_date] => 2024-08-28 10:24:49 [post_modified] => 2024-09-11 15:45:08 [ID] => 6483 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 26ae119e-22e0-41a9-9126-0db92541e8a7 [etat_fiche_online] => en_ligne [date_application] => 28-03-2016 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15452-T1 [keywords] => TNF alpha blocking agent, immune checkpoint inhibitor, combination [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => SEGUI Bruno,BERTRAND Florie,ANDRIEU-ABADIE Nathalie,MEYER Nicolas,COLACIOS Céline [number_application] => European Procedure (Patents) (EPA) - 28 Janv. 2016 - 16 305 085.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 49 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Method, Oncology [taxonomieurl] => Method, Oncology ) [50] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-treating-cancer/ [post_content] => Tumour-specific molecular targets and alternative therapeutic strategies for triplenegative breast cancer (TNBC) are urgently needed. The protease cathepsin D (cath-D) is aberrantly secreted and a marker of poor prognosis in breast cancer. Using degradomic analyses by TAILS, we discovered that the matricellular protein SPARC is a substrate of extracellular cath-D. In vitro, cath-D induced limited proteolysis of SPARC C-terminal extracellular Ca2+ binding domain at acidic pH, leading to the production of SPARC fragments (34-, 27-, 16-, 9-, and 6-kDa). SPARC cleavage also occurred in vivo in TNBC and mouse mammary tumours.Moreover, the C-terminal 9-kDa SPARC fragment inhibited MDA-MB-231 TNBC celladhesion and spreading on fibronectin, and stimulated their migration, endothelial transmigration and invasion more potently than full-length SPARC. These results highlight a novel crosstalk between proteases and matricellular proteins in the TNBC microenvironment through limited proteolysis of SPARC, and reveal that the 9-kDa C-terminal SPARC fragment is an attractive therapeutic target for TNBC.Thus, the invention relates to an inhibitor of SPARC fragment for use for treating cancer, and in particularly triple cancer negative breast cancer. [post_date] => 2024-08-28 10:24:47 [post_modified] => 2024-09-11 15:45:42 [ID] => 6480 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 406d38ac-2403-eb05-6a4e-646dd426c8a4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO20377-T1 [keywords] => [pub_scient_inv_dispo] => Alcaraz LB, Mallavialle A, Mollevi C, Boissière-Michot F, Mansouri H, Simony-Lafontaine J, Laurent-Matha V, Chardès T, Jacot W, Turtoi A, Roger P, Guiu S, Liaudet-Coopman E. SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. Int J Cancer. 2023 Mar 15;152(6):1243-1258. doi: 10.1002/ijc.34345. Epub 2022 Nov 30. PMID: 36346290; PMCID: PMC10099777. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => LIAUDET-COOPMAN Emmanuelle,MALLAVIALLE Aude,ALCARAZ CACCHIA Lindsay [number_application] => European Procedure (Patents) (EPA) - 21 Oct. 2020 - 20 306 254.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 50 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Breast Cancer, Drug, Lead - validation in vivo, Method, Oncology, Product, Protein [taxonomieurl] => Antibody, Biologic, Breast Cancer, Drug, Lead - validation in vivo, Method, Oncology, Product, Protein ) [51] => stdClass Object ( [post] => stdClass Object ( [post_title] => COMBINATION FOR TREATING CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/combination-for-treating-cancer-2/ [post_content] => The present invention relates to the treatment of cancer and particularly of lung cancer. In the present study, the inventors analyzed the role of the Notch pathway in EGFR-driven lung adenocarcinoma (LUAD) using complex genetic mouse models and patient derived xenografts. They found that, similarly to KRAS-driven LUAD, EGFR-driven LUAD shows both Notch pathway hyperactivation and addiction to its activity. Importantly, combination of EGFR tyrosine Kinase Inhibitors (TKIs) with Notch inhibition re-sensitizes LUAD cells harboring gatekeeper mutations EGFRT790M or EGFRC797S to gefitinib and osimertinib, respectively. Moreover, they show that pSTAT3, which is known to increase upon EGFR TKI treatment, directly binds to the HES1 promoter and represses HES1 expression. Finally, high HES1 expression levels correlate with shorter progression free survival and its expression increases upon progression in EGFR mutated patients under TKI treatment. Thus, the present invention relates to a combination of a tyrosine-kinase inhibitor (TKI) against epidermal growth factor receptor (EGFR) and an inhibitor of the Notch signalling pathway for use in the treatment of a cancer in a subject in need thereof. [post_date] => 2024-08-28 10:24:41 [post_modified] => 2024-09-11 15:45:03 [ID] => 6473 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f0a8ac2f-b36a-fe56-5ffc-5b80086c4f1c [etat_fiche_online] => en_ligne [date_application] => 19-07-2018 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17398-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MARAVER Antonio,BOUSQUET Emilie [number_application] => European Procedure (Patents) (EPA) - 19 Juil. 2018 - 18 305 991.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Lung cancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 51 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Lung cancer, Method, Oncology [taxonomieurl] => Drug, Lung cancer, Method, Oncology ) [52] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-treatment-of-cancer-disease-by-targeting-an-epigenetic-factor/ [post_content] => The present invention relates to a method for preventing or treating a cancer disease by targeting the epigenetic factor Chromodomain on Y-like 2 (CDYL2). The inventors found that CDYL2 is commonly over-expressed in cancer and high CDYL2 levels correlate with poor prognosis in a number of cancer types even in drug resistant cancer. CDYL2 upregulation in a breast cancer cell line induced migration, invasion, stem-like phenotypes, as well as an epithelial-to-mesenchymal transition (EMT). Due to the importance of EMT and stemness in therapeutic resistance and relapse in cancer, the inventors propose that CDYL2 inhibition will also be beneficial to the treatment of such cancers. Furthermore RNAi inhibition of CDYL2 diminished these same EMT-associated processes in the mesenchymal-like breast cancer cell line. Finally ablating the expression of CDYL2 with RNAi 1) stimulates the expression of genes associated with an anti-tumor immune response (such as gene involved in interferon response) and 2) inhibits lung tumorigenesis in a preclinical model (mouse injected with the triple negative MDA-MB-231 cell line). These results show that CDYL2 as a strong candidate proto-oncogene and therapeutic target in cancer and also contributes to the anti-tumoral immune response escape. [post_date] => 2024-08-28 10:24:39 [post_modified] => 2024-09-11 15:45:25 [ID] => 6469 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 85db0a91-b353-13c0-1809-646dd3b972bb [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19474-T1 [keywords] => [pub_scient_inv_dispo] => Siouda M, Dujardin AD, Barbollat-Boutrand L, Mendoza-Parra MA, Gibert B, Ouzounova M, Bouaoud J, Tonon L, Robert M, Foy JP, Lavergne V, Manie SN, Viari A, Puisieux A, Ichim G, Gronemeyer H, Saintigny P, Mulligan P. CDYL2 Epigenetically Regulates MIR124 to Control NF-u03baB/STAT3-Dependent Breast Cancer Cell Plasticity. iScience. 2020 Jun 26;23(6):101141. doi: 10.1016/j.isci.2020.101141. Epub 2020 May 6. PMID: 32450513; PMCID: PMC7251929. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MULLIGAN Peter,SAINTIGNY Pierre,SIOUDA Maha [number_application] => European Procedure (Patents) (EPA) - 05 Févr. 2020 - 20 305 101.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 52 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Breast Cancer, Drug, Oncology, Target, Target, Validation in vivo [taxonomieurl] => Breast Cancer, Drug, Oncology, Target, Target, Validation in vivo ) [53] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTI-MÜLLERIAN INHIBITING SUBSTANCE ANTIBODIES AND USES THEREOF [guid] => https://technology-offers.inserm-transfert.com/offer/anti-m-Üllerian-inhibiting-substance-antibodies-and-uses-thereof/ [post_content] => In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients’ tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis. [post_date] => 2024-08-28 10:24:37 [post_modified] => 2024-09-11 15:45:24 [ID] => 6466 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b022768f-f206-c830-72fc-646dd25cb0df [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19400-T1 [keywords] => [pub_scient_inv_dispo] => Chauvin M, Garambois V, Choblet S, Colombo PE, Chentouf M, Gros L, De Brauwere DP, Duonor-Cerutti M, Dumas K, Robert B, Jarlier M, Martineau P, Navarro-Teulon I, Pépin D, Chardès T, Pèlegrin A. Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival. Int J Oncol. 2021 Jul;59(1):43. doi: 10.3892/ijo.2021.5223. Epub 2021 May 20. PMID: 34013359; PMCID: PMC8131086. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => PELEGRIN André,CHAUVIN Maëva,DI CLEMENTE RENAULD-BESSE Nathalie,MARTINEAU Pierre,CHENTOUF Myriam,ROBERT Bruno [number_application] => European Procedure (Patents) (EPA) - 27 Sept. 2019 - 19 306 213.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Ovarian cancerTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 53 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Drug, Lead - validation in vivo, Oncology, Ovarian cancer, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Drug, Lead - validation in vivo, Oncology, Ovarian cancer, Product, Product, Protein ) [54] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD TO GENERATE IMPROVING CAR-T CELLS [guid] => https://technology-offers.inserm-transfert.com/offer/method-to-generate-improving-car-t-cells/ [post_content] => The present invention relates to the adoptive therapy using notably CAR-T cells. Herethe inventors used a lentiviral vector approach to silence RINF expression in a shRNA dependent manner and evaluate the consequences of RINF silencing on human CAR-T cells proliferation ex vivo and their functionality and capacity to eradicate tumor cells in vivo. More, the proposed methodology to improve CAR-T cells persistence and efficacy by disrupting RINF/CXXC5 is not restricted to patients suffering from hematological or solid cancers (anti-CD19, anti-EGFR, anti-BCMAu2026) but could be also used to improve the efficacy of ACT in non-cancer diseases by such as lupus (1), cardiac fibrosis (2) or aging related-disorders (3).Thus, the present invention relates to an immune cell characterized in that it is defective for RINF. [post_date] => 2024-08-28 10:24:37 [post_modified] => 2024-09-11 15:45:24 [ID] => 6465 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f609a524-5630-11ef-91d3-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO21116-T1 [keywords] => [pub_scient_inv_dispo] => Astori A, Matherat G, Munoz I, Gautier EF, Surdez D, Zermati Y, Verdier F, Zaidi S, Feuillet V, Kadi A, Lauret E, Delattre O, Lefèvre C, Fontenay M, Ségal-Bendirdjian E, Dusanter-Fourt I, Bouscary D, Hermine O, Mayeux P, Pendino F. The epigenetic regulator RINF (CXXC5) maintains SMAD7 expression in human immature erythroid cells and sustains red blood cells expansion. Haematologica. 2022 Jan 1;107(1):268-283. doi: 10.3324/haematol.2020.263558. PMID: 33241676; PMCID: PMC8719099. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => PENDINO Frédéric,DONNADIEU Emmanuel,AN Dongjie,FUMAGALLI Mattia [number_application] => European Procedure (Patents) (EPA) - 07 Oct. 2022 - 22 306 511.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 54 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cell therapy, Method, Oncology [taxonomieurl] => Biologic, Cell therapy, Method, Oncology ) [55] => stdClass Object ( [post] => stdClass Object ( [post_title] => Bispecific antibody targeting transferrin receptor 1 and soluble antigen [guid] => https://technology-offers.inserm-transfert.com/offer/bispecific-antibody-targeting-transferrin-receptor-1-and-soluble-antigen/ [post_content] => The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of the bispecific antibody with TfR1 increases its persistence in vivo through an FcRn-like mechanism. It has been demonstrated on MCF7 cell line that the bispecific antibody induces soluble antigen (IL6) uptake through TfR1 mediated endocytosis. Effects of the bispecific antibody on XG6 cell lines viability have been demonstrated, notably on iron and IL-6 deprivation. Hence, the inventors design an improved sweeping antibody which can specifically target tumors and inflammatory cells expressing TfR1. By its unique mode of interaction with TfR1, its ability to induce soluble uptake antigen through TfR1 mediated endocytosis and its capacity to deprive cells of iron, known for being required in tumors growth and progression and development of inflammatory pathologies, the bispecific antibody can be used in the treatment of cancer and inflammatory pathologies. [post_date] => 2024-08-28 10:24:33 [post_modified] => 2024-09-11 15:45:21 [ID] => 6461 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 180622e4-562f-11ef-865a-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO16065-T1 [keywords] => Bispecific antibody [pub_scient_inv_dispo] => Neiveyans M, Melhem R, Arnoult C, Bourquard T, Jarlier M, Busson M, Laroche A, Cerutti M, Pugnière M, Ternant D, Gaborit N, Chardès T, Poupon A, Gouilleux-Gruart V, Pèlegrin A, Poul MA. A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs. 2019 Apr;11(3):593-605. doi: 10.1080/19420862.2018.1564510. Epub 2019 Feb 18. PMID: 30604643; PMCID: PMC6512944. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => POUL Marie-Alix,LAROCHE Adrien [number_application] => European Procedure (Patents) (EPA) - 20 Nov. 2018 - 18 306 524.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 55 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Drug, Method, Oncology, Protein [taxonomieurl] => Antibody, Biologic, Drug, Method, Oncology, Protein ) [56] => stdClass Object ( [post] => stdClass Object ( [post_title] => BAY-1895344 (Elimusertib) from Bayer in adult and pediatric liver cancers [guid] => https://technology-offers.inserm-transfert.com/offer/bay-1895344-elimusertib-from-bayer-in-adult-and-pediatric-liver-cancers/ [post_content] => Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy followed by surgical removal of the tumor and adjuvant chemotherapy. However, some hepatoblastomas develop resistance to chemotherapy during the initial neoadjuvant chemotherapy or after tumor recurrence, and the molecular determinants of cisplatin resistance are yet to be discovered. In contrast to hepatoblastomas, pediatric HCCs respond poorly to chemotherapy, and as in adults, they have a poor prognosis if not completely removed by surgery. There is thus an urgent need for new therapeutic strategies to overcome this resistance. Now the inventors demonstrate that Elimusertib and Cisplatin combination shows synergistic efficacy on tumor cell viability inhibition in pediatric liver cancer cell lines. The present invention thus relates to the combination of cisplatin and Elimusertib for the treatment of pediatric liver cancers. [post_date] => 2024-08-28 10:24:30 [post_modified] => 2024-09-11 15:45:18 [ID] => 6456 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4cb828f4-562d-11ef-9e3d-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO21518-T1 [keywords] => Pediatric liver cancers; combination treatment; Cisplatin + Elimusertib [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => REBOUISSOU Sandra,NAULT Jean-charles,PILET Jill,HIRSCH Théo,ZUCMAN-ROSSI Jessica,MOREL-RIBEIRO Pierre [number_application] => European Procedure (Patents) (EPA) - 21 Déc. 2021 - 21 306 870.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Liver CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 56 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Liver Cancer, Method, Oncology [taxonomieurl] => Drug, Liver Cancer, Method, Oncology ) [57] => stdClass Object ( [post] => stdClass Object ( [post_title] => New method for treating melanoma using a TNFalpha blocking agent [guid] => https://technology-offers.inserm-transfert.com/offer/new-method-for-treating-melanoma-using-a-tnfalpha-blocking-agent/ [post_content] => TNF alpha blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF alpha expression. [post_date] => 2024-08-28 10:24:26 [post_modified] => 2024-09-11 15:44:59 [ID] => 6450 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 725f8aaa-3c4a-4931-9ebe-6d07373bd823 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14057-T1 [keywords] => melanoma, TNFalpha inhibitors; MHC1 [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => COLACIOS Céline,LEVADE Thierry,ANDRIEU-ABADIE Nathalie,ROCHAIX Philippe,ROCHOTTE Julia,BENOIST Hervé,BERTRAND Florie [number_application] => European Procedure (Patents) (EPA) - 12 Mai 2014 - 14 305 687.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 57 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Method, Oncology [taxonomieurl] => Drug, Melanoma, Method, Oncology ) [58] => stdClass Object ( [post] => stdClass Object ( [post_title] => SK2 INHIBITOR FOR THE TREATMENT OF PANCREATIC CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/sk2-inhibitor-for-the-treatment-of-pancreatic-cancer/ [post_content] => Pancreatic Ductal Adenocarcinoma (PDAC) still represents a therapeutic dead-end. Theinventors report that the K+ channel SK2 is stimulated by secreted cues from cancer-associated fibroblasts (CAF) leading to the activation of an Integrin-EGFR-AKT signaling axis whichparticipates to the acquisition of pro-metastatic features. The inventors show that SK2 acts as a pivotal signaling regulator as being both a direct target of AKT and an amplifier of AKT downstream transduction. The present invention relates to a method of treatment of pancreaticcancer in a patient in need thereof comprising a therapeutically effective amount of SK2inhibitor. [post_date] => 2024-08-28 10:24:24 [post_modified] => 2024-09-11 15:44:58 [ID] => 6448 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d9759138-5596-11ef-9961-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO21393-T1 [keywords] => [pub_scient_inv_dispo] => Rapetti-Mauss R, Nigri J, Berenguier C, Finetti P, Tubiana SS, Labrum B, Allegrini B, Pellissier B, Efthymiou G, Hussain Z, Bousquet C, Dusetti N, Bertucci F, Guizouarn H, Melnyk P, Borgese F, Tomasini R, Soriani O. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer. Gut. 2023 Apr;72(4):722-735. doi: 10.1136/gutjnl-2021-326610. Epub 2022 Sep 1. PMID: 36882214. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => SORIANI Olivier,RAPETTI-MAUSS Raphaël,BORGESE Mauro Franck,TOMASINI Richard [number_application] => European Procedure (Patents) (EPA) - 10 Août 2022 - 22 306 211.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Pancreatic CancerTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 58 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Oncology, Pancreatic Cancer, Target, Target, Validation in vivo [taxonomieurl] => Drug, Oncology, Pancreatic Cancer, Target, Target, Validation in vivo ) [59] => stdClass Object ( [post] => stdClass Object ( [post_title] => SIGMAR1 LIGAND FOR THE TREATMENT OF PANCREATIC CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/sigmar1-ligand-for-the-treatment-of-pancreatic-cancer/ [post_content] => Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cellsand evaluated Sig-1R implication in stromal cues integration by PCC from signalingtransmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartmentsThe present invention relates to method for the treatment of pancreatic cancer in apatient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand [post_date] => 2024-08-28 10:24:24 [post_modified] => 2024-09-11 15:44:58 [ID] => 6447 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7cdc5c9a-5596-11ef-b6a8-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO21102-T1 [keywords] => [pub_scient_inv_dispo] => Potier-Cartereau M, Raoul W, Weber G, Mahéo K, Rapetti-Mauss R, Gueguinou M, Buscaglia P, Goupille C, Le Goux N, Abdoul-Azize S, Lecomte T, Fromont G, Chantome A, Mignen O, Soriani O, Vandier C. Potassium and Calcium Channel Complexes as Novel Targets for Cancer Research. Rev Physiol Biochem Pharmacol. 2022;183:157-176. doi: 10.1007/112_2020_24. PMID: 32767122. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => SORIANI Olivier,BORGESE Mauro Franck,RAPETTI-MAUSS Raphaël,TOMASINI Richard,MELNYK Patricia [number_application] => European Procedure (Patents) (EPA) - 10 Août 2022 - 22 306 212.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Pancreatic CancerTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 59 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Oncology, Pancreatic Cancer, Target [taxonomieurl] => Drug, Oncology, Pancreatic Cancer, Target ) [60] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING MELANOMA [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-melanoma-4/ [post_content] => Inventors have shown that targeting DDR1 and DDR2 collagen receptors by Imatinib resensitizes melanoma tumors to BRAFV600E to targeted therapy and normalizes the fibrotic stromal reaction. These findings provide the rationale to combine Imatinib (or other DDR inhibitors) and MAPK-targeting agents to disrupt the influence of the matrix microenvironment in order to delay or prevent the emergence of therapy-resistant cells. They have shown that inhibition of DDR1 and DDR2 kinase activities by Imatinib suppressed the protection of melanoma cells against Vemurafenib (BRAFi) and Trametinib (MEKi) co-drugging and led to cell cycle arrest and cell death. Similar biochemical cell cycle and apoptotic events were promoted in presence of Nilotinib. They validated this anti-tumor activity of Imatinib combined with Vemurafenib in a pre-clinical xenograft model of melanoma. Accordingly, the present invention relates to a method for treating melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of : i) an inhibitor of BRAF, ii) an inhibitor of MEK, and iii) an inhibitor of DDR1/2. [post_date] => 2024-08-28 10:24:23 [post_modified] => 2024-09-11 15:44:57 [ID] => 6446 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4a2b2be8-a311-c19b-de78-5b8015a9e476 [etat_fiche_online] => en_ligne [date_application] => 20-06-2018 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18220-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => TARTARE-DECKERT Sophie,BERESTJUK Ilona,DECKERT Marcel [number_application] => European Procedure (Patents) (EPA) - 20 Juin 2018 - 18 305 776.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 60 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Method, Oncology, Target, Validation in vivo [taxonomieurl] => Drug, Melanoma, Method, Oncology, Target, Validation in vivo ) [61] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING LUNG CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-lung-cancer/ [post_content] => Cholesterol efflux pathways have anti-inflammatory and anti-proliferative properties that could be exploited in tumor biology to unravel cancer vulnerabilities. Using a mouse model of lung tumor bearing KRASG12D mutation, the inventors identified that disruption of cholesterol efflux pathways by specific inactivation of Abca1 and Abcg1 in epithelial cancer progenitor cells and to some extent in macrophages promoted a pro-tolerogenic tumor microenvironment (TME). In particular, the inventors show that cholesterol removal therapy with cyclodextrin inhalation also reduced tumor burden in progressing tumor by suppressing the proliferation and expansion of epithelial progenitor cells of tumor-origin. The inventors’ results position cholesterol removal therapy as a putative metabolic target in lung cancer progenitor cells. The presentinvention relates to a method for the treatment of a lung cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of cyclodextrin. [post_date] => 2024-08-28 10:24:21 [post_modified] => 2024-09-11 15:44:56 [ID] => 6442 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fcbe6420-5592-11ef-ba8d-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO21062-T1 [keywords] => [pub_scient_inv_dispo] => Guilbaud E, Barouillet T, Ilie M, Borowczyk C, Ivanov S, Sarrazy V, Vaillant N, Ayrault M, Castiglione A, Rignol G, Brest P, Bazioti V, Zaitsev K, Lebrigand K, Dussaud S, Magnone V, Bertolotto C, Marchetti S, Irondelle M, Goldberg I, Huby T, Westerterp M, Gautier EL, Mari B, Barbry P, Hofman P, Yvan-Charvet L. Cholesterol efflux pathways hinder KRAS-driven lung tumor progenitor cell expansion. Cell Stem Cell. 2023 Jun 1;30(6):800-817.e9. doi: 10.1016/j.stem.2023.05.005. PMID: 37267915. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => YVAN-CHARVET Laurent,ILIE Marius,HOFMAN Paul [number_application] => European Procedure (Patents) (EPA) - 31 Mai 2023 - 23 305 858.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Lung cancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 61 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Lung cancer, Method, Oncology [taxonomieurl] => Drug, Lung cancer, Method, Oncology ) [62] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE TREATMENT OF ANAPLASTIC LARGE CELL LYMPHOMA [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-treatment-of-anaplastic-large-cell-lymphoma/ [post_content] => Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphomaaffects lymph nodes and extra-nodal sites with characteristic skin lesions. Approximatively half of the tumors express the NPM1-ALK fusion from the translocation t(2;5)(p23;q32). In the present study, the inventors identify ROR2 as progressively up regulated thoughttumorigenesis. Patient samples show a significantly high ROR2 expression (transcriptomicdata) as well as a strong ROR2 protein expression (IHC) with some tumors displaying a clearmembrane signal. ROR2 mRNA expression level is also positively correlated to NPM-ALKexpression level in tumor cells and is not expressed in normal T cells. In addition, ROR2 protein level is significantly increased in resistant cells to the ALK inhibitor, crizotinib, used in clinical trials for children with refractory tumors. This result opens the road to ROR2 specific therapies: ROR2 inhibitors, monoclonal antibodies therapies or even ROR2 specific CAR cells, including for ALCL ALK(+) resistant tumors. [post_date] => 2024-08-28 10:24:18 [post_modified] => 2024-09-11 15:44:55 [ID] => 6440 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6b8762ad-8372-b99a-70e0-6446728779b8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21072-T1 [keywords] => [pub_scient_inv_dispo] => Babin L, Darchen A, Robert E, Aid Z, Borry R, Soudais C, Piganeau M, De Cian A, Giovannangeli C, Bawa O, Rigaud C, Scoazec JY, Couronné L, Veleanu L, Cieslak A, Asnafi V, Sibon D, Lamant L, Meggetto F, Mercher T, Brunet E. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells. Mol Cancer. 2022 Mar 4;21(1):65. doi: 10.1186/s12943-022-01520-0. PMID: 35246138; PMCID: PMC8895835. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BRUNET Erika,LAMANT Laurence,MERCHER Thomas,MEGGETTO-PRADELLE Fabienne,BABIN Loélia,DARCHEN Alice,ROBERT Elie [number_application] => European Procedure (Patents) (EPA) - 09 Avr. 2021 - 21 305 467.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LymphomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 62 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Lymphoma, Method, Oncology [taxonomieurl] => Drug, Lymphoma, Method, Oncology ) [63] => stdClass Object ( [post] => stdClass Object ( [post_title] => CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY [guid] => https://technology-offers.inserm-transfert.com/offer/chimeric-proteins-and-methods-of-immunotherapy/ [post_content] => Chimeric proteins for cancer immunotherapy can combine different activities bydisplaying both agonistic and antagonistic properties on a single molecule. However, those usually exhibit toxicities related to their potency being exerted in the entire organism and notonly in tissues relevant for cancer treatment. This may be solved by using appropriatevectorization of the chimeric proteins to the tumour microenvironment, where immune cells interact with tumour cells expressing immunomodulatory molecules.The present invention relates to a nucleic acid encoding a chimeric protein or a chimericprotein having a general structure of: N terminus - (a) - (b) - (c) - C terminus, wherein: (a) is a signaling and/or targeting domain, (b) is a linker (b) is a functional linker and (c) is a signaling and/or targeting domain or N terminus - (c) - (b) - (a) - C terminus, wherein: (c) is a signaling and/or targeting domain, (b) is a linker (b) is a functional linker and (a) is a signaling and/or targeting domain. [post_date] => 2024-08-27 11:33:07 [post_modified] => 2024-09-11 15:44:54 [ID] => 6433 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 96960cc6-5564-11ef-b222-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO18386-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => BOISGERAULT Nicolas,PETITHOMME Tacien [number_application] => European Procedure (Patents) (EPA) - 30 Juil. 2021 - 21306069.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 63 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Hit - validation in vitro, Oncology, Product, Protein, Recombinant protein [taxonomieurl] => Biologic, Drug, Hit - validation in vitro, Oncology, Product, Protein, Recombinant protein ) [64] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING MELANOMA [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=6429 [post_content] => Metastatic uveal melanomas are highly resistant to all existing treatments. Here, a kinome-wide CRISPR-Cas9 knockout screen, revealed that the LKB1-SIK2 module plays a critical role in constraining uveal melanoma cell tumorigenesis. The inventors’ results demonstrate that a combination of SLC8A1 inhibitor and mitochondria-targeted antioxidant has an enhanced cell death efficacy in LKB1 and SIK2-negative uveal melanoma cells. They also designed a LKB1 loss gene signature that is predictive of patient survival and treatment response. Their data thus identify new prognosis markers, and metabolic vulnerability, thereby providing a therapeuticstrategy for these subtypes of metastatic uveal melanomas.The present invention relates to a method for treating melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a combination of SLC8A1 inhibitor and mitochondria-targeted antioxidant. [post_date] => 2024-08-27 11:33:04 [post_modified] => 2024-09-11 15:44:52 [ID] => 6429 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a64882f2-555f-11ef-a73f-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO23060-T1 [keywords] => [pub_scient_inv_dispo] => Proteau S, Krossa I, Husser C, Guéguinou M, Sella F, Bille K, Irondelle M, Dalmasso M, Barouillet T, Cheli Y, Pisibon C, Arrighi N, Nahon-Estève S, Martel A, Gastaud L, Lassalle S, Mignen O, Brest P, Mazure NM, Bost F, Baillif S, Landreville S, Turcotte S, Hasson D, Carcamo S, Vandier C, Bernstein E, Yvan-Charvet L, Levesque MP, Ballotti R, Bertolotto C, Strub T. LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition. EMBO Mol Med. 2023 Dec 7;15(12):e17719. doi: 10.15252/emmm.202317719. Epub 2023 Nov 15. PMID: 37966164; PMCID: PMC10701601. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => BERTOLOTTO Corine [number_application] => European Procedure (Patents) (EPA) - 26 Mai 2023 - 23 305 842.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 64 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Method, Oncology [taxonomieurl] => Drug, Melanoma, Method, Oncology ) [65] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR TREATING NOTCH1-DRIVEN CANCERS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-treating-notch1-driven-cancers/ [post_content] => T-cell acute lymphoblastic leukemias (T-ALL) are aggressive hematological malignancies associated with poor clinical outcome. TP53 alterations (TP53Alt) were rarely identified in TALL at diagnosis and their prognostic impact remains unclear. In a cohort of 476 adults and pediatric T-ALL, TP53Alt were observed in 4% of cases and were associated with chemoresistance and poor prognosis. APR-246, a small compound which restores wild-type configuration to mutated p53, showed efficacy in T-ALL harboring TP53 mutations. More importantly, in TP53 germline T-ALL, Notch1 pathway gain of function mutations were associated with substantial sensitivity to APR-246. Mechanistically, Notch1 activation via p53 downregulation and subsequent ferroptosis induction led to preferential APR-246 sensitivity.Given that Notch1 pathway oncogenic activation is present in more than 70% of T-ALLs, these observations pave the way for promising perspectives in T-ALL treatment which could benefit from the Achilles heel associated with Notch1 activation sensitizing leukemia cells to APR-246-induced ferroptosis, thus extending the use of APR-246 in T-ALL beyond TP53 alterations. [post_date] => 2024-08-27 11:33:00 [post_modified] => 2024-09-11 15:44:50 [ID] => 6423 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 58c27485-7818-cdd7-5cfa-644665d47742 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21439-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ASNAFI Vahid,SIMONIN Mathieu,HERMINE Olivier [number_application] => International Procedure (PCT) - 26 Nov. 2021 - PCT/IB2021/000837 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 65 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Method, Oncology, Small Molecule [taxonomieurl] => Drug, Method, Oncology, Small Molecule ) [66] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-treatment-of-adult-t-cell-leukemia-lymphoma/ [post_content] => Adult T-cell leukemia/lymphoma (ATL) is an aggressive proliferation of mature activated CD4+ T cells associated with the human T-cell lymphotropic virus type I (HTLV-I). The inventors performed an integrated genomic analysis of a retrospective cohort of 62 ATL patients mainly originating from Africa and the Caribbean area. In particular, they identified a subset of mutations in the TCRF-?B pathway (PLCG1, CARD11, PRKCB, CBLB, IRF4, CSNK1A1, FYN, RHOA, VAV1). Furthermore, the inventors investigated the effects of an anti-CD3 antibody (OKT3) exposure on 4 ATL samples including 2 cases harboring CARD11 and PRKCB gain of function alterations and 2 cases without any TCR pathway mutation. The data suggest that ATL harboring TCR pathway mutations clearly responded to anti-CD3 (Fig. 1B, red + OKT3) and died by apoptosis possibly by a mechanism resembling AICD. Importantly, these TCR-pathwayFKB mutated patients also showed poorer outcome as compared to unmutated cases. Accordingly, the present invention relates to a method of treating adult T-cell leukemia/lymphoma (ATL) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-CD3 antibody. [post_date] => 2024-08-27 11:32:58 [post_modified] => 2024-09-11 15:44:50 [ID] => 6422 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => baa84702-3088-7771-2496-5f6d984dee50 [etat_fiche_online] => en_ligne [date_application] => 02-10-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19389-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ASNAFI Vahid,GHYSDAEL Jacques,HERMINE Olivier,MARÇAIS Ambroise [number_application] => European Procedure (Patents) (EPA) - 02 Oct. 2019 - 19 306 263.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LeukemiasTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 66 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Leukemias, Method, Oncology, Target [taxonomieurl] => Drug, Leukemias, Method, Oncology, Target ) [67] => stdClass Object ( [post] => stdClass Object ( [post_title] => Nanoblade technology: High efficiency delivery of CRISPRs components in primary cells by Virus Like Particles. [guid] => https://technology-offers.inserm-transfert.com/offer/nanoblade-technology-high-efficiency-delivery-of-crisprs-components-in-primary-cells-by-virus-like-particles/ [post_content] => The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid. [post_date] => 2024-08-27 11:15:14 [post_modified] => 2024-09-11 15:44:44 [ID] => 6412 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 034d3319-5469-4d03-ba17-fb9491c41785 [etat_fiche_online] => en_ligne [date_application] => 20-10-2015 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15247-T1 [keywords] => CRISPR; Cas9; Virology; Gene editing; Gene therapy [pub_scient_inv_dispo] => Efficient genome editing in primary cells and in vivo using viral-derived ’Nanoblades’ loaded with Cas9/sgRNA ribonucleoproteins https:/www.biorxiv.org/content/early/2017/10/12/202010 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => gene_editing [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 67 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gene editing, Hit - validation in vitro, Oncology, Others, Product, Product [taxonomieurl] => Drug, Gene editing, Hit - validation in vitro, Oncology, Others, Product, Product ) [68] => stdClass Object ( [post] => stdClass Object ( [post_title] => Exon skipping therapy of Erythropoietic Protoporphyria [guid] => https://technology-offers.inserm-transfert.com/offer/exon-skipping-therapy-of-erythropoietic-protoporphyria/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucletotide (ASO) comprising the sequence 5’ gcagcctgagaaatgtttt 3’ to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA. [post_date] => 2024-08-27 11:14:04 [post_modified] => 2024-09-11 15:40:34 [ID] => 6411 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8c75fd78-97b2-40f1-b673-6aeda1fd4c41 [etat_fiche_online] => en_ligne [date_application] => 13-06-2013 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO12380-T1 [keywords] => Exon Skipping; Erythropoietic Protoporphyria; Orphan Drug Disease, Ferrochelatase [pub_scient_inv_dispo] => Am J Hum Genet. 2014 Apr 3;94(4):611-7. doi: 10.1016/j.ajhg.2014.02.010. Epub 2014 Mar 27. [access_to_detailed_offer] => /wp-content/uploads/BIO12380-T1_GOUYA.pdf [rare_disease] => true [second_indication] => false [inventors] => DEYBACH Jean-charles,OUSTRIC Vincent,PUY Hervé [number_application] => European Procedure (Patents) (EPA) - 13 Juin 2013 - 13 305 796.8 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Genetic DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 68 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antisense Oligonucleotide, Drug, Gene therapy, Genetic Disorders, Hit - validation in vitro, Oligonucleotide, Product, Product [taxonomieurl] => Antisense Oligonucleotide, Drug, Gene therapy, Genetic Disorders, Hit - validation in vitro, Oligonucleotide, Product, Product ) [69] => stdClass Object ( [post] => stdClass Object ( [post_title] => NOVEL MELANOMA ANTIGEN PEPTIDE AND USES THEREOF [guid] => https://technology-offers.inserm-transfert.com/offer/novel-melanoma-antigen-peptide-and-uses-thereof/ [post_content] => The invention relates to peptides derived from the MELOE antigen for therapeutic vaccination against cancer. A phase I clinical trial for ex-vivo therapy of melonama is ongoing. [post_date] => 2024-08-27 11:14:04 [post_modified] => 2024-09-11 15:40:31 [ID] => 6410 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 10e34f65-25b2-44b6-9ada-6b8aa6a00e56 [etat_fiche_online] => en_ligne [date_application] => 22-05-2012 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO12113-T1 [keywords] => MELOE, antigen, cancer, melanoma, TIL, vaccination [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ROGEL Anne,LANG François,BOBINET Mathilde [number_application] => International Procedure (PCT) - 22 Mai 2012 - PCT/IB2012/001310 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 69 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cell therapy, Clinical Trial, Drug, Melanoma, Oncology, Phase 1, Product [taxonomieurl] => Biologic, Cell therapy, Clinical Trial, Drug, Melanoma, Oncology, Phase 1, Product ) [70] => stdClass Object ( [post] => stdClass Object ( [post_title] => Hydrophobically modified Antisense Oligonucleotides comprising a cetal group or a triple alkyl chain to improve intracellular delivery and efficacy of antisense oligonucleiotide [guid] => https://technology-offers.inserm-transfert.com/offer/hydrophobically-modified-antisense-oligonucleotides-comprising-a-cetal-group-or-a-triple-alkyl-chain-to-improve-intracellular-delivery-and-efficacy-of-antisense-oligonucleiotide/ [post_content] => The present invention concerns an oligonucleotide modified by substitution at the 3’ or the 5’ end by at least triple alkyl chain or at least one ketal functional group, wherein the ketal carbon bears two hydrocarbon chains. The invention also concerns the use of the hydrophobically modified oligonucleotides as a medicament, in particular for use for treating cancer. The autors show lipid conjugate Antisense Oligonucleotide (L-ASO) are capable of inhibiting prostate cancer in vivo and have no toxicity in mice (Karaki S et al. 2017 J Control Release, 258:1-9). The addition of a lipid chain on the 5’ part of the antisense oligonucleotide enables inhibiting specifically u201cUD proteinu201d, even in the absence of the transfection agent. The lipid modification strongly enhances the ability of ASO to reduce u201cUD proteinu201d expression leading to a strong reduction of tumor progression in a murin xenograft model of Castration Resistant prostate cancer. The L-ASO have been validated in others therapeutic indications. These modifications allow advantages over standard ASO: 1/ Delivery enhancement, Stability, biodisponibility; 2/ Internalisation without any transfection agents; 3/ Encapsulation of different molecules like chemotherapies (L-ASOs self-assembly give sphericals nanoparticles, which are prone to host drug molecules within their hydrophobic cores: for instance Paclitaxel). [post_date] => 2024-08-27 11:14:03 [post_modified] => 2024-09-11 15:40:29 [ID] => 6409 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9feb2cd5-4695-4988-8688-b1305f763336 [etat_fiche_online] => en_ligne [date_application] => 05-06-2013 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => CHIM13035-T1 [keywords] => Nucleic acids, Antisense, Oligonuceotides; Encapsulation; Nanoparticles. [pub_scient_inv_dispo] => J Control Release. 2017 Jul 28;258:1-9. doi: 10.1016/j.jconrel.2017.04.042. Epub 2017 May 1.Bioconjug Chem. 2013 Aug 21;24(8):1345-55.Chem Soc Rev. 2011 Dec;40(12):5844-54. doi: 10.1039/c1cs15038c. Epub 2011 May 24. [access_to_detailed_offer] => /wp-content/uploads/CHIM13035-T1_BARTHELEMY.pdf [rare_disease] => false [second_indication] => false [inventors] => ACUNZO Julie,OUMZIL Khalid,GISSOT Arnaud,ROCCHI Palma [number_application] => International Procedure (PCT) - 05 Juin 2013 - PCT/IB2013/001516 [technology_engineering] => drug_delivery [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Prostate CancerTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 70 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antisense Oligonucleotide, Drug, Drug delivery, Hit - validation in vivo, Oligonucleotide, Oncology, Product, Product, Prostate Cancer [taxonomieurl] => Antisense Oligonucleotide, Drug, Drug delivery, Hit - validation in vivo, Oligonucleotide, Oncology, Product, Product, Prostate Cancer ) [71] => stdClass Object ( [post] => stdClass Object ( [post_title] => Novel target and mAb candidates for the treatment of HCMV infection [guid] => https://technology-offers.inserm-transfert.com/offer/novel-target-and-mab-candidates-for-the-treatment-of-hcmv-infection/ [post_content] => The present invention relates to a method for treating an infection, particularly HCMV infection. To date, there are very few reports on the role of DC-SIGN+ dendritic cells in very early phases of viral infections. By using four anti-human DC-SIGN monoclonal antibodies, the inventors have demonstrated that DC-SIGN might be considered as the most important receptor for both pre- and post-fusion HCMV gB on monocyte-derived dendritic cells (MDDCs). In particular, the invention relates to a method for treating an infection in a subject in need thereof comprising a step of administering to said subject an agent that blocks the interaction between DC-SIGN and an infectious ligand. [post_date] => 2024-08-27 11:14:02 [post_modified] => 2024-09-11 15:40:20 [ID] => 6408 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a4c4fde4-5d4b-4ed4-a90e-76b7676c4c5d [etat_fiche_online] => en_ligne [date_application] => 23-01-2017 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO16304-T1 [keywords] => Infectious Diseases, Antivirals, HCMV, DC-SIGN [pub_scient_inv_dispo] => Org Biomol Chem. 2017 Sep 20;15(36):7660-7671. doi: 10.1039/c7ob01569k. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HALARY Franck,PIN Jean-Jacques,RAZANAJAONA-DOLL Diane [number_application] => European Procedure (Patents) (EPA) - 23 Janv. 2017 - 17305064.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Infectious DiseasesTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 71 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Drug, Infectious Diseases, Lead - validation in vivo, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Drug, Infectious Diseases, Lead - validation in vivo, Product, Product, Protein ) [72] => stdClass Object ( [post] => stdClass Object ( [post_title] => Improved vector for driving the targeted integration of a transgene into an eukaryotic genome. [guid] => https://technology-offers.inserm-transfert.com/offer/improved-vector-for-driving-the-targeted-integration-of-a-transgene-into-an-eukaryotic-genome/ [post_content] => The present invention relates to polypeptide for engineering integrase chimeric proteins and their use in gene therapy. A key challenge for gene transfer based on the use of retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis and induction of the DNA damage response due to the presence of double stranded DNA. One approach to avoid insertional mutagenesis is to target the transgene integration to a specific location on the genome.Here autors describe an interaction between Ty1 integrase and the AC40 subunit of Pol III and demonstrate that AC40 is the predominant determinant targeting Ty1 integration upstream of Pol IIIu2013transcribed genes. Lack of an integrase-AC40 interaction dramatically alters target site choice, leading to a redistribution of Ty1 insertions in the genome, mainly to chromosome ends. The mechanism of target specificity allows Ty1 to proliferate and yet minimizes genetic damage to its host. Accordingly, the domain of Ty1 responsible for the interaction with the RNA polymerase III is suitable to engineering integrase of retrovirus so as to drive the targeted integration of a transgene into a eukaryotic genome. [post_date] => 2024-08-27 11:14:01 [post_modified] => 2024-09-11 15:42:48 [ID] => 6407 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cc69e496-7878-4ba2-8f9f-a0c91cc90782 [etat_fiche_online] => en_ligne [date_application] => 13-02-2015 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15039-T1 [keywords] => polypeptide, retroviral vector, integrase, Ty1, AC40, retrotransposon, insertional mutagenesis [pub_scient_inv_dispo] => Science. 2015 May 1;348(6234):585-8. doi: 10.1126/science.1259114. [access_to_detailed_offer] => /wp-content/uploads/BIO15039-T1_LESAGE.pdf [rare_disease] => false [second_indication] => false [inventors] => BRIDIER-NAHMIAS Antoine,WERNER Michel [number_application] => European Procedure (Patents) (EPA) - 13 Févr. 2015 - 15305217.0 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OthersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 72 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Gene therapy, Gene Therapy, Hit - validation in vitro, Others, Product, Product [taxonomieurl] => Biologic, Drug, Gene therapy, Gene Therapy, Hit - validation in vitro, Others, Product, Product ) [73] => stdClass Object ( [post] => stdClass Object ( [post_title] => Nanoparticle based glue, Biocompatible sealant for surgery [guid] => https://technology-offers.inserm-transfert.com/offer/nanoparticle-based-glue-biocompatible-sealant-for-surgery/ [post_content] => The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.Inventors demonstrated that rapid and strong adhesion by aqueous solutions of nanoparticles can be advantageously used in very different clinical situations. For skin wounds a remarkable aesthetic healing was obtained and repair procedure does not require any specific preparation or training. Bleeding control and tissue repair by nanobridging shown here in the case of liver could be used on spleen, kidney, heart, and lungs surgeries. When tight sealing is needed nanobridging could complement anastomosis and classical suturing protocols. The possibility of securing medical devices could open new applications in repair and regenerative medicine. From chemistry standpoint, the principle illustrated here has used silica and iron oxide nanoparticles but not limited to these nanoparticle and they are many possible choices of sizes, forms and surface chemistries. In particular, nanoparticles with intrinsic biological effects such as silver nanoparticles for skin infection or drug delivery systems could provide useful options. Translation to clinical practice will require careful safety and toxicity investigations. A better understanding of biological mechanisms of the adhesion by nanobridging will guide the design of future-generation tissue adhesives. [post_date] => 2024-08-27 11:14:01 [post_modified] => 2024-09-11 15:42:46 [ID] => 6406 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ba60b42f-e0a1-47ae-a364-a5bfeaf754c2 [etat_fiche_online] => en_ligne [date_application] => 17-02-2014 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13377-T1 [keywords] => Nanoparticles; Biomaterials; Regenerative medecine; skin wounds; tissue repair; Bleeding control; tight sealing; liver surgeries; spleen surgeries, kidney surgeries, heart surgeries, lungs surgeries [pub_scient_inv_dispo] => Angew Chem Int Ed Engl. 2014 Jun 16;53(25):6369-73. doi: 10.1002/anie.201401043. Epub 2014 Apr 16. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MARCELLAN Alba,LEIBLER Ludwik,PELLE Anne [number_application] => European Procedure (Patents) (EPA) - 10 Déc. 2013 - 13 306 692.8 [technology_engineering] => biomaterials [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OthersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 73 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biomaterials, Drug, Hit - validation in vivo, Others, Polymer, Product, Product [taxonomieurl] => Biomaterials, Drug, Hit - validation in vivo, Others, Polymer, Product, Product ) [74] => stdClass Object ( [post] => stdClass Object ( [post_title] => Ex vivo gene therapy based vaccine with nucleic acid molecule encoding for CD70 for the treatment of B-cell malignancies [guid] => https://technology-offers.inserm-transfert.com/offer/ex-vivo-gene-therapy-based-vaccine-with-nucleic-acid-molecule-encoding-for-cd70-for-the-treatment-of-b-cell-malignancies/ [post_content] => The present invention relates to a method of treating a B-cell malignancy in a subject using a vaccine composition comprising a population of malignant B cells from said subject transformed with a nucleic acid molecule encoding for a CD70 polypeptide.Epstein-Barr virus (EBV) infection in humans is a major trigger of malignant and non-malignant B cell proliferations. The inventors showed that EBV-specific T lymphocytes cannot expand properly when stimulated with CD70-deficient EBV-infected cells, while expression of CD70 restores expansion. In particular, the present invention relates to a method of treating a B-cell malignancy in a subject in need thereof comprising i) providing a sample of malignant B cells obtained from the subject ii) isolating and culturing a population of malignant B cells from the sample of step i), iii) introducing in the population malignant B cells of step ii) a nucleic acid molecule encoding for a CD70 polypeptide and iv) administering to the subject a therapeutically effective amount of the population of malignant B cells of step iii). [post_date] => 2024-08-27 11:14:00 [post_modified] => 2024-09-11 15:42:42 [ID] => 6405 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 08e6392d-deda-4368-8bc4-2babf166ab1e [etat_fiche_online] => en_ligne [date_application] => 22-04-2016 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO16135-T1 [keywords] => B-malignancies, CD70, CD27, cell therapy ,B leukemia, lymphoma, Epstein-Barr virus, Vaccine, ex vivo gene therapy [pub_scient_inv_dispo] => J Exp Med. 2017 Jan;214(1):73-89. doi: 10.1084/jem.20160784. Epub 2016 Dec 23. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => FISCHER Alain,IZAWA Kazushi,MARTIN (INSERM) Emmanuel [number_application] => European Procedure (Patents) (EPA) - 22 Avr. 2016 - 16 305 471.1 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LymphomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 74 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Burkitt Lymphoma, Drug, Gene therapy, Lymphoma, Method, Oligonucleotide, Oncology, Target, Validation in vitro [taxonomieurl] => Burkitt Lymphoma, Drug, Gene therapy, Lymphoma, Method, Oligonucleotide, Oncology, Target, Validation in vitro ) [75] => stdClass Object ( [post] => stdClass Object ( [post_title] => CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair [guid] => https://technology-offers.inserm-transfert.com/offer/ctip-fusion-to-cas9-enhances-transgene-integration-by-homology-dependent-repair-2/ [post_content] => The present invention relates to nuclease protein fusions for enhancing genome editing by homology-directed transgene integration (HDI).The inventors found that the rate of HDI mediated by the CRISPR-Cas9 system may be substantially improved by providing the Cas9 nuclease in the form of a fusion protein with at least the N-terminal domain of the CtIP protein. CtIP proteins are involved in the early steps of homologous recombination. In addition, the inventors identified the subdomains of the N-terminal domain of the CtIP protein that are important for improving the HDI rate.Thus, the invention relates to fusion proteins comprising a Cas9 protein, a tetramerization domain of a CtIP protein and a dimerization domain of a CtIP protein. Particularly, the inventors have tested these fusion proteins HEK293 cells, RG37DR cells and Sprague-Dawley rats. [post_date] => 2024-08-27 11:13:59 [post_modified] => 2024-09-11 15:42:38 [ID] => 6404 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 74038319-c062-4172-871e-71068b58c043 [etat_fiche_online] => en_ligne [date_application] => 09-03-2018 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO16366-T1 [keywords] => Genome editing, homologuous recombinant integration [pub_scient_inv_dispo] => Nat Commun. 2018 Mar 19;9(1):1133. doi: 10.1038/s41467-018-03475-7. [access_to_detailed_offer] => /wp-content/uploads/BIO16366-T1_CONCORDET.pdf [rare_disease] => false [second_indication] => false [inventors] => CONCORDET Jean-Paul,ANEGON Ignacio,LOPEZ Bernard,GIOVANNANGELI Carine,CHARPENTIER Marine [number_application] => European Procedure (Patents) (EPA) - 10 Mars 2017 - 17 305 260.6 [technology_engineering] => gene_editing [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OthersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 75 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gene editing, Lead - validation in vitro, Oligonucleotide, Others, Product, Product [taxonomieurl] => Drug, Gene editing, Lead - validation in vitro, Oligonucleotide, Others, Product, Product ) [76] => stdClass Object ( [post] => stdClass Object ( [post_title] => MitoCeption: novel method for the intracellular transfer of isolated mitochondria in recipient cells [guid] => https://technology-offers.inserm-transfert.com/offer/mitoception-novel-method-for-the-intracellular-transfer-of-isolated-mitochondria-in-recipient-cells/ [post_content] => The present invention relates to a method for the intercellular transfer of an amount of mitochondria isolated from a population of donor cells into a population of recipient cells.Mitochondria activity is central to cell and tissue homeostasis. Mitochondrial dysfunction and the energy metabolism reprogramming it induces are the hallmarks of many genetic diseases. They also play a key role in tumor progression and resistance to therapy. These essential roles of mitochondria, added to their recently documented cell-cell transfer capacity, explain the current burst of interest they trigger. Here a methodology (MitoCeption) that allows the quantitative transfer of mitochondria, isolated from cell type A, to cell type B is described. Autors validated and quantified the effective mitochondria transfer on different cell types, by confocal imaging and flow cytometry. [post_date] => 2024-08-27 11:13:52 [post_modified] => 2024-09-11 15:41:53 [ID] => 6403 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2daa9dcb-41b6-4c97-83c9-faa8417b4241 [etat_fiche_online] => en_ligne [date_application] => 16-07-2014 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO12385-T1 [keywords] => Mesenchymal Steml Cell, Mesenchymal Stroma Cell, mitochondria transfers, tumor, intercellular, MitoCeption [pub_scient_inv_dispo] => Sci Rep. 2015 Mar 13;5:9073. doi: 10.1038/srep09073.J Vis Exp. 2017 Feb 22;(120). doi: 10.3791/55245. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => cell_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 76 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cell therapy, Cell therapy, Drug, Method, Oncology [taxonomieurl] => Biologic, Cell therapy, Cell therapy, Drug, Method, Oncology ) [77] => stdClass Object ( [post] => stdClass Object ( [post_title] => CDC25A phosphatase inhibitor for use in thetreatment of a drug resistant cancer and/or in the prevention of tumor relapse [guid] => https://technology-offers.inserm-transfert.com/offer/cdc25a-phosphatase-inhibitor-for-use-in-thetreatment-of-a-drug-resistant-cancer-and-or-in-the-prevention-of-tumor-relapse/ [post_content] => The invention relates to a CDC25A phosphatase inhibitor for use in the treatment of drug resistant cancer or for use in the prevention of tumor relapse in a patient suffering or having suffered from cancer.In a preferred embodiment, the drug resistant cancer according to the invention is associated with a mutated FLT3-ITD such as Acute Myeloid Leukemia (AML).Autors demonstrate that inhibiting CDC25A reduces proliferation and induces monocytic differentiation of FLT3-ITD-positive AML cells in vitro and in vivo, and they argue for a central function of this phosphatase in the hematopoieticdifferentiation arrest of these cells. [post_date] => 2024-08-27 11:13:46 [post_modified] => 2024-09-11 15:41:39 [ID] => 6402 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 65442075-db31-4991-a3e0-f273f1332f95 [etat_fiche_online] => en_ligne [date_application] => 24-09-2014 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14117-T1 [keywords] => CDC25A phosphatase inhibitor, AML, FLT3-ITD, antisense oligonucleotide [pub_scient_inv_dispo] => Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BERTOLI Sarah [number_application] => European Procedure (Patents) (EPA) - 26 Sept. 2014 - 14 306 492.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LeukemiasTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 77 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Acute Myelocytic Leukemia (AML), Drug, Leukemias, Oncology, Target, Target, Validation in vivo [taxonomieurl] => Acute Myelocytic Leukemia (AML), Drug, Leukemias, Oncology, Target, Target, Validation in vivo ) [78] => stdClass Object ( [post] => stdClass Object ( [post_title] => Pharmacologically Active Microcarriers for efficient integration of transplanted cells in the host tissue [guid] => https://technology-offers.inserm-transfert.com/offer/pharmacologically-active-microcarriers-for-efficient-integration-of-transplanted-cells-in-the-host-tissue/ [post_content] => This invention results from Pharmacologically Active Microcarriers (PAM) which are based on a biocompatible and biodegradable material. These particles made with poly(D,L-lactic-coglycolic acid) (PLGA) and coated with adhesion molecules may serve as a support for cell culture and may be used as cell carriers presenting a controlled delivery of active protein. They can thus support the survival and differentiation of the transported cells as well as their microenvironment and allow efficient integration of transplanted cells in the host tissue.The autors have demonstrated the therapeutic potential of PAM in various clinical applications (parkinson disease, cartilage repair, ischaemic stroke, regeneration of post-ischemic tissues,...).Exclusive license available outside cell therapy for animal osteoarticular and pulmonary diseases. [post_date] => 2024-08-27 11:13:45 [post_modified] => 2024-09-11 15:41:37 [ID] => 6401 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 742e47ee-1016-47e8-8279-2c327533fe25 [etat_fiche_online] => en_ligne [date_application] => 03-05-2002 [date] => [bd_referent] => Elodie ACLOQUE [bd_referent_id] => [contact_email] => Elodie.ACLOQUE@inserm-transfert.fr [contact_phone] => [reference_online] => GBM01306-T1 [keywords] => cartilage repair, ischaemic stroke, regeneration of post-ischemic tissues, microparticle, Biomaterial, cell therapy, Regenerative medecine, cell delivery, Polymer [pub_scient_inv_dispo] => - Technology: Biomaterials. 2005 Jun;26(17):3727-37.Eur J Pharm Biopharm. 2008 Sep;70(1):127-36. doi: 10.1016/j.ejpb.2008.03.006. Epub 2008 Mar 16.Eur J Pharm Sci. 2012 Jan 23;45(1-2):128-37. doi: 10.1016/j.ejps.2011.10.030. Epub 2011 Nov 9.- Cartilage repair:Biomaterials. 2010 Sep;31(25):6485-93. doi: 10.1016/j.biomaterials.2010.05.013. Epub 2010 Jun 8.J Control Release. 2013 Aug 28;170(1):99-110. doi: 10.1016/j.jconrel.2013.04.017. Epub 2013 May 3.- Parkinson disease: Cell Transplant. 2004;13(5):573-83.Biomaterials. 2007 Apr;28(11):1978-88. Epub 2007 Jan 4.Bone. 2007 Feb;40(2):360-73. Epub 2006 Nov 3.Biomaterials. 2011 Feb;32(6):1560-73. doi: 10.1016/j.biomaterials.2010.10.041. Epub 2010 Nov 12.Stem Cells Transl Med. 2015 Jun;4(6):670-84. doi: 10.5966/sctm.2014-0139. Epub 2015 Apr 29.- Ischaemic stroke: J Neurochem. 2011 Dec;119(5):972-88. doi: 10.1111/j.1471-4159.2011.07272.x. Epub 2011 May 13.Acta Biomater. 2015 Mar;15:77-88. doi: 10.1016/j.actbio.2014.12.017. Epub 2014 Dec 31.- Regeneration of post-ischemic tissues:Eur J Pharm Biopharm. 2012 Aug;81(3):609-16. doi: 10.1016/j.ejpb.2012.04.014. Epub 2012 Apr 26.J Cell Mol Med. 2013 Jan;17(1):192-204. doi: 10.1111/j.1582-4934.2012.01662.x. Epub 2013 Jan 11. [access_to_detailed_offer] => /wp-content/uploads/GBM01306-T1_MONTERO-MENEI.pdf [rare_disease] => false [second_indication] => false [inventors] => VENIER Marie-Claire,BENOIT Jean-Pierre,MENEI Philippe,TATARD Valérie [number_application] => France (NP) - 03 Mai 2002 - 02 05574 [technology_engineering] => biomaterials [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Parkinson's DiseaseTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 78 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Biomaterials, Cell therapy, Central Nervous System, Drug, Hit - validation in vivo, Parkinson's Disease, Product, Product, Stem cell therapy [taxonomieurl] => Biologic, Biomaterials, Cell therapy, Central Nervous System, Drug, Hit - validation in vivo, Parkinson's Disease, Product, Product, Stem cell therapy ) [79] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF DIAGNOSING ACUTE CIRCULATORY FAILURE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-diagnosing-acute-circulatory-failure/ [post_content] => Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure. [post_date] => 2024-07-08 13:19:50 [post_modified] => 2024-09-11 15:54:20 [ID] => 6377 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8b126ed0-3ab1-11ef-a77a-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 06-10-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22443-D1 [keywords] => acute circulatory failure, Blood Redox potential, Diagnosis, Prognosis, Cardiopulmoanry bypass (CBP) [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => GALINIER Anne,LABASTE François,PEY Vincent,MINVILLE Vincent,STEPHAN Marion,DRAY Cédric [number_application] => European Procedure (Patents) (EPA) - 06 Oct. 2022 - 22 306 499.9 - PCT/EP2023/077580 on 05/10/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => other [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Acute heart failureTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 79 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Acute heart failure, Biomarker, Biomarker, Cardiovascular Diseases, Devices, Human POC, In vitro diagnostic medical device, Other, Product [taxonomieurl] => Acute heart failure, Biomarker, Biomarker, Cardiovascular Diseases, Devices, Human POC, In vitro diagnostic medical device, Other, Product ) [80] => stdClass Object ( [post] => stdClass Object ( [post_title] => Use of Hedgehog inhibitors for the treatment of mastocytosis [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-hedgehog-inhibitors-for-the-treatment-of-mastocytosis/ [post_content] => The inventors demonstrate for the first time the activation of the Hedgehog (HH) signaling pathway in normal and abnormal human mast cells (MCs). These results prompt the inventors to explore the consequence of the inhibition of the HH pathway, especially the canonical pathway, on MC proliferation. They demonstrate that Hedgehog inhibitors inhibit proliferation and induces apoptosis of mast cells. Accordingly the present invention relates to a method of treating a mast cell disease in a patient in need there of comprising administering to the patient a therapeutically effective amount of a Hedgehog inhibitor. [post_date] => 2024-06-07 09:32:46 [post_modified] => 2024-09-11 15:45:04 [ID] => 6292 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 266ccf96-e6e8-504f-a28d-5f85a1eb066b [etat_fiche_online] => en_ligne [date_application] => 18-05-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17083-T1 [keywords] => mastocytosis, combination [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO17083-T1_MAOUCHE.pdf [rare_disease] => false [second_indication] => false [inventors] => MAOUCHE-CHRETIEN Leila,BODEMER Christine,HERMINE Olivier,POLIVKA Laura [number_application] => European Procedure (Patents) (EPA) - 18 Mai 2017 - 17 305 573.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 80 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Method, Oncology, Target, Validation in vivo [taxonomieurl] => Drug, Method, Oncology, Target, Validation in vivo ) [81] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS AND THETREATMENT OF GRAFT-VERSUS-HOST DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-and-thetreatment-of-graft-versus-host-disease/ [post_content] => The invention relates to methods for the prediction and the treatment of risk of acute graft versus host disease. The inventors demonstrated that an alteration of CD73-mediated regulatory function of DP8u03b1 Tregs could contribute to the acute GvHD pathophysiology. In particular, the present invention relates to method of determining whether a subject has or is at 0 a risk of developing graft-versus-host disease (GvHD) comprising the steps of: i) determining the level of CD73 expression by DP8u03b1 TREGS in a sample obtained from the subject, ii) comparing the level determined at step i) with a predetermined reference value wherein detecting differential between the level of CD73 expression by DP8u03b1 TREGS determined at step i) and the predetermined reference value is indicative of whether a subject has or is at a risk of developing graft-versus-host disease (GvHD). [post_date] => 2024-06-07 09:32:27 [post_modified] => 2024-09-19 15:00:02 [ID] => 6291 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c0566656-6833-11ee-9b5c-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO20418-T1 [keywords] => [pub_scient_inv_dispo] => Blood. 2022; Godefroy et al. CD73-Expressing Microbiota-Reactive DP8u03b1 Regulatory T Cells Are Lacking in Acute GvHD Patients and Prevent Disease Development in a Pre-Clinical In Vivo Humanized Mouse Model of GvHD [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO20418-Godefroy_T1.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => GODEFROY Emmanuelle,CHEVALLIER Patrice,ALTARE Frédéric,JOTEREAU Francine [number_application] => European Procedure (Patents) (EPA) - 04 Nov. 2020 - 20 306 320.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• TransplantationTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 81 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Graft Versus Host Disease (GVHD), Immunology, Method, Target, Transplantation [taxonomieurl] => Drug, Graft Versus Host Disease (GVHD), Immunology, Method, Target, Transplantation ) [82] => stdClass Object ( [post] => stdClass Object ( [post_title] => FC-engineered anti-human IgE antibodies and methods of use [guid] => https://technology-offers.inserm-transfert.com/offer/fc-engineered-anti-human-ige-antibodies-and-methods-of-use/ [post_content] => The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (Fcu03b3Rs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human Fcu03b3Rs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab:hIgE immune complexes can induce anaphylaxis when injected in mice expressing human Fcu03b3Rs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated. These variants did not induce anaphylaxis when injected into mice expressing human Fcu03b3Rs and could be thus used for the treatment of IgE-mediated disease. Thus invention relates to a recombinant immunoglobulin heavy chain protein which comprises at least one mutation in the Fc portion and recombinant antibody comprising said heavy chain protein. [post_date] => 2024-06-07 09:31:27 [post_modified] => 2024-09-20 14:25:02 [ID] => 6290 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b6271760-b37a-11ee-80e9-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO60360-T1 [keywords] => Inflammation - Anaphylaxis - Antibody - Side effect [pub_scient_inv_dispo] => The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcu03b3 receptors Balbino B. et al. J Clin Invest. 2020 Mar 2;130(3):1330-1335 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO60360-T1_Reber.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => REBER Laurent,BRUHNS Pierre,BALBINO Bianca [number_application] => United States Of America (PSP) - 13 Avr. 2018 - 62/657,401 [technology_engineering] => antibodies_nanobodies [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 82 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibodies nanobodies, Biologic, Drug, Immunology, Inflammation, Method, Product [taxonomieurl] => Antibodies nanobodies, Biologic, Drug, Immunology, Inflammation, Method, Product ) [83] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF ETV3 or ETV6 INHIBITORS FOR BLOCKING THE DIFFERENTIATION OF MONOCYTES INTO DENDRITIC CELLS [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-etv3-or-etv6-inhibitors-for-blocking-the-differentiation-of-monocytes-into-dendritic-cells/ [post_content] => In inflamed tissues, monocytes differentiate into macrophages (mo-Mac) or dendritic cells (mo-DC). In chronic non-resolving inflammation, mo-DC are major drivers of pathogenic events. Manipulating monocyte differentiation would therefore represent an attractive therapeutic strategy. Here the inventors show that the transcriptional repressors ETV3 and ETV6 control monocyte differentiation into mo-DC. To validate the physiological relevance of these findings, the inventors generated mice deficient for ETV6 in monocytes. Deficient mice show spontaneous expression of interferon-stimulated genes, confirming that ETV6 regulates interferon responses in vivo. Furthermore, deficient mice display impaired mo-DC differentiation during peritonitis and less severe symptoms in experimental autoimmune encephalomyelitis. The findings identify ETV3 and ETV6 as a therapeutic target to redirect monocyte differentiation in inflammatory disorders. [post_date] => 2024-06-07 09:31:27 [post_modified] => 2024-09-20 15:05:02 [ID] => 6289 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 56490a45-58c8-75c3-ab30-616836acead6 [etat_fiche_online] => en_ligne [date_application] => 2021-09-01 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO21335-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => SEGURA Elodie,VILLAR Javiera [number_application] => European Procedure (Patents) (EPA) - 01 Sept. 2021 - 21 306 195.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 83 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Inflammation, Oligonucleotide, Target, Target [taxonomieurl] => Drug, Immunology, Inflammation, Oligonucleotide, Target, Target ) [84] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-modulating-innate-lymphoid-cell-activity-antibody-drug-conjugates-and-uses-in-therapy/ [post_content] => The present invention relates to methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy. The inventors showed in a model of murine cytomegalovirus infection, that glucocorticoid receptor expression in innate lymphoid cells plays an essential early role in regulating host protection against inflammation-induced tissue damage. Mechanistically, they demonstrated for the first time that endogenous glucocorticoids produced shortly after infection promote the expression of the immune checkpoint PD1 on the surface of natural killer cells. This glucocorticoid-PD1 pathway acts to limit the production of interferon-u03b3 by NK cells. The modulation of the glucocorticoid-PD1 pathway in order to increase or decrease the activity of ILCs would permit to treat either cancers and infectious diseases or autoimmune and inflammatory diseases. In particular, the present invention relates to a method of modulating innate lymphoid cell activity which comprises modulating the activity of glucocorticoid receptor. [post_date] => 2024-06-07 09:31:26 [post_modified] => 2024-09-11 15:44:41 [ID] => 6288 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9fba0eb1-e710-a7a7-03cd-5afc3f31d179 [etat_fiche_online] => en_ligne [date_application] => 22-03-2018 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17668-T1 [keywords] => Innate lymphoid cell - Innate immunity - glucocorticoid receptor - inflammation-induced tissue damage - immune checkpoint PD1 [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => UGOLINI Sophie,QUATRINI Linda [number_application] => European Procedure (Patents) (EPA) - 22 Mars 2018 - 18 305 319.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 84 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Inflammation [taxonomieurl] => Drug, Immunology, Inflammation ) [85] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF TCR-DEFICIENT CAR-TREGS IN COMBINATION WITH ANTI-TCR COMPLEX MONOCLONAL ANTIBODIES FOR INDUCING DURABLE TOLERANCE [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-tcr-deficient-car-tregs-in-combination-with-anti-tcr-complex-monoclonal-antibodies-for-inducing-durable-tolerance/ [post_content] => The present invention is defined by the claims. In particular, the present invention relates to the use of TCR-deficient CAR-Tregs in combination with anti-TCR complex monoclonal antibodies for inducing durable tolerance. [post_date] => 2024-06-07 09:31:25 [post_modified] => 2024-09-20 15:55:02 [ID] => 6287 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bb50d920-b37e-11ee-91a7-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO22067-T1 [keywords] => TCR-deficient CAR-Treg - Anti-TCR complex - Stability of CAR-Treg [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO22067-T1_Zuber.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => ZUBER Julien,CHARBONNIER Soeli,BLEIN Tifanie [number_application] => European Procedure (Patents) (EPA) - 18 Févr. 2022 - 22 305 182.2 [technology_engineering] => cell_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 85 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cell therapy, Cell therapy, Cellular immunotherapy, Drug, Identification, Immunology, Inflammation, Target, Target [taxonomieurl] => Biologic, Cell therapy, Cell therapy, Cellular immunotherapy, Drug, Identification, Immunology, Inflammation, Target, Target ) [86] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF TG2 INHIBITORS FOR IMPROVING MUCOCILIARY CLEARANCE IN RESPIRATORY DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-tg2-inhibitors-for-improving-mucociliary-clearance-in-respiratory-diseases/ [post_content] => In asthma, modification of gel-forming respiratory mucins leading to their tethering to the apical pole of epithelial cells, are believed to participate in airway obstruction by mucus plugs. These changes have been linked to local production of Th2 cytokines, resulting in mucus cell hyperplasia and increased MUC5AC production. The inventors showed that severe eosinophil asthma was associated with overexpression of transglutaminase 2 (TG2), an enzyme recently involved in intestinal mucin reticulation. Moreover, the bronchial epithelium from asthmatic patients or control subjects was reconstituted in vitro by culturing cells at the air-liquid interface and the hypersecretory differentiation was modeled by exposing control bronchial epithelial to IL-13. The inventors showed TG2 expression was upregulated upon IL-13-mediated hypersecretory differentiation and correlated with MUC5AC expression. IL-13 promoted MU5AC tethering to in vitro reconstituted hypersecretory epithelium, and this was blocked by a TG2 inhibitor. In conclusion, the inventors showed that TG2 participates in respiratory mucin modifications in asthma, and contribute to mucus tethering to the airway wall, supporting the use of TG2 inhibitors for improving mucociliary clearance in asthma, but more generally in respiratory diseases [post_date] => 2024-06-07 09:31:25 [post_modified] => 2024-09-20 17:00:02 [ID] => 6286 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6cd93c8f-f3b8-b3c6-bff8-60e71bd2126e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO20412-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => LETUVE Severine,GUILLOT Loïc,TAILLE Camille,ROBBE MASSELOT Catherine,SALLON Céline [number_application] => European Procedure (Patents) (EPA) - 15 Oct. 2020 - 20 306 214.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 86 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => [taxonomieurl] => ) [87] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF IL-36 INHIBITORS FOR THE TREATMENT OF NETHERTON SYNDROME [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-il-36-inhibitors-for-the-treatment-of-netherton-syndrome/ [post_content] => Netherton syndrome (NS) is a rare recessive skin disorder caused by loss-of-function mutations in SPINK5 encoding the protease inhibitor LEKTI. NS patients present with typical ichthyosis linearis circumflexa (NS-ILC) or scaly erythroderma (NS-SE). Here the inventors employed a combination of several molecular profiling methods to comprehensively characterize the skin, immune cells and allergic phenotypes of NS-ILC and NS-SE patients. In particular, they studied a cohort of 13 NS patients comprising 9 NS-ILC and 4 NS-SE. Integrated multi-omics revealed abnormal epidermal proliferation and differentiation and IL-17/IL-36 signatures in lesion skin and in blood in both NS endotypes. This study thus identifies IL-17/IL-36 as predominant signaling axes in both NS endotypes and unveils molecular features distinguishing NS-ILC and NS-SE. In particular, blocking of IL36 signaling would therefore represent a novel therapeutic strategy for NS, in particular in NS-SE patients. [post_date] => 2024-06-07 09:31:25 [post_modified] => 2024-09-23 19:15:02 [ID] => 6285 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f086e2c7-6249-18d2-0488-62ed193923f2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO20216-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO20216-T1_Hovnanian.pdf [rare_disease] => 1 [second_indication] => 0 [inventors] => HOVNANIAN Alain,BARBIEUX Claire,PETROVA Evgeniya,GOUIN Olivier [number_application] => European Procedure (Patents) (EPA) - 12 Juil. 2021 - 21 305 968.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DermatologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 87 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Method [taxonomieurl] => Dermatology, Method ) [88] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR PREDICTING AND PREVENTING POSTOPERATIVE COMPLICATIONS AFTER CARDIAC SURGERY WITH CARDIOPULMONARY BY-PASS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-predicting-and-preventing-postoperative-complications-after-cardiac-surgery-with-cardiopulmonary-by-pass/ [post_content] => Cardiopulmonary by-pass (CBP) during cardiac surgery leads to deleterious systemic inflammatory response. In a prospective cohort of 46 patients older than 18 years and eligible for non-urgent cardiac surgery with CPB, measurement of sTREM-1 in the plasma was performed immediately after the onset of anesthesia (H0) and 2 and 24 hours after CBP. After CBP, sTREM-1 significantly increased at H2 and at H24 (p [post_date] => 2024-06-07 09:26:03 [post_modified] => 2024-09-11 15:54:07 [ID] => 6284 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 80efbd8e-ab16-11ee-9206-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 11-10-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21316-D1 [keywords] => Cardiopulmonary by-pass (CBP), sTrem-1, severe organ failure, prognosis [pub_scient_inv_dispo] => Front Cardiovasc Med, 2023 Jul 13, Vandestienne et al., Soluble TREM-1 plasma levels are associated with acute kidney injury, acute atrial fibrillation and prolonged ICU stay after cardiac surgery- a proof-concept stud, doi: 10.3389/fcvm.2023.1098914. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => AIT-OUFELLA Hafid,CLAVIER Thomas [number_application] => European Procedure (Patents) (EPA) - 11 Oct. 2021 - 21 306 422.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Cardiovascular DiseasesTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 88 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Cardiovascular Diseases, Immunoassay, Pre-Analytic Validation [taxonomieurl] => Biomarker, Cardiovascular Diseases, Immunoassay, Pre-Analytic Validation ) [89] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR DIAGNOSING COLLAGEN DEGRADATATION ASSOCIATED DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-diagnosing-collagen-degradatation-associated-disease/ [post_content] => The Inventors have developed an ELISA of a new molecular marker detecting a neoepitope generated from the cleavage of the u03b11 chain of type III collagen within its helical domain. Serum levels of this marker were significantly increased in patients with RA and is significantly associated to CRP and ESR levels. Indeed, they demonstrated that the median serum HELIX-III levels were significantly higher in patients with moderate (p=0027) and active RA (p=00004) compared with those in age-matched controls. The present invention relates to an antibody recognizing an epitope having SEQ ID NO :1 of collagen protein and its uses for diagnostic, prognostic and monitoring purposes. [post_date] => 2024-06-07 09:26:02 [post_modified] => 2024-09-11 15:54:07 [ID] => 6283 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fd4b0ab4-ab20-11ee-b80a-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 01-02-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21443-D1 [keywords] => Rheumatoid Arthritis, collagene degradation, prognosis [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => CHAPURLAT Roland,GARNERO Patrick,GINEYTS Evelyne [number_application] => European Procedure (Patents) (EPA) - 01 Févr. 2022 - 22 305 111.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Rheumatoid ArthritisTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 89 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Analytic validation, Biomarker, Immunoassay, Immunology, Protype kit, Rheumatoid Arthritis [taxonomieurl] => Analytic validation, Biomarker, Immunoassay, Immunology, Protype kit, Rheumatoid Arthritis ) [90] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-and-treatment-of-t-cell-lymphomas/ [post_content] => T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The Inventors showed that malignant T cells express CD33 in patients with Sézary syndrome, mycosis fungoides and Hepatosplenic T-cell lymphoma (HSTL). CD33 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. [post_date] => 2024-06-07 09:26:02 [post_modified] => 2024-09-11 15:54:12 [ID] => 6282 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 79326c9e-b6a7-11ee-b367-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 15-04-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO22146-D1 [keywords] => CD33, Diagnostic, Treatment Prediction, T-cell Lymphoma, Sézary Syndrome, Flow-Cytometry [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => BENSUSSAN Armand,BAGOT Martine,DE MASSON Adele,GIUSTINIANI Jérôme [number_application] => European Procedure (Patents) (EPA) - 15 Avr. 2022 - 22 305 558.3 and PCT/EP2023/059761 on 14/04/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 90 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Human POC, Immunoassay, Lymphoma, Oncology, Sezary syndrome [taxonomieurl] => Biomarker, Human POC, Immunoassay, Lymphoma, Oncology, Sezary syndrome ) [91] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS AND TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-and-treatment-of-acute-lymphoblastic-leukemia/ [post_content] => The present invention relates to a method of treating acute lymphoblastic leukemia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent capable of inducing cell death of CCR8 expressing cancer cells. The present invention also relates to a method of diagnosing acute lymphoblastic leukemia in a patient comprising detecting the expression level of CCR8 in a sample obtained from the patient. [post_date] => 2024-06-07 09:26:01 [post_modified] => 2024-09-11 15:54:14 [ID] => 6280 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9d45c4d6-bc4d-11ee-87ca-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 30-06-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO22280-D1 [keywords] => acute lymphoblastic leukemia, diagnostic, Predictive, Compagnon diagnostic, CCR8 [pub_scient_inv_dispo] => not published [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => BENSUSSAN Armand,ORTONNE Nicolas,DE MASSON Adele,BAGOT Martine,GIUSTINIANI Jérôme,LEMONNIER François,SOULIER Jean,GACHET Stéphanie,CLAPPIER Emmanuelle [number_application] => European Procedure (Patents) (EPA) - 30 Juin 2022 - 22 305 958.5 and PCT/EP2023/067924 on 09/01/2024 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LeukemiasTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 91 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Acute Lymphocytic Leukemia (ALL), Biomarker, Biomarker, Immunoassay, In vitro poc, Leukemias, Method, Oncology, Target [taxonomieurl] => Acute Lymphocytic Leukemia (ALL), Biomarker, Biomarker, Immunoassay, In vitro poc, Leukemias, Method, Oncology, Target ) [92] => stdClass Object ( [post] => stdClass Object ( [post_title] => GARP AS A BIOMARKER AND BIOTARGET IN T-CELL MALIGNANCIES [guid] => https://technology-offers.inserm-transfert.com/offer/garp-as-a-biomarker-and-biotarget-in-t-cell-malignancies/ [post_content] => The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has also been shown to be overexpressed in samples from patients with acute lymphoblastic leukemia. GARP therefore appears as a diagnostic marker, for monitoring T-cell malignancies, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of T-cell malignancies. [post_date] => 2024-06-07 09:26:01 [post_modified] => 2024-09-11 15:54:15 [ID] => 6279 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 45aa7cfa-bc69-11ee-8024-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 22-07-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => BIO22282-D1 [keywords] => Sezary Syndrome, GARP, Diagnostic, Compagnon Diagnostic, Flow Cytometry [pub_scient_inv_dispo] => Not Published [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => BENSUSSAN Armand,DE MASSON Adele,BAGOT Martine,LEMONNIER François,ORTONNE Nicolas,GIUSTINIANI Jérôme [number_application] => European Procedure (Patents) (EPA) - 22 Juil. 2022 - 22 306 100.3 and PCT/EP2023/070250 on 04/08/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 92 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Method, Oncology, Sezary syndrome, Target [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Method, Oncology, Sezary syndrome, Target ) [93] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITION TO IDENTIFY AND TREAT SUBJECTS RESISTING TO CHEMOTHERAPY TREATMENT [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-composition-to-identify-and-treat-subjects-resisting-to-chemotherapy-treatment-2/ [post_content] => The present invention relates to a method for treating a subject suffering from a cancer comprising a step of administering said subject with a therapeutically effective amount of an inhibitor of NETs. By in vitro experiments, inventors have demonstrated that inhibiting the formation of NETs with a PAD4 inhibitor or digesting the NET-DNA scaffold with DNase I during PMA-induced NET formation overcame the chemoresistance induced by the NET CM in vitro.They have also generated data in vivo and shown that targeting of NETs with either a PAD4 inhibitor or DNase I enhanced chemotherapy efficacy. PAD4 inhibition and DNase I treatment not only eliminated NETs in the metastatic lungs and in the plasma, but also reduced neutrophil recruitment to the lungs. [post_date] => 2024-06-07 09:26:01 [post_modified] => 2024-09-11 15:54:15 [ID] => 6278 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 41cb4076-c1da-11ee-8f59-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 05-07-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21413-D1 [keywords] => Breast Cancer, NETs, chemotherapy, treatment response prediction, prognosis [pub_scient_inv_dispo] => Cancer Cell. 2023 Apr 10;41(4):757-775.e10. doi:10.1016/j.ccell.2023.03.008. [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => GAGGIOLI Cédric,MOUSSET Alexandra,ALBRENGUES Jean [number_application] => European Procedure (Patents) (EPA) - 05 Juil. 2022 - 22 306 004.7 and PCT/EP2023/068444 on 04/07/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• OncologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 93 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Animal POC, Biomarker, Breast Cancer, Immunoassay, Oncology [taxonomieurl] => Animal POC, Biomarker, Breast Cancer, Immunoassay, Oncology ) [94] => stdClass Object ( [post] => stdClass Object ( [post_title] => LRRC33 AS A BIOMARKER AND BIOTARGET IN CUTANEOUS T-CELL LYMPHOMAS [guid] => https://technology-offers.inserm-transfert.com/offer/lrrc33-as-a-biomarker-and-biotarget-in-cutaneous-t-cell-lymphomas/ [post_content] => The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of LRRC33 by Sézary cells. LRRC33 therefore appears as a diagnostic marker, for monitoring Sézary syndrome, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of cutaneous T cell-lymphomas. [post_date] => 2024-06-07 09:26:00 [post_modified] => 2024-09-11 15:54:16 [ID] => 6277 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cd0699da-c1dd-11ee-a538-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 29-07-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22283-D1 [keywords] => Sezary Synrdome, Diagnostic, cutaneous T cell-lymphomas, Flow-Cytometry [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => BENSUSSAN Armand,GIUSTINIANI Jérôme,DE MASSON Adele,ORTONNE Nicolas [number_application] => European Procedure (Patents) (EPA) - 29 Juil. 2022 - 22 306 146.6 and PCT/EP2023/070960 on 28/07/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 94 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Method, Oncology, Sezary syndrome, Target [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Method, Oncology, Sezary syndrome, Target ) [95] => stdClass Object ( [post] => stdClass Object ( [post_title] => INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY FOROVERCOMING IMMUNOTHERAPY RESISTANCE IN CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/inhibitors-of-the-ceramide-metabolic-pathway-forovercoming-immunotherapy-resistance-in-cancer/ [post_content] => Advanced cutaneous melanoma can be treated by immunotherapy targeting immune check points such as PD-1 and CTL-A4. However, 50% of patients do no respond because of primary or acquired resistance mechanism. Thus, new targets for addressing the treatment of said resistance are highly needed. The inventors show that TNF (Tumour Necrosis Factor) and ceramide metabolism alterations in melanoma cells contribute to melanoma progression and resistance to immunotherapies. In particular, the inventors demonstrate that TNF is a potent modulator of ceramide metabolism and TNF-mediated ceramide metabolism changes contribute to various biological processes such as cell proliferation, cell death and cell differentiation. Among the biological processes by which TNF triggers melanoma immune escape and resistance to immunotherapies, TNF triggers a dedifferentiation process of melanoma cells associated with the reduction of melanocytic antigen expression and epithelial to mesenchymal transition. Finally, the inventors show that glycosphingolipid pattern in plasma can predict the clinical outcome of advanced melanoma treated with ipilimumab and nivolumab. Accordingly, ceramide metabolites and metabolizing-enzymes can be new therapeutic targets and/or biomarkers in advanced melanoma patients treated with immunotherapies. [post_date] => 2024-06-07 09:26:00 [post_modified] => 2024-09-11 15:54:16 [ID] => 6276 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 500ea7c2-c1e9-11ee-b058-506b8df7f2c7 [etat_fiche_online] => en_ligne [date_application] => 06-09-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => [reference_online] => BIO22410-D1 [keywords] => melanoma, resistance mechanism, Immune Check Point, Ceramide metabolite [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => MEYER Nicolas; ANDRIEU-ABADIE Nathalie; MONTFORT Anne; DUFAU Corine; GENAIS Matthieu; SEGUI Bruno; JUNG Benjamin; DELORD Jean-Pierre; LEVADE Thierry [number_application] => European Procedure (Patents) (EPA) - 06 Sept. 2022 - 22 306 318.1 and PCT/EP2023/074343 on 06/09/2023 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => mass_spectrometry [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• MelanomaTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 95 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Human POC, Mass spectrometry, Melanoma, Oncology [taxonomieurl] => Biomarker, Human POC, Mass spectrometry, Melanoma, Oncology ) [96] => stdClass Object ( [post] => stdClass Object ( [post_title] => Novel B-Raf inhibitors devoid of rapid metabolism and of binding to Pregnane X Receptor [guid] => https://technology-offers.inserm-transfert.com/offer/novel-b-raf-inhibitors-devoid-of-rapid-metabolism-and-of-binding-to-pregnane-x-receptor/ [post_content] => The present invention relates to N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenylsulfonamide compounds which are useful as inhibitors of protein kinases, more specifically BRAF or mutant forms thereof, to pharmaceutical composition comprising such compounds, and to uses of such compounds in the treatment or prevention of diseases associated with deregulated protein kinase activity, such as cancer. [post_date] => 2023-05-24 10:15:02 [post_modified] => 2024-09-11 15:45:10 [ID] => 4931 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => db16775c-4f9b-f329-849f-5f8955f49e80 [etat_fiche_online] => en_ligne [date_application] => 05-12-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => CHIM18530-T1 [keywords] => BRAF inhibitors [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO18530-T1_LABESSE.pdf [rare_disease] => false [second_indication] => false [inventors] => LABESSE Gilles,COHEN-GONSAUD Martin,BOURGUET William,GELIN Muriel,GUICHOU Jean-François,BALAGUER Patrick,SCHNEIDER Mélanie [number_application] => European Procedure (Patents) (EPA) - 05 Déc. 2019 - 19 306 579.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 96 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Hit - validation in vitro, Melanoma, Oncology, Product, Product, Small Molecule [taxonomieurl] => Drug, Hit - validation in vitro, Melanoma, Oncology, Product, Product, Small Molecule ) [97] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITION TO IDENTIFY AND TREAT SUBJECTS RESISTING TO CHEMOTHERAPY TREATMENT [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-composition-to-identify-and-treat-subjects-resisting-to-chemotherapy-treatment/ [post_content] => The present invention relates to a method for treating a subject suffering from a cancer comprising a step of administering said subject with a therapeutically effective amount of an inhibitor of NETs.By in vitro experiments, inventors have demonstrated that inhibiting the formation of NETs with a PAD4 inhibitor or digesting the NET-DNA scaffold with DNase I during PMAinduced NET formation overcame the chemoresistance induced by the NET CM in vitro.They have also generated data in vivo and shown that targeting of NETs with either a PAD4 inhibitor or DNase I enhanced chemotherapy efficacy. PAD4 inhibition and DNase I treatment not only eliminated NETs in the metastatic lungs and in the plasma, but also reduced neutrophil recruitment to the lungs. [post_date] => 2023-05-23 13:15:01 [post_modified] => 2024-09-11 15:45:13 [ID] => 4929 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => eca55176-add7-39d4-ef34-645d0a4e69fd [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21413-T1 [keywords] => Metastasis, Breast Cancer, Chemotherapy resistance [pub_scient_inv_dispo] => Cancer Cell. 2023 Apr 10;41(4):757-775.e10. doi:10.1016/j.ccell.2023.03.008. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GAGGIOLI Cédric,MOUSSET Alexandra,ALBRENGUES Jean [number_application] => European Procedure (Patents) (EPA) - 05 Juil. 2022 - 22 306 004.7 [technology_engineering] => [multidisciplinary_field] => resistance [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 97 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Biomarker, Breast Cancer, Drug, Enzyme, Method, Oncology, Protein, Resistance, Target, Validation in vivo [taxonomieurl] => Biologic, Biomarker, Breast Cancer, Drug, Enzyme, Method, Oncology, Protein, Resistance, Target, Validation in vivo ) [98] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEW STRATEGY TARGETING STROMA/TUMOR CELL CROSSTALK TO TREAT A CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/new-strategy-targeting-stroma-tumor-cell-crosstalk-to-treat-a-cancer/ [post_content] => In this study, the Inventors report that CD9 is a key component of PC-associated CAFsderived ANXA6+-EVs. They determined that CD9 is expressed by PC-associated CAFs in vitro as well as in vivo. Targeting CD9 impaired CAFs-derived ANXA6+-EVs uptake by pancreatic cancer cells, which consequently decreases their migratory abilities. Signaling pathway arrays highlighted p38/MAPK as activated in pancreatic cancer cells following CAFs-derived ANXA6+/CD9+-EVs uptake. The use of CD9 blocking antibody, p38 siRNA or chemical inhibitors impaired pancreatic cancer cells abilities following incubation with CAFs-derived ANXA6+/CD9+-EVs. Finally, they revealed CD9 expression as an independent poor-prognosis marker in human PC samples. Collectively their data highlight the key role of CD9 in CAFs erived ANXA6+-EVs internalization by pancreatic cancer cells and the consequent, and mandatory, activation of p38/MAPK pathway to foster their migratory abilities. Measuring the oncogenic CAFs-derived ANXA6+/CD9+-EVs then limiting their action on pancreatic cancer cells abilities might be a promising option for PC stratification and treatment. [post_date] => 2023-05-15 13:55:02 [post_modified] => 2024-09-11 15:43:28 [ID] => 4928 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => baf356b8-6bde-e8d3-c6f4-64622b53b487 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21093-T1 [keywords] => [pub_scient_inv_dispo] => Sci Signal. 2022 Aug 2;15(745):eabg8191. doi: 10.1126/scisignal.abg8191. Epub 2022 Aug 2. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => TOMASINI Richard,TUBIANA Sarah,NIGRI Jérémy [number_application] => European Procedure (Patents) (EPA) - 22 Nov. 2021 - 21 306 624.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• Pancreatic CancerTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 98 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Oncology, Pancreatic Cancer, Target [taxonomieurl] => Oncology, Pancreatic Cancer, Target ) [99] => stdClass Object ( [post] => stdClass Object ( [post_title] => MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES LOADED WITH AT LEAST ONE PHOTOSENSITIZER AND USES THEREOF FOR THE TREATMENT OF PERITONEAL CARCINOMATOSIS [guid] => https://technology-offers.inserm-transfert.com/offer/mesenchymal-stem-cell-derived-extracellular-vesicles-loaded-with-at-least-one-photosensitizer-and-uses-thereof-for-the-treatment-of-peritoneal-carcinomatosis/ [post_content] => Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients. Treatment of residual microscopic disease remains a challenge with new anticancer modalities development. Now, the inventors propose an innovative therapeutic management of peritoneal carcinomatosis (PC) that is bio-inspired and tumor-targeted by engineering MSC-derived EVs to encapsulate a photosensitizer (mTHPC) for improved photodynamic therapy efficiency and safety. In this work, the inventors first evaluated the biodistribution of EVs-mTHPC in a murine PC model and highlighted superior accumulation of mTHPC in the tumor compared to other mTHPC formulations (free drug and liposomal one (Foslip®). The effectiveness of PDT mediated by mTHPC vectorized in EVs has then been evaluated in PC. In accordance with pharmacokinetics, the results revealed both an enhanced light-induced therapeutic efficiency in terms of tumoral cytotoxicity, safety for surrounding tissue after laser irradiation, immunomodulation and improved survival time. Thus, the present invention relates to mesenchymal stem cell derived extracellular vesicles loaded with at least one photosensitizer and uses thereof for the treatment of peritoneal carcinomatosis. [post_date] => 2023-05-15 13:25:01 [post_modified] => 2024-09-11 15:45:01 [ID] => 4927 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 538561fa-6f78-e8a3-8e0b-6462244969bf [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19434-T1 [keywords] => Oncology, photodynamic therapy, MSC, peritoneal
carcinomatosis, pleural metastasis [pub_scient_inv_dispo] => Amandine Pinto et al. ACS Nano 2021, 15, 2, 3251u20133263 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => POCARD Marc,PIFFOUX Max,MARANGON Iris,WILHEM Claire,GAZEAU Florence,PINTO Amandine,SILVA (BRUN-GRAEPPI) Amanda K. Andriola [number_application] => European Procedure (Patents) (EPA) - 21 Nov. 2019 - 19 306 495.3 [technology_engineering] => cell_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Colorectal CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 99 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cell therapy, Cell therapy, Colorectal Cancer, Drug, Method, Oncology, Product, Stem cell therapy [taxonomieurl] => Biologic, Cell therapy, Cell therapy, Colorectal Cancer, Drug, Method, Oncology, Product, Stem cell therapy ) [100] => stdClass Object ( [post] => stdClass Object ( [post_title] => Anti-PTF1a antibodies [guid] => https://technology-offers.inserm-transfert.com/?p=4900 [post_content] => Two rabbits (A and B) were immunized with a mix of two synthetic peptides of murine PTF1a sequence (one N-term peptide, KSFDNIENEPPFEFVS (aa 309-324) and one C-term peptide, EDFFTDQSSRDPLED (aa 24-38)) conjugated to keyhole limpet haemocyanin. C-term and N-term peptides have 100 % identity with rat sequence and 93% with human sequence.We call our antibodies 7A (from rabbit A) and 7B (from rabbit B).We designed Biacore experiments with immobilized peptides to test their specificity against immunogenic peptides (see Figure 1). 7A recognizes C-term sequence better than N-term sequence. 7B recognizes C-term sequence but not N-term sequence (see Figure 1).Antibody 7B was purified against the « wrong peptide, N-term » but the flow through fraction has been kept. It has been tested and shows preserved immunoreactivity against C-terminal sequence (see Figure 1) and detects PTF1a in Western-Blot (see Figure 3).We successfully used antibodies 7A and 7B in immunohistochemistry on human and mouse pancreas (see publication 1 and 3 and also see immunofluorescence in Figure 2), in immunocytochemistry of rat pancreatic acinar cells (see publication 1), Western-blot analysis of nuclear and cytoplasmic extracts of rat pancreatic acinar cells (see publication 1), of murine pancreatic acinar protein extracts (see publication 2), of transfected HEK cells (see publication 2), and in immunoprecipitation experiments (see publication 2). Antibodies 7A and 7B are specific of pancreatic acinar cells and do not recognize any other proteins in Western-blot analysis of pancreatic ductal cells or COS cells (see Figure 3). Figure 3 also shows the absence of non specific bands. We can provide around 30 ml of 7A antibody, 2 ml of unpurified 7B and 6 ml of 7B flow-through.We also have lesser quantities of intermediate bleeds. Their specificity towards peptide antigens was also tested by Biacore, we can provide these results on demand in case of interest. We did not tested them in WB and IF/IHC. [post_date] => 2023-03-31 16:40:02 [post_modified] => 2024-09-11 16:06:33 [ID] => 4900 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-98cbf752da3dcd111e4a9277903c44c6 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00632 [keywords] => pancreatic acinar cells; acinar-to ductal metaplasia; development; reprogramming; embryonic nervous system; plasticity [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Academic ResearchUses:
• Pancreatic CancerTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => [first_name] => [last_name] => [wp_capabilities] => [wp_user_level] => [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 100 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diabetes, ELISA (or compatible technique), Gastrointestinal Diseases, Immunocytochemistry, Immunofluorescence, Immunohistochemistry - Paraffin, Immunohistochemistry u2013 Frozen, Immunoprecipitation, Metabolic Disorders, Mouse, Oncology, Pancreatic Cancer, Pancreatic exocrine tumor, Pancreatitis, Rabbit, Type 1 Diabetes (Juvenile Diabetes), Western Blot [taxonomieurl] => Academic Research, Diabetes, ELISA (or compatible technique), Gastrointestinal Diseases, Immunocytochemistry, Immunofluorescence, Immunohistochemistry - Paraffin, Immunohistochemistry u2013 Frozen, Immunoprecipitation, Metabolic Disorders, Mouse, Oncology, Pancreatic Cancer, Pancreatic exocrine tumor, Pancreatitis, Rabbit, Type 1 Diabetes (Juvenile Diabetes), Western Blot ) [101] => stdClass Object ( [post] => stdClass Object ( [post_title] => CD38 AS A BIOMARKER AND BIOTARGET IN CELL-LYMPHOMAS [guid] => https://technology-offers.inserm-transfert.com/offer/cd38-as-a-biomarker-and-biotarget-in-cell-lymphomas/ [post_content] => T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. Now the inventors showed the expression of CD38 by Sézary cells and in CD4+ blood cells of patients with Sezary syndrome. CD38 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CD38-expressing cancer cells would eliminate tumor cells. [post_date] => 2023-03-08 15:25:03 [post_modified] => 2024-09-11 15:53:59 [ID] => 4898 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b7d9537d-495e-95f4-cace-64089b6c863f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO22037-D1 [keywords] => cutaneous T-cell lymphoma, Sézary syndrome, Diagnostic, Treatment Response Prediction, Prognosis CD38 [pub_scient_inv_dispo] => J Invest Dermatol, 2023 Jan 28, Ta et al., CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas, doi: 10.1016/j.jid.2023.01.009. Online ahead of print. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BENSUSSAN Armand,BAGOT Martine,BATTISTELLA Maxime,DE MASSON Adele,MOINS Hélène [number_application] => European Procedure (Patents) (EPA) - 31 Janv. 2022 - 22 305 106.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => imaging,immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 101 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Imaging, Immunoassay, Lymphoma, Oncology, Sezary syndrome, Target [taxonomieurl] => Biomarker, Biomarker, Human POC, Imaging, Immunoassay, Lymphoma, Oncology, Sezary syndrome, Target ) [102] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING TRIPLE NEGATIVE BREAST CANCER (TNBC) [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-triple-negative-breast-cancer-tnbc/ [post_content] => Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a long follow-up by immunohistochemistry. They show that SPARC expression was detected in cancer cells (42.4%), cancer-associated fibroblasts (CAFs) (88.1%), TAMs (77.1%), endothelial cells (75.2%) and TILs (9.8%). Recurrence-free survival (RFS) was significantly lower for patients with a positive expression of SPARC in CAFs (SPARC+ CAFs) with a median follow-up of 5.4 years. SPARC expression in CAFs was found to be an independent prognostic factor in multivariate analysis. Accordingly, the present invention relates to a method for predicting the survival time of a subject suffering from triple-negative breast cancer (TNBC) comprising determining the expression level of Secreted Protein Acidic and Rich in Cysteine (SPARC) in cancer-associated fibroblasts (CAFs) in a biological sample obtained from the subject wherein said positive expression of SPARC in CAFs (SPARC+CAFs) correlates with a short survival time of the subject. [post_date] => 2023-03-08 14:15:02 [post_modified] => 2024-09-11 15:53:59 [ID] => 4897 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 354f3f52-e37a-ef4c-c595-64088c3184a7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO21444-D1 [keywords] => triple negative breast cancer (TNBC), Prognosis, Treatment Response Prediction, SPARC [pub_scient_inv_dispo] => Int J Cancer, 2023 Mar 15, Alcaraz et al, SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity, doi: 10.1002/ijc.34345. Epub 2022 Nov 30. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => LIAUDET-COOPMAN Emmanuelle,ROGER Pascal,GUIU Séverine,ALCARAZ CACCHIA Lindsay [number_application] => European Procedure (Patents) (EPA) - 03 Nov. 2021 - 21 306 545.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => imaging,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• OncologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 102 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Breast Cancer, Imaging, Method, Oncology, Pre-Analytic Validation, Target, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Breast Cancer, Imaging, Method, Oncology, Pre-Analytic Validation, Target, Transcriptomics ) [103] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR DIAGNOSING COLORECTAL CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-diagnosing-colorectal-cancer/ [post_content] => The present invention relates to the diagnosing of colorectal cancer. The inventors have thus designed an efficient, rapid and cost-effective method to purify and analyse mRNA from small volumes of blood plasma. They found that the RPS28, B2M, TIMP-1 and CLU levels were significantly higher in metastatic colorectal cancer patients. Thus, the present invention relates to a method for diagnosing a colorectal cancer in a subject in need thereof comprising i) determining in a sample obtained from the subject the expression levels of at least one biomarker selected from the group consisting of RPS28, B2M, TIMP-1 and CLU mRNAs. [post_date] => 2023-03-08 13:50:01 [post_modified] => 2024-09-11 15:53:58 [ID] => 4896 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cdd61d66-d036-3cb7-28ca-640885f41931 [etat_fiche_online] => en_ligne [date_application] => 08-02-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO21297-D1 [keywords] => Colorectal Cancer, Metastatis Colorectal Cancer, Diagnosis, RNA signature [pub_scient_inv_dispo] => Sci Rep, 2023 Feb 15, Grosgeorges et al., A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer, doi: 10.1038/s41598-023-29948-4. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BLACHE Philippe [number_application] => European Procedure (Patents) (EPA) - 08 Févr. 2022 - 22305131.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Colorectal CancerTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 103 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Colorectal Cancer, Oncology, Pre-Analytic Validation, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Colorectal Cancer, Oncology, Pre-Analytic Validation, Transcriptomics ) [104] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR IMPROVING THE EFFICACY OF HDAC INHIBITOR THERAPY AND PREDICTING THE RESPONSE TO TREATMENT WITH HDAC INHIBITOR [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-improving-the-efficacy-of-hdac-inhibitor-therapy-and-predicting-the-response-to-treatment-with-hdac-inhibitor/ [post_content] => Investigating the impact of Tau protein expression in cancer cell lines, Inventors have demonstrated that the Tau expression is associated with an increased resistance to HDAC inhibittors. Briefly in the present invention, inventors report that Tau expression in breast cancer cell lines causes resistance to the anti-cancer effects of histone deacetylase inhibitors, by preventing histone deacetylase inhibitor-inducible gene expression and remodeling of chromatin structure. Inventors identify Tau as a protein recognizing and binding to core histone when H3 and H4 are devoid of any post-translational modifications or acetylated H4 that increases the Tau’s affinity. In addition, they demonstrate that the interaction between Tau and histones prevents further histone H3 post-translational modifications induced by histone deacetylase-inhibitor treatment by maintaining a more compact chromatin structureThe present invention relates to means to improve the bioavailability of histone deacetylase (HDAC) inhibitor and thereby also improve the efficacy of histone deacetylase (HDAC) inhibitor treatments. [post_date] => 2023-03-07 16:10:01 [post_modified] => 2024-09-11 15:53:57 [ID] => 4895 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 79000cd7-7510-dd4b-cdca-6407556dc2c5 [etat_fiche_online] => en_ligne [date_application] => 20-09-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20332-D1 [keywords] => Tau inhibitor, HDAC inhibitor, Treatment response prediction, Breast Cancer, Companion Diagnostics [pub_scient_inv_dispo] => Front Cell Dev Biol, 2021 Oct 14, Rico et al, Tau Stabilzes Chromatin Compaction, doi: 10.3389/fcell.2021.740550. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => RICO Thomas,LEFEBVRE Bruno,BUEE Luc [number_application] => European Procedure (Patents) (EPA) - 20 Sept. 2021 - 21 306 299.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 104 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Breast Cancer, Immunoassay, In vitro poc, Method, Oncology [taxonomieurl] => Biomarker, Biomarker, Breast Cancer, Immunoassay, In vitro poc, Method, Oncology ) [105] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEW BIOMARKERS OF ALCOHOL USE DISORDERS [guid] => https://technology-offers.inserm-transfert.com/offer/new-biomarkers-of-alcohol-use-disorders/ [post_content] => The present invention relates to a method for predicting alcohol use disorder. The objective of this study was to validate the possibility of performing a plasma assay and to quantify the value of four plasmatic biomarkers of brain damage in patient with AUD, either at the onset of alcohol withdrawal in patients admitted for alcohol cessation or in abstinent patients with history of AUD. The inventors also 1) analysed the correlation between the levels of these biomarkers; 2) compared patients in alcohol cessation and abstinent patients; 3) analysed the association of these biomarkers, in alcohol cessation group, with the severity of alcohol withdrawal expressed by the dose of diazepam needed to control the signs of alcohol withdrawal the day after admission (D1) or the signs of neurologic severity of alcohol withdrawal on D1 expressed by WE’s symptoms. They showed that plasmatic Tau, NFL and UCHL1 are biomarkers of alcohol use disorders in alcoholic patients notably after cessation. Thus the invention relates a method for predicting alcohol use disorders (AUD) and their complications in a subject in need thereof comprising i) determining in a sample obtained from the subject the expression levels of at least one biomarker selected from the group consisting of Tau, NFL and UCHL1. [post_date] => 2023-03-06 10:05:17 [post_modified] => 2024-09-11 15:53:52 [ID] => 4893 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a6d3ef02-a1a3-f19e-069b-6405ae37835e [etat_fiche_online] => en_ligne [date_application] => 21-06-2022 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO21348-D1 [keywords] => Alcohol Use Disorder, Diagnosis, Prognosis, Blood Biomarker, Alcohol Withdrawal [pub_scient_inv_dispo] => Addict Biol, 2022 Nov 27, Clergue-Duval et al, Plasma tau, NfL, GFAP and UCHL1 as candidate biomarkers of alcohol withdrawal-associated brain damage: A pilot study, doi: 10.1111/adb.13232. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => VORSPAN Florence,CLERGUE-DUVAL Virgile,BELLIVIER Frank,QUESTEL Frank,PAQUET Claire [number_application] => European Procedure (Patents) (EPA) - 21 Juin 2022 - 22 305 898.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• AddictionTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 105 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Addiction, Alcohol addiction, Biomarker, Biomarker, Central Nervous System, Human POC, Immunoassay [taxonomieurl] => Addiction, Alcohol addiction, Biomarker, Biomarker, Central Nervous System, Human POC, Immunoassay ) [106] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEW METHOD TO DIAGNOSE INFLAMMATORY DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/new-method-to-diagnose-inflammatory-diseases/ [post_content] => The present invention relates to the diagnostic of inflammatory diseases. The inventors described methods using NET biomarkers as diagnostic biomarkers for inflammatory diseases. COVID-19, Lupus or mCRC are used here as illustrative models for investigating an inflammatory disease. Examples in highlighting variation of the respective correlation of NET biomarkers in this invention rely on the determination of the NET main constituents: (i), DNA as determined by examining the amount of circulating DNA (cirDNA) that corresponds to the amount of NET as being degradation by-products that are released into the circulation; (ii) NE; and (iii), MPO; as well as the detection of a blood compound being indirectly associated to NET formation like the anti-cardiolipin auto-antibody. The invention provides threshold values of NE, MPO, cir-nDNA, and cir-mtDNA blood concentrations and of MNR that can be combined to diagnose/screen individuals. Thus the invention relates to a method for diagnosing a subject for an inflammatory disease comprising the steps of i) determining in a sample obtained from the subject the level of at least one marker selected in the group consisting in NET protein markers, cir-nDNA, cir-mtDNA and/or a cir-DNA fragmentation index. [post_date] => 2023-03-03 19:15:02 [post_modified] => 2024-09-11 15:53:52 [ID] => 4892 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 635af42c-f35f-1a1e-6418-64023a0de313 [etat_fiche_online] => en_ligne [date_application] => 06-08-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20525-D1 [keywords] => Inflammatory disease, Diagnosis, Net protein marker, cf-DNA, cir-DNA fragmentation index, Neutrophil extracellular traps (NET) [pub_scient_inv_dispo] => J Med Virol. 2023 Jan, Pisareva et al., Persistence of neutrophil extracellular traps and anticardiolipin auto?antibodies in post?acute phase COVID?19 patients, doi: 10.1002/jmv.28209Genome Med. 2022, Pisareva et al. Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA ,doi: 10.1186/s13073-022-01125-8 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => THIERRY Alain,PISAREVA Ekaterina,PASTOR Brice [number_application] => European Procedure (Patents) (EPA) - 06 Août 2021 - 21 306 103.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,sequencing [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• ImmunologyTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 106 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Inflammation, Sequencing [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Inflammation, Sequencing ) [107] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND KITS FOR IDENTIFYING AND QUANTIFYING STORAGE-INDUCED MICROERYTHROCYTES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-kits-for-identifying-and-quantifying-storage-induced-microerythrocytes/ [post_content] => Refrigerated storage of red cell concentrates (RCC) for transfusion is associated with the accumulation of various alterations to the red blood cells (RBCs). Among these, a subpopulation of small RBCs defined as storage-induced microerythrocytes (SMEs) accumulates during storage. The SMEs subpopulation correlates with transfusion recovery. Quantification of this morphologically-altered RBC subpopulation using flow cytometry would be a valuable tool to evaluate RCC quality. In the present invention, RBC obtained at the beginning or at the end of storage from RCC stored in SAGM in blood bank conditions were treated with a carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) staining protocol and were finally analysed by flow cytometry to assess the intensity of CFSE staining. The inventors observed the accumulation of a CFDA-SEhigh subpopulation by flow cytometry that accounted for 0.8% and 36.3% at day 3 and 42 of storage, respectively. Images confirmed that the CFDA-SEhigh subpopulation mostly contains SMEs. Thus SMEs can now be simply quantified using a common fluorescent dye and a standard flow cytometer. [post_date] => 2023-03-03 17:30:01 [post_modified] => 2024-09-11 15:53:49 [ID] => 4891 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2f545daf-b231-c294-bd6f-6402219fe7d4 [etat_fiche_online] => en_ligne [date_application] => 14-12-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20517-D1 [keywords] => Red Blood Cell Concentrate, Transfusion, storage-induced microerythrocytes [pub_scient_inv_dispo] => Front Physiol, 2022 Feb 23, Marin et al., Storage-Induced Micro-Erythrocytes Can Be Quantified and Sorted by Flow Cytometry, doi: 10.3389/fphys.2022.838138. eCollection 2022. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => AMIREAULT Pascal,BUFFET Pierre,ROUSSEL Camille,MARIN Mickaël,PELTIER Sandy,DUSSIOT Michaël [number_application] => European Procedure (Patents) (EPA) - 14 Déc. 2021 - 21 306 765.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Hematological DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 107 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Hematological Disorders, Human POC, Method [taxonomieurl] => Biomarker, Biomarker, Hematological Disorders, Human POC, Method ) [108] => stdClass Object ( [post] => stdClass Object ( [post_title] => IVIG Composition and Method of Treatment of Antibody Deficient Patients [guid] => https://technology-offers.inserm-transfert.com/offer/ivig-composition-and-method-of-treatment-of-antibody-deficient-patients/ [post_content] => The invention is in the field of therapy of antibody deficiencies such as immune diseases and inflammatory disorders. The inventors demonstrate for the first time the convergence of intestinal IgA and serum IgG responses toward the same microbial targets, under homeostatic conditions. Private anti-microbiota IgG specificities are induced in IgA-deficient patients, but are not found in IgG pools from healthy donors, partially explaining why substitutive IgG (IVIG) cannot regulate antibody deficiency-associated gut dysbiosis and intestinal translocation. Finally, in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Accordingly, the invention relates to IVIGs (Intravenous immunoglobulins) composition containing at least 1% of immunoglobulins (Ig) from SIgAd (Selective IgA deficiency) patient and their use in the treatment of antibody deficiency disorders such as immune diseases, inflammatory disorders and autoimmune disease. [post_date] => 2023-03-03 10:35:02 [post_modified] => 2024-09-11 15:43:12 [ID] => 4890 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a8686d96-5e02-ef05-8ae9-6401b92e86f3 [etat_fiche_online] => en_ligne [date_application] => 28-10-2019 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18376-T1 [keywords] => IgG, IgA, IVIG, Antibody deficiencies [pub_scient_inv_dispo] => J Allergy Clin Immunol. 2019 Apr;143(4):1575-1585.e4. doi: 10.1016/j.jaci.2018.09.036. Epub 2018 Dec 13 [access_to_detailed_offer] => /wp-content/uploads/BIO18376-T1_Gorochov.pdf [rare_disease] => false [second_indication] => false [inventors] => GOROCHOV Guy,FADLALLAH Jehane,LARSEN Martin,STERLIN Delphine [number_application] => European Procedure (Patents) (EPA) - 29 Oct. 2018 - 18 306 409.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 108 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Target, Target, Validation in vivo [taxonomieurl] => Drug, Immunology, Target, Target, Validation in vivo ) [109] => stdClass Object ( [post] => stdClass Object ( [post_title] => Use of IRAP Inhibitors for the Treatment of Inflammatory Diseases [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4887 [post_content] => Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute degranulation is followed by a late activation phase involving synthesis and secretion of cytokines, growth factors and other inflammatory molecules via the constitutive pathway that remains ill-defined. Here the inventors describe a role for an insulin-responsive vesicle-like endosomal compartment, marked by insulin-regulated aminopeptidase (IRAP), in the secretion of TNF-? and IL-6 in mast cells and macrophages. IRAP-deficient mice are protected from TNF-dependent kidney injury and inflammatory arthritis. In the absence of IRAP, TNF fails to be efficiently exported from the Golgi. Chemical targeting of IRAP+ endosomes reduced pro-inflammatory cytokine secretion thereby highlighting this compartment as a promising target for the therapeutic control of inflammation. Thus the present invention relates to the use of IRAP inhibitors for the treatment of inflammatory diseases. [post_date] => 2024-06-07 11:32:27 [post_modified] => 2024-09-24 11:10:03 [ID] => 4887 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 48831228-be8e-a547-3fc4-63ff57c3bcf0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO21469-T1 [keywords] => IRAP, Inflammatory diseases, Mast cells, Macrophages [pub_scient_inv_dispo] => J Allergy Clin Immunol. 2023 Jan 25;S0091-6749(23)00090-8. doi: 10.1016/j.jaci.2023.01.014 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO21469-T1_Hermine.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => HERMINE Olivier,RIGNAULT-BRICARD Rachel,VAN ENDERT Peter,DUSSIOT Michaël,TROVATI MACIEL Thiago,WEIMERSHAUS Mirjana,CARVALHO Caroline [number_application] => European Procedure (Patents) (EPA) - 01 Déc. 2021 - 21 306 677.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Rheumatoid ArthritisTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 109 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Rheumatoid Arthritis, Target, Target, Validation in vivo [taxonomieurl] => Drug, Immunology, Rheumatoid Arthritis, Target, Target, Validation in vivo ) [110] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-modulating-macrophages-polarization/ [post_content] => Inventors have surprisingly found that Emricasan is a much more potent inhibitor of monocyte differentiation compared to q-VD-OH by its ability to efficiently inhibit caspase-8, which is instrumental to this process. In addition, they have demonstrated that Emricasan alleviates the IL4-mediated M2-like polarization of human macrophages. Moreover, Emricasan also hampers bleomycin-induced pulmonary fibrosis in mice, a disease associated with an infiltration of M2-macrophages. Finally, caspase-8 deficient mice were found to be resistant to bleomycin-induced pulmonary fibrosis. As a whole, their findings indicate that the beneficial effect of Emricasan relies on its ability to inhibit caspase-8, and its capacity to prevent monocyte differentiation and M2 polarization of macrophages. Accordingly, the invention relates to a caspase 8 inhibitor for use in the polarization of macrophages. [post_date] => 2023-02-23 17:05:20 [post_modified] => 2024-09-20 16:10:02 [ID] => 4881 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6fdd1ad6-e3c1-3723-2694-5f6d9adbd36f [etat_fiche_online] => en_ligne [date_application] => 2019-10-03 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO19407-T1 [keywords] => [pub_scient_inv_dispo] => Reprogramming monocyte-derived macrophages through caspase inhibition Chantreuil P et al. OncoImunology 2022 VOL 11 issue 1 Article: 2015859 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO19407-T1_Auberger.pdf [rare_disease] => 1 [second_indication] => 0 [inventors] => AUBERGER Patrick,JACQUEL Arnaud,CHANTREUIL Paul,ROBERT Guillaume [number_application] => European Procedure (Patents) (EPA) - 03 Oct. 2019 - 19 306 276.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 110 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Idiopathic pulmonary fibrosis, Method, Respiratory Disease, Small Molecule, Target, Validation in vivo [taxonomieurl] => Drug, Idiopathic pulmonary fibrosis, Method, Respiratory Disease, Small Molecule, Target, Validation in vivo ) [111] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING PULMONARY ALVEOLAR PROTEINOSIS RELATED TO MARS MUTATIONS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-pulmonary-alveolar-proteinosis-related-to-mars-mutations/ [post_content] => The present invention relates to a method for treating pulmonary alveolar proteinosis related to MARS gene mutations in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of supplementation of methionine and/or its derivatives. Pulmonary alveolar proteinosis related to mutations in the gene encoding the methionine tRNA synthetase is a severe, early-onset lung disease that also associates liver involvement, failure to thrive, and systemic inflammation. Inventors describe an infant affected by this disease who was successfully treated by oral methionine supplementation. After three months of treatment she was free of respiratory symptoms, inflammation and cholestasis resolved, and there was a catchup in growth. Her bronchoalveolar lavage fluid was free of extracellular lipoproteinaceous material. Functional assays on peripheral monocytes, initially altered, normalized. This study paves the way for similar strategies in other tRNA synthetase deficiencies. [post_date] => 2023-02-23 16:45:05 [post_modified] => 2024-09-20 16:05:03 [ID] => 4880 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 84b62e04-15fc-a86a-aa8b-62ece2350fd1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO20130-T1 [keywords] => [pub_scient_inv_dispo] => Methionine supplementation for multi-organ dysfunction in MetRS-related pulmonary alveolarproteinosis Hadchouel A. et al. Eur Respir J. 2021 Sep 9:2101554. [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO20130-T1_Hadchouel.pdf [rare_disease] => 1 [second_indication] => 0 [inventors] => HADCHOUEL-DUVERGE Alice,SCHIFF Manuel,PONTOIZEAU Clément [number_application] => European Procedure (Patents) (EPA) - 26 Mai 2021 - 21 305 689.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 111 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Clinical Trial, Drug, Method, Phase 2, Respiratory Disease [taxonomieurl] => Clinical Trial, Drug, Method, Phase 2, Respiratory Disease ) [112] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF B CELL DEPLETING AGENTS FOR THE TREATMENT OF RHEUMATIC HEART DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-b-cell-depleting-agents-for-the-treatment-of-rheumatic-heart-disease/ [post_content] => Rheumatic heart disease (RHD) ranks as one of the most serious cardiovascular scourges of the past century and remains a force to be reckoned with in the developing world. Using the B-HOT panel, developed in part by our team, and based on heatmap analysis, we show two distinct transcriptomic profiles between inflammatory burden region of RHD valves patients (n=13) and control valves (without lesions, n=10). Our differential gene expression analysis between those 2 groups show several genes overexpressed in RHD group compared to control valves. Interestingly, and as potential therapeutic targets, genes related to CD20 (MS4A1, MS4A2) are among genes that are differentially expressed. Taken together, these results suggest a potential role for CD20 in inflammatory responses of RHD valves lesions. Anti-CD20 antibodies, like Rituximab (CD20), would be potential therapeutic molecules to be used on RHD patients. [post_date] => 2023-02-23 15:15:03 [post_modified] => 2024-09-11 15:43:06 [ID] => 4879 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ce9308ca-9289-ff19-b38d-62b18b93779b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21254-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => JOUVEN Xavier,LOUPY Alexandre [number_application] => European Procedure (Patents) (EPA) - 01 Juin 2021 - 21 305 727.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Cardiovascular DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 112 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Candidate drug, Cardiovascular Diseases, Drug, Method [taxonomieurl] => Candidate drug, Cardiovascular Diseases, Drug, Method ) [113] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR IMPROVING RELAXATION OF STRIATED MYOCYTES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-improving-relaxation-of-striated-myocytes/ [post_content] => The Inventors developed conditions allowing to efficiently detect differences in cardiomyocytes relaxation phases associated with increased cardiomyocytes stiffness. Theyused a library of patient-specific human induced pluripotent stem cells (hiPSC) either from healthy donors or carrying mutations (i.e., MYH7 and BRAF mutations) associated with hypertrophic cardiomyopathy, a condition typically associated with impaired diastolic function as well as an increase in cardiomyocytes passive stiffness. They performed a high throughput screening on hiPSC-derived cardiac cells to identify microRNAs capable of modifying the relaxation rates of cardiomyocytes. In particular, they set up a large-scale functional genomics using miRNAs screening. All identified miRNAs were tested for their impact on cardiac cells movement and calcium transient. miRNAs with the highest impact were in particular tested on ECTs and changes in diastolic function, were measured and compared to the results obtained at the cell level. They manipulated the most interesting ’hits’ in 3D models using similar readouts as in primary assays. They tested the impact of the positive ’hits’ in mechanical models (developed during the exploratory part) and establish physiological and biochemical mechanisms of action of the identified key proteins. They finally identified two promisingmiRNAs that could be used for improving striated myocytes relaxation and, more generally, to alleviate symptoms related to striated muscle stiffness, in particular in the context of heartfailure with a preserved ejection fraction (HFpEF). [post_date] => 2023-02-23 15:05:19 [post_modified] => 2024-09-11 15:43:06 [ID] => 4878 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c167f7c9-b3f0-fd79-5cf9-62b18b033159 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21052-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => true [inventors] => HULOT Jean-Sébastien,VERMERSCH Eva [number_application] => European Procedure (Patents) (EPA) - 09 Juil. 2021 - 21 305 954.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Left ventricular dysfunctionTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 113 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cardiovascular Diseases, Drug, Hit - validation in vivo, Left ventricular dysfunction, Oligonucleotide, Product, Product [taxonomieurl] => Cardiovascular Diseases, Drug, Hit - validation in vivo, Left ventricular dysfunction, Oligonucleotide, Product, Product ) [114] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF INHIBITORS OF PHOSPHATASE ACTIVITY OF SOLUBLE EPOXIDE FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-inhibitors-of-phosphatase-activity-of-soluble-epoxide-for-the-treatment-of-cardiometabolic-diseases/ [post_content] => The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by potentiating and/or exacerbating hypertension, hyperlipidemia, atherosclerosis and cardiomyopathy, leading to increasing use of the term u201ccardiometabolic diseaseu201d (CMD) to encompass the many facets of this complex syndrome. The inventors assessed the role of the soluble epoxide hydrolase (she) phosphatase domain in metabolism and cardiovascular system, by generating sEH phosphatase knock-in (KI) animals (rats). They unexpectedly revealed that inhibition of the phosphatase domain of sEH could improve cardiac systolic function, decrease body weight, increase insulin sensitivity. More over under high fat diet, the animals have a decreased body weight gain, were protected against the development of insulin resistance, hepatic steatosis and cardiac hypertrophy. Inhibition of the phosphatase domain of sEH could thus represent a new pharmacological target in the treatment of cardiometabolic diseases. [post_date] => 2023-02-23 13:45:03 [post_modified] => 2024-09-11 15:44:14 [ID] => 4876 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e8a6cf26-882e-d19c-4b34-5cd038a94335 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18299-T1 [keywords] => [pub_scient_inv_dispo] => Hydrolase activity) Varennes, Olivier et al. u201cThe Metabolism of Epoxyeicosatrienoic Acids by Soluble Epoxide Hydrolase Is Protective against the Development of Vascular Calcification.u201d International journal of molecular sciences vol. 21,12 4313. 17 Jun. 2020, doi:10.3390/ijms21124313 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => true [inventors] => BELLIEN Jérémy,DJERADA Zoubir [number_application] => European Procedure (Patents) (EPA) - 17 Sept. 2018 - 18 306 207.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Cardiovascular DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 114 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cardiovascular Diseases, Drug, Target, Target, Validation in vivo [taxonomieurl] => Cardiovascular Diseases, Drug, Target, Target, Validation in vivo ) [115] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF TREATMENT OF INFLAMMATORY BOWEL DISEASES [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4875 [post_content] => Inventor’s general objective was to investigate the potential role of mucosal thrombin in intestinal inflammation and its mechanisms of action. First, they evaluated whether there is an increased presence of active thrombin in Crohn’s Disease (CD): both in patient tissues and in an animal models of IBD. Second, they investigated the effects on mucosal damage and tissue dysfunction resulting from the intracolonic administration of thrombin at a dose comparable to what was detected in the tissue of CD patients. Third, they demonstrated in IBD mouse model that pharmacological inhibition of mucosal thrombin activity is a new therapeutic approach to this debilitating condition, such inhibition, allows to significantly decrease all inflammatory parameters including the fecal bleeding score. Finally, inventors showed that human mucosa- associated commensal biofilms exposed to increasing concentrations of human thrombin exhibited increase in their virulent properties specifically, increased bacterial invasion into human epithelial cell line). So, the present invention relates to a method for preventing or treating inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) by targeting locally the mucosal Thrombin. [post_date] => 2023-02-23 15:45:03 [post_modified] => 2024-09-20 15:05:04 [ID] => 4875 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 59b453b1-8fe6-2524-8bb6-63f5dab07682 [etat_fiche_online] => en_ligne [date_application] => 2021-09-06 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO20161-T1 [keywords] => Mucosal thrombin antagonist, PAR1 antagonist, Inflammatory bowel disease [pub_scient_inv_dispo] => J Crohns Colitis. 2021 May 4;15(5):787-799. doi: 10.1093/ecco-jcc/jjaa229.Nat Commun. 2019 Jul 19;10(1):3224. doi: 10.1038/s41467-019-11140-w.Br J Pharmacol. 2018 Sep;175(18):3656-3668. doi: 10.1111/bph.14430. Epub 2018 Aug 7. [access_to_detailed_offer] => /wp-content/uploads/BIO20161-T1_Vergnolles.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => VERGNOLLE Nathalie,DERAISON Céline,MOTTA Jean-Paul [number_application] => European Procedure (Patents) (EPA) - 07 Sept. 2020 - 20305988.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 115 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target, Target, Validation in vivo [taxonomieurl] => Drug, Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target, Target, Validation in vivo ) [116] => stdClass Object ( [post] => stdClass Object ( [post_title] => Safety and Efficacy of MAIT cells for Adoptive Cell Therapy Prevention of GvHD [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4873 [post_content] => The inventors explored in an allogeneic situation the regulatory potential of Mucosal-Associated Invariant T cells (MAIT cells), a population of unconventional T cells that exhibit potent antibacterial activity, expressing a semi-invariant TCR which recognizes vitamin B2 derivatives of microbial origin presented by the MR1 molecule. In particular, the inventors used i) an allogenic reaction model in vitro (mixed lymphocyte reaction, MLR) and ii) murine model of xenogeneic aGvHD They first verified that human MAIT cells do not proliferate in response to allogeneic stimulation in vitro (MLR) or in vivo (immunodeficient mice) alone but require for their expansion both an inflammatory environment and TCR ligation by its ligand. In contrast, MAIT cells are able to inhibit the proliferation of allospecific LT in vitro in a dose-dependent manner. Furthermore, the adoptive transfer of MAIT cells in a mouse model of xeno-GVHD resulted in a delay in early or late GvHD development. Altogether, these data describe a new regulatory function of MAIT cells in an allogeneic context, allowing us to consider their use in cell therapy to limit GvHD. [post_date] => 2024-06-07 11:32:26 [post_modified] => 2024-09-18 18:20:02 [ID] => 4873 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7abf7cf5-e918-a9a7-96ef-6013e3c4bf40 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO20499-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => CAILLAT-ZUCMAN Sophie,TALVARD-BALLAND Nana [number_application] => European Procedure (Patents) (EPA) - 10 Déc. 2020 - 20 306 528.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• TransplantationTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 116 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Graft Versus Host Disease (GVHD), Immunology, Method, Transplantation [taxonomieurl] => Drug, Graft Versus Host Disease (GVHD), Immunology, Method, Transplantation ) [117] => stdClass Object ( [post] => stdClass Object ( [post_title] => New Method to Treat Acidosis Related Diseases [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4856 [post_content] => The present invention relates to the treatment of acidosis related diseases. In this study, the inventors have investigated how human monocytes adapt, survive and differentiate into macrophages under lactic acidosis. Experiments were conducted under atmospheric oxygen and in the presence of glucose, to rule out an effect of oxygen or glucose deprivation. Prolonged exposure to LA affected monocyte/macrophage metabolism. Extracellular acidosis induced mitochondrial membrane depolarization and significantly decreased nutrient consumption, resulting in a dependence of the macrophages on a transient phase of autophagy for survival. In fasting conditions, hepatocytes produce the ketone bodies acetoacetate (AcAc) and ?-hydroxybutyrate (?-OHB) that constitute alternative fuel for extrahepatic cells. The inventors found here that AcAc protected the mitochondria from acidosis-induced depolarization and mitophagy, allowing the cells to continue to metabolize nutrients, thereby avoiding the need for self-catabolism to survive. Acetoacetate therefore appears to be a crucial alternative fuel metabolite of potential therapeutic interest to increase tissue tolerance to lactic acidosis. Thus, the invention relates to the acetoacetate (AcAc) for use in the treatment of acidosis related diseases. [post_date] => 2023-02-23 15:50:04 [post_modified] => 2024-09-18 19:00:02 [ID] => 4856 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4263e7f2-4e21-f34b-939a-63f0f6f1cdaa [etat_fiche_online] => en_ligne [date_application] => 2022-07-07 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19221-T1 [keywords] => Acetoacetate, Acidosis [pub_scient_inv_dispo] => Nat Commun. 2021 Dec 8;12(1):7115. doi: 10.1038/s41467-021-27426-x [access_to_detailed_offer] => /wp-content/uploads/BIO19221-T1_Delneste.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => DELNESTE Yves,ASFAR Pierre,BEAUVILLAIN Céline,JEANNIN Pascale,PROCACCIO Vincent [number_application] => European Procedure (Patents) (EPA) - 08 Juil. 2021 - 21305941.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 117 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Hit - validation in vitro, Immunology, Method, Product, Small Molecule [taxonomieurl] => Drug, Hit - validation in vitro, Immunology, Method, Product, Small Molecule ) [118] => stdClass Object ( [post] => stdClass Object ( [post_title] => Targeting the Secreted IgE Poly-A Signal Allows Specific Inhibition of Allergen-Specific IgE Production [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4854 [post_content] => Immunoglobulins (Ig) are expressed either on the surface of B cells or as secreted antibodies by plasma cells that represents the final stage of B cell differentiation. The present invention involves the use of antisense oligonucleotides (ASOs) for either reducing the production of the secreted form or either reducing the production of the membrane form. In particular, the inventors show that antisense oligonucleotides masking the secretory polyadenylation signal induce a decrease in the production of the secreted immunoglobulin. Inversely, antisense oligonucleotides masking the membrane polyadenylation signal induce a decrease in the production of the membrane-anchored immunoglobulin. The proof of concept has been obtained using an ASO hybridizing to the polyadenylation signal (PAS) sequence of the transcript encoding the secreted form of IgE. Indeed, the targeting of this PAS sequence induces a drastic decrease in IgE production. Thus the choice of the right antisense oligonucleotide would be suitable for the treatment of diseases associated to B-cell development (e.g. autoimmune diseases, inflammation or B-cell malignancies). [post_date] => 2023-03-01 11:45:04 [post_modified] => 2024-09-11 15:43:09 [ID] => 4854 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2bccbaca-279c-4d92-e2bd-5e7cee46eee7 [etat_fiche_online] => en_ligne [date_application] => 03-06-2020 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19135-T1 [keywords] => Antisens oligonucleotide, Immunoglobulin, Allergy, B Cell Lymphomas [pub_scient_inv_dispo] => J Allergy Clin Immunol. 2022 May;149(5):1795-1801. doi: 10.1016/j.jaci.2021.09.039. Epub 2021 Nov 2 [access_to_detailed_offer] => /wp-content/uploads/BIO19135-T1_Delpy.pdf [rare_disease] => false [second_indication] => false [inventors] => DELPY Laurent,MARCHALOT Anne,COGNE Michel,LAFFLEUR Brice [number_application] => European Procedure (Patents) (EPA) - 04 Juin 2019 - 19305716.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 118 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Allergies, Antisense Oligonucleotide, Drug, Hit - validation in vivo, Immunology, Oligonucleotide, Product, Product [taxonomieurl] => Allergies, Antisense Oligonucleotide, Drug, Hit - validation in vivo, Immunology, Oligonucleotide, Product, Product ) [119] => stdClass Object ( [post] => stdClass Object ( [post_title] => New Vaccinal Strategy to Prevent or Treat Rheumatoid Arthritis [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4852 [post_content] => The present invention relates to field of treatment of rheumatoid arthritis. The inventors propose that PAD4, one of the enzymes which convert arginine into citrulline, is a target antigen for T cells that help the production of ACPA. They recently demonstrated that PAD immunization triggers anti-citrullinated fibrinogen antibody production in normal mice. Here, they demonstrate that the risk (OR) to develop RA associated with each of 12 HLA-DRB1 genotype correlates with the likelihood for the two HLA-DR molecules encoded by each genotype to bind at least one random peptide from PAD4, but not from citrullinated or native fibrinogen. PBLs from patients wih RA, PsA and controls proliferate to PAD4 and they identify, notably, a peptide from PAD4, p8 (SEQ ID NO: 6), that stimulates T cells from RA patients and a few patients with PsA. Proliferative responses to p8 are associated with RA, shared epitope positive HLA-DR alleles and antibodies to PAD4. Thus the present invention relates to a peptide derived from the PAD4 protein and its use in the treatment and prevention of rheumatoid arthritis. [post_date] => 2024-09-20 14:55:07 [post_modified] => 2024-09-20 14:55:07 [ID] => 4852 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 56531647-e1b3-c5ed-c71f-63f087837c1d [etat_fiche_online] => en_ligne [date_application] => 2020-03-06 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19058-T1 [keywords] => Rheumatoid arthritis, Vaccine, PAD4 [pub_scient_inv_dispo] => Arthritis Rheumatol. 2020 Jun;72(6):903-911. doi: 10.1002/art.41189. Epub 2020 Apr 26Proc Natl Acad Sci USA. 2017 Nov 21;114(47):E10169-E10177. doi: 10.1073/pnas.1713112114. Epub 2017 Nov 6. [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO19058-T1_Roudier-1.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => ROUDIER Jean,AUGER Isabelle,BALANDRAUD Nathalie [number_application] => European Procedure (Patents) (EPA) - 07 Mars 2019 - 19 305 265.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Rheumatoid ArthritisTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 119 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Identification, Immunology, Rheumatoid Arthritis, Target, Target, Vaccine [taxonomieurl] => Biologic, Drug, Identification, Immunology, Rheumatoid Arthritis, Target, Target, Vaccine ) [120] => stdClass Object ( [post] => stdClass Object ( [post_title] => Nanobody Against ELA2A to Treat Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4844 [post_content] => The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn’s Disease, Ulcerative Colitis, Celiac disease, and Pouchitis. [post_date] => 2023-03-02 18:00:02 [post_modified] => 2024-09-20 15:05:05 [ID] => 4844 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ff687fe5-66f8-4c70-afed-266b69a3dbd3 [etat_fiche_online] => en_ligne [date_application] => 2017-06-16 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO1508601 -T1 [keywords] => Inflammatory Bowel Diseases, ELA2A [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO1508601-T1_Vergnolles.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => ROLLAND Corinne,DERAISON Céline [number_application] => European Procedure (Patents) (EPA) - 16 Juin 2016 - 16 305 731.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 120 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Target, Target, Validation in vivo [taxonomieurl] => Drug, Immunology, Target, Target, Validation in vivo ) [121] => stdClass Object ( [post] => stdClass Object ( [post_title] => Hepcidin Antagonists for Use in the Treatment of Inflammation [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4840 [post_content] => The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases. TLR4-dependant intestinal hepcidin induces neutrophil migration and intestinal inflammation, and are expressed by lipopolysaccharides. The hepcidin is a proinflammatory molecule in macrophages which demonstrated its interest in inflammatory bowel diseases (IBDs). [post_date] => 2024-10-08 18:20:02 [post_modified] => 2024-10-08 18:20:04 [ID] => 4840 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e5e439de-495a-4d49-957e-11a2cb9e35e5 [etat_fiche_online] => en_ligne [date_application] => 2016-03-14 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO14455-T1 [keywords] => Hepcidin, Inflammatory Bowel Disease, Inflammation [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO14455-Hepcidin-Antagonists-for-Use-in-the-Treatmet-Of-Inflammation.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => ZUMERLE Sara,MATHIEU Jacques [number_application] => European Procedure (Patents) (EPA) - 13 Mars 2015 - 15 159 033.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 121 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Identification, Immunology, Product, Target [taxonomieurl] => Drug, Identification, Immunology, Product, Target ) [122] => stdClass Object ( [post] => stdClass Object ( [post_title] => UALH hAR cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4825 [post_content] => UALH were generated by transfection of osteocarcinoma cancer U2OS cells with the (ARE-RAD9)6-collagenase-Luciferase-SV40-hygromycin plasmid. UALH hAR cells were generated by co-transfection of UALH cells with the plasmids pSG5-hAR-puromycin and pSG5-hAR-Renilla-luciferase-(ARE-RAD9)6-collagenase-Luciferase-SV40-neomycin. The plasmid (ARE RAD9)6-Coll-Luc-SVNeo contains a luciferase gene driven by the mouse mammary tumor virus promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-human AR-puromycin enables to express the human androgen receptor (hAR). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. The plasmid pSG5-hAR-Renilla-Neomycin contains the gene coding for hAR under the control of the SV40 promoter, the Renilla luciferase reporter gene under the control of the constitutive human cytomegalovirus (CMV), the firefly luciferase gene under the control of six androgen response elements (ARE) from the RAD9 gene promoter and placed upstream of the collagenase promoter, and the resistance gene to neomycin under the control of the SV40 promoter. This third plasmid has been included to over-express both AR and luciferase expression. [post_date] => 2023-05-19 18:45:04 [post_modified] => 2024-09-11 16:06:53 [ID] => 4825 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-e175521807d9221bcb51cfb4f70e2210 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00586 [keywords] => hAR, luciferase, pharmaceutical and environmental androgens [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 122 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [123] => stdClass Object ( [post] => stdClass Object ( [post_title] => HAHLH (hAhR) cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4817 [post_content] => HAHLH were generated by transfection of cervical cancer HeLa cells with the XRE(TnGCGTG)3-TATA-Luciferase-SV40-Hygromycin plasmid. The plasmid XRE(TnGCGTG)3-TATA -Luc-SVHygro contains a luciferase gene driven by three AhR responsive elements and a hygromycin gene under the control of SV40 promoter. [post_date] => 2023-05-19 18:45:02 [post_modified] => 2024-09-11 16:07:23 [ID] => 4817 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-eb4d18694df3a5f1e8e09f99bdbbf8e9 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00618 [keywords] => hAhR, luciferase, pharmaceutical and environmental hAhR ligands [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 123 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [124] => stdClass Object ( [post] => stdClass Object ( [post_title] => UALH cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4816 [post_content] => UALH were generated by transfection of osteocarcinoma cancer U2OS cells with the (ARE-RAD9)6-collagenase-Luciferase-SV40-hygromycin plasmid. The plasmid (ARE RAD9)6-Coll-Luc-SVNeo contains a luciferase gene driven by the mouse mammary tumor virus promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. [post_date] => 2023-05-19 18:45:04 [post_modified] => 2024-09-11 16:07:22 [ID] => 4816 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-8171feb486e7066faae644917086480b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00624 [keywords] => Luciferase, pharmaceutical and environmental androgens [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 124 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [125] => stdClass Object ( [post] => stdClass Object ( [post_title] => UG5LN cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4811 [post_content] => UG5LN were generated by transfection of osteocarcinoma cancer U20S cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. [post_date] => 2023-05-19 18:45:04 [post_modified] => 2024-09-11 16:07:21 [ID] => 4811 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-0756651e80aa8e920dd619a0c56d9a98 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00625 [keywords] => luciferase, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 125 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [126] => stdClass Object ( [post] => stdClass Object ( [post_title] => UG5LN GAL4-hMR cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4810 [post_content] => UG5LN were generated by transfection of osteocarcinoma cancer U2OS cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid.UG5LN GAL4-hMR cells were generated by transfection of UG5LN cells with the pSG5-puro plasmid pSG5-GAL4-human MR-puromycin.The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter.The pSG5-puro plasmid pSG5-human GAL4-hMR-puromycin enables to express the DNA binding domain of the yeast activator GAL4 (GAL4 DBD) followed by the ligand binding domain of the human mineralocorticoid receptor (hMR LBD). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:04 [post_modified] => 2024-09-11 16:07:22 [ID] => 4810 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-8b13f884f6f209aed1c4aaea96785ea7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00626 [keywords] => hMR, luciferase, metabolism, clearance, colon and liver cancer, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 126 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [127] => stdClass Object ( [post] => stdClass Object ( [post_title] => HRLN (hRAR alpha) cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4809 [post_content] => HRLN were generated by transfection of cervical cancer HeLa cells with the (RARE)3-TK-Luciferase-SV40-Neomycin plasmid. The plasmid (RARE)3-TK-Luc-SVNeo contains a luciferase gene driven by three retinoid receptor responsive element (RARE) in front of thymidine kinase promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. [post_date] => 2023-05-19 18:45:04 [post_modified] => 2024-09-11 16:07:23 [ID] => 4809 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-a6c318b4f97cf4bf75b451aa1529feac [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00623 [keywords] => hRAR alpha, luciferase, natural, pharmaceutical and environmental retinoids [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 127 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [128] => stdClass Object ( [post] => stdClass Object ( [post_title] => HELN hRAR alpha cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4808 [post_content] => HELN were generated by transfection of cervical cancer HeLa cells with the ERE-betaGlobin-Luciferase-SV40-Neomycin plasmid.HELN hRAR alpha cells were generated by transfection of HELN cells with the pSG5-puro plasmid pSG5-human RAR alpha (ER alpha DBD)-puromycin.The plasmid ERE-betaGlob-Luc-SVNeo contains a luciferase gene driven by estrogen receptor responsive element (ERE) in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter.The pSG5-puro plasmid pSG5-human RAR alpha (ER alpha DBD)-puromycin enables to express the human retinoid receptor alpha in which the DNA binding domain (DBD) has been replaced by the estrogen receptor alpha DBD. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-09-11 16:07:22 [ID] => 4808 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-5f9ba119f5dccb076aab23f276b5a475 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00620 [keywords] => hRAR alpha, luciferase, natural, pharmaceutical and environmental retinoids [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 128 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [129] => stdClass Object ( [post] => stdClass Object ( [post_title] => HG5LN GAL4-rTR beta cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4806 [post_content] => HG5LN were generated by transfection of cervical cancer HeLa cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. HG5LN GAL4-rTRalpha cells were generated by transfection of HG5LN cells with the plasmid pSG5-GAL4-rat TR beta-puromycin. The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-GAL4-rTR beta-puromycin enables to express the DNA binding domain of the yeast activator GAL4 (GAL4 DBD) followed by the ligand binding domain of the rat thyroid receptor beta (rTR beta LBD). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-09-11 16:07:23 [ID] => 4806 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-b2b8762b18ed68bbf957f7a48a33b017 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00621 [keywords] => TR beta, luciferase, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 129 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [130] => stdClass Object ( [post] => stdClass Object ( [post_title] => HELN cell line [guid] => https://technology-offers.inserm-transfert.com/?p=4805 [post_content] => HELN were generated by transfection of cervical cancer HeLa cells with the ERE-betaGlobin-Luciferase-SV40-Neomycin plasmid. The plasmid ERE-betaGlob-Luc-SVNeo contains a luciferase gene driven by estrogen receptor responsive element (ERE) in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. [post_date] => 2023-05-19 18:45:02 [post_modified] => 2024-09-11 16:07:22 [ID] => 4805 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-4f6945067a8862a6501d664323f007c4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00619 [keywords] => Estrogen receptors, luciferase, pharmaceutical and environmental estrogens [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 130 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [131] => stdClass Object ( [post] => stdClass Object ( [post_title] => HMLN (hGR) cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4745 [post_content] => HMLN were generated by transfection of cervical cancer HeLa cells with the MMTV- -Luciferase-SV40-Neomycin plasmid. HMLN hGR alpha cells were generated by transfection of HMLN cells with the plasmid pSG5-human GR-puromycin. The plasmid MMTV-Luc-SVNeo contains a luciferase gene driven by the mouse mammary tumor virus promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-human GR-puromycin enables to express the human glucocorticoid receptor (hGR). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-09-11 16:07:20 [ID] => 4745 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 71370af0-6266-a236-34d2-63777d0aae67 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00589 [keywords] => hGR, luciferase, pharmaceutical and environmental glucocorticoids [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 131 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [132] => stdClass Object ( [post] => stdClass Object ( [post_title] => HG5LN hPXR cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4744 [post_content] => HG5LN were generated by transfection of cervical cancer HeLa cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. HG5LN GAL4-hPXR cells were generated by transfection of HG5LN cells with the plasmid pSG5-GAL4-human PXR-puromycin. The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-human GAL4-hPXR-puromycin enables to express the DNA binding domain of the yeast activator GAL4 (GAL4 DBD) followed by the ligand binding domain of the human pregnane X receptor (hPXR LBD). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-08-28 12:24:18 [ID] => 4744 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9fc202c3-819b-2dfb-9b6b-63777def7f4a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00588 [keywords] => hPXR, luciferase, metabolism, clearance, colon and liver cancer, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 132 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [133] => stdClass Object ( [post] => stdClass Object ( [post_title] => HELN hPR (hERalpha DBD) cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4743 [post_content] => HELN were generated by transfection of cervical cancer HeLa cells with the ERE-betaGlobin-Luciferase-SV40-Neomycin plasmid.HELN hPR cells were generated by transfection of HELN cells with the pSG5-puro plasmid pSG5-human PR (ER alpha DBD)-puromycin.The plasmid ERE-betaGlob-Luc-SVNeo contains a luciferase gene driven by estrogen receptor responsive element (ERE) in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter.The pSG5-puro plasmid pSG5-human PR (ER alpha DBD)-puromycin enables to express the human progesterone receptor in which the DNA binding domain (DBD) has been replaced by the estrogen receptor alpha DBD. [post_date] => 2023-01-30 10:57:18 [post_modified] => 2024-09-11 16:07:21 [ID] => 4743 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a535c23a-9edb-59e4-8172-63777c012626 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00587 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 133 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [134] => stdClass Object ( [post] => stdClass Object ( [post_title] => HG5LN rTR alpha cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4741 [post_content] => HG5LN were generated by transfection of cervical cancer HeLa cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. HG5LN GAL4-rTRalpha cells were generated by transfection of HG5LN cells with the plasmid pSG5-GAL4-rat TR alpha-puromycin. The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-GAL4-rTR alpha-puromycin enables to express the DNA binding domain of the yeast activator GAL4 (GAL4 DBD) followed by the ligand binding domain of the rat thyroid receptor alpha (rTR alpha LBD). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-09-11 16:07:20 [ID] => 4741 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5dd60d72-7873-3a02-a60a-63777cfcd18f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00585 [keywords] => TR alpha, luciferase, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 134 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [135] => stdClass Object ( [post] => stdClass Object ( [post_title] => MELN (hER alpha) cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4739 [post_content] => MELN were generated by transfection of breasr cancer MCF-7 cells with the ERE-betaGlobin-Luciferase-SV40-Neomycin plasmid. The plasmid ERE-betaGlob-Luc-SVNeo contains a luciferase gene driven by estrogen receptor responsive element (ERE) in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. [post_date] => 2023-05-19 18:45:04 [post_modified] => 2024-09-11 16:07:19 [ID] => 4739 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1b1ca0ec-8e8f-c1f6-7836-63777c2b94f2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00583 [keywords] => Estrogen receptor alpha, luciferase, pharmaceutical and environmental estrogens [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 135 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [136] => stdClass Object ( [post] => stdClass Object ( [post_title] => PALM cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4738 [post_content] => PALM were generated by co-transfection of cervical cancer PC3 cells with the MMTV-Luciferase-SV40-Neomycin and the pSG5-human AR-puromycin plasmids. The plasmid MMTV-Luc-SVNeo contains a luciferase gene driven by the mouse mammary tumor virus promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-human AR-puromycin enables to express the human androgen receptor (hAR). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:04 [post_modified] => 2024-09-11 16:07:21 [ID] => 4738 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d985a667-8441-aa27-d893-63777c36447f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00582 [keywords] => hAR, luciferase, pharmaceutical and environmental androgens [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 136 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [137] => stdClass Object ( [post] => stdClass Object ( [post_title] => PrkcdG510S/G510S mice - Preclinical model of lupus [guid] => https://technology-offers.inserm-transfert.com/?p=4736 [post_content] => We introduced the Prkcd G510S mutation that we previously associated to a Mendelian cause of SLE in the mouse genome, by means of CRISPR-Cas9 gene editing. PrkcdG510S/G510S mice recapitulate the human phenotype, presenting with glomerulonephritis, splenomegaly, and various serum autoantibodies, including anti-nuclear, and had reduced lifespan. We demonstrate that this phenotype is linked to a B cell autonomous role of PRKCD in immune regulation. The penetrance of the lupus phenotype is 100% in this mouse model. [post_date] => 2023-01-04 18:55:01 [post_modified] => 2024-09-11 16:07:02 [ID] => 4736 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-763ebd15132adf8b48bc5caef4d59e38 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00581 [keywords] => Lupus mouse model; autoimmunity mouse model; preclinical model of lupus [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Proof of concept in vivoUses:
• Systemic Lupus ErythematosusTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => [first_name] => [last_name] => [wp_capabilities] => [wp_user_level] => [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 137 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Genomic variability, Immunology, Inflammation, Lupus nephritis, Proof of concept in vivo, Systemic Lupus Erythematosus [taxonomieurl] => Academic Research, Genomic variability, Immunology, Inflammation, Lupus nephritis, Proof of concept in vivo, Systemic Lupus Erythematosus ) [138] => stdClass Object ( [post] => stdClass Object ( [post_title] => HG5LN GAL4-hPPAR beta/delta cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4722 [post_content] => HG5LN were generated by transfection of cervical cancer HeLa cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. HG5LN GAL4-hPPAR beta/delta cells were generated by transfection of HG5LN cells with the plasmid pSG5-GAL4-human PPAR beta/delta-puromycin. The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-human GAL4-hPPAR beta/delta -puromycin enables to express the DNA binding domain of the yeast activator GAL4 (GAL4 DBD) followed by the ligand binding domain of the human peroxisome proliferator activated receptor receptor beta/delta (hPPAR beta/delta LBD). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-09-11 16:07:21 [ID] => 4722 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d90b8c45-e96f-5d99-6701-6363dd1eac3c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00569 [keywords] => hPPAR beta/delta, luciferase, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 138 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [139] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING CELL SENESCENCE ACCUMULATION RELATED DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-cell-senescence-accumulation-related-disease-2/ [post_content] => The inventors have surprisingly demonstrated that GD3 positive senescent cells inhibit NK cell in vitro and in vivo while GD3 negative senescent cells is associated with NK cell functionality, both with human or murine cells. The inventors’ results bring the proof of concept that GD3 expression may represent a Senescence-associated Immune Checkpoint (SIC) that determines senescent cell immunogenicity and identify GD3 and more generally SIC as a multi-hit target for age-associated diseases. Thus, GD3 may be a major step forward in the development of efficient anti-senescence immunotherapies. In particular, the present invention relates to a method for identifying whether a cell is in senescence process comprising the steps of: i) measuring the co-expression level of ST8Sia1 (GD3) with a senescence marker in a biological sample; ii) comparing the co-expression level measured at step i) with its predetermined reference value, and iii) concluding that the cell is in senescence process when the co-expression level of GD3 with a senescence marker is higher than its predetermined reference value or concluding that cell is not in senescence process when the co-expression level of GD3 with a senescence marker is lower or similar than its predetermined reference value. The present invention also relates a method for treating senescent cells accumulation related disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a GD3 inhibitor. [post_date] => 2022-11-03 13:35:01 [post_modified] => 2024-09-11 15:53:38 [ID] => 4719 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9cf2f804-ee40-2efb-a29f-6363b88bd3f0 [etat_fiche_online] => en_ligne [date_application] => 23-04-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19413-D1 [keywords] => Senescent cells, ageing, Scenescence-associated Immune Checkoint [pub_scient_inv_dispo] => https:/doi.org/10.1101/2021.04.23.440408 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CHERFILS Julien,GILSON Eric,ILTIS Charlène [number_application] => United States Of America (PSP) - 23 Avr. 2021 - 63/178,738 [technology_engineering] => [multidisciplinary_field] => ageing [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Respiratory DiseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 139 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Ageing, Animal POC, Biomarker, Biomarker, Idiopathic pulmonary fibrosis, Immunoassay, Method, Respiratory Disease, Transcriptomics [taxonomieurl] => Ageing, Animal POC, Biomarker, Biomarker, Idiopathic pulmonary fibrosis, Immunoassay, Method, Respiratory Disease, Transcriptomics ) [140] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEW METHOD TO EVALUATE PANCREATIC PROGNOSIS [guid] => https://technology-offers.inserm-transfert.com/offer/new-method-to-evaluate-pancreatic-prognosis/ [post_content] => The present invention relates to the prediction of the survival time of a patient suffering of a pancreatic cancer. In this study, the inventors aimed to determine whether PDAC could be stratified on the basis of their GT gene expression profiles involved in the biosynthesis of glycoconjugates. By using bioinformatic analysis of RNA-seq data focused on 169 GT genes from patient-derived xenografts (PDX), they have identified a combination of 19 GT, which was able to discriminate 3 clusters of PDAC associated with specific molecular profiles and clinical features of patients. These GT genes were validated on public databases as a prognostic glyco-signature, which could allow best patient care in the future and also highlight new potential targets for diagnosis and prognosis of PDAC. Thus, the invention relates to a method for predicting the survival time of a patient suffering from a pancreatic cancer comprising i) determining in a sample obtained from the patient the expression level of at least one gene selected in the group consisting in GALNT9, A4GNT, B3GALT5, B3GNT6, C1GALT1, FUT2, FUT3, FUT4, FUT6, GALNT4, GALNT6, GALNT12, GCNT1, GYG2, LFNG, MGAT5, ST6GALNAC1, ST8SIA3 and XYLT. [post_date] => 2022-10-19 14:20:02 [post_modified] => 2024-09-11 15:53:37 [ID] => 4709 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1c5f04b0-a0b9-4136-cada-634ffc218b81 [etat_fiche_online] => en_ligne [date_application] => 29-03-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19060-D1 [keywords] => Pancreatic Cancer, RNA signatiure, RNA-Seq, Glycoprotein metabolism signature, Prognosis [pub_scient_inv_dispo] => EBioMedicine, 2021 Sep, Abd-El-Halim et al. , A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis, doi: 10.1016/j.ebiom.2021.103541. Epub 2021 Aug 20. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MAS Eric,SILVY Françoise,IOVANNA Juan-Lucio,DUSETTI Nelson,MOHAMED ABD-EL-HALIM Yousra [number_application] => European Procedure (Patents) (EPA) - 29 Mars 2021 - 21 305 391.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Pancreatic CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 140 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Method, Oncology, Pancreatic Cancer, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Method, Oncology, Pancreatic Cancer, Transcriptomics ) [141] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS CCR8 [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-and-treatment-of-t-cell-lymphomas-ccr8/ [post_content] => T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sézary cells and showed the expression of CCR8 (CD198) by Sézary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas. [post_date] => 2022-10-19 13:40:03 [post_modified] => 2024-09-11 15:53:36 [ID] => 4708 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 589a57bb-131a-c004-478b-634ff3314d7c [etat_fiche_online] => en_ligne [date_application] => 23-03-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO21120-D1 [keywords] => T-Cell Lymphoma, Diagnostic, Prognosis, CCR8, FACS based approach [pub_scient_inv_dispo] => Blood Adv, 2022 Jun 14, Giustiniani et al., CCR8 is a new therapeutic target in cutaneous T-cell lymphomas, doi: 10.1182/bloodadvances.2021006512. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BENSUSSAN Armand,DE MASSON Adele,BATTISTELLA Maxime,GIUSTINIANI Jérôme,BAGOT Martine,ORTONNE Nicolas,MARIE-CARDINE Anne [number_application] => European Procedure (Patents) (EPA) - 23 Mars 2021 - 21 305 356.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 141 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Method, Oncology, Sezary syndrome [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Lymphoma, Method, Oncology, Sezary syndrome ) [142] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR DIAGNOSING PANCREATIC CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-diagnosing-pancreatic-cancer/ [post_content] => The present invention relates to the diagnostics of pancreatic cancer. The inventors engineered a novel biomarker discovery approach, tailored for PDAC, which is all-patient inclusive, termed PanEXPEL. This approach offers access to PDAC clinical material before any treatment is applied. The method benefits from clinical biopsy, yet does not interfere with that diagnostic procedure. It can be integrated seamlessly into clinical routine, and is compatible with any type of OMICS profiling. PanEXPEL relies on the interstitial tissue fluid released from the lesion during diagnostic biopsy by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). This is the first technique that allows both clinicians and researchers to analyze identical material in the field of proteomics biomarker research. Here, they demonstrate the potential of PanEXPEL methodology by identifying a PDAC early detection signature through proteomics and subsequent statistical learning. Thus, the present invention relates to a method for diagnosing a pancreatic cancer in a subject in need thereof comprising determining in a sample obtained from the subject the expression levels of at least one biomarker selected from the group consisting of AGR2, ANXA2, ANXA3, ANXA4, CECAM6, CYP2S1, DMBT1, KRT7, KRT8, KRT17, KRT18, KRT19, MAL2, MYH14, OLFM4, PIGR, SERPINB5, SERPINH1, and TIMP1. [post_date] => 2022-10-19 10:05:16 [post_modified] => 2024-09-11 15:53:35 [ID] => 4707 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3079991a-090f-5093-3642-634fc1855a42 [etat_fiche_online] => en_ligne [date_application] => 17-03-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20559-D1 [keywords] => Pancreatic Cancer, Machine learning, Protein Signature Score, Mass spectrometry, Preservcyte [pub_scient_inv_dispo] => Endoscopy, 2022 May 5, Souche et al., Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples, doi: 10.1055/a-1550-2503.Clinical Trial: NCT03791073. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => TURTOI Andrei,COLINGE Jacques,SOUCHE François Régis,TOSATO Guillaume [number_application] => European Procedure (Patents) (EPA) - 17 Mars 2021 - 21 305 326.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => mass_spectrometry [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Pancreatic CancerTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 142 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Mass spectrometry, Oncology, Pancreatic Cancer, Pre-Analytic Validation [taxonomieurl] => Biomarker, Biomarker, Mass spectrometry, Oncology, Pancreatic Cancer, Pre-Analytic Validation ) [143] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR PRONOSIS AND TREATING A PATIENT SUFFERING FROM CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-pronosis-and-treating-a-patient-suffering-from-cancer/ [post_content] => Complement components form a plasma innate immune cascade but could also serve as multitasking proteins, as they have functions beyond this system. Here, we show that complement FH is locally expressed by multiple types of human tumors. We provide a paradigm shift for the impact of FH on cancer progression, showing a previously unrecognized, intracellular function of FH outside the complement cascade, while the canonical, complement-regulatory function had no effect. Int-FH served as a driver of the proliferation and migration of ccRCC and lung ADK cells but not of normal cells or lung SCC cells. The presence of int-FH staining in tumor cells indicated poor prognosis for ccRCC and lung ADK.Thus, the invention relates to a method for predicting the survival time of a patient suffering from a cancer, comprising i) determining in a sample obtained from the patient the expression level of int-FH ii) comparing the expression level determined at step i) with its predetermined reference value and iii) providing a prognosis when the expression level determined at step i) is modulated compared to its predetermined reference value. [post_date] => 2022-10-19 08:15:02 [post_modified] => 2024-09-11 15:53:33 [ID] => 4705 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bf18fd78-0b25-5f8e-e328-634fa6646948 [etat_fiche_online] => en_ligne [date_application] => 12-02-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19289-D1 [keywords] => intracellular-FH, pronostic, companion diagnostic, Solid tumor, Kidney Cancer, Lung Cancer, Liver Cancer, IHC [pub_scient_inv_dispo] => Cancer Immunol Res,Epub 2021 May 26, Daugan et a., Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade, doi: 10.1158/2326-6066.CIR-20-0787. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ROUMENINA Lubka,REVEL Margot,CREMER Isabelle,DAUGAN Marie,SAUTES-FRIDMAN Catherine,FRIDMAN Wolf Herman (Hervé) [number_application] => European Procedure (Patents) (EPA) - 12 Févr. 2021 - 21 305 187.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 143 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Method, Oncology, Pre-Analytic Validation, Solid Tumors [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Method, Oncology, Pre-Analytic Validation, Solid Tumors ) [144] => stdClass Object ( [post] => stdClass Object ( [post_title] => BILE SALTS BACTOSENSOR AND USE THEREOF FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES [guid] => https://technology-offers.inserm-transfert.com/offer/bile-salts-bactosensor-and-use-thereof-for-diagnostic-and-therapeutic-purposes-2/ [post_content] => Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are thoroughly modified by the resident gut microbiota. Bile acids act as versatile signaling molecules with a variety of endocrine functions and are linked to several diseases. In particular, serum and urinary bile salts represent biomarkers for early diagnostics of liver dysfunction, yet their current detection methods are impractical and hard to scale. Here the inventors engineered engineered synthetic bile salt receptors using VtrA as sensing domains connected to E. coli CadC system which activates transcription upon dimerization. The performance of the system was assayed for various selection of promoters and they can show that fine tunable response that may be reached by changing expression levels of the bile salt receptor. By performing multiple rounds of directed evolution of the VtrA sensor the inventors obtained a collection of variants with a lower limit of detection and a higher sensitivity. Finally, they show that their bactosensor can detect pathological bile-salt concentrations in samples from patients with liver dysfunction. The present invention thus relates to bile salts bactosensor and use thereof for diagnostic and therapeutic purposes. [post_date] => 2022-10-11 15:20:01 [post_modified] => 2024-09-11 15:53:31 [ID] => 4696 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7a10898c-b241-39d6-73f2-63457fd48808 [etat_fiche_online] => en_ligne [date_application] => 08-02-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20498-D1 [keywords] => Liver Dysfunctions, Bile Salts concentration, Synthetic Biology [pub_scient_inv_dispo] => Nat Commun,2021 Sep 1, Chang et al., Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples, doi: 10.1038/s41467-021-25538-y. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BONNET Jérôme,CHANG Hung Ju [number_application] => European Procedure (Patents) (EPA) - 08 Févr. 2021 - 21 305165.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,other [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 144 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Gastrointestinal Diseases, Human POC, Immunoassay, Liver Disease, Method, Other, Others, Product [taxonomieurl] => Biomarker, Gastrointestinal Diseases, Human POC, Immunoassay, Liver Disease, Method, Other, Others, Product ) [145] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF ASSESSING THE RISK OF DEVELOPING PROGRESSIVEMULTIFOCAL LEUKOENCEPHALOPATHY IN PATIENTS TREATED WITHVLA-4 ANTAGONISTS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-assessing-the-risk-of-developing-progressivemultifocal-leukoencephalopathy-in-patients-treated-withvla-4-antagonists/ [post_content] => Natalizumab a monoclonal antibody is associated with the risk of progressive multifocal leukoencephalopathy (PML), an infection caused by the John Cunningham (JC) virus. The inventors explored the hypothesis that bacteria should be involved in the onset of PML in connection to the HLA-DR haplotype in multiple sclerosis (MS) patients. Thus 625 MS patients starting Natalizumab therapy from the BIONAT study were followed prospectively. Among those patients, 12 developed a PML. Outside the BIONAT cohort, we included nine additional MS patients with PML who had been referred to our center. For each patient, blood metagenomics sequencing and sequencing-based typing for HLA-DRB1*15:01 ancestral haplotype were determined. HLA-DRB1*15:01 haplotype carriers show a protection against PML (p=0.03). Among blood taxa, at genus level, Phyllobacterium was only significantly associated in HLA-DRB1*15:01 haplotype carriers with an inflammatory marker (p2% have an odds ratio of 4.55 (95% confidence intervals 1.82-11.37; p=0.001) of developing or having PML under NTZ treatment. In conclusion, the inventors showed a relation between the HLA-DRB1*15:01 haplotype, the circulating microbiota and the risk of PML. The interaction between blood microbiota and the HLA-DRB1*15:01 haplotype may play a role in the virulence of the viruses. [post_date] => 2022-10-07 17:15:01 [post_modified] => 2024-09-11 15:53:30 [ID] => 4695 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => af52c228-abda-e587-f4cf-6340538181fe [etat_fiche_online] => en_ligne [date_application] => 29-01-2021 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19385-D1 [keywords] => Natalizumab; progressive multifocal leukoencephalopathy (PML); multiple sclerosis (MS) patients; HLA-DR haplotype; Microbiota [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => AMAR Jacques,BRASSAT David,PIGNOLET Béatrice [number_application] => European Procedure (Patents) (EPA) - 29 Janv. 2021 - 21305115.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => genomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Multiple sclerosisTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 145 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Central Nervous System, Genomics, Human POC, Method, Multiple sclerosis [taxonomieurl] => Biomarker, Biomarker, Central Nervous System, Genomics, Human POC, Method, Multiple sclerosis ) [146] => stdClass Object ( [post] => stdClass Object ( [post_title] => HG5LN GAL4-hPPAR gamma cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4694 [post_content] => HG5LN were generated by transfection of cervical cancer HeLa cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. HG5LN GAL4-hPPAR gamma cells were generated by transfection of HG5LN cells with the plasmid pSG5-GAL4-human PPAR gamma-puromycin. The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-human GAL4-hPPAR gamma-puromycin enables to express the DNA binding domain of the yeast activator GAL4 (GAL4 DBD) followed by the ligand binding domain of the human peroxisome proliferator activated receptor receptor gamma (hPPAR gamma LBD). Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-09-11 16:07:28 [ID] => 4694 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a837823d-780e-37e7-d0ac-6340300ec59d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00559 [keywords] => hPPAR gamma, luciferase, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 146 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [147] => stdClass Object ( [post] => stdClass Object ( [post_title] => HG5LN GAL4-hPPAR alpha cell line [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4693 [post_content] => HG5LN were generated by transfection of cervical cancer HeLa cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. HG5LN GAL4-hPPAR alpha cells were generated by transfection of HG5LN cells with the plasmid pSG5-GAL4-human PPAR alpha-puromycin. The plasmid (GAL4RE)5-betaGlob-Luc-SVNeo contains a luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of beta-globin promoter and a neomycin phosphotransferase gene under the control of SV40 promoter. The pSG5-puro plasmid pSG5-human GAL4-hPPAR alpha-puromycin enables to express the DNA binding domain of the yeast activator GAL4 (GAL4 DBD) followed by the ligand binding domain of the human peroxisome proliferator activated receptor receptor alpha hPPAR alpha LBD. Puromycin N-acetyl transferase selection marker expression confers resistance to puromycin. [post_date] => 2023-05-19 18:45:03 [post_modified] => 2024-09-11 16:06:39 [ID] => 4693 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a3290466-1dcd-2832-4de6-63402f057000 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00558 [keywords] => hPPAR alpha, luciferase, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 147 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [148] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR INCREASING FETAL HEMOGLOBIN CONTENT IN EUKARYOTIC CELLS AND USES THEREOF FOR THE TREATMENT OF HEMOGLOBINOPATHIES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-increasing-fetal-hemoglobin-content-in-eukaryotic-cells-and-uses-thereof-for-the-treatment-of-hemoglobinopathies/ [post_content] => The clinical severity of ?-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal ?-globin chain production at adult age, a condition termed hereditary persistence of fetal hemoglobin (HPFH). Here, the inventors have compared the extent of fetal hemoglobin (HbF) de-repression following CRISPR-Cas9-mediated targeting of different regions of the HBG1 and HBG2 promoters in an adult erythroid cell line (HUDEP-2). They achieved a potent and pancellular HbF re-activation upon disruption of binding sites for ?-globin repressors located in both HBG1 and HBG2 genes. They validated these findings in Red Blood Cells (RBCs) derived from genome edited Sickle Cell Disease (SCD) patient hematopoietic stem/progenitor cells. Overall, this study identified a binding site for an HbF repressor as a novel and potent target for the treatment of ?-hemoglobinopathies. Accordingly, the present invention relates to a method for increasing fetal hemoglobin content in a eukaryotic cell comprising the step of disrupting the binding site for Leukemia/lymphoma-related factor (LRF) in the HBG1 or HBG2 promoter. [post_date] => 2022-09-29 12:45:01 [post_modified] => 2024-09-11 15:43:46 [ID] => 4674 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7bbee3bd-79af-8c13-5e3d-5cd01f794ee8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18215-T1 [keywords] => CRISPR [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => MICCIO Annarita,WEBER Leslie [number_application] => European Procedure (Patents) (EPA) - 11 Sept. 2018 - 18 306 191.0 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hematological DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 148 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Candidate drug, Drug, Gene Therapy, Gene therapy, Hematological Disorders, Product, Thalassemia [taxonomieurl] => Biologic, Candidate drug, Drug, Gene Therapy, Gene therapy, Hematological Disorders, Product, Thalassemia ) [149] => stdClass Object ( [post] => stdClass Object ( [post_title] => Transgenic mouse model for myotonic dystrophy: DM300 carrying 300 CTG repeats [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4651 [post_content] => Transgenic mouse model carrying the myotonic dystrophy type 1 (DM1) locus (45kb of human sequences) with the DMPK gene and about 300 unstable CTG repeats. [post_date] => 2022-12-01 16:25:01 [post_modified] => 2024-09-11 16:06:55 [ID] => 4651 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => aa47c641-0cb7-8572-9837-6332eec6b27f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00522 [keywords] => Myotonic dystrophy; Trinucleotide repeat instability [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => true [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• MusculoskeletalTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Geneviève GOURDON [first_name] => Geneviève [last_name] => GOURDON [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 149 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Central Nervous System, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Musculoskeletal, Proof of concept in vivo [taxonomieurl] => Academic Research, Central Nervous System, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Musculoskeletal, Proof of concept in vivo ) [150] => stdClass Object ( [post] => stdClass Object ( [post_title] => NANOPARTICLES FOR TREATING OR PREVENTING A CARDIOMYOPATHY AND ANTHRACYCLINE-CYTOTOXICITY, AND THEIR ADMINISTRATION AS AN AEROSOL [guid] => https://technology-offers.inserm-transfert.com/offer/nanoparticles-for-treating-or-preventing-a-cardiomyopathy-and-anthracycline-cytotoxicity-and-their-administration-as-an-aerosol/ [post_content] => Anthracyclines such as doxorubicin are chemotherapeutic molecules are also widely incorporated in many chemotherapy protocols. However, their clinical use is still limited by time- and dose-dependent cardiotoxicity. Herein the inventors have determined the therapeutic potential of acidic nanoparticles (NPs) in doxo-treated cardiac cells. In particular, they have identified a set of grafted nanoparticles as non-toxic and which rapidly internalize into lysosomes in cardiac cells. Such NPs improve lysosomal acidification and autophagic flux blockade caused by bafilomycin A1, chloroquine and doxorubicin, resulting in reduced oxidative stress, preserved mitochondrial integrity and improved cell survival. Thus, the invention relates to a biocompatible and biodegradable nanoparticle having a diameter of 100 nm or less, wherein the nanoparticle is selected from: a poly(lactic-co-glycolic acid) (PLGA) nanoparticle, a poly(lactic acid) (PLA) nanoparticle, a poly(glutamic acid) (PGA) nanoparticle, a polycaprolactone (PCL) nanoparticle, and/or a polyester nanoparticle; for use in a method for treating or preventing a cardiomyopathy or anthracycline cytotoxicity. [post_date] => 2022-09-22 16:10:01 [post_modified] => 2024-09-11 15:44:19 [ID] => 4647 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 71ec5824-9107-5022-8029-632c7ec6e1f5 [etat_fiche_online] => en_ligne [date_application] => 26-08-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => CHIM1902901-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => PEREZ Jeanne,LECHEVALLIER Séverine,SANTIN Yohan,VERELST Marc Raoul Joseph [number_application] => European Procedure (Patents) (EPA) - 10 Sept. 2020 - 20 306 004.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• CardiomyopathyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 150 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cardiomyopathy, Cardiovascular Diseases, Drug, Method, Target, Validation in vitro [taxonomieurl] => Cardiomyopathy, Cardiovascular Diseases, Drug, Method, Target, Validation in vitro ) [151] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INDUCING IMMUNE TOLERANCE BY MUCOSAL VACCINATION WITH FC-COUPLED ANTIGENS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-inducing-immune-tolerance-by-mucosal-vaccination-with-fc-coupled-antigens/ [post_content] => The present invention relates to methods and pharmaceutical compositions of inducing immune tolerance by mucosal vaccination with Fc-coupled antigens. In particular, the present invention relates to a method for inducing tolerance to one antigen of interest in a subject in need thereof, comprising the mucosal administration to the subject of a therapeutically effective amount of a recombinant chimeric construct comprising a FcRn targeting moiety and an antigen-containing moiety. [post_date] => 2022-09-22 15:50:01 [post_modified] => 2024-09-11 15:43:36 [ID] => 4646 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e2ee384e-4ba7-4c8b-9078-7a3b6b0f65ac [etat_fiche_online] => en_ligne [date_application] => 17-07-2015 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15274-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/Licensing-opportunity-Immunology-Therapeutic-June2018_Mallone.pdf [rare_disease] => false [second_indication] => false [inventors] => GUPTA Nimesh,CULINA Slobodan,LACROIX-DESMAZES Sébastien [number_application] => European Procedure (Patents) (EPA) - 17 Juil. 2015 - 15 306 169.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 151 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Type 1 Diabetes (Juvenile Diabetes), Vaccine [taxonomieurl] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Type 1 Diabetes (Juvenile Diabetes), Vaccine ) [152] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTIGENIC PEPTIDES DERIVING FROM UROCORTIN 3 AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES [guid] => https://technology-offers.inserm-transfert.com/offer/antigenic-peptides-deriving-from-urocortin-3-and-uses-thereof-for-the-diagnosis-and-treatment-of-type-1-diabetes/ [post_content] => Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?- cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by ? cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies.Inflammatory cytokines increased ?-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known ?-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel ?-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D. [post_date] => 2022-09-22 15:45:01 [post_modified] => 2024-09-11 15:43:34 [ID] => 4645 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f03a03ce-ea32-fc97-db9a-5afaa97453d5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17685-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MALLONE Roberto,GONZALEZ-DUQUE Sergio,AFONSO Georgia,VINH Joëlle,VERDIER Yann,AZOURY Marie Eliane [number_application] => European Procedure (Patents) (EPA) - 16 Mars 2018 - 18 305 288.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 152 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Target, Type 1 Diabetes (Juvenile Diabetes) [taxonomieurl] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Target, Type 1 Diabetes (Juvenile Diabetes) ) [153] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTIGENIC PEPTIDES DERIVING FROM PCSK2 AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES [guid] => https://technology-offers.inserm-transfert.com/offer/antigenic-peptides-deriving-from-pcsk2-and-uses-thereof-for-the-diagnosis-and-treatment-of-type-1-diabetes/ [post_content] => Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by ? cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased ?-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known ?-cell antigens and several insulin granule proteins. PCSK2 was identified as a novel ?-cell antigen, which was processed into HLA-A2-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from PCSK2 and uses thereof for the diagnosis and treatment of T1D. [post_date] => 2022-09-22 15:45:01 [post_modified] => 2024-09-11 15:43:34 [ID] => 4644 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8e3207e5-b026-af6e-a005-5afaa96719d0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17684-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MALLONE Roberto,VERDIER Yann,AZOURY Marie Eliane,VINH Joëlle,AFONSO Georgia,GONZALEZ-DUQUE Sergio [number_application] => European Procedure (Patents) (EPA) - 16 Mars 2018 - 18 305 287.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 153 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Target, Type 1 Diabetes (Juvenile Diabetes) [taxonomieurl] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Target, Type 1 Diabetes (Juvenile Diabetes) ) [154] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTIGENIC PEPTIDES DERIVING FROM SECRETOGRANIN V AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES [guid] => https://technology-offers.inserm-transfert.com/offer/antigenic-peptides-deriving-from-secretogranin-v-and-uses-thereof-for-the-diagnosis-and-treatment-of-type-1-diabetes/ [post_content] => Despite the notion that human CD8+ T cells are the final mediators of autoimmune ?- cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by ? cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies.Inflammatory cytokines increased ?-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known ?-cell antigens and several insulin granule proteins. Secretogranin V (SCG5/7B2) was identified as a novel ?-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. HLA-A2-bound neo-epitopes were also represented and originated from an alternative SCG5-009 mRNA splice isoform. Accordingly, the present invention relates to antigenic peptides derived from secretogranin V and uses thereof for the diagnosis and treatment of T1D. [post_date] => 2022-09-22 15:40:01 [post_modified] => 2024-09-11 15:43:35 [ID] => 4643 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 23ce2ead-0d7c-be83-5642-5afaa9b5b3a0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17382-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MALLONE Roberto,GONZALEZ-DUQUE Sergio,VINH Joëlle,COLLI Maikel Luis,AFONSO Georgia,VERDIER Yann,LAKS EIZIRIK Decio [number_application] => European Procedure (Patents) (EPA) - 16 Mars 2018 - 18 305 286.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 154 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Target, Type 1 Diabetes (Juvenile Diabetes) [taxonomieurl] => Biologic, Diabetes, Drug, Metabolic Disorders, Product, Target, Type 1 Diabetes (Juvenile Diabetes) ) [155] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF AGENTS CAPABLE OF INDUCING LC3-ASSOCIATED PHAGOCYTOSIS FOR TREATING SUSTAINED INFLAMMATION IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-agents-capable-of-inducing-lc3-associated-phagocytosis-for-treating-sustained-inflammation-in-patients-suffering-from-chronic-liver-disease/ [post_content] => Sustained hepatic and systemic inflammation, in particular originating from monocyte/macrophages, is a driving force for chronic liver disease progression to cirrhosis and underlies the development of multiorgan failure. Therefore, reprogramming monocyte/macrophage phenotype has emerged as an interesting strategy to limit inflammation during chronic liver injury. The inventors report here that a non-canonical form of autophagy, LC3-associated phagocytosis (LAP), is endogenously enhanced in blood and liver monocytes from cirrhotic patients and is negatively correlated to the levels of inflammatory markers in these patients. Pharmacological inhibition of LAP components or genetic disruption of LAP (Rubicon-deficient mice in myeloid cells), exacerbates the inflammatory signature in isolated human cirrhotic monocytes and the hepatic inflammatory profile in mice with chronic liver injury, resulting in enhanced liver fibrosis. Mice overexpressing human Fc?RIIA in CD11b+ cells show enhanced LAP in response to chronic liver injury, and are protected against inflammation and liver fibrosis. Finally, endogenous activation of LAP is lost in monocytes from severe cirrhotic patients with massive systemic inflammation, and restored upon exposure to intravenous monomeric Immunoglobulin (IVIg). These data shed light on a novel role for LAP in the protection against inflammation during cirrhosis and its progression to severe stages and thus suggest that agents capable of inducing LAP are suitable for treating sustained inflammation in patients suffering from chronic liver disease [post_date] => 2022-09-22 15:35:01 [post_modified] => 2024-09-11 15:43:45 [ID] => 4642 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 19823eb7-e775-604c-08ce-5d2f47daa778 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18182-T1 [keywords] => [pub_scient_inv_dispo] => Autophagy. 2020 Aug;16(8):1526-1528. doi: 10.1080/15548627.2020.1770979. Epub 2020 May 31. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => LOTERSZTAJN Sophie,BEN MKADDEM Sanae,WAN JingHong,MONTEIRO-COSTA Renato,WEISS Emmanuel,CODOGNO Patrice,SAVEANU Loredana [number_application] => European Procedure (Patents) (EPA) - 16 Janv. 2019 - 19 305 050.7 [technology_engineering] => [multidisciplinary_field] => fibrosis [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 155 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Fibrosis, Gastrointestinal Diseases, Liver Disease, Method, Non-Alcoholic Steatohepatitis, Target [taxonomieurl] => Drug, Fibrosis, Gastrointestinal Diseases, Liver Disease, Method, Non-Alcoholic Steatohepatitis, Target ) [156] => stdClass Object ( [post] => stdClass Object ( [post_title] => GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING [guid] => https://technology-offers.inserm-transfert.com/offer/gdf3-as-biomarker-and-biotarget-in-post-ischemic-cardiac-remodeling-2/ [post_content] => Markers of an intense scarring process in the early phase post- myocardial infarction (MI) are still undetermined, and the identification of patients at higher risk of developing large adverse fibrotic remodeling and heart failure remains challenging. Here, the inventors demonstrate the modulation in the paracrine behavior of resident PW1+ cells in scarring cardiac tissue post-MI and the differential abundance of 12 candidate markers in their secretome. Of these, growth differentiation factor 3 (GDF3), a member of transforming growth factor-? family, upregulates proliferation of cardiac fibroblasts, which are instrumental in fibrosis. GDF3 is upregulated in the scarred tissue and plasma of mice and humans post-MI, with the highest plasma levels predicting higher fibrotic cardiac remodeling and cardiac dilation. The inventors thus reveal the previously unidentified function of GDF3 in predicting adverse fibrotic cardiac remodeling post-MI. Thus the present invention relates to the use of GDF3 as biomarker and biotarget in post-ischemic cardiac remodeling. [post_date] => 2022-09-20 17:00:02 [post_modified] => 2024-09-11 15:43:57 [ID] => 4633 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 16a6e18b-76f1-f037-8dd7-6026a0116f3d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO20319-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HULOT Jean-Sébastien [number_application] => European Procedure (Patents) (EPA) - 05 Oct. 2020 - 20 306 156.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Chronic Heart FailureTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 156 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biomarker, Cardiovascular Diseases, Chronic Heart Failure, Drug, Target, Target, Validation in vitro [taxonomieurl] => Biomarker, Cardiovascular Diseases, Chronic Heart Failure, Drug, Target, Target, Validation in vitro ) [157] => stdClass Object ( [post] => stdClass Object ( [post_title] => Intestinal Cathelicidin Antimicrobial Peptide Shapes the Gut Microbiota to Educate the Immune System and Prevent Pancreatic Autoimmunity [guid] => https://technology-offers.inserm-transfert.com/?post_type=inserm_forms&p=4610 [post_content] => The present invention relates to the treatment of autoimmune diseases. The inventors determined that the cathelicidin related antimicrobial peptide (CRAMP) expression was defective in the colon of newborn NOD mice and that this defect was responsible for early dysbiosis. Dysbiosis stimulated the colonic epithelium to produce type I IFNs that pathologically imprinted the local immune system during the pre-weaning period. This miseducation of the immune system promoted the pancreatic autoimmune response and the development of diabetes. Increasing colonic CRAMP expression in newborn NOD mice, by local CRAMP treatment or by CRAMP-expressing probiotic, restored colonic homeostasis, and halted the diabetogenic response preventing autoimmune diabetes. Thus, they identified whether a defective colonic expression in the CRAMP antimicrobial peptide promotes autoimmunity in the pancreas. The use of CRAMP-expressing probiotic can be very helpful to treat autoimmune diseases and particularly autoimmune type 1 diabetes or obesity. Thus, the present invention relates to a recombinant CRAMP-expressing food-grade bacterium and its use in the treatment of autoimmune diseases. [post_date] => 2024-06-07 11:32:26 [post_modified] => 2024-09-19 14:30:02 [ID] => 4610 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 346378e8-7ff7-ce01-d6ff-62ff97a46016 [etat_fiche_online] => en_ligne [date_application] => 2021-08-06 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO21500-T1 [keywords] => Probiotic, antimicrobial peptide, autoimmune diseases, type 1 diabete [pub_scient_inv_dispo] => Intestinal Cathelicidin Antimicrobial Peptide Shapes a Protective Neonatal Gut Microbiota Against Pancreatic Autoimmunity. Liang and al. Gastroenterology. 2022.https://doi.org/10.1053/j.gastro.2021.12.272 [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => DIANA Julien,SUN Jia [number_application] => European Procedure (Patents) (EPA) - 06 Août 2021 - 21 306 102.1 [technology_engineering] => peptides [multidisciplinary_field] => microbiota [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 157 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Inflammation, Microbiota, Others, Peptides, Product, Product [taxonomieurl] => Drug, Immunology, Inflammation, Microbiota, Others, Peptides, Product, Product ) [158] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF ALARMINS AS BIOMARKERS FOR ASSESSING ISCHEMIAREPERFUSION INJURY SEVERITY AFTER SOLID ORGAN TRANSPLANTATION [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-alarmins-as-biomarkers-for-assessing-ischemiareperfusion-injury-severity-after-solid-organ-transplantation/ [post_content] => The inventors aim to assess IL-33 and HMGB1 contributions as alarmins to I injury following solid organ transplantation in particular liver transplantation. This study was conducted from a prospective biological collection and a clinical database of 40 liver transplant recipients in Tours hospital center. Serum IL-33 and HMGB1 levels were determined at graft reperfusion, at the end of the liver transplantation and at postoperative day 1 and 3. A post-reperfusion liver biopsy was systematic. Serum IL-33 increase is associated with: i) severe-moderate liver lesions; ii) an early allograft dysfunction; iii) a post-reperfusion syndrome occurrence; iv) a post liver transplantation acute kidney injury occurrence. Serum HMGB1 increase is associated with: i) an early allograft dysfunction; ii) a post-reperfusion syndrome occurrence. IL-33 and HMGB1 thus contribute as alarmins to I injury in human liver transplantation. Their serum levels are predictive of I injury severity and its clinical impact. Serum assay for IL-33 and HMGB1 upon graft reperfusion could be used as early biomarkers of early allograft function in solid organ transplantation, in particular in liver transplantation. [post_date] => 2022-08-16 15:40:01 [post_modified] => 2024-09-11 15:53:29 [ID] => 4609 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6f3e4c0b-a3d7-9edc-cee4-62fbb0713572 [etat_fiche_online] => en_ligne [date_application] => 16-12-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20448-D1 [keywords] => Liver Transplant, Alarmin, Ischemia-reperfusion injury assessment, Immunoassay [pub_scient_inv_dispo] => Front Immunol, 2021 Sep 21, Barbier L, Endogenous Interleukin-33 Acts as an Alarmin in Liver Ischemia-Reperfusion and Is Associated With Injury After Human Liver Transplantation, doi: 10.3389/fimmu.2021.744927. eCollection 2021. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HERBELIN André,ROBIN Aurelie,BARBIER Louise,SALAME Ephrem,SINDAYIGAYA Remy,GOMBERT Jean-Marc [number_application] => European Procedure (Patents) (EPA) - 16 Déc. 2020 - 20 306 584.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• TransplantationTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 158 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Liver transplantation, Method, Transplantation [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Liver transplantation, Method, Transplantation ) [159] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING SKIN AFFLICTIONS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-skin-afflictions/ [post_content] => The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hcKO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue. [post_date] => 2022-08-03 09:35:01 [post_modified] => 2024-09-11 15:43:39 [ID] => 4606 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 110518f9-c5aa-9781-343e-5b35e8f276fa [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17663-T1 [keywords] => Exosomes; CD98; Wound healing [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => FERAL Chloé,ESTRACH Soline,TISSOT Floriane,CAILLETEAU Laurence [number_application] => European Procedure (Patents) (EPA) - 02 Mai 2018 - 18 170 458.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 159 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Drug, Method, Others, Product, Wounds [taxonomieurl] => Dermatology, Drug, Method, Others, Product, Wounds ) [160] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD TO TREAT AND STRATIFICATE A PATIENT SUFFERINGFROM A CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/method-to-treat-and-stratificate-a-patient-sufferingfrom-a-cancer/ [post_content] => The present invention relates to the stratification and treatment of patients suffering of cancer. Due to the fact that anti-PD1 therapy targets lymphocytes and the efficiency of anti-cancer therapy is measured by the impact on the tumor cells, the inventors postulated that studying the molecular mechanisms of resistance of anti-PD1 therapy should take into consideration existing intercellular communication between lymphocytes and tumor cells. As exosomes are the carriers for the intercellular transfer of the miRNA responsible of chemoresistance, they herein investigated whether exposure of T cells to anti-PD1 therapy might promote the expression of exosomal miRNA (exomiR) causing the chemoresistance of cancer cells. Surprisingly, they found that anti-PD1 exposure of T-cell promotes an enrichment of exosomal miRNA-4315. They also noted that exosomal miRNA-4315 induced a phenomenon of apopto-resistance to conventional chemotherapies in cancer cells receiving exosomal miRNA-4315. At molecular level, they discern that the apopto-resistance phenomenon was associated with the miRNA-4315-mediated down-regulation of Bim, a pro-apoptotic protein. In cellular and mice models, they observed that the BH3 mimetic agent ABT263 circumvented this resistance. Thus, the invention relates to methods of stratification using exosomal miRNA-4315 and method of treatment of patients suffering of cancer using BH3 mimetic agent. [post_date] => 2022-07-15 15:20:01 [post_modified] => 2024-09-11 15:53:28 [ID] => 4601 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => dc20c299-0ed8-f858-29c8-6156d830761e [etat_fiche_online] => en_ligne [date_application] => 14-09-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20408-D1 [keywords] => Exoxome, PD1 treatment response prediction, Pan-Cancer [pub_scient_inv_dispo] => Cell Death Dis. 2020 Dec 11;11(12):1048. Guyon et al. Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells doi: 10.1038/s41419-020-03224-z. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CARTRON Pierre-François,BOUGRAS-CARTRON Gwenola [number_application] => European Procedure (Patents) (EPA) - 14 Sept. 2020 - 20306025.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 160 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Oncology, Solid Tumors, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Oncology, Solid Tumors, Transcriptomics ) [161] => stdClass Object ( [post] => stdClass Object ( [post_title] => GDF3 AS BIOMARKER AND BIOTARGET IN POST-ISCHEMIC CARDIAC REMODELING [guid] => https://technology-offers.inserm-transfert.com/offer/gdf3-as-biomarker-and-biotarget-in-post-ischemic-cardiac-remodeling/ [post_content] => Markers of an intense scarring process in the early phase post- myocardial infarction (MI) are still undetermined, and the identification of patients at higher risk of developing large adverse fibrotic remodeling and heart failure remains challenging. Here, the inventors demonstrate the modulation in the paracrine behavior of resident PW1+ cells in scarring cardiac tissue post-MI and the differential abundance of 12 candidate markers in their secretome. Of these, growth differentiation factor 3 (GDF3), a member of transforming growth factor-? family, upregulates proliferation of cardiac fibroblasts, which are instrumental in fibrosis. GDF3 is upregulated in the scarred tissue and plasma of mice and humans post-MI, with the highest plasma levels predicting higher fibrotic cardiac remodeling and cardiac dilation. The inventors thus reveal the previously unidentified function of GDF3 in predicting adverse fibrotic cardiac remodeling post-MI. Thus the present invention relates to the use of GDF3 as biomarker and biotarget in post-ischemic cardiac remodeling. [post_date] => 2022-07-15 15:20:01 [post_modified] => 2024-09-11 15:53:27 [ID] => 4600 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 65147522-4472-093f-29d3-6229c34b1bfd [etat_fiche_online] => en_ligne [date_application] => 05-10-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20319-D1 [keywords] => Prognosis, Risk Prediction, Myocardial Infarction, GDF3, Fibrotic cardiac remodeling [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HULOT Jean-Sébastien [number_application] => European Procedure (Patents) (EPA) - 05 Oct. 2020 - 20 306 156.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Myocardial InfarctionTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 161 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Cardiovascular Diseases, Immunoassay, Method, Myocardial Infarction, Pre-Analytic Validation, Target [taxonomieurl] => Biomarker, Biomarker, Cardiovascular Diseases, Immunoassay, Method, Myocardial Infarction, Pre-Analytic Validation, Target ) [162] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS AND THETREATMENT OF GRAFT-VERSUS-HOSTDISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-and-thetreatment-of-graft-versus-hostdisease/ [post_content] => The invention relates to methods for the prediction and the treatment of risk of acute graft versus host disease. The inventors demonstrated that an alteration of CD73-mediated regulatory function of DP8? Tregs could contribute to the acute GvHD pathophysiology. In particular, the present invention relates to method of determining whether a subject has or is at a risk of developing graft-versus-host disease (GvHD) comprising the steps of: i) determining the level of CD73 expression by DP8? TREGS in a sample obtained from the subject, ii) comparing the level determined at step i) with a predetermined reference value wherein detecting differential between the level of CD73 expression by DP8? TREGS determined at step i) and the predetermined reference value is indicative of whether a subject has or is at a risk of developing graft-versus-host disease (GvHD). [post_date] => 2022-07-15 15:15:01 [post_modified] => 2024-09-11 15:53:25 [ID] => 4598 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bf9f08f4-aad6-7851-b8f2-6229cca9f520 [etat_fiche_online] => en_ligne [date_application] => 04-11-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20418-D1 [keywords] => Graft-versus-host disease, Prognosis, CD73 expression on Treg cells, hematological malignancies, allogeneic hematopoietic stem cell transplantation [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GODEFROY Emmanuelle,CHEVALLIER Patrice,ALTARE Frédéric,JOTEREAU Francine [number_application] => European Procedure (Patents) (EPA) - 04 Nov. 2020 - 20 306 320.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• TransplantationTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 162 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Graft Versus Host Disease (GVHD), Human POC, Immunoassay, Immunology, Method, Transplantation [taxonomieurl] => Biomarker, Biomarker, Graft Versus Host Disease (GVHD), Human POC, Immunoassay, Immunology, Method, Transplantation ) [163] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING UVEAL MELANOMA [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-predicting-and-treating-uveal-melanoma-2/ [post_content] => Here, in multi-scale analyses using single-cell RNA sequencing of six different primary uveal melanomas, inventors uncover a previously unrecognized intratumor heterogeneity at the genetic and transcriptomic level. They identify distinct transcriptional cell states and diverse tumor-associated populations in a subset of primary uveal melanomas. [post_date] => 2022-07-15 15:10:01 [post_modified] => 2024-09-11 15:53:25 [ID] => 4597 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d2dac1d7-258e-3d5b-2a89-61572a588ca5 [etat_fiche_online] => en_ligne [date_application] => 16-11-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20429-D1 [keywords] => RNA signature, Prognosis, Uveal Melanoma, Intratumor heterogeneity [pub_scient_inv_dispo] => Cell Death Differ., 2021 Jun 28, Pandiani et al, Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease., DOI: 10.1038/s41418-020-00730-7Prog Retin Eye Res, 2021 Apr 13, Strub et al, Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology, DOI: 10.1016/j.preteyeres.2021.100968 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BERTOLOTTO Corine,BALLOTTI Robert,STRUB Thomas,PANDIANI Charlotte [number_application] => European Procedure (Patents) (EPA) - 16 Nov. 2020 - 20 306 384.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• MelanomaTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 163 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Melanoma, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Melanoma, Oncology, Transcriptomics ) [164] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING UVEAL MELANOMA [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-predicting-and-treating-uveal-melanoma/ [post_content] => Here, in multi-scale analyses using single-cell RNA sequencing of six different primary uveal melanomas, inventors uncover a previously unrecognized intratumor heterogeneity at the genetic and transcriptomic level. They identify distinct transcriptional cell states and diverse tumor-associated populations in a subset of primary uveal melanomas. They also decipher a gene regulatory network underlying an invasive and poor prognosis state driven in part by the transcription factor HES6, a member of the NOTCH signaling pathway. HES6 heterogenous expression has been validated by RNAscope assays within primary uveal melanomas, which unveils the existence of these cells conveying a dismal prognosis in tumors diagnosed with a favorable outcome using bulk analyses. Depletion of HES6 impairs growth, migration and metastatic dissemination, demonstrating essential roles of HES6 in uveal melanoma progression. [post_date] => 2022-07-15 15:10:01 [post_modified] => 2024-09-11 15:53:24 [ID] => 4596 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8017a2c5-7783-edb1-0876-615720179f66 [etat_fiche_online] => en_ligne [date_application] => 16-11-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19426-D2 [keywords] => Uveal Melanoma, RNA Signatures, Prognosis, Intratumoral heterogeneity [pub_scient_inv_dispo] => Cell Death Differ., 2021 Jun 28, Pandiani et al, Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease., DOI: 10.1038/s41418-020-00730-7Prog Retin Eye Res, 2021 Apr 13, Strub et al, Translation of single-cell transcriptomic analysis of uveal melanomas to clinical oncology, DOI: 10.1016/j.preteyeres.2021.100968 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BERTOLOTTO Corine,PANDIANI Charlotte,BALLOTTI Robert,STRUB Thomas [number_application] => European Procedure (Patents) (EPA) - 16 Nov. 2020 - 20 306 385.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• MelanomaTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 164 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Melanoma, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Melanoma, Oncology, Transcriptomics ) [165] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF THE EMM ANTIGEN AS A BIOMARKER OF INHERITED GPI DEFICIENCIES [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-the-emm-antigen-as-a-biomarker-of-inherited-gpi-deficiencies/ [post_content] => Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency (IGD) disorders. Here, the inventors reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, they demonstrate that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, the inventors show that the decrease in Emm expression in several IGD patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system and have important implications for understanding the biological function of human free GPI. [post_date] => 2022-07-15 14:50:02 [post_modified] => 2024-09-11 15:53:23 [ID] => 4594 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 90558cf5-74b9-a44d-5f5f-62d174f466a7 [etat_fiche_online] => en_ligne [date_application] => 09-12-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20561-D1 [keywords] => Emm antigen, Inherited GPI deficiency, paroxysmal nocturnal hemoglobinuria [pub_scient_inv_dispo] => Blood, 2021 Jul 1, Duval R et al., Inherited glycosylphosphatidylinositol defects cause the rare Emm-negative blood phenotype and developmental disorders ,doi: 10.1182/blood.2020009810. [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => PEYRARD Thierry,DUVAL Romain,HERMINE Olivier,COLIN-ARONOVICZ Yves,AZOUZI Slim,LE VAN KIM Caroline [number_application] => European Procedure (Patents) (EPA) - 09 Déc. 2020 - 20 306 520.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Hematological DisordersTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 165 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Anemia, Biomarker, Biomarker, Hematological Disorders, Human POC, Immunoassay [taxonomieurl] => Anemia, Biomarker, Biomarker, Hematological Disorders, Human POC, Immunoassay ) [166] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF RETINOIC ACID RECEPTOR (RAR) AGONISTS FORREVERSIN G, PREVENTING, OR DELAYING CALCIFICATION OF AORTICVALVE [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-retinoic-acid-receptor-rar-agonists-forreversin-g-preventing-or-delaying-calcification-of-aorticvalve/ [post_content] => Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve - a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RAR? activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve. [post_date] => 2022-06-21 09:25:01 [post_modified] => 2024-09-11 15:43:31 [ID] => 4589 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9e50d4c1-3b66-460d-8f21-5df8ac71932f [etat_fiche_online] => en_ligne [date_application] => 02-10-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17543-T1 [keywords] => Calcification [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => SUSEN Sophie,SOTTEJEAU Yoann,CORSEAUX Delphine,SOQUET Jérôme,VAN BELLE Eric,STAELS Bart,DUPONT Annabelle,ROSA Mickael [number_application] => European Procedure (Patents) (EPA) - 02 Oct. 2019 - 19 306 256.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Aortic valve diseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 166 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Aortic valve diseases, Cardiovascular Diseases, Drug, Method, Target, Validation in vivo [taxonomieurl] => Aortic valve diseases, Cardiovascular Diseases, Drug, Method, Target, Validation in vivo ) [167] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF MAST CELL STABILIZER FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-mast-cell-stabilizer-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction/ [post_content] => Heart failure with preserved ejection fraction (HFpEF) which results from diastolic dysfunction is a growing epidemiologic problem. However, the pathophysiology of this disease is poorly understood. Our goal is to investigate whether microvessel disease may promote HFpEF. To do so we have used Leptin receptor deficient (Leprdb/db) female mice as a model of HFpEF and performed a transcriptomic analysis via RNA sequencing of the cardiac vascular fraction of both these mice and their control Leprdb/+littermates. In Leprdb/db female mice, end diastolic pressure (EDP) signing diastolic dysfunction is significantly increased from 3 month of age. It is correlated with a cardiac and cardiomayocyte hypertrophy, vascular leakage, endothelial cell activation and leucocyte infiltration. As expected, the RNA sequencing analysis confirmed endothelial dysfunction. Besides, it also revealed a strong increase in several mast cell markers. We confirmed, via histology, an accumulation of mast cells in the heart of Leprdb/db mice. Importantly, it was associated with increased levels of circulating IgE. Leprdb/db mice were then treated or not with Cromolyn sodium, an inhibitor of mast cell degranulation. After a month treatment, EDP was significantly reduced in Leprdb/db mice demonstrating the critical role of mast cell in the development of diastolic dysfunction in diabetic obese mice. [post_date] => 2022-06-21 09:05:17 [post_modified] => 2024-09-11 15:44:15 [ID] => 4588 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9cd40436-25f2-584f-0e45-5e2995b0a436 [etat_fiche_online] => en_ligne [date_application] => 12-11-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19459-T1 [keywords] => Cardiology, cadiovascular diseases, Heart Failure, [pub_scient_inv_dispo] => Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):e193-e207. doi: 10.1161/ATVBAHA.121.315900. Epub 2021 Feb 11. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => RENAULT Marie-Ange,GUIMBAL Sarah,COUFFINHAL Thierry,CHAPOULY Candice [number_application] => European Procedure (Patents) (EPA) - 12 Nov. 2019 - 19208649.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Chronic Heart FailureTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 167 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cardiovascular Diseases, Chronic Heart Failure, Drug, Method, Small Molecule, Target, Validation in vivo [taxonomieurl] => Cardiovascular Diseases, Chronic Heart Failure, Drug, Method, Small Molecule, Target, Validation in vivo ) [168] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR DIAGNOSIS AND MONITORING OF TOXIC EPIDERMAL NECROLYSIS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-diagnosis-and-monitoring-of-toxic-epidermal-necrolysis-2/ [post_content] => In the present invention, inventors investigate the representation of T cell subsets in Toxic epidermal necrolysis (TEN) a life-threatening cutaneous adverse drug reaction (cADR), characterized by massive epidermal necrosis. To better understand why skin symptoms are so severe in TEN disease, inventors conducted a prospective immunophenotyping study on skin samples and blood from 18 TEN patients, using mass cytometry and next generation TCR sequencing. Deep sequencing of the T cell receptor CDR3 repertoire revealed massive expansion of unique CDR3 clonotypes in blister cells. Over-represented clonotypes were mainly effector memory CD8+CD45RA-CCR7- T cells, and expressed high levels of cytotoxic (Granulysin and Granzymes A & B) and activation (CD38) markers. Thus present invention relates to non-invasive, specific and rapid methods for diagnostic and monitoring Toxic Epidermal Necrolysis. More specifically present invention relates to methods for diagnosis and/or monitoring of Toxic Epidermal Necrolysis through detection of a specific population of T ymphocytes in a subject. The present invention also relates to a method of preventing or treating a Toxic Epidermal Necrolysis in a subject in need thereof. [post_date] => 2022-06-10 15:00:01 [post_modified] => 2024-09-11 15:53:17 [ID] => 4586 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4c3b44b8-d882-9815-da47-62a3535cd372 [etat_fiche_online] => en_ligne [date_application] => 27-11-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19417-D1 [keywords] => Toxic epiderm necrolysis (TEN), cutaneous adverse drug reaction (cADR), T cell subsets [pub_scient_inv_dispo] => Sci Adv, 2021 Mar 19, Villani et al, Massive clonal expansion of polycytotoxic skin and blood CD8 + T cells in patients with toxic epidermal necrolysis , doi: 10.1126/sciadv.abe0013. Print 2021 Mar. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => VOCANSON Marc,NOSBAUM Audrey,VILLANI Axel,ROZIERES Aurore [number_application] => European Procedure (Patents) (EPA) - 27 Nov. 2020 - 20 306 460.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• DermatologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 168 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Dermatology, Human POC, Immunoassay, Target [taxonomieurl] => Biomarker, Biomarker, Dermatology, Human POC, Immunoassay, Target ) [169] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR PREDICTING THE RESPONSE TO TNF INHIBITORS [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-predicting-the-response-to-tnf-inhibitors/ [post_content] => Rheumatoid arthritis (RA) is the most prevalent chronic autoimmune inflammatory rheumatism. Its pathophysiology is largely dependent on TNF. Severe RA as well as several other inflammatory and autoimmune diseases are treated with TNF inhibitors (TNFi). However, to date only 30-50% achieve low disease activity or remission with this treatment regimen and some patients experience secondary non-response or relapse. Herein, the inventors evaluated by RT-qPCR the mRNA expression of CD36, which was already described to be regulated by TNFi5, some specific NRF2 target genes (FBX030, GABARA, LBR, MAFG, OSGIN1, HMOX1), which play a role in the anti-oxidative stress response or anti-inflammatory pathway, and the expression of CSMD1, an anti-inflammatory gene that we observed as up-regulated by all TNFi. Interestingly, they observed 2 different subsets of healthy donors: (i) donors in which TNFi stimulation increased mRNA of target genes in macrophages and (ii) conversely donors with no significant upregulation in transcription of these target genes. Then they classified donors two different status, u201cactivatorsu201d or u201cnon-activatorsu201d of tmTNF reverse signaling after TNFi stimulation, which correlates to clinically responder and non-responders to TNFi. Thus, based on all these observations, they developed an in vitro method for predicting the response to TNF inhibitors in patient in need thereof. [post_date] => 2022-05-25 13:55:01 [post_modified] => 2024-09-11 15:53:26 [ID] => 4582 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3416c253-412f-3f44-634e-6229f2c67c1a [etat_fiche_online] => en_ligne [date_application] => 20-10-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19272-D1 [keywords] => Treatment Response Prediction, Rhumatoid Arthritis, TNFinhibitor treatments, CD36 [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DAVIGNON Jean-Luc,DEGBOE Yannick,CONSTANTIN Arnaud,DIALLO Katy,BARON Michel,RAUWEL Benjamin,BOYER Jean-Frédéric [number_application] => European Procedure (Patents) (EPA) - 20 Oct. 2020 - 20 306 247.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Rheumatoid ArthritisTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 169 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunology, Method, Rheumatoid Arthritis, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunology, Method, Rheumatoid Arthritis, Transcriptomics ) [170] => stdClass Object ( [post] => stdClass Object ( [post_title] => Vaccine model based on recombinant hydrophobic protein and saponin [guid] => https://technology-offers.inserm-transfert.com/?p=4560 [post_content] => The Bd37 is an erythrocyte binding protein anchored at the surface of the parasite Babesia divergens. B. divergens is an Apicomplexa parasite, mostly of veterinary importance but able to infect humans after tick-bites. The lab model of bovine and human babesiosis is provided by the gerbils Meriones unguiculatus infected by Babesia divergens.Recombinant hydrophobic Bd37 is able to induce complete protective immune response when mixed with saponin, in contrast to hydrophilic Bd37 which only induce non-protective antibodies. [post_date] => 2022-04-21 16:24:07 [post_modified] => 2024-09-11 16:07:17 [ID] => 4560 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b7711302-9b77-ddd4-0f70-626a982c4ee8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00511 [keywords] => POC in vivo, vaccine, Apicomplexa, parasite, adjuvant, [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Others [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Infectious DiseasesTherapy Area:
• OthersType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => [first_name] => [last_name] => [wp_capabilities] => [wp_user_level] => [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 170 [terms] => Array ( [0] => Others ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases ) [171] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR DETECTING THE PRESENCE OF PEMPHIGUS-SPECIFIC AUTOANTIBODIES IN A SAMPLE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-detecting-the-presence-of-pemphigus-specific-autoantibodies-in-a-sample/ [post_content] => Pemphigus is a group of rare autoimmune diseases that causes blistering of the skin and mucous membranes, and includes pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Patients with pemphigus have various combinations of autoantibodies to keratinocyte muscarinic acetylcholine receptor subtype M3 (CHRM3), the secretory pathway Ca2+/Mn2+-ATPase isoform 1 (SPCA1), and desmocollin 3 (DSC3). However, there is still a need to characterize these autoantibodies and optimize their detection for diagnosis and disease monitoring. The inventors now developed an ALBIA for the 3 proteins and successfully detected and quantified the presence of auto-antibodies directed against each of these antigens in pemphigus patients. Furthermore, they showed that detection and quantification of anti-SPCA1 and/or anti-CHRM3 were also associated to a risk of relapse in the first year following the treatment using rituximab as a first-line agent. The present invention thus relates to methods for detecting the presence of said pemphigus-specific autoantibodies. [post_date] => 2022-03-07 15:14:56 [post_modified] => 2024-09-11 15:53:06 [ID] => 4551 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 440d04dd-711d-d454-318e-6222442c8f7a [etat_fiche_online] => en_ligne [date_application] => 27-08-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20361-D1 [keywords] => PEMPHIGUS, Diagnostic, ALBIA ELISA [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BOYER Olivier,JOLY Pascal,LEMIEUX Alexandre,GOLINSKI Marie-Laure [number_application] => European Procedure (Patents) (EPA) - 27 Août 2020 - 20 305 958.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• ImmunologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 171 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Immunology, Method, Pre-Analytic Validation [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Immunology, Method, Pre-Analytic Validation ) [172] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR PROGNOSIS AND MONITORING OF CRITICAL FORM OF CORONAVIRUS INFECTION [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-prognosis-and-monitoring-of-critical-form-of-coronavirus-infection/ [post_content] => In the present invention, inventors investigate the representation of neutrophil subsets in severe and critical COVID-19 patients based on Intensive Care Units (ICU) and non-ICU admission. The results show that 80% of ICU patients develop strong myelemia with CD10-CD64+ immature neutrophils. Cellular profiling revealed two distinct neutrophil subsets expressing either the LOX?1 or CD123 marker, both overrepresented in ICU patients compared to non-ICU patients. The proportion of LOX-1-expressing immature neutrophils positively correlated with clinical severity, with the cytokine storm (IL-1?, IL-6, IL-8, TNF?), and with intravascular coagulation. Importantly, high proportions of LOX-1+-immature neutrophils are associated with higher risk of severe thrombosis. The present invention relates to non-invasive, specific and rapid methods for prognostic and monitoring the severe / critical form of coronavirus infection. More specifically present invention relates to methods for prognosis and/or monitoring of the critical form of coronavirus infection through detection of a specific population of neutrophils in a covid patient. The present invention also relates to a method of preventing or treating a coronavirus infection in a subject in need thereof [post_date] => 2022-03-07 15:14:55 [post_modified] => 2024-09-11 15:53:05 [ID] => 4550 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c44167c0-7fc8-71a1-889c-6050c1a342e0 [etat_fiche_online] => en_ligne [date_application] => 23-07-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20308-D1 [keywords] => COVID19, Severe form Prognosis, Lox1+ immature neutrophils [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => COMBADIERE Christophe,COMBADIERE Béhazine [number_application] => European Procedure (Patents) (EPA) - 23 Juil. 2020 - 20 305 847.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Infectious DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 172 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Infectious Diseases, Target [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Infectious Diseases, Target ) [173] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR PREDICTING SURVIVAL TIME IN PATIENTS SUFFERING FROM CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-predicting-survival-time-in-patients-suffering-from-cancer/ [post_content] => The inventors found that metabolic gene signatures of human pan-tumor associated myeloid cells correlate with patient survival and cancer cell mitotic index. Indeed by crossing i) metabolic genes expression from single cell RNA-seq data of myeloid cell subsets, and ii) their functional metabolism by SCENITH, a method to determine in parallel the phenotype and metabolic state of the immune, stromal and tumor cells, the inventors identified glycolytic and respiratory metabolic gene signatures which predict survival time in patients. They found that in different human tumors, the glycolytic signature was associated with significantly reduced patient survival, while a respiratory gene signature correlated with increased survival. Moreover they demonstrated that the presence of glycolytic myeloid cells in the tumor correlates with malignancy.Thus the present invention relates to new gene signatures that are suitable for predicting survival time in patients suffering from cancer and for diagnosing malignancy tumor. [post_date] => 2022-03-07 15:14:55 [post_modified] => 2024-09-11 15:53:04 [ID] => 4548 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => daeff71f-3333-ec0a-e33c-622231ae51cf [etat_fiche_online] => en_ligne [date_application] => 22-07-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20108-D1 [keywords] => Metabolic gene expression signature, Solid Tumors, Prognosis [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ARGUELLO Rafael José,SAMAD Bushra,COMBES Alexis,PIERRE Philippe,KRUMMEL Matthew [number_application] => European Procedure (Patents) (EPA) - 22 Juil. 2020 - 20 305 841.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 173 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Method, Oncology, Pre-Analytic Validation, Solid Tumors, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Method, Oncology, Pre-Analytic Validation, Solid Tumors, Transcriptomics ) [174] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF CD160 AS A BIOMARKER IN ACUTE MYELOID LEUKEMIA [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-cd160-as-a-biomarker-in-acute-myeloid-leukemia/ [post_content] => Natural killer (NK) cells are innate cytotoxic lymphoid cells (ILCs) involved in the killing of infected and tumor cells. Several NK cell subsets have been reported in humans, but their heterogeneity between tissues remains to be fully characterized. The inventors previously showed, by single-cell RNA sequencing (scRNAseq) in human and mouse NK cells from spleen and blood, that the two major subsets, NK1 and NK2, are similar in different organs and species. They report here the identification, at single-cell resolution, of three subpopulations of NK cells in human bone marrow and an additional adaptive cell-like NK population in some cytomegalovirus-seropositive individuals. Pseudotime analysis identified a minor subset of resident CD56bright NK cells, NK0 cells, as the precursor of both circulating CD56dim NK1-like NK cells and CD56bright NK2-like in the human bone marrow and spleen at steady state. Transcriptomic profiles of bone marrow NK cells from patients with acute myeloid leukemia (AML), a bone marrow disease, showed a stress-induced repression of NK cell effector functions relative to healthy NK cells, thus highlighting the profound impact of the disease on NK cell heterogeneity. Finally, the inventors investigated the potential role of CD160 in AML disease development and progression further, by studying the clinical outcome of cancer patients. Survival was much higher in patients with CD160-high AML than in those with CD160-low cancer, suggesting that CD160 is an anti-tumor biomarker in AML. [post_date] => 2022-03-07 15:14:54 [post_modified] => 2024-09-11 15:53:03 [ID] => 4547 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => aab6af2e-5cbf-6739-866a-622222fb9fca [etat_fiche_online] => en_ligne [date_application] => 15-07-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20350-D1 [keywords] => AML, NK CD160+ cells, CD160, Prognosis [pub_scient_inv_dispo] => Cell Mol Immunol, 2021 May 18, Crinier et al, Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia, doi: 10.1038/s41423-020-00574-8. Epub 2020 Nov 25. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => VIVIER Eric,NARNI-MANCINELLI Emilie,CRINIER Adeline,ESCALIERE Bertrand,DUMAS Pierre-Yves [number_application] => European Procedure (Patents) (EPA) - 15 Juil. 2020 - 20 305 811.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LeukemiasTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 174 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Acute Myelocytic Leukemia (AML), Biomarker, Biomarker, Human POC, Leukemias, Method, Oncology [taxonomieurl] => Acute Myelocytic Leukemia (AML), Biomarker, Biomarker, Human POC, Leukemias, Method, Oncology ) [175] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF SLAMF1 AS A BIOMARKER IN COLORECTAL CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-slamf1-as-a-biomarker-in-colorectal-cancer/ [post_content] => Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that differ from conventional T lymphocytes in having no antigen-specific receptors. ILCs include natural killer (NK) cells, ILC1, ILC2, ILC3 and lymphoid tissue-inducer cell (LTi) subsets. Tumor ILCs are frequently found in various cancers, but their roles in cancer immunity and immunotherapy remain much less clear than those of other lymphocytes, such as T cells and NK cells. The inventors report here the single-cell characterization of blood and gut ILC subsets in healthy conditions and in colorectal cancer (CRC). The healthy gut contains ILC1s, ILC3s, and ILC3Ks, but no ILC2s. Additional tumor-specific ILC1-like and ILC2 subsets were identified in CRC patients. SLAMF1 (signaling lymphocytic activation molecule family member 1, CD150) was found to be selectively expressed on tumor-specific ILCs (TILCs). More importantly, the inventors show that higher levels of SLAMF1, including protein levels, RNA level as well as levels of SLAMF1+ ILCs were observed in CRC patients. The SLAMF1-high group of rectal cancer patients had a significantly higher survival rate than the SLAMF1-low group, suggesting that SLAMF1 is an anti-tumor biomarker in CRC. [post_date] => 2022-03-07 15:14:54 [post_modified] => 2024-09-11 15:53:03 [ID] => 4546 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c054f1e6-6253-dc67-2307-62221b19367f [etat_fiche_online] => en_ligne [date_application] => 06-07-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20264-D1 [keywords] => Colorectal Cancer, Patient prognosis, SLAMF1, Innate Lymphoid Cells [pub_scient_inv_dispo] => Cell Rep Med, 2021 Jul 27, Qi Jingjing et al., Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression, doi: 10.1016/j.xcrm.2021.100353. eCollection 2021 Aug 17. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => VIVIER Eric,CRINIER Adeline,SU Bing,NARNI-MANCINELLI Emilie,QI Jingjing,ESCALIERE Bertrand [number_application] => European Procedure (Patents) (EPA) - 06 Juil. 2020 - 20 305 763.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Colorectal CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 175 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Colorectal Cancer, Human POC, Immunoassay, Method, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Colorectal Cancer, Human POC, Immunoassay, Method, Oncology, Transcriptomics ) [176] => stdClass Object ( [post] => stdClass Object ( [post_title] => BILE SALTS BACTOSENSOR AND USE THEREOF FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES [guid] => https://technology-offers.inserm-transfert.com/offer/bile-salts-bactosensor-and-use-thereof-for-diagnostic-and-therapeutic-purposes/ [post_content] => Bile salts are steroid acids derived from cholesterol in the liver, are released into the gastrointestinal tract to aid in digestion and are thoroughly modified by the resident gut microbiota. Bile acids act as versatile signaling molecules with a variety of endocrine functions and are linked to several diseases. In particular, serum and urinary bile salts represent biomarkers for early diagnostics of liver dysfunction, yet their current detection methods are impractical and hard to scale. Here the inventors engineered engineered synthetic bile salt receptors using TcpP as sensing domains connected to E. coli CadC system which activates transcription upon dimerization. The performance of the system was assayed for various selection of promoters and they can show that fine tunable response that may be reached by changing expression levels of the bile salt receptor. By performing multiple rounds of directed evolution of the TcpP sensor the inventors obtained a collection of variants with a lower limit of detection and a higher sensitivity. Finally, they show that their bactosensor can detect pathological bile-salt concentrations in samples from patients with liver dysfunction. The present invention thus relates to bile salts bactosensor and use thereof for diagnostic and therapeutic purposes. [post_date] => 2022-03-07 15:14:53 [post_modified] => 2024-09-11 15:53:02 [ID] => 4545 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b35d4d82-2880-295a-5af3-622211562c33 [etat_fiche_online] => en_ligne [date_application] => 17-06-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20281-D1 [keywords] => bactosensor, Bile Salts, Liver dysfonction [pub_scient_inv_dispo] => Nat Commun,2021 Sep 1, Chang et al., Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples, doi: 10.1038/s41467-021-25538-y. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BONNET Jérôme,GRACY Jérôme,COHEN-GONSAUD Martin,CHANG Hung Ju [number_application] => European Procedure (Patents) (EPA) - 17 Juin 2020 - 20 305 662.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => imaging [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 176 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Gastrointestinal Diseases, Human POC, Imaging, Liver Disease, Method, Product [taxonomieurl] => Biomarker, Gastrointestinal Diseases, Human POC, Imaging, Liver Disease, Method, Product ) [177] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-treatment-and-diagnostic-of-pathological-conditions-associated-with-intense-stress/ [post_content] => The present invention relates to a method for preventing or treating pathological conditions associated with intense stress such as Post-Traumatic Stress Disorder (PTSD) by targeting the endogenous PAI-1 (Type 1 Plasminogen Activator Inhibitor). In the present invention, inventors demonstrate that there is a shift in the balance between the expression of tPA and PAI-1 proteins in a hippocampal region of a preclinical model of Post-Traumatic Stress (PTSD), is responsible for the transition between moderate stress which increases memory and facilitates adaptation and intense stress intense stress which induce pathological memories. In conditions of moderate stress, glucocorticoid hormones (GC) increase the expression of the tPA protein in the hippocampal brain region which by triggering the Erk1/2MAPK cascade strengthens memory. When stress is particularly intense, very high levels of GC then increase the production of PAI-1 protein, which by blocking the activity of tPA induces PTSD-like memories. Accordingly, inhibition of PAI-1 activity represent a new therapeutic approach to this debilitating condition and PAI-1 body fluid level in patient after trauma could be a predictive biomarker of the subsequent appearance of PTSD. [post_date] => 2022-03-07 15:14:53 [post_modified] => 2024-09-11 15:53:01 [ID] => 4543 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2abf668e-5438-3883-8c7b-6156b80d368e [etat_fiche_online] => en_ligne [date_application] => 25-06-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19520-D1 [keywords] => PTSD, Risk Prediction, Treatment Response, PAI-1 [pub_scient_inv_dispo] => Mol Psychiatry, 2021 Jan 28, Bouarab et al., PAI-1 protein is a key molecular effector in the transition from normal to PTSD-like fear memory, DOI: 10.1038/s41380-021-01024-1 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => REVEST Jean-Michel,PIAZZA Pier-Vincenzo,VALLEE Monique,DESMEDT Aline [number_application] => European Procedure (Patents) (EPA) - 25 Juin 2020 - 20305702.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Post-Traumatic Stress Disorder (PTSD)Therapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 177 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Animal POC, Biomarker, Biomarker, Central Nervous System, Immunoassay, Post-Traumatic Stress Disorder (PTSD), Target [taxonomieurl] => Animal POC, Biomarker, Biomarker, Central Nervous System, Immunoassay, Post-Traumatic Stress Disorder (PTSD), Target ) [178] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR TREATING AND PROGNOSING CANCER LIKE GLIOBLASTOMA [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-treating-and-prognosing-cancer-like-glioblastoma/ [post_content] => The present invention relates the treatment and prognostic of cancer like glioblastoma. Here, the inventors focused their study on the impact of presence of N6-adenosine methylation in miRNA-200b-3p in samples of patients suffering from glioblastoma multiforme (GBM). Their study was particularly focused on the impact of miRNA-200b-3p and its adenosine methylation on the expression of XIAP. XIAP acts as an anti-apoptotic protein via the inhibition of caspase-3 and -7 activation and high XIAP expression is associated with a poor survival in several solid tumors. Thus, the miR-200b-3p-mediated repression of XIAP mRNA expression appears as a mechanism governing the caspase-3 and -7 activity and the apoptosis. In theory, in the presence of miR-200b-3p, XIAP mRNA expression is repressed and caspase-3 and -7 can be activated to promote apoptosis. Thus, the present invention relates to an in vitro method for determining the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the miR-200b-3p and/or the N6-adenosine methylated miRNA-200b-3p (miR-200b-3p m6A) in a sample from said patient and to the N6-adenosine methylated miRNA-200b-3p (miR-200b-3p m6A) for use in the treatment of a cancer in a subject in need thereof. [post_date] => 2022-03-07 15:14:53 [post_modified] => 2024-09-11 15:53:00 [ID] => 4542 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7d9c5cce-0fc7-fc92-98bc-615f0c41fcc8 [etat_fiche_online] => en_ligne [date_application] => 10-06-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20202-D1 [keywords] => miRNA, Glioblastoma, prognosis, miR-200b-3p [pub_scient_inv_dispo] => Mol Ther Nucleic Acids. 2020 Aug 14;22:72-83. Briand et al. N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool doi: 10.1016/j.omtn.2020.08.010. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CARTRON Pierre-François,BOUGRAS-CARTRON Gwenola,SERANDOUR Aurélien,BRIAND Joséphine [number_application] => European Procedure (Patents) (EPA) - 10 Juin 2020 - 20305630.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• GliomaTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 178 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Glioma, Human POC, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Glioma, Human POC, Oncology, Transcriptomics ) [179] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR DETECTING THE PRESENCE OF CORONAVIRUS-SPECIFIC ANTIBODIES IN A SUBJECT [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-detecting-the-presence-of-coronavirus-specific-antibodies-in-a-subject/ [post_content] => Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26u201332 kilobases in length. In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, reliable diagnostic methods are highly desirable. In particular, the development and availability of tests for the detection and quantification of anti-SARS-CoV-2 antibodies in subjects with COVID-19 is of strong diagnostic interest. The present fulfils this need. In particular, the inventors developed an Adressable Laser Beads ImmunoAssay (ALBIA) method based on the use of particles conjugated with a coronaviral polypeptides (S1,S2, S2’, N, PL-Pro). More particularly, the inventors show that detection and titration of anti-SARS-Cov-2 Spike S1 IgG and IgM antibodies are feasible by said method. [post_date] => 2022-03-07 15:14:52 [post_modified] => 2024-09-11 15:53:00 [ID] => 4541 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d5870a47-b548-7d26-771c-6050ca13af72 [etat_fiche_online] => en_ligne [date_application] => 14-04-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20194-D1 [keywords] => COVID19, Serology Test [pub_scient_inv_dispo] => Front Microbiol. 2020 Nov 26;11:603931. Drouot L et al. Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay. doi: 10.3389/fmicb.2020.603931. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BOYER Olivier,DROUOT Laurent [number_application] => European Procedure (Patents) (EPA) - 14 Avr. 2020 - 20 315 157.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Infectious DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 179 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Analytic validation, Biomarker, Biomarker, Immunoassay, Infectious Diseases, Method [taxonomieurl] => Analytic validation, Biomarker, Biomarker, Immunoassay, Infectious Diseases, Method ) [180] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR DISCONTINUING A TREATMENT WITH A TYROSINEKINASE INHIBITOR (TKI) [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-discontinuing-a-treatment-with-a-tyrosinekinase-inhibitor-tki/ [post_content] => The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells in subject and concluding that the treatment with a TKI should be discontinued when the number and/or frequency of innate CD8 T-cells is higher than the predetermined reference value. Inventors evaluated whether innate CD8(+) T-cells are an early target of CML therapy success. Among peripheral blood effector CD8(+) T-cells, inventors shown that both number and/or frequency and functional signatures of innate CD8(+) T-cells are enhanced as early as 3 months of therapy. Strikingly, they observe that patients with high innate CD8(+) T-cell number and/or frequency at 3 months and/or diagnosis achieve a DMR earlier than patients with low innate CD8(+) T-cell number. Furthermore, a higher number and/or frequency of high innate CD8(+) T-cell patients achieved a stable DMR for over 2 years. Collectively, these findings highlight innate CD8(+) T-cells as a potential marker for both CML therapy success and therapy discontinuation eligibility. [post_date] => 2022-03-07 15:14:51 [post_modified] => 2024-09-11 15:52:59 [ID] => 4536 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cedfccb5-3ab9-dda4-ff09-5f3e860aca86 [etat_fiche_online] => en_ligne [date_application] => 05-02-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19174-D1 [keywords] => BCR-ABL; TKI response prediction [pub_scient_inv_dispo] => Sci Rep., 2020 Feb 24, Barbarin et al, Innate T-?? lymphocytes as new immunological components of anti-tumoral off-target effects of the tyrosine kinase inhibitor dasatinib, DOI: 10.1038/s41598-020-60195-z [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HERBELIN André,CAYSSIALS Emilie,BARBARIN Alice,LEFEVRE Lucie,ROY Lydia,GOMBERT Jean-Marc [number_application] => European Procedure (Patents) (EPA) - 05 Févr. 2020 - 20 305 107.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => other [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LeukemiasTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 180 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Chronic Myelocytic Leukemia (CML), Human POC, Leukemias, Method, Oncology, Other [taxonomieurl] => Biomarker, Chronic Myelocytic Leukemia (CML), Human POC, Leukemias, Method, Oncology, Other ) [181] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEW SEROLOGICAL MARKER FOR THE LATENT FORM OF TOXOPLASMOSIS [guid] => https://technology-offers.inserm-transfert.com/offer/new-serological-marker-for-the-latent-form-of-toxoplasmosis/ [post_content] => In the present invention, inventors report the characterization of BCLA (Brain Cyst Load-associated Antigen), a protein exclusively expressed during the bradyzoite stage of the parasite. In cysts directly purified from the brain of mice, the protein is distributed within and at the surface of the cyst. ELISA antibody capture using a combination of serologically reactive BCLA peptides and a recombinantly expressed c-terminal domain (rBCLA) constitutes an efficient serological marker of latent infection with a high sensitivity that is clearly and exclusively correlated with the presence of cysts in the brain of mice. Antibodies directed against BCLA antigen have been detected in human patients with enriched titers in patients qualified as seropositive to Sag1 or tachyzoite related antigens. Further correlation in humans between anti-BCLA IgG synthesis and cysts is brought by significantly stronger recorded titers in pathological panels strongly related to the presence of cyst.Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BCLA, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite/cyst). This specific protein and its antigenic fragments can be used to detect autoantibodies in the sera of patient for the diagnosis of the latent form of Toxoplasmosis. The invention also relates to derived antibodies, generated by BCLA immunisation that specifically binds this new protein [post_date] => 2022-03-07 15:14:51 [post_modified] => 2024-09-11 15:53:12 [ID] => 4534 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1827e7d6-2273-397e-d333-5e2ef39145c5 [etat_fiche_online] => en_ligne [date_application] => 12-11-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18361-D1 [keywords] => BCLA, ELISA, Toxoplasmosis [pub_scient_inv_dispo] => BMC Biol. 2021 Feb 9, Dard C et al., A brain cyst load-associated antigen is a Toxoplasma gondii biomarker for serodetection of persistent parasites and chronic infection, doi: 10.1186/s12915-021-00959-9. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HAKIMI Mohamed Ali,BRENIER-PINCHART Marie-Pierre,SWALE Christopher,DARD Céline,PELLOUX Hervé [number_application] => European Procedure (Patents) (EPA) - 12 Nov. 2019 - 19208644.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• Protozoal infectionTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 181 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Immunoassay, Infectious Diseases, Method, Protozoal infection, Toxoplasmosis [taxonomieurl] => Biomarker, Immunoassay, Infectious Diseases, Method, Protozoal infection, Toxoplasmosis ) [182] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR DIAGNOSING NASAL INTESTINAL TYPE ADENOCARCINOMAS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-diagnosing-nasal-intestinal-type-adenocarcinomas/ [post_content] => The present invention relates to methods and compositions for the diagnostic and for the treatment of nasal intestinal type adenocarcinomas (ITAC). The inventors used a non-invasive brushing technique, which permits to identify transcriptomic and methylation modifications that are consistent with phenotypic profiles and ITACs natural history. Thus, they identified CACNA1C as a new predictive marker of ITAC. In particular, the invention relates to a method of determining whether a subject has or is at risk of having nasal intestinal type adenocarcinoma (ITAC) comprising determining the expression level of CACNA1C in a sample wherein said expression level indicates whether the subject has or is at risk of having a nasal intestinal type adenocarcinoma (ITAC) [post_date] => 2022-03-07 15:14:50 [post_modified] => 2024-09-11 15:53:14 [ID] => 4531 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 74ba1136-0fc3-ba01-53c0-5f3d28013b35 [etat_fiche_online] => en_ligne [date_application] => 17-10-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19398-D1 [keywords] => Q-PCR, Epigenetics, Transcriptomics, Diagnostic in sinonasal tumors, intestinal type adenocarcinomas (ITACs) [pub_scient_inv_dispo] => Clin Epigenetics, 2021 Sep 25, Gallet et al., Integrative genomics analysis of nasal intestinal-type adenocarcinomas demonstrates the major role of CACNA1C and paves the way for a simple diagnostic tool in male woodworkers, doi: 10.1186/s13148-021-01122-5. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HOULGATTE Rémi,GUEANT Jean-Louis,OUSSALAH Abderrahim,JANKOWSKI Roger,GALLET Patrice [number_application] => European Procedure (Patents) (EPA) - 17 Oct. 2019 - 19 306 355.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => epigenetics,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Nasopharyngeal cancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 182 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Epigenetics, Human POC, Method, Nasopharyngeal cancer, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Epigenetics, Human POC, Method, Nasopharyngeal cancer, Oncology, Transcriptomics ) [183] => stdClass Object ( [post] => stdClass Object ( [post_title] => SINGLE-CELL RNA SEQUENCING METHOD FOR THE ANALYSIS OF B AND T CELL TRANSCRIPTOME IN PHENOTYPICALLY DEFINED B AND T CELL SUBSETS [guid] => https://technology-offers.inserm-transfert.com/offer/single-cell-rna-sequencing-method-for-the-analysis-of-b-and-t-cell-transcriptome-in-phenotypically-defined-b-and-t-cell-subsets/ [post_content] => Single-cell RNA sequencing (scRNAseq) allows the identification, characterization, and quantification of cell types in a tissue. When focused on the adaptive immune system’s T and B cells, scRNAseq carries the potential to track the clonal lineage of each analyzed cell through the unique rearranged sequence of its antigen receptor (TCR or BCR, respectively), and link it to the functional state inferred from transcriptome analysis. Computational approaches to infer clonality and maturation status (for BCR only) from scRNAseq datasets of T and B cells have been developed but there are cumbersome and not costly effective. The inventors have now developed a FACS-based 5’-end RNAseq method, in particular a FACS-based 5’-end scRNAseq method, for cost effective integrative analysis of B and T cell transcriptome and paired BCR and TCR repertoire in phenotypically defined B and T cell subsets. In particular, the method of the present invention includes a reverse transcription step that uses a number of different well specific template switching oligonucleotides (TSO) to introduce a well-specific DNA barcode in the 5’-end of cDNAs. [post_date] => 2022-03-07 15:14:50 [post_modified] => 2024-09-11 15:52:59 [ID] => 4530 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f2aed85d-6f5a-0405-09a1-5e3c50c1e9bc [etat_fiche_online] => en_ligne [date_application] => 08-08-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18301-D1 [keywords] => single-cell RNA sequencing (scRNAseq) method
B and T cell transcriptome caracaterization
[pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MILPIED Pierre,ATTAF Noudjoud,GIL Laurine,CERVERA-MARZAL Inaki [number_application] => European Procedure (Patents) (EPA) - 08 Août 2019 - 19 190 782.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 183 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Method, Product, Transcriptomics [taxonomieurl] => Method, Product, Transcriptomics ) [184] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF DETERMINING WHETHER PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA WILL ACHIEVE A RESPONSE TO AN MYC-TARGETING THERAPY [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-determining-whether-patients-suffering-from-acute-myeloid-leukemia-will-achieve-a-response-to-an-myc-targeting-therapy/ [post_content] => Deciphering the impact of metabolic intervention on response to anticancer therapy represents a path toward improved clinical responses. Here, the inventors identify amino acid-related pathways connected to the folate cycle whose activation predicts sensitivity to MYC-targeting therapies in acute myeloid leukemia (AML). They establish that folate restriction and deficiency of the rate-limiting folate-cycle enzyme, MTHFR ? which exhibits reduced-function polymorphisms in about 10% of Caucasians ? enhance resistance to MYC targeting by BET and CDK7 inhibitors in cell lines, primary patient samples and syngeneic mouse models of AML. Further, this effect is abrogated by supplementation with the MTHFR enzymatic product, CH3-THF. Mechanistically, folate cycle disturbance reduces H3K27/K9 histone methylation, and activates a SPI1 transcriptional program counteracting the effect of BET inhibition. Thus the data provide a rationale for screening MTHFR polymorphisms and the folate cycle status to exclude patients least likely and nominate those most likely to benefit from MYC-targeting therapies. [post_date] => 2022-03-07 15:14:49 [post_modified] => 2024-09-11 15:52:58 [ID] => 4529 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a714d7c1-ec7f-040c-f45b-5e55457b89e1 [etat_fiche_online] => en_ligne [date_application] => 16-10-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18323-D1 [keywords] => Drug Resistance Prediction, Cellular Metabolic status, BET inhibitor [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ITZYKSON Raphael,PUISSANT Alexandre [number_application] => European Procedure (Patents) (EPA) - 16 Oct. 2019 - 19 306 350.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => epigenetics,genomics,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LeukemiasTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 184 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Acute Lymphocytic Leukemia (ALL), Animal POC, Biomarker, Biomarker, Epigenetics, Genomics, Leukemias, Method, Oncology, Transcriptomics [taxonomieurl] => Acute Lymphocytic Leukemia (ALL), Animal POC, Biomarker, Biomarker, Epigenetics, Genomics, Leukemias, Method, Oncology, Transcriptomics ) [185] => stdClass Object ( [post] => stdClass Object ( [post_title] => New biomarkers for predicting antipsychotic treatment response in a patient with schizophrenia [guid] => https://technology-offers.inserm-transfert.com/offer/new-biomarkers-for-predicting-antipsychotic-treatment-response-in-a-patient-with-schizophrenia/ [post_content] => A fundamental shortcoming in the current treatment of schizophrenia is the lack of valid criteria to predict who will respond to antipsychotic treatment. The identification of blood-based biological markers of the therapeutic response would enable clinicians to identify the subgroup of patients in whom conventional antipsychotic treatment is ineffective and offer alternative treatments. As part of the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) programme, the inventors conducted a transcriptome analysis on 188 subjects with first episode psychosis, all of whom were subsequently treated with amisulpride for 4 weeks. They identify 32 genes for which the expression changed after treatment in good responders only. Among these genes, the expression of ALPL, a gene involved in vitamin B6 metabolism, as well as CA4, DHRS13, and HOMER3 predicted response status before treatment. Using genotypic variations associated with expression changes, the inventors built a response eQTL-based polygenic score that predicted poor response to medication. Thus, the present invention relates to a method for predicting the response to antipsychotic drugs comprising determining the expression of the ALPL, CA4, DHRS13, or HOMER3 and/or an eQTL-based polygenic score. [post_date] => 2022-03-07 15:14:49 [post_modified] => 2024-09-11 15:52:57 [ID] => 4527 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e6ede2e3-b4d4-cd94-a5f9-5e0b2707370c [etat_fiche_online] => en_ligne [date_application] => 24-04-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19073-D1 [keywords] => RNA-Seq, RT-PCR, Transcriptomics, Treatment Response in Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Psychosis [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => JAMAIN Stéphane,TROUDET Réjane [number_application] => European Procedure (Patents) (EPA) - 24 Avr. 2019 - 19 305 528.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• SchizophreniaTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 185 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Central Nervous System, Human POC, Schizophrenia, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Central Nervous System, Human POC, Schizophrenia, Transcriptomics ) [186] => stdClass Object ( [post] => stdClass Object ( [post_title] => New biomarkers and targets for prognosis in patients with renal cell carninomas [guid] => https://technology-offers.inserm-transfert.com/offer/new-biomarkers-and-targets-for-prognosis-in-patients-with-renal-cell-carninomas/ [post_content] => Renal Cell Carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells and has a worldwide mortality. However, mortality rates have barely improved over the last 20 years. Novel biomarkers and biomarkers are thus urgently required for this cancer. The inventors have devised a strategy to produce mouse cancer cell lines of progressively enhanced aggressiveness and specialization. The mouse renal cancer cell line RENCA was serially passaged in vivo using multiple implantation strategies designed to replicate different aspects of primary tumour growth and metastasis. Transcriptomic and epigenomic data has been acquired for the derived cell lines and primary analyses have been performed. The inventors then selected plurality of genes with no reported role in RCC which were upregulated in their specialized cell lines, and checked their relevance in patient data and clinical samples. This approach contributes to identify 4 serum biomarkers, namely IL-34, SAA2, PONL1 and CFB that are suitable for predicting survival time in patients suffering from RCC. The inventors also validated that the 4 proteins are also biotargets for the treatment of RCC. [post_date] => 2022-03-07 15:14:48 [post_modified] => 2024-09-11 15:52:56 [ID] => 4526 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 36784a66-e0c2-6e15-3bf1-5d949244ef6b [etat_fiche_online] => en_ligne [date_application] => 05-03-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18474-D1 [keywords] => ELISA, IHC, RT-PCR, Immunoassay, Transcriptomics, Treatment Response, Prognosis in Cancer, RCC, Renal Cell Carcinoma [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BIKFALVI Andreas,DUFIES Maeva,COOLEY Lindsay,PAGES Gilles,FALCIANI Francesco,CLARKE Kim,SOULEYREAU Wilfried [number_application] => European Procedure (Patents) (EPA) - 05 Mars 2019 - 19305252.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 186 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Solid Tumors, Target, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Solid Tumors, Target, Transcriptomics ) [187] => stdClass Object ( [post] => stdClass Object ( [post_title] => Methods and kits for determining treatment response with an immune checkpoint inhibitor from patients suffering from cancer [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-kits-for-determining-treatment-response-with-an-immune-checkpoint-inhibitor-from-patients-suffering-from-cancer/ [post_content] => To overcome the difficulty in achieving a quantitative assessment of CTL function in clinical settings, the inventors aimed at developing a new method inspired by their knowledge of the CTL/tumor target biology and based on flow cytometry. In particular, to directly detect the earliest steps of tumor cell resistance to CTL attack at the lytic synapse the inventors developed a method to monitor CTL/tumor cells interaction in the presence of FM1-43, a fluorescent lipophilic dye that rapidly intercalates into lipid bilayer during the membrane turnover that accompanies plasma membrane reparation. This assay allows the inventors to measure reparative membrane turnover of tumor cells under CTL attack by FACS analysis at the whole tumor cell population level. They initially applied this approach to compare the response of melanoma cell (D10 cells) to CTL attack as compared to conventional target cells that are sensitive to CTL mediated cytotoxicity (EBV-transformed B cells, JY cells). The methodology allows to rapidly assessing the synaptic resistance of tumor target cells to CTL attack and the intrinsic capacity of CD8+CTL to efficiently kill their target cells. Thus, the present invention relates to methods and kit for assaying lytic potential of immune effector cells and uses thereof in diagnostic assays. [post_date] => 2022-03-07 15:14:47 [post_modified] => 2024-09-11 15:52:54 [ID] => 4523 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9855889a-138a-4226-51a7-5d0761ece3e0 [etat_fiche_online] => en_ligne [date_application] => 28-11-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18284-D1 [keywords] => Flow Cytometry, Immunoassay, Method, Technology, Treatment Response in Cancer [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => VALITUTTI Salvatore,FILALI Liza,MUELLER Sabina,PUISSEGUR Marie-Pierre [number_application] => European Procedure (Patents) (EPA) - 28 Nov. 2018 - 18 306 576.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 187 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Immunoassay, In vitro poc, Method, Oncology [taxonomieurl] => Biomarker, Immunoassay, In vitro poc, Method, Oncology ) [188] => stdClass Object ( [post] => stdClass Object ( [post_title] => Biomarker and Methods for diagnosing or predicting risk of liver dysfunction [guid] => https://technology-offers.inserm-transfert.com/offer/biomarker-and-methods-for-diagnosing-or-predicting-risk-of-liver-dysfunction/ [post_content] => Most chronic liver diseases are notoriously asymptomatic, until cirrhosis with clinical decompensation occurs. The use of early diagnosis strategies is vital to maintain patients in a symptom-free state and to delay decompensation, and thus improve the outcome. Albumin (HAS) undergoes several post-translational modifications in hepatocytes but clinical relevance of some of these modifications has been recently investigated in advanced liver diseases. Now, the inventors demonstrate that the binding capacities of some ligands, measured by inductively coupled plasma mass spectrometry (ICP-MS), are significantly different between cirrhotic patients and patients with no liver dysfunctions. The decreased binding capacities in cirrhotic patients were paralleled by the presence of significantly higher HSA isoforms. Animal experimentations were also conducted to explore the precocity of HSA modifications in the course of chronic liver dysfunction. This allow the inventors to assume that the most important modifications of albumin structure due to liver dysfunction could be revealed by measuring the unbound fraction of specific ligands spiked in serum. [post_date] => 2022-03-07 15:14:47 [post_modified] => 2024-10-22 12:00:03 [ID] => 4522 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bdeb6403-1219-3d03-718f-5cb48fec41da [etat_fiche_online] => en_ligne [date_application] => 2018-11-20 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18286-D1 [keywords] => Mass Spectrometry, Diagnostic, Risk Prediction in Liver Dysfunction, Liver Cancer, Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, NASH [pub_scient_inv_dispo] => Sci Rep, 2024 Jan 16, El Balkhi et al., Early detection of liver injuries by the Serum enhanced binding test sensitive to albumin post-transcriptional modifications, ;14(1):1434. doi: 10.1038/s41598-024-51412-0. [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => EL BALKHI Souleiman,SAINT-MARCOUX Franck,WOILLARD Jean-Baptiste [number_application] => European Procedure (Patents) (EPA) - 20 Nov. 2018 - 18 306 528.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => mass_spectrometry [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 188 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Gastrointestinal Diseases, Human POC, Liver Disease, Mass spectrometry [taxonomieurl] => Biomarker, Biomarker, Gastrointestinal Diseases, Human POC, Liver Disease, Mass spectrometry ) [189] => stdClass Object ( [post] => stdClass Object ( [post_title] => Biomarker for assessing or predicting the severity of asthma or allergic disease [guid] => https://technology-offers.inserm-transfert.com/offer/biomarker-for-assessing-or-predicting-the-severity-of-asthma-or-allergic-disease/ [post_content] => The present invention relates to allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determine its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9-/-) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer’s patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy. [post_date] => 2022-03-07 15:14:47 [post_modified] => 2024-09-11 15:52:52 [ID] => 4521 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3db2797b-bbc8-ecc9-890b-5c386b1599ca [etat_fiche_online] => en_ligne [date_application] => 05-09-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18315-D1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CARIOU Bertrand,BOUCHAUD Grégory,MAGNAN Antoine,LE MAY Cedric [number_application] => European Procedure (Patents) (EPA) - 05 Sept. 2018 - 18 306 169.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• ImmunologyTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 189 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Allergies, Animal POC, Biomarker, Biomarker, Immunoassay, Immunology, Transcriptomics [taxonomieurl] => Allergies, Animal POC, Biomarker, Biomarker, Immunoassay, Immunology, Transcriptomics ) [190] => stdClass Object ( [post] => stdClass Object ( [post_title] => IN VITRO METHOD FOR DETERMINING THELIKELIHOOD OF OCCURRENCE OF AN ACUTE MICROVASCULAR REJECTION (AMVR) AGAINST A RENAL ALLOGRAFT IN AN INDIVIDUAL [guid] => https://technology-offers.inserm-transfert.com/offer/in-vitro-method-for-determining-thelikelihood-of-occurrence-of-an-acute-microvascular-rejection-amvr-against-a-renal-allograft-in-an-individual/ [post_content] => The present invention relates to the field of organ transplant and the issues associated with transplant rejection. Antibody-mediated rejection (AMR) is associated with a poor transplant outcome. Pathogenic alloantibodies are usually directed against human leucocyte antigens (HLAs). However, evidence of AMR in the absence of anti-HLA antibodies suggests the presence of non-anti-HLA antibodies, identified as anti-endothelial cell antibodies (AECAs). The inventors have demonstrated that kidney recipients who experienced acute rejection with microvascular inflammation within the first 3 months after transplantation in the absence of anti-HLA donor-specific antibodies, carried, before transplantation, unknown AECAs in their sera that specifically targeted the glomerular microvascular endothelium. Thus, the present invention relates to in vitro methods and kits for determining the likelihood of occurrence of an acute microvascular rejection (AMVR) against a renal allograft in an individual.Scientific publication(s):J Am Soc Nephrol, 2019 Apr, Delville M. et al., Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens, doi: 10.1681/ASN. [post_date] => 2022-02-21 09:43:06 [post_modified] => 2024-08-28 12:17:46 [ID] => 4518 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 374100db-35a0-d6c1-7487-5e3d5fe64a61 [etat_fiche_online] => en_ligne [date_application] => 11-01-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO17499-D1 [keywords] => ELISA, Flow Cytometry, Flow Cytometry Bead Based, Immunoassay, Risk Prediction, Prognosis in Kidney Graft Rejection, AMR, Antibody-Mediated Rejection, Acute Microvascular Rejection (AMVR)
[pub_scient_inv_dispo] => J Am Soc Nephrol, 2019 Apr, Delville M. et al., Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens, doi: 10.1681/ASN.
[access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => ANGLICHEAU Dany,CHARREAU Béatrice [number_application] => European Procedure (Patents) (EPA) - 11 Janv. 2019 - 19 305 037.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• TransplantationTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 190 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Kidney Transplantation, Transplantation [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Immunology, Kidney Transplantation, Transplantation ) [191] => stdClass Object ( [post] => stdClass Object ( [post_title] => QUALITY CONTROL DEVICES AND METHODS FOR MAGNETIC RESONANCE IMAGING SYSTEMS [guid] => https://technology-offers.inserm-transfert.com/offer/quality-control-devices-and-methods-for-magnetic-resonance-imaging-systems/ [post_content] => The invention relates to quality control devices and methods for magnetic resonanceimaging (MRI) systems, more particularly for medical imaging applications. An example isstereotactic surgery where MRI images are combined with X-ray images to accuratelylocate a target in a subject.A test device (1), and an associated method using said test object, are used toeasily detect a faulty calibration or a malfunction of an MRI device.The test device includes:a hermetically sealable hollow body (20) having a substantially cylindrical shape,a support frame (22) configured to be removably inserted in the hollow body anddefining a target region (V22) having a substantially cylindrical shape; anda plurality of target objects (24) made of a material visible on X-ray images and MRIimages said target objects being arranged in the target region and being attached to thesupport frame. [post_date] => 2022-02-14 10:00:30 [post_modified] => 2024-09-11 15:57:49 [ID] => 4517 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b49a47d1-5840-a4dd-6b41-62069351160e [etat_fiche_online] => en_ligne [date_application] => 07-08-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => MECA19061-R1 [keywords] => Medical Imaging, Quality Control Fantom, MRI systems, Stereotactic deformation [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => 0 [second_indication] => 0 [inventors] => BARANTIN Laurent,DESTRIEUX Christophe [number_application] => European Procedure (Patents) (EPA) - 07 Août 2019 - 19 306008.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• Central Nervous SystemTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 191 [terms] => Array ( [0] => Research ) [taxonomie] => Central Nervous System, Device, Product, Prototype validated, Validated in a relevant environment [taxonomieurl] => Central Nervous System, Device, Product, Prototype validated, Validated in a relevant environment ) [192] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF DETERMINING THE ETIOLOGY OF ACUTE ISCHEMIC STROKES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-determining-the-etiology-of-acute-ischemic-strokes/ [post_content] => Determining acute ischemic stroke (AIS) etiology is crucial for guidance of secondary prevention. Here, the inventors performed a correlation analysis between AIS etiology and AIS thrombus cellular composition and content, as assessed using quantitative biochemical assays. In particular, homogenates of 250 AIS patient thrombi were prepared by mechanical grinding. Platelet, red blood cell, and leukocyte content of AIS thrombi were estimated by quantification of glycoprotein (GP)VI, heme, and DNA in thrombus homogenates. AIS etiology was defined as cardioembolic, non-cardioembolic, or embolic stroke of undetermined source (ESUS), according to the TOAST classification. Cardioembolic thrombi were richer in DNA (35.8 vs 13.8 ng/mg, p [post_date] => 2022-01-20 08:22:38 [post_modified] => 2024-09-11 15:52:48 [ID] => 4511 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 78328473-2d16-9324-8a01-61dc273e94bc [etat_fiche_online] => en_ligne [date_application] => 27-05-2020 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO20245-D1 [keywords] => Differential diagnossi; Stroke Etioldy; Cardioembolic Stroke; Non Cardioembolic Stroke; Embolic Stroke [pub_scient_inv_dispo] => Stroke, 2020 Sep;51(9):2810-2816. Di Meglio et al, DNA Content in Ischemic Stroke Thrombi Can Help Identify Cardioembolic Strokes Among Strokes of Undetermined Cause doi: 10.1161/STROKEAHA.120.029134. Epub 2020 Aug 19. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MAZIGHI Mikhael,OLLIVIER Véronique,BLANC Raphaël,DESILLES Jean-Philippe,SOLO NOMENJANAHARY Mialitiana,HO-TIN-NOE Benoît,DI MEGLIO Lucas,PIOTIN Michel [number_application] => European Procedure (Patents) (EPA) - 27 Mai 2020 - 20 305 551.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• StrokeTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 192 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Central Nervous System, Immunoassay, Method, Pre-Analytic Validation, Stroke [taxonomieurl] => Biomarker, Central Nervous System, Immunoassay, Method, Pre-Analytic Validation, Stroke ) [193] => stdClass Object ( [post] => stdClass Object ( [post_title] => Treatment of pregnant women affected with polycystic ovary syndrome [guid] => https://technology-offers.inserm-transfert.com/offer/treatment-of-pregnant-women-affected-with-polycystic-ovary-syndrome/ [post_content] => [post_date] => 2022-01-20 08:22:34 [post_modified] => 2024-09-11 15:42:49 [ID] => 4510 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2dec1208-a2af-4f35-9135-8c7bf118cee4 [etat_fiche_online] => en_ligne [date_application] => 31-03-2017 [date] => [bd_referent] => Gregoire SERRA [bd_referent_id] => [contact_email] => gregoire.serra@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17095-T1 [keywords] => [pub_scient_inv_dispo] => Tata B, Mimouni NEH, Barbotin AL, Malone SA, Loyens A, Pigny P, Dewailly D, Catteau-Jonard S, Sundström-Poromaa I, Piltonen TT, Dal Bello F, Medana C, Prevot V, Clasadonte J and Giacobini P (2018) Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nature Medicine. DOI: 10.1038/s41591-018-0035-5. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GIACOBINI Paolo,PREVOT Vincent [number_application] => European Procedure (Patents) (EPA) - 31 Mars 2017 - 17 305 385.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Women healthTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 193 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Lead - validation in vivo, Product, Target, Women health, Women infertility [taxonomieurl] => Drug, Lead - validation in vivo, Product, Target, Women health, Women infertility ) [194] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF IL-6 INHIBITORS FOR THE TREATMENT OF ACUTE CHEST SYNDROME IN PATIENTS SUFFERING FROM SICKLE CELL DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-il-6-inhibitors-for-the-treatment-of-acute-chest-syndrome-in-patients-suffering-from-sickle-cell-disease/ [post_content] => Acute chest syndrome (ACS) is a common and potentially lethal form of acute lung injury in sickle cell disease (SCD). Because pathophysiology remains unclear, therapeutic options are limited to supportive care with empiric antibiotics and red cell transfusion in case of aggravation. A role of inflammation mediated by endothelial and immune cells has been suspected but the levels of pro-inflammatory cytokines and chemokines in the lungs during ACS have not yet been investigated. Here the inventors report dramatically high levels of IL6, unlike IL-1? and TNF-?, in the sputum from SCD children during ACS (n=12) compared with non-ACS sputum (n=6). By contrast, plasma IL-6 levels were not significantly increased during ACS (n=12), compared with vaso-occlusive crisis (n=12), steady state (n=12) and 15 healthy controls (n=9). IL-6 levels were more than 0-fold higher in sputum than in plasma, suggesting increased local production by inflammatory cells during ACS. Sputum levels of IL8, CCL2 and CCL3 chemokines were also increased during ACS, which may contribute to the recruitment of innate immune cells, such as neutrophils and monocytes, in the lungs. The results strongly suggest an involvement of these inflammatory mediators in ACS pathophysiology and open new therapeutic perspectives, in particular with IL-6 inhibitors. [post_date] => 2022-01-14 10:26:36 [post_modified] => 2024-09-11 15:43:30 [ID] => 4509 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => be60ae67-e523-0694-f597-602e405f0f3f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO20503-T1 [keywords] => Repurposing; Sickle Cell Disease; Acute Chest Syndrome; IL-6 [pub_scient_inv_dispo] => Am J Hematol. 2021 Dec 7. doi: 10.1002/ajh.26433. Online ahead of print. [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => ALLALI Slimane,TROVATI MACIEL Thiago,RIGNAULT-BRICARD Rachel,HERMINE Olivier [number_application] => European Procedure (Patents) (EPA) - 05 Nov. 2020 - 20 306 334.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hematological DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 194 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Anemia, Biologic, Clinical Trial, Drug, Hematological Disorders, Method, Phase 1, Sickle Cell Disease [taxonomieurl] => Anemia, Biologic, Clinical Trial, Drug, Hematological Disorders, Method, Phase 1, Sickle Cell Disease ) [195] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF AN AGENT CAPABLE OF INHIBITING THE ACTIVATION OF MAIT CELLS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-an-agent-capable-of-inhibiting-the-activation-of-mait-cells-for-the-treatment-of-obesity-and-obesity-related-disorders/ [post_content] => Obesity is associated with low-grade inflammation in adipose tissue (AT) and dysfunctional adipocytes producing inflammatory molecules. A recent study reveals profound MAIT cell abnormalities in patients harboring metabolic disorders, suggesting their potential role in these pathologies. Now the inventors show that MAIT cells induce adipose tissue and ileum dysfunction and inflammation in obese mice. Moreover, the inventors show that a treatment with an agent capable of inhibiting the activation of MAIT cells (i.e. Ac-6-FP) during high fat diet (HFD) improved metabolic parameters and in particular insulin sensitivity. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of obesity and obesity-related disorders. [post_date] => 2021-12-13 08:59:12 [post_modified] => 2024-09-11 15:43:50 [ID] => 4489 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 867e9415-1200-c29a-84e9-5d3731107c49 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19113-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => LEHUEN-MONTEIRO Agnès,TOUBAL Amine [number_application] => European Procedure (Patents) (EPA) - 19 Mars 2019 - 19 305 332.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ObesityTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 195 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Drug, Metabolic Disorders, Method, Obesity, Protein, Target, Validation in vivo [taxonomieurl] => Antibody, Biologic, Drug, Metabolic Disorders, Method, Obesity, Protein, Target, Validation in vivo ) [196] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-the-treatment-of-acute-ischemic-stroke/ [post_content] => An easily administrable drug treatment to increase the recanalization rate associated with intravenously t-Pa would represent a major advance in the acute ischemic stroke (AIS) management. The inventors demonstrate that thrombi are encapsulated by Neutrophil extracellular traps (NETS) network, which confer tPA resistance. In fact, in presence of DNAse I, tPA-induced fibrinolysis is accelerated, whereas DNAse alone is inefficient. These results suggest that a co-therapy associating tPA and DNAse I may potentialize tPA efficacy. Accordingly, the present invention relates to a method of treating an acute ischemic stroke (AIS) in a patient in need thereof comprising administering to the patient a therapeutically effective combination of t-PA and recombinant DNAse, wherein administration of the combination results in enhanced therapeutic efficacy relative to the administration of t-PA alone. [post_date] => 2021-12-13 08:59:11 [post_modified] => 2024-09-11 15:43:40 [ID] => 4487 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4bfadbff-97e2-4154-8b70-c915fc565562 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17115-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DESILLES Jean-Philippe,BLANC Raphaël,MAZIGHI Mikhael,DI MEGLIO Lucas,DUCROUX Célina,OLLIVIER Véronique,MICHEL Jean-Baptiste,BOISSEAU William,PIOTIN Michel,HO-TIN-NOE Benoît,LOYAU Stéphane [number_application] => European Procedure (Patents) (EPA) - 16 Mai 2017 - 17 305 556.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• StrokeTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 196 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Central Nervous System, Clinical Trial, Drug, Phase 1, Stroke, Target [taxonomieurl] => Central Nervous System, Clinical Trial, Drug, Phase 1, Stroke, Target ) [197] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR PREDICTING AND TREATING CARDIAC DYSFUNCTION [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-predicting-and-treating-cardiac-dysfunction/ [post_content] => Ageing myocardium undergoes structural and functional changes characterized by progressive cardiomyocyte hypertrophy, interstitial fibrosis and inflammation ultimately leading to diastolic and systolic dysfunction. Whilst most focus has been placed on established risk factors such as dyslipidaemia, hypertension and obesity in accelerating cardiac ageing, a potential role for amino acids has received little attention. Here the inventors show that increased phenylalanine (PA) levels induced in vitro cytosolic oxidative stress and senescence whilst in vivo led to senile-like cardiac deterioration in young mice. Moreover, they demonstrated that hepatic PA catabolism declined with age in a p21-dependent manner, whilst p21 deficiency prevented age-related cardiac dysfunction. Finally, the inventors found that Pah cofactor BH4 reversed the age-related rise in plasma PA levels and senile cardiac alterations. These observations have immediate implications for promoting cardiac health and healthspan and suggest that phenylalanine can be used as a biomarker and biotarget of cardiac dysfunction. [post_date] => 2021-12-13 08:59:10 [post_modified] => 2024-09-11 15:43:55 [ID] => 4486 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a640e4c4-0717-f641-cbca-5daebbd52ca6 [etat_fiche_online] => en_ligne [date_application] => 15-07-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19286-T1 [keywords] => [pub_scient_inv_dispo] => Circulation. 2021 Aug 17;144(7):559-574. doi: 10.1161/CIRCULATIONAHA.121.054204. Epub 2021 Jun 24. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DERUMEAUX Geneviève,SAWAKI Daigo,CZIBIK Gabor [number_application] => European Procedure (Patents) (EPA) - 15 Juil. 2019 - 19 186 370.3 [technology_engineering] => [multidisciplinary_field] => ageing [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Chronic Heart FailureTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 197 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Ageing, Biomarker, Cardiovascular Diseases, Chronic Heart Failure, Drug, Method, Target, Validation in vivo [taxonomieurl] => Ageing, Biomarker, Cardiovascular Diseases, Chronic Heart Failure, Drug, Method, Target, Validation in vivo ) [198] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTI- PROTEASE NEXIN-1 CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF [guid] => https://technology-offers.inserm-transfert.com/offer/anti-protease-nexin-1-conformational-single-domain-antibodies-and-uses-thereof/ [post_content] => The present invention relates to anti-protease nexin-1 (PN-1) conformational single domain antibodies and uses thereof in particular in the therapeutic field for the treatment of haemorrhagic diseases [post_date] => 2021-12-13 08:59:10 [post_modified] => 2024-09-11 15:43:53 [ID] => 4485 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c819b2fe-0d21-ae4b-556e-5db07fa0055b [etat_fiche_online] => en_ligne [date_application] => 20-06-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19217-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => BOUTON Marie-christine,LENTING Petrus,CHRISTOPHE Olivier,DENIS Cécile [number_application] => European Procedure (Patents) (EPA) - 20 Juin 2019 - 19 305 797.3 [technology_engineering] => antibodies_nanobodies [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hematological DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 198 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibodies nanobodies, Antibody, Biologic, Drug, Hematological Disorders, Hemophilia, Hit - validation in vitro, Product, Product, Protein [taxonomieurl] => Antibodies nanobodies, Antibody, Biologic, Drug, Hematological Disorders, Hemophilia, Hit - validation in vitro, Product, Product, Protein ) [199] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN MICROVASCULAR DYSFUNCTION [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-topical-pharmaceutical-compositions-for-the-treatment-of-skin-microvascular-dysfunction-2/ [post_content] => Microvascular dysfunction remains a major contributor to the development of skin complications. The inventors assessed the impact of the local inhibition of soluble epoxide hydrolase (sEH), which metabolizes vasodilator and anti-inflammatory epoxyeicosanoids, on the diabetic skin microvascular dysfunction. The inventors have therefore developed some formulations of sEH inhibitors (GSK2256294 and t-AUCB) for topical administration. In particular, they show that an aqueous gel containing 400 mg/L t-AUCB dissolved in 50% dimethylsulfoxide (DMSO) allowed a stable and continuous diffusion of t-AUCB from 2 hours after application on skin pig ears to over a period of 24h. Compared to a control gel, the gel with t-AUCB did not significantly modify the basal skin blood flow but improved the altered hyperemic response of db/db mice 2 hours after application. The results show that the topical administration of a sEH inhibitor improves the skin microcirculatory function, representing a promising pharmacological approach to prevent the development of skin complications especially in diabetic patients. [post_date] => 2021-12-13 08:59:09 [post_modified] => 2024-09-23 19:10:01 [ID] => 4484 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 297991cf-4fe6-5e20-7443-5e3d424dd498 [etat_fiche_online] => en_ligne [date_application] => 2018-10-10 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO17360-T1 [keywords] => Skin complications, skin ulcers, diabetes, systemic sclerosis, soluble epoxide hydrolase, sEH [pub_scient_inv_dispo] => Diab Vasc Dis Res. 2019 Nov;16(6):523-529. doi: 10.1177/1479164119860215. Epub 2019 Jul 3. [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO17360-T1_Bellien.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => BELLIEN Jérémy,ROUSTIT Matthieu,CRACOWSKI Jean-luc,SKIBA Mohamed,BOUNOURE Frédéric,SAVINA Yann [number_application] => European Procedure (Patents) (EPA) - 10 Oct. 2018 - 18 306 336.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 199 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Drug, Method, Skin ulcers, Target, Validation in vivo [taxonomieurl] => Dermatology, Drug, Method, Skin ulcers, Target, Validation in vivo ) [200] => stdClass Object ( [post] => stdClass Object ( [post_title] => CORRECTION OF BETA-THALASSEMIA PHENOTYPE BY GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELL [guid] => https://technology-offers.inserm-transfert.com/offer/correction-of-beta-thalassemia-phenotype-by-genetically-engineered-hematopoietic-stem-cell/ [post_content] => The present invention relates to a genetically modified hematopoietic stem cell(HSC) comprising, in at least one ?-globin gene comprised in the genome thereof, at least one transgene encoding a functional ?-like globin protein, the said transgene being placed under the control of the endogenous promoter of the said at least one ?-globin gene [post_date] => 2021-12-13 08:59:09 [post_modified] => 2024-09-11 15:44:15 [ID] => 4483 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 35904c42-713d-905f-010b-5ddd5223b1d0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19153-T1 [keywords] => Biologic; Cell Therapy; Gene Therapy; Genetic Disorders; Hematological Disorders; Others; Product;Therapeutic [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => AMENDOLA Mario,PAVANI Giulia [number_application] => European Procedure (Patents) (EPA) - 12 Avr. 2019 - 19 305 484.8 [technology_engineering] => cell_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hematological DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 200 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cell therapy, Cell therapy, Drug, Hematological Disorders, Product, Product, Thalassemia [taxonomieurl] => Biologic, Cell therapy, Cell therapy, Drug, Hematological Disorders, Product, Product, Thalassemia ) [201] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR DIAGNOSIS AND MONITORING OF TOXIC EPIDERMAL NECROLYSIS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-diagnosis-and-monitoring-of-toxic-epidermal-necrolysis/ [post_content] => In the present invention, inventors investigate the representation of T cell subsets in Toxic epidermal necrolysis (TEN) a life-threatening cutaneous adverse drug reaction (cADR), characterized by massive epidermal necrosis. To better understand why skin symptoms are so severe in TEN disease, inventors conducted a prospective immunophenotyping study on skin samples and blood from 18 TEN patients, using mass cytometry and next generation TCR sequencing. Deep sequencing of the T cell receptor CDR3 repertoire revealed massive expansion of unique CDR3 clonotypes in blister cells. Over-represented clonotypes were mainly effector memory CD8+CD45RA-CCR7- T cells, and expressed high levels of cytotoxic (Granulysin and Granzymes A & B) and activation (CD38) markers. Thus present invention relates to non-invasive, specific and rapid methods for diagnostic and monitoring Toxic Epidermal Necrolysis. More specifically present invention relates to methods for diagnosis and/or monitoring of Toxic Epidermal Necrolysis through detection of a specific population of T ymphocytes in a subject. The present invention also relates to a method of preventing or treating a Toxic Epidermal Necrolysis in a subject in need thereof. [post_date] => 2021-12-13 08:59:07 [post_modified] => 2024-09-26 14:55:02 [ID] => 4482 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a5d8e26b-19c1-8ed4-f9bd-60e71e4f3121 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO19417-T1 [keywords] => Toxic epidermal necrolysis [pub_scient_inv_dispo] => Villani et al., Sci. Adv. Mar 19;7(12) [access_to_detailed_offer] => [rare_disease] => 1 [second_indication] => 0 [inventors] => VOCANSON Marc,NOSBAUM Audrey,VILLANI Axel,ROZIERES Aurore [number_application] => European Procedure (Patents) (EPA) - 27 Nov. 2020 - 20 306 460.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 201 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Drug, Target, Validation in vivo [taxonomieurl] => Dermatology, Drug, Target, Validation in vivo ) [202] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF ANTAGONISTS OF TH17 CYTOKINES FOR THE TREATMENT OF BRONCHIAL REMODELING IN PATIENTS SUFFERING FROM ALLERGIC ASTHMA [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-antagonists-of-th17-cytokines-for-the-treatment-of-bronchial-remodeling-in-patients-suffering-from-allergic-asthma/ [post_content] => Bronchial remodelling is a prominent feature of severe asthma and a potential therapeutic target. Some data indicate that Th17 cytokines in particular IL-22 may be involved in remodelling processes in vitro, and in skin remodelling in vivo. The aim of the inventors was to evaluate if Th17 cytokines are involved in bronchial remodelling in a severe model of allergic asthma, and if this was amplified by co-sensitization with NOD2 agonist, MDP, a ligand favouring Th17 polarization. Dog allergen challenge led to a predominant neutrophilic infiltration in Broncho-alveolar lavage (BAL), increased dog-specific IgE production, airways hyperresponsiveness, and increased Th17 cytokine production. Increased bronchial remodeling was observed in dog allergen challenged mice compared to control. IL-22 deficiency decreased airway hyperresponsiveness, bronchial mucus production as well as peribronchial collagen deposition, in the allergen-challenged group. Th17 cytokines in particular IL-22 participate in the bronchial remodeling in a chronic model of neutrophilic asthma, and may represent a therapeutic target in severe asthma [post_date] => 2021-12-13 08:59:06 [post_modified] => 2024-09-20 17:25:02 [ID] => 4481 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d6f1e814-2cc8-da13-9733-60e71e0079e2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO16260-T1 [keywords] => Asthma [pub_scient_inv_dispo] => Plé C. et al. PLoSOne. 2015 Apr 10;10(4):e0122372. [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO16260-T1_Tsicopoulos.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => TSICOPOULOS Anne,VORNG Han,AIT YAHIA SENDID Saliha,NANOU Julie,BOUTE Mélodie,CHENIVESSE Cécile [number_application] => European Procedure (Patents) (EPA) - 25 Sept. 2018 - 18 306 243.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 202 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Asthma, Drug, Respiratory Disease, Target, Validation in vivo [taxonomieurl] => Asthma, Drug, Respiratory Disease, Target, Validation in vivo ) [203] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR TREATING T- HELPER TYPE 2 MEDIATED DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-treating-t-helper-type-2-mediated-disease/ [post_content] => The present invention relates to the treatment of T- helper type 2 (Th2)-mediated disease. Here, the inventors set out to investigate at the genome level the effects of SETDB1- dependent H3K9me3 deposition on CD4 T cell activation, differentiation and commitment. By using conditional Setdb1-/- mice, they show that SETDB1 restricts Th1 cell priming and ensures Th2 cell integrity. Unlike their wild-type counterparts, SETDB1-deficient Th2 cells readily express the entire Th1 gene network when exposed to the Th1-instructing cytokine IL12. More, SETDB1 methylates H3K9 at a subset of ERVs that flank and repress Th1 enhancers or behave themselves as cis-regulatory elements of a large network of Th1 genes, including Ifng, Stat4, Runx3 and Tbx21. Therefore, H3K9me3 deposition by SETDB1 locks the Th1 gene expression program and thus ensures T cell lineage integrity by repressing a repertoire of ERVs that have been co-opted to behave as Th1 lineage-specific cis-regulatory modules. Thus, the invention relates to a SETDB1 inhibitor for use in a method for increasing the Th1/Th2 ratio of an immune response in a subject in need thereof. [post_date] => 2021-12-13 08:59:06 [post_modified] => 2024-09-20 16:55:04 [ID] => 4479 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2c85c7d3-432b-69fa-233f-5e7cedc51cf5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO18140-T1 [keywords] => Asthma [pub_scient_inv_dispo] => AdoueV. et al. Immunity (2019) 50(3):629-644 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO18140-T1_Joffre.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => JOFFRE Olivier,MALBEC Agathe,BINET Bénédicte,ADOUE Véronique,LAVIOLETTE Karl [number_application] => European Procedure (Patents) (EPA) - 31 Oct. 2018 - 18 306 432.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 203 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Asthma, Drug, Respiratory Disease, Target, Validation in vivo [taxonomieurl] => Asthma, Drug, Respiratory Disease, Target, Validation in vivo ) [204] => stdClass Object ( [post] => stdClass Object ( [post_title] => Use of coumarin derivatives for the preparation of drugs for treating skin diseases [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-coumarin-derivatives-for-the-preparation-of-drugs-for-treating-skin-diseases/ [post_content] => Kallikrein proteolytic cascade plays a crucial role in various skin diseases. A series of coumarinic derivatives were identified with IC50 in the nanomolar range against kallikreins. Identified coumarinic derivatives are devoided of any cellular toxicity and demonstrated potent in vivo proteolysis inhibition [post_date] => 2021-12-13 08:59:06 [post_modified] => 2024-09-11 15:43:39 [ID] => 4478 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 96129c6e-e753-da64-2f8b-60e71b466bc8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18503-T1 [keywords] => Netherton syndrome [pub_scient_inv_dispo] => Tan X. et al. J Med Chem. 2015 Jan 22;58(2):598-612 [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => HOVNANIAN Alain,REBOUD-RAVAUX Michèle,PAGANO Maurice,TAN Xiao,QIN Lixian,PIROTTE Bernard,FURIO Laetitia [number_application] => European Procedure (Patents) (EPA) - 15 Juil. 2011 - 11 305 931.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 204 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Drug, Method, Target, Validation in vitro [taxonomieurl] => Dermatology, Drug, Method, Target, Validation in vitro ) [205] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTIBODIES SPECIFIC FOR IL20-RB AND USES THEREOF FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/antibodies-specific-for-il20-rb-and-uses-thereof-for-the-treatment-of-acute-exacerbation-of-chronic-obstructive-pulmonary-disease/ [post_content] => Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected by S. pneumoniae and protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb. [post_date] => 2021-12-13 08:59:05 [post_modified] => 2024-10-09 08:45:03 [ID] => 4477 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 18b52ac3-ca0c-ee3e-a803-60e7197a2b10 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO18240-T1 [keywords] => COPD [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => GOSSET Philippe,MARTINEAU Pierre,ROBERT Bruno,LE ROUX Mélina,CHENTOUF Myriam,PICHAVANT Muriel [number_application] => European Procedure (Patents) (EPA) - 04 Sept. 2019 - 19 306 068.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 205 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Chronic Obstructive Pulmonary Disease (COPD), Drug, Lead - validation in vivo, Obstructive pulmonary disease, Product, Product, Protein, Respiratory Disease [taxonomieurl] => Antibody, Biologic, Chronic Obstructive Pulmonary Disease (COPD), Drug, Lead - validation in vivo, Obstructive pulmonary disease, Product, Product, Protein, Respiratory Disease ) [206] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-jak-inhibitors-for-the-treatment-of-painful-conditions-involving-nav1-7-channels/ [post_content] => An increasing body of evidence suggests that Nav1.7 encoded by SCN9A gene may play a key role in various pain states, including acute, inflammatory and/or neuropathic pain.The inventors now report an efficient treatment for severe cases of primary erythromelagia linked to a specific SCN9A mutation. In particular the inventors demonstrated that the inhibition of JAK2 produces a rightward shift in the voltage dependent activation of mutantNav1.7 channels, thereby normalizing the function of mutant Nav1.7 channels. On this basis, the inventors treated a patient suffering from PE with very severe refractory pain with a JAK2 inhibitor (ruxolitinib) and showed the therapy leads to considerable reduction of pain. Accordingly, the present invention relates to the use of JAK inhibitors for the treatment of painful conditions involving Nav1.7 channels. [post_date] => 2021-12-13 08:59:05 [post_modified] => 2024-10-03 14:15:02 [ID] => 4476 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 694c6be6-e0ee-8637-0c55-6012dcf46f6f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO19150-T1 [keywords] => Primary erythermalgia [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO19150-T1_Bodemer.pdf [rare_disease] => 1 [second_indication] => 0 [inventors] => BODEMER Christine,GRECO Céline,DELMAS Patrick [number_application] => European Procedure (Patents) (EPA) - 16 Avr. 2019 - 19 305 488.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 206 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Drug, Method, Target, Validation in vitro [taxonomieurl] => Dermatology, Drug, Method, Target, Validation in vitro ) [207] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING IN A SUBJECT SUFFERING FROM ECTODERMAL DYSPLASIAS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-promoting-wound-healing-in-a-subject-suffering-from-ectodermal-dysplasias/ [post_content] => The present invention relates to a method for promoting wound healing in a subject suffering from Ectodermal dysplasia in need thereof comprising a step of administering subcutaneously, intradermally or topically to said subject a therapeutically effective amount of a compound which restores the activity of p63. Inventors have performed a primary culture of patient keratinocytes suffering from ectodermal dysplasias with two compounds which restore the activity of p63 (e.g.STIMA-1 and/or PRIMA-1Met). They have shown that there is an important differentiation of the keratinocytes of said patient compared to the cells not treated with these compounds. They observed that the activity of p63 mutated is restored, thus the proliferation and differentiation of keratinocytes from the patient are activated. Moreover, inventors have used PRIMA-1Met by topical application on a young patient suffering from ectodermal dysplasias and shown that said patient presents an improvement on her hand. Typically, severe skin erosions (on hands and feet) are healing when PRIMA-1Met is administered topically on the hand. [post_date] => 2021-12-13 08:59:05 [post_modified] => 2024-09-23 18:55:03 [ID] => 4474 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4de80d99-5b41-6c2a-1cae-6012d8f96390 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO16331-T1 [keywords] => [pub_scient_inv_dispo] => Cell Death Dis. 2020 Jan 16;11(1):30. doi: 10.1038/s41419-020-2223-8. [access_to_detailed_offer] => [rare_disease] => 1 [second_indication] => 0 [inventors] => ABERDAM Daniel,ABERDAM Edith,HADJ-RABIA Smail,CISTERNINO Salvatore [number_application] => European Procedure (Patents) (EPA) - 16 Juil. 2018 - 18 305 964.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 207 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Clinical Trial, Dermatology, Drug, Method, Small Molecule, Wounds [taxonomieurl] => Clinical Trial, Dermatology, Drug, Method, Small Molecule, Wounds ) [208] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING CELL SENESCENCE ACCUMULATION RELATED DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-cell-senescence-accumulation-related-disease/ [post_content] => The inventors have surprisingly demonstrated that GD3 positive senescent cells inhibit NK cell in vitro and in vivo while GD3 negative senescent cells is associated with NK cell functionality, both with human or murine cells. The inventors/’ results bring the proof of concept that GD3 expression may represent a Senescence-associated Immune Checkpoint (SIC) that determines senescent cell immunogenicity and identify GD3 and more generally SIC as a multi-hit target for age-associated diseases. Thus, GD3 may be a major step forward in the development of efficient anti-senescence immunotherapies. In particular, the present invention relates to a method for identifying whether a cell is in senescence process comprising the steps of: i) measuring the coexpression level of ST8Sia1 (GD3) with a senescence marker in a biological sample; ii) comparing the co-expression level measured at step i) with its predetermined reference value, and iii) concluding that the cell is in senescence process when the co-expression level of GD3 with a senescence marker is higher than its predetermined reference value or concluding that cell is not in senescence process when the co-expression level of GD3 with a senescence marker is lower or similar than its predetermined reference value. The present invention also relates a method for treating senescent cells accumulation related disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a GD3 inhibitor. [post_date] => 2021-12-13 08:59:04 [post_modified] => 2024-09-20 16:45:13 [ID] => 4473 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 89634d2e-53eb-c154-d732-619cba18e29a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO19413-T1 [keywords] => Senescence, IPF [pub_scient_inv_dispo] => https://doi.org/10.1101/2021.04.23.440408 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO19413-T1_Cherfils.pdf [rare_disease] => 1 [second_indication] => 1 [inventors] => CHERFILS Julien,GILSON Eric,ILTIS Charlène [number_application] => United States Of America (PSP) - 23 Avr. 2021 - 63/178,738 [technology_engineering] => [multidisciplinary_field] => ageing [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 208 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Ageing, Drug, Idiopathic pulmonary fibrosis, Method, Respiratory Disease, Target, Target, Validation in vivo [taxonomieurl] => Ageing, Drug, Idiopathic pulmonary fibrosis, Method, Respiratory Disease, Target, Target, Validation in vivo ) [209] => stdClass Object ( [post] => stdClass Object ( [post_title] => Selective pharmacological inhibition of Epac1 for the treatment of idiopathic pulmonary fibrosis [guid] => https://technology-offers.inserm-transfert.com/offer/selective-pharmacological-inhibition-of-epac1-for-the-treatment-of-idiopathic-pulmonary-fibrosis/ [post_content] => The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IPF. The inventors showed that EPAC1 inhibitors, in particular CE3F4 and AM-0001, represent a promising therapeutic strategy for treating patients with pulmonary fibrosis. The present invention thus relates to an EPAC1 inhibitor for use in the treatment and/or prevention of idiopathic pulmonary fibrosis. [post_date] => 2021-12-13 08:59:04 [post_modified] => 2024-09-20 17:00:03 [ID] => 4472 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7526aca8-21e5-4068-ca39-5e29a7720e34 [etat_fiche_online] => en_ligne [date_application] => 2019-12-13 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => CHIM19384-T1 [keywords] => IPF, Pulmonary, Fibrosis, Idiopathic Pulmonary Fibrosis, Epac1, Respiratory diseases [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => 0 [second_indication] => 0 [inventors] => LEZOUALC’H Frank,BISSERIER Malik,HADRI Lahouaria [number_application] => European Procedure (Patents) (EPA) - 13 Déc. 2019 - 19306645.3. [technology_engineering] => [multidisciplinary_field] => fibrosis [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Respiratory DiseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 209 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Fibrosis, Idiopathic pulmonary fibrosis, Lead - validation in vivo, Method, Product, Respiratory Disease, Small Molecule [taxonomieurl] => Drug, Fibrosis, Idiopathic pulmonary fibrosis, Lead - validation in vivo, Method, Product, Respiratory Disease, Small Molecule ) [210] => stdClass Object ( [post] => stdClass Object ( [post_title] => Use of new biomarker for selecting and determining response to exercise regimen [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-new-biomarker-for-selecting-and-determining-response-to-exercise-regimen/ [post_content] => Exercise improves metabolic health and prevents the complications of obesity and type 2 diabetes. The inventors hypothesized that skeletal muscle contraction produces a cellular stress signal triggering adipose tissue lipolysis to sustain fuel availability during exercise. They aimed at identifying novel exercise-regulated exerkines, able to promote lipolysis. Growth and Differentiation Factor 15 (GDF15) gene expression and secretion increased rapidly upon skeletal muscle contraction. GDF15 protein was up-regulated in conditioned media from both acute and chronic exercise-stimulated myotubes. The inventors further show that physiological concentrations of recombinant GDF15 protein increase lipolysis in human adipose tissue. The inventors herein provide the first evidence that GDF15 is a novel exerkine produced by skeletal muscle contraction and able to target human adipose tissue to promote lipolysis. GDF15 could thus be suitable as a marker of exercise management. [post_date] => 2021-09-29 16:11:03 [post_modified] => 2024-09-11 15:52:38 [ID] => 4457 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => aefb4952-de73-a2e0-e79c-5e13412aec96 [etat_fiche_online] => en_ligne [date_application] => 29-07-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19224-D1 [keywords] => ELISA, RT-PCR, Immunoassay, Transcriptomics, Treatment Response in Metabolism, Cardiovascular, obesity
Physical activity [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MORO Cédric,LAURENS Claire [number_application] => European Procedure (Patents) (EPA) - 29 Juil. 2019 - 19 305 985.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• ObesityTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 210 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Metabolic Disorders, Obesity, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Metabolic Disorders, Obesity, Transcriptomics ) [211] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD FOR EARLY PREDICTION OF NEURODEGENERATIVE DECLINE [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-early-prediction-of-neurodegenerative-decline/ [post_content] => The present invention relates to a method for predicting risks of neurodegenerative decline of a patient, especially of mild cognitive impairment (MCI). Strokes and Parkinson’s disease are frequently associated with occurrence of long-term cognitive impairment or dementia with still incompletely resolved mechanisms. The discovery of diagnostic and predictive biomarkers thus remains a major challenge. The method of the invention uses radiomics corresponding to texture features extracted from a plurality of previously-acquired medical brain images and correlated with previously-acquired clinical and/or biological data. A classifier is trained beforehand for learning these radiomics, and then operated on radiomics computed from at least one brain image of a patient to generate a score representative of its risks of neurodegenerative decline. By applying this method on a cohort of 90 MCI and non-MCI patients, the inventors show that MCI patients could be early predicted with a mean accuracy of 80%.In the same way, the method was able to discriminate very early stages of cognitive decline in a Parkinson’s disease population of 100 patients. [post_date] => 2021-07-05 16:11:03 [post_modified] => 2024-09-11 15:53:15 [ID] => 4448 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 64a209b7-1e6a-f624-3f5f-5e3d6eddcaac [etat_fiche_online] => en_ligne [date_application] => 07-03-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => MECA17605-D1 [keywords] => IA, Predictive Model, Mild Cognitive Impairment [pub_scient_inv_dispo] => Transl Stroke Res, 2020 Aug 11, Betrouni N et al., Texture Features of Magnetic Resonance Images: an Early Marker of Post-stroke Cognitive Impairment, doi: 10.1007/s12975-019-00746-3. Epub 2019 Nov 1.Mov Disord, 2020 Mar 3, Betrouni N et al., Texture features of magnetic resonance images: A marker of slight cognitive deficits in Parkinson’s disease, doi: 10.1002/mds.27931. Epub 2019 Nov 23. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BETROUNI Nacim,BORDET Régis [number_application] => European Procedure (Patents) (EPA) - 07 Mars 2018 - 18 305 244.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => imaging [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Cognitive disordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 211 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Central Nervous System, Cognitive disorders, Imaging, Method, Mild cognitive impairment, Pre-Analytic Validation [taxonomieurl] => Biomarker, Central Nervous System, Cognitive disorders, Imaging, Method, Mild cognitive impairment, Pre-Analytic Validation ) [212] => stdClass Object ( [post] => stdClass Object ( [post_title] => Cellular Fibronectin Toolset [guid] => https://technology-offers.inserm-transfert.com/?p=4442 [post_content] => Expression vectors encoding human cellular fibronectin variants harboring the alternatively spliced Extra Domains B and/or A (or neither) ; fibronectin variant-expressing cells and purified recombinant cellular fibronectin variant proteins. [post_date] => 2021-04-19 18:33:07 [post_modified] => 2024-09-04 13:45:18 [ID] => 4442 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-375e64aa85fe622cba54e50679b8a4f3 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00508 [keywords] => extracellular matrix; fibrosis; angiogenesis; tumor microenvironment [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Others [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• Respiratory DiseaseTherapy Area:
• OthersType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Ellen VAN OBBERGHEN-SCHILLING [first_name] => Ellen [last_name] => VAN OBBERGHEN-SCHILLING [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 212 [terms] => Array ( [0] => Others ) [taxonomie] => Academic Research, Cardiovascular Diseases, Diagnostic, e-health, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Respiratory Disease [taxonomieurl] => Academic Research, Cardiovascular Diseases, Diagnostic, e-health, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Respiratory Disease ) [213] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-shp2-inhibitors-for-the-treatment-of-insulin-resistance/ [post_content] => Despite reaching an epidemic status worldwide, metabolic disorders, notably diabetes, still miss efficient and specific therapeutic strategies because of their multifactorial origin. SHP2 is a ubiquitous tyrosine phosphatase that regulates major signalling pathways (e.g. MAPK, PI3K) in response to many growth factors. The inventors evaluate whether chronic inhibition of SHP2 could improve insulin sensitivity in animal models. Obese diabetic mice were thus treated by gavage (50mg / kg / day). And the inventors note a significant improvement in the glucose tolerance of the treated animals compared to their control, with a decreased fasting blood glucose, without any change in weight or body composition. Accordingly, the present invention relates to use of SHP2 inhibitors for the treatment of insulin resistance. [post_date] => 2021-02-12 17:10:04 [post_modified] => 2024-09-11 15:44:13 [ID] => 4436 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a038b6f4-6f79-4390-4191-5cd024638199 [etat_fiche_online] => en_ligne [date_application] => 23-11-2018 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18132-T1 [keywords] => [pub_scient_inv_dispo] => Sci Transl Med. 2021 Apr 28;13(591):eabe2587. doi: 10.1126/scitranslmed.abe2587. Epub 2021 Apr 28. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => YART Armelle,DRAY Cédric,TAJAN Mylène,PRADERE Jean-Philippe,PACCOUD Romain,VALET Philippe [number_application] => European Procedure (Patents) (EPA) - 23 Nov. 2018 - 18 306 558.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 213 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Diabetes, Drug, Metabolic Disorders, Method, Small Molecule, Target, Type 2 Diabetes, Validation in vivo [taxonomieurl] => Diabetes, Drug, Metabolic Disorders, Method, Small Molecule, Target, Type 2 Diabetes, Validation in vivo ) [214] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-the-treatment-of-chronic-kidney-disease/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of chronic kidney disease. The inventors used the CMap resources to identify the sesquiterpene lactone parthenolide that was subsequently analyzed for its in vivo capacity to reduce the development of DKD in the type I diabetes mouse model.In particular, the invention relates to a method of treating chronic kidney disease (CKD) in patient in need thereof comprising administering to the patient a therapeutically effective amount of Dimethylaminoparthenolide (DMAPT). [post_date] => 2021-02-12 16:55:02 [post_modified] => 2024-09-11 15:44:17 [ID] => 4435 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7f258d19-60d5-1a86-511f-60000cdbb2f7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO20193-T1 [keywords] => [pub_scient_inv_dispo] => Sci Rep. 2020 Sep 10;10(1):14898. doi: 10.1038/s41598-020-71950-7. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => SCHANSTRA Joost,SCHILTZ Odile,BASCANDS Jean-Loup,KLEIN Julie [number_application] => European Procedure (Patents) (EPA) - 11 Juin 2020 - 20305636.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 214 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Diabetes, Diabetic nephropathy, Drug, Metabolic Disorders, Method, Target, Validation in vivo [taxonomieurl] => Diabetes, Diabetic nephropathy, Drug, Metabolic Disorders, Method, Target, Validation in vivo ) [215] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF PI3KC2¿ INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITY [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-pi3kc2-inhibitors-for-the-preservation-of-vascular-endothelial-cell-barrier-integrity/ [post_content] => Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemiaeperfusion (I) models and improves neurological outcome. The genetic inhibition stabilizes the bloodu2013brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the presentinvention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2? inhibitor. [post_date] => 2021-02-12 15:55:03 [post_modified] => 2024-09-11 15:44:13 [ID] => 4433 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e356fd6a-7adb-3d4e-087a-5cd03ba957c8 [etat_fiche_online] => en_ligne [date_application] => 12-06-2018 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18162-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GRATACAP Marie-Pierre,PAYRASTRE Bernard,ANQUETIL Typhaine,CHICANNE Gaëtan,JAFFRE Aude,LARRUE Vincent,SOLINHAC Romain,DARCOURT Jean,VANHAESEBROECK Bart,VIVIEN Denis [number_application] => European Procedure (Patents) (EPA) - 15 Juin 2018 - 18 305 735.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Vascular dysfunctionTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 215 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cardiovascular Diseases, Drug, Target, Target, Validation in vivo, Vascular dysfunction [taxonomieurl] => Cardiovascular Diseases, Drug, Target, Target, Validation in vivo, Vascular dysfunction ) [216] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEUTRALIZING GRANZYME B FOR PROVIDING CARDIOPROTECTION IN A SUBJECT WHO EXPERIENCED A MYOCARDIAL INFARCTION [guid] => https://technology-offers.inserm-transfert.com/offer/neutralizing-granzyme-b-for-providing-cardioprotection-in-a-subject-who-experienced-a-myocardial-infarction/ [post_content] => The present invention relates to a method for providing cardioprotection in a subject who experienced a myocardial infarction comprising administering the subject with a therapeutically effective amount of a Granzyme B inhibitor. Here, the inventors show that following acute MI in mice, CD8+ T lymphocytes are quickly recruited and activated in the ischemic heart tissue, and release Granzyme B leading to cardiomyocyte apoptosis and deterioration of myocardial function. Antibody-mediated (CD8specific antibody) depletion of CD8+ T lymphocytes decreases Granzyme B content and apoptotic within the myocardium and inflammatory response. mAb mediated-CD8 depletion limits myocardial injury and improves heart function. These effects are recapitulated in mice with CD8+ T cell selective Granzyme B deficiency in mice. Granzyme B is also produced by other cell types such as NK cells. Global Granzyme B deletion (GzmB-/- mice) decreases apoptotic within the myocardium, reduces local pro-inflammatory signature and ultimately limits infarct size after MI. The inventors also show that elevated circulating levels of Granzyme B in patients with acute MI predict increased risk of death at 1-year follow-up. The work unravels a previously unsuspected pathogenic role of Granzyme B following acute ischemia, and identifies novel therapeutic targets for this devastating condition. [post_date] => 2021-02-12 15:10:04 [post_modified] => 2024-09-11 15:41:13 [ID] => 4432 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 77896bbc-7b7f-9b5f-70ad-5daebfe94481 [etat_fiche_online] => en_ligne [date_application] => 02-08-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19344-T1 [keywords] => [pub_scient_inv_dispo] => In progress [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Myocardial InfarctionTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 216 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cardiovascular Diseases, Drug, Myocardial Infarction, Target, Target, Validation in vivo [taxonomieurl] => Cardiovascular Diseases, Drug, Myocardial Infarction, Target, Target, Validation in vivo ) [217] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING ASTHMA AND ALLERGIC DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-asthma-and-allergic-diseases-2/ [post_content] => The present invention relates to allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determine its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9-/-) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer’s patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy. [post_date] => 2020-11-16 09:47:02 [post_modified] => 2024-10-08 19:25:04 [ID] => 4420 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cfacea85-cd0e-2bfd-0c88-5f8d56305d58 [etat_fiche_online] => en_ligne [date_application] => 2018-09-05 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO18315-T1 [keywords] => PCSK9 Pathway, Allergy, Asthma, HDM, antibody, small molecule, siRNA, oligonucleotide [pub_scient_inv_dispo] => Lorant, Victoria et al. /u201cPCSK9 inhibition protects mice from food allergy./u201d Translational research : the journal of laboratory and clinical medicine vol. 272 (2024): 151-161. doi:10.1016/j.trsl.2024.03.001 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO18315-T1_Cariou.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => CARIOU Bertrand,BOUCHAUD Grégory,MAGNAN Antoine,LE MAY Cedric [number_application] => European Procedure (Patents) (EPA) - 05 Sept. 2018 - 18 306 169.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 217 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Allergies, Antibody, Biologic, Drug, Immunology, Product, Protein, Target, Validation in vivo [taxonomieurl] => Allergies, Antibody, Biologic, Drug, Immunology, Product, Protein, Target, Validation in vivo ) [218] => stdClass Object ( [post] => stdClass Object ( [post_title] => HLA-Class II Artificial Antigen Presenting Cells in CD4 + T Cell-Based Immunotherapy [guid] => https://technology-offers.inserm-transfert.com/offer/hla-class-ii-artificial-antigen-presenting-cells-in-cd4-t-cell-based-immunotherapy/ [post_content] => CD4 T cell help is essential to promote robust cytotoxic T cell responses and could be harnessed to improve outcomes of cancer immunotherapy. To induce CD4+ T cell responses, the inventors have developed artificial antigen presenting cells (AAPCs) that derived from a mouse fibroblast cell line genetically modified to express a single human leukocyte antigen class II molecule (HLA-DR), the human CD80 costimulation as well as CD54 and CD58 adhesion molecules and that constitutively express an antigen (Ag) in peptide or protein forms in different compartments involved in the major histocompatibility complex class II Ag presentation pathway. In particular, the inventors show that the AAPC expressing the Ag peptide in the endoplasmic reticulum (ER) or protein at the plasma membrane were more potent than Epstein-Barr virus (EBV)-transformed B cells to present epitopes to specific CD4+ T-cells. Interestingly, AAPC targeting the Ag peptide in the ER was more efficient than peptide-pulsed AAPC or autologous APC to amplify memory Ag-specific CD4+ T cells that harbor a Th1 profile and express granzyme B. So, the AAPC system is a reliable and standardized tool to generate a high number of Ag-specific CD4+ with effector functions useful for a cancer adoptive immunotherapy. Thus, the present inventions relate to - an artificial antigen presenting cell that constitutively expresses an antigen along with a HLA-class II molecule and uses thereof in particular for amplifying and/or activating a population of antigen-specific CD4+ T cells.- method of amplifying a population of antigen-specific memory CD4+ T cells using artificial presenting cells expressing HLA class II molecules.In particular, the present invention relate to a method of amplifying a population of antigen-specific memory CD4+ T cells comprising the steps of i) providing a population of artificial antigen presenting cells consisting host cells that are genetically modified to stably express at least one MHC class II molecule along with at least one accessory molecule ii) loading the population of artificial antigen presenting cells of step i) with an amount of at least one antigen of interest and iii) coculturing the suitable population of a T cells with the population of artificial antigen presenting cells of step ii). [post_date] => 2020-10-19 10:00:05 [post_modified] => 2024-09-11 15:58:00 [ID] => 4415 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => dc1ae0ca-7599-43f7-b7a4-46a5f32930e5 [etat_fiche_online] => en_ligne [date_application] => 04-12-2015 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15322-R1 [keywords] => HLA-II APC, T-Cell Immunotherapy, Chronical Viral Infection, Cancer, AutoImmune Disease, Transplantation [pub_scient_inv_dispo] => Front Immunol. 2019 May 17;10:1081. doi: 10.3389/fimmu.2019.01081. eCollection 2019.Immunol Cell Biol. 2016 Aug;94(7):662-72. doi: 10.1038/icb.2016.25. Epub 2016 Feb 29. [access_to_detailed_offer] => /wp-content/uploads/BIO15322-R1_LATOUCHE.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => TOUTIRAIS Olivier,LE MAUFF QUESTER Brigitte [number_application] => European Procedure (Patents) (EPA) - 04 Déc. 2015 - 15 306 925.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• Research toolField of development:
• ImmunologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 218 [terms] => Array ( [0] => Research ) [taxonomie] => Immunology, Method, Research tool [taxonomieurl] => Immunology, Method, Research tool ) [219] => stdClass Object ( [post] => stdClass Object ( [post_title] => Novel melanoma antigens [guid] => https://technology-offers.inserm-transfert.com/offer/novel-melanoma-antigens/ [post_content] => The invention relates to melanoma antigen named MELOE and their use for preventing, treating and diagnosing melanoma. [post_date] => 2020-10-16 07:58:02 [post_modified] => 2024-09-11 15:44:02 [ID] => 4410 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f62aa12d-9b53-45fd-bb92-865ddcf4ef4e [etat_fiche_online] => en_ligne [date_application] => 02-09-2008 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO08305-T1 [keywords] => Melanoma, antigen, peptide, MELOE-1, MELOE-2 [pub_scient_inv_dispo] => Oncoimmunology 2019 : Cancer Vaccines: Designing Artificial Synthetic Long Peptides to Improve Presentation of Class I and Class II T Cell Epitopes by Dendritic CellsJ Exp Med. 2008, 205 (11), 2673-82/tCancer Immunol Immunother 2011 60 (3), 327-37 Eur. J. Immunol. 2010. 40: 1786u201394 /tPLoS One. 2013; 8(9): e75421 [access_to_detailed_offer] => /wp-content/uploads/BIO08305-T1_LABARRIERE.pdf [rare_disease] => false [second_indication] => false [inventors] => MOREAU-AUBRY Agnès,GODET Yann [number_application] => European Procedure (Patents) (EPA) - 02 Sept. 2008 - 08 305 517.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 219 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Clinical Trial, Drug, Melanoma, Oncology, Phase 1, Product, Vaccine [taxonomieurl] => Biologic, Clinical Trial, Drug, Melanoma, Oncology, Phase 1, Product, Vaccine ) [220] => stdClass Object ( [post] => stdClass Object ( [post_title] => Anti-Cathepsin D human antibody for Triple Negative Breast Cancer Treatment [guid] => https://technology-offers.inserm-transfert.com/offer/anti-cathepsin-d-human-antibody-for-triple-negative-breast-cancer-treatment/ [post_content] => Inventors have generated two human anti-cath-D scFv fragments cloned in the human IgG1 ??format (F1 and E2) that efficiently bind to human and mouse cath-D, even at the acidic pH of the TNBC microenvironment. F1 and E2 accumulated in TNBC MDAMB- 231 tumor xenografts, inhibited tumor growth and improved mice survival without apparent toxicity. Using this xenograft model, they found that the Fc function of F1 was essential for maximal tumor inhibition. Inventors have shown that the anti-cath-D antibody F1 treatment prevented the recruitment of tumor-associated macrophages and myeloid-derived suppressor cells within the tumor, a specific effect associated with a less immunosuppressive tumor microenvironment. Moreover F1 inhibited tumor growth of TNBC patient-derived xenografts (PDXs). This preclinical proof-of-concept study validates the feasibility and efficacy of an immunomodulatory antibody-based strategy against cath-D to treat patients with TNBC. Accordingly, the present invention relates to an anti-cath-D antibody which inhibits the tumor recruitment of immunosuppressive tumor-associated macrophages M2 and myeloid-derived suppressor cells for use in the treatment of cancer. [post_date] => 2020-10-16 07:33:01 [post_modified] => 2024-09-11 15:45:06 [ID] => 4408 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8fe28353-c0c2-4fab-9ef6-ab72d2131702 [etat_fiche_online] => en_ligne [date_application] => 22-05-2015 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO14138-T1 [keywords] => Triple Negative Breast Cancer [pub_scient_inv_dispo] => J Immunother Cancer 2019 Feb doi: 10.1186/s40425-019-0498-zOncotarget 015 Sep 6 (29), 28084-103 29 doi : 10.18632/oncotarget.4394FASEB J. 2012 Dec;26(12):5172-81. doi: 10.1096/fj.12-205229. J Cell Sci. 2010 Oct 1;123(Pt 19):3336-46. doi: 10.1242/jcs.070938. [access_to_detailed_offer] => /wp-content/uploads/BIO14138-T1_LIAUDET-COOPMAN.pdf [rare_disease] => false [second_indication] => false [inventors] => MARTINEAU Pierre,CHARDES Thierry,ASHRAF Yahya [number_application] => European Procedure (Patents) (EPA) - 22 Mai 2015 - 15 305 775.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 220 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Breast Cancer, Drug, Lead - validation in vivo, Oncology, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Breast Cancer, Drug, Lead - validation in vivo, Oncology, Product, Product, Protein ) [221] => stdClass Object ( [post] => stdClass Object ( [post_title] => TRIARYLPYRIDINE COMPOUNDS AND USE THEREOF FOR TREATING CANCER [guid] => https://technology-offers.inserm-transfert.com/offer/triarylpyridine-compounds-and-use-thereof-for-treating-cancer/ [post_content] => The invention relates to new bis-triazole 2,4,6-triarylpyridines compounds and their use in the field of oncology, in particular in the prevention and/or treatment of cancer disease. The inventors have observed that the new bis-triazole 2,4,6-triarylpyridines were able to induce cancer cells death either as a standalone or, synergistically, in combination with a lysosomotropic agent, such as chloroquine. The compounds were active against a variety of cancer cells such as HeLa (cervical cancer cell), A549 (lung carcinoma), and PDX-2 or PDX-3 (lung adenocarcinoma). The invention also relates to compositions and methods for prevention and/or treatment of cancer diseases using the new bis-triazole 2,4,6-triarylpyridines compounds. [post_date] => 2020-10-13 12:50:02 [post_modified] => 2024-09-11 15:41:07 [ID] => 4400 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e6fdd5fb-3ea6-63b9-b200-5f859c56db20 [etat_fiche_online] => en_ligne [date_application] => 20-05-2020 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => CHIM20164-T1 [keywords] => lung carcinoma, lung adenocarcinoma [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO20164-T1_MERGNY.pdf [rare_disease] => false [second_indication] => false [inventors] => DAS Rabindra Nath,MERGNY Jean-Louis,GUILLON Jean,BEAUVARLET Jennifer,DJAVAHERI-MERGNY Mojgan [number_application] => European Procedure (Patents) (EPA) - 29 Mai 2020 - 20305567.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 221 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cervical cancer, Drug, Lead - validation in vitro, Oncology, Product, Product, Small Molecule [taxonomieurl] => Cervical cancer, Drug, Lead - validation in vitro, Oncology, Product, Product, Small Molecule ) [222] => stdClass Object ( [post] => stdClass Object ( [post_title] => A CXCR3B antagonist for the treatment of Vitiligo [guid] => https://technology-offers.inserm-transfert.com/offer/a-cxcr3b-antagonist-for-the-treatment-of-vitiligo/ [post_content] => The present invention relates to a method for treating vitiligo in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an antagonist of CXCR3B. Inventors have demonstrated that in skin and blood samples obtained from vitiligo subjects the population of the innate immune system is increased (NK and ILC1 cells). For the first time, inventors have shown that melanocytes express CXCR3, more particularly CXCR3B (RNA and protein expressions). They have shown that the expression of CXCR3B on melanocytes is responsible of the destruction of melanocytes upon local stimulation with CXCL10. Inventors have demonstrated for the first time that siRNA of CXCR3B or CXCR3B antagonist prevent the CXL10-induced apoptosis of melanocytes. This initial apoptosis of melanocyte triggers the secondary adaptive immunity against melanocytes that further destroys the remaining melanocytes. Accordingly, the inventors have found a new target to prevent and treat vitiligo. [post_date] => 2020-10-12 13:58:01 [post_modified] => 2024-09-24 13:30:02 [ID] => 4394 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8d6d0bdd-953d-086e-6109-5aba07ad82c0 [etat_fiche_online] => en_ligne [date_application] => 2018-02-16 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO18027-T1 [keywords] => CXCR3B, Melanocytes, Vitiligo, small molecule, antibody [pub_scient_inv_dispo] => Nat Commun. 2019 May 16;10(1):2178. doi: 10.1038/s41467-019-09963-8. [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO18027-T1_Passeron.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => PASSERON Thierry,TULIC Meri [number_application] => European Procedure (Patents) (EPA) - 16 Févr. 2018 - 18 305 161.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• DermatologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 222 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Dermatology, Drug, Identification, Target, Target, Vitiligo [taxonomieurl] => Dermatology, Drug, Identification, Target, Target, Vitiligo ) [223] => stdClass Object ( [post] => stdClass Object ( [post_title] => Histone chaperone HIRA inhibitor for treating Hepatitis B Virus infection [guid] => https://technology-offers.inserm-transfert.com/offer/histone-chaperone-hira-inhibitor-for-treating-hepatitis-b-virus-infection/ [post_content] => The present invention concerns an inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus. Inventors show that the knock-down of histone chaperone HIRA before HBV inoculation led to a strong decrease in HBV cccDNA (covalently closed circular DNA) accumulation and stable rcDNA (relaxed circular DNA) levels, in HepG2-NTCP cell line, indicating either a possible incomplete or delayed rcDNA to cccDNA transition. This effect was independent from HBx protein expression in Primary human hepatocytes (PHH). HIRA is able to interact with cccDNA and its recruitment is concomitant with deposition of histone variant H3.3 in HepG2-NTCP cell line. HIRA was able to interact with HBc (HBV capsid protein) in infected hepatocytes and in an HepaRG cell line expressing HBc in an inducible manner. [post_date] => 2020-10-09 13:24:02 [post_modified] => 2024-09-11 15:42:32 [ID] => 4391 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d22ae223-3c82-31f8-87cb-5b36551b70a4 [etat_fiche_online] => en_ligne [date_application] => 01-09-2017 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17369-T1 [keywords] => HBV, HIRA inhibitor, siRNA, oligonucleotide
[pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO17369-T1_ZOULIM.pdf [rare_disease] => false [second_indication] => false [inventors] => ZOULIM Fabien,TESTONI Barbara,LOCATELLI Maëlle,QUIVY Jean-Pierre [number_application] => European Procedure (Patents) (EPA) - 01 Sept. 2017 - 17 306 134.2 [technology_engineering] => nucleic_acids [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hepatitis bTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 223 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antisense rnai oligonucleotide, Drug, Hepatitis b, Infectious Diseases, Nucleic acids, Oligonucleotide, Product, Target, Validation in vitro [taxonomieurl] => Antisense rnai oligonucleotide, Drug, Hepatitis b, Infectious Diseases, Nucleic acids, Oligonucleotide, Product, Target, Validation in vitro ) [224] => stdClass Object ( [post] => stdClass Object ( [post_title] => A Pak1/2 inhibitor for the treatment of Psoriasis and other NLRP3 Inflammasome mediated IL1b dependent disorders [guid] => https://technology-offers.inserm-transfert.com/offer/a-pak1-2-inhibitor-for-the-treatment-of-psoriasis-and-other-nlrp3-inflammasome-mediated-il1b-dependent-disorders/ [post_content] => The present invention relates to a PAK-1 and/or PAK-2 inhibitor for use in the treatment of NLRP3 inflammasome mediated IL-1beta dependent disorders in a subject in need thereof. Inventors invalidated PAK-1 and/or PAK-2 in BMDM by transfecting siRNA targeting either PAK-1 and/or PAK-2 (PAK-3 is predominantly expressed in the brain). After 72 hours of siRNA expression, cells were stimulated by LPS and the CNF1 toxin for 8 hours. They observed that cells invalidated for PAK-1 had a reduced Caspase-1 activation compared to the control cells or cells invalidated for PAK-2. Similar results were observed when the IL-1ß maturation was monitored. Confirming this data, the use of PAK-1 inhibitors (IPA-3 and FRAX597) were sufficient to block the IL-1ß maturation observed in macrophages treated with LPS and CNF1 as well as Caspase-1 activation measured using FAM-FLICA. [post_date] => 2020-10-09 12:42:02 [post_modified] => 2024-09-23 19:10:04 [ID] => 4387 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4ed47c6e-8516-f846-09d7-5d67fbdc4fb8 [etat_fiche_online] => en_ligne [date_application] => 2019-04-17 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO18509-T1 [keywords] => Psoriasis, PAK inhibitor, NLRP3, inflammasome, Inflammation, Auto-immunity [pub_scient_inv_dispo] => [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO18509-T1_Boyer.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => BOYER (NICE) Laurent,VISVIKIS Orane,MUNRO Patrick,LOUBATIER Céline,DOYE Anne,TORRE Cédric,MICHEL Grégory,COURJON Johan-Victor,DUFIES Océane [number_application] => European Procedure (Patents) (EPA) - 17 Avr. 2019 - 19 305 502.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• PsoriasisTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 224 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Psoriasis, Target, Target, Validation in vitro [taxonomieurl] => Drug, Immunology, Psoriasis, Target, Target, Validation in vitro ) [225] => stdClass Object ( [post] => stdClass Object ( [post_title] => Anti-Neurotensin mAb for the treatment of cancer [guid] => https://technology-offers.inserm-transfert.com/offer/anti-neurotensin-mab-for-the-treatment-of-cancer/ [post_content] => The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2 in the, a H- CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having 90% of identity with SEQ ID NO:6, a L-CDR2 having 90% of identity with SEQ ID NO:7 and a L-CDR3 region having 90% of identity with SEQ ID NO: 8. The present invention also provides the use of such antibodies in the treatment of cancer. [post_date] => 2020-10-09 10:19:02 [post_modified] => 2024-09-11 15:43:43 [ID] => 4385 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f35ef81d-ee39-4e75-8467-16dc12465d1c [etat_fiche_online] => en_ligne [date_application] => 02-06-2014 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO14015-T1 [keywords] => [pub_scient_inv_dispo] => Cancer Letters 444 (2019) 147u2013161 [access_to_detailed_offer] => /wp-content/uploads/BIO14015-T1_FORGEZ.pdf [rare_disease] => false [second_indication] => false [inventors] => [number_application] => European Procedure (Patents) (EPA) - 02 Juin 2014 - 14 305 825.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Lung cancerTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 225 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Drug, Lead - validation in vivo, Lung cancer, Non-Small Cell Lung Cancer (NSCLC), Oncology, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Drug, Lead - validation in vivo, Lung cancer, Non-Small Cell Lung Cancer (NSCLC), Oncology, Product, Product, Protein ) [226] => stdClass Object ( [post] => stdClass Object ( [post_title] => Combination of Arsenic and Interferon alpha for the treatment of Myeloproliferative Disorders [guid] => https://technology-offers.inserm-transfert.com/offer/combination-of-arsenic-and-interferon-alpha-for-the-treatment-of-myeloproliferative-disorders/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. In particular, the present invention relates to a method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound. [post_date] => 2020-10-09 07:33:02 [post_modified] => 2024-09-11 15:43:40 [ID] => 4383 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 39cbdfcc-a0dc-4c18-8a76-a437b8e809ca [etat_fiche_online] => en_ligne [date_application] => 18-01-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO16455-T1 [keywords] => Melanoma, Combination, Myeloproliferative disorders [pub_scient_inv_dispo] => Int J Cancer 2014 Feb 15;134(4):988-96 [access_to_detailed_offer] => /wp-content/uploads/BIO16455-T1_DE-THE.pdf [rare_disease] => false [second_indication] => true [inventors] => BLAUDIN DE THE Hugues,VILLEVAL Jean-luc,PLO-AZEVEDO Isabelle,LALLEMAND-BREITENBACH Valérie,KILADJIAN Jean-Jacques,CASSINAT Bruno [number_application] => European Procedure (Patents) (EPA) - 18 Janv. 2017 - 17 305 053.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hematological DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 226 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Hematological Disorders, Method, Myeloproliferative disorders, Target, Validation in vivo [taxonomieurl] => Drug, Hematological Disorders, Method, Myeloproliferative disorders, Target, Validation in vivo ) [227] => stdClass Object ( [post] => stdClass Object ( [post_title] => Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. [guid] => https://technology-offers.inserm-transfert.com/offer/retinoic-acid-and-arsenic-trioxide-trigger-degradation-of-mutated-npm1-resulting-in-apoptosis-of-aml-cells/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid. [post_date] => 2020-10-09 07:21:01 [post_modified] => 2024-09-11 15:43:32 [ID] => 4381 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 48fb14b1-551e-42c7-830c-cb7dafceaffb [etat_fiche_online] => en_ligne [date_application] => 30-12-2013 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13408-T1 [keywords] => AML - Combination - Arsenate [pub_scient_inv_dispo] => Blood. 2015 May 28;125(22):3447-54. doi: 10.1182/blood-2014-11-612416. Epub 2015 Mar 23. [access_to_detailed_offer] => /wp-content/uploads/BIO13408-T1_DE-THE-1.pdf [rare_disease] => false [second_indication] => true [inventors] => MARTELLI Maria Paola,FALINI Brunangelo,BAZARBACHI Ali,EL HAJJ Hiba [number_application] => European Procedure (Patents) (EPA) - 30 Déc. 2013 - 13 306 891.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LeukemiasTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 227 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Acute Myelocytic Leukemia (AML), Drug, Leukemias, Method, Oncology [taxonomieurl] => Acute Myelocytic Leukemia (AML), Drug, Leukemias, Method, Oncology ) [228] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS FOR THE DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-the-diagnosis-and-treatment-of-gastrointestinal-stromal-tumors/ [post_content] => The present invention relates to the diagnosis of gastrointestinal stromal tumors (GISTs). The present invention also relates to methods and compositions for the treatment of gastrointestinal stromal tumors (GISTs). [post_date] => 2020-10-02 08:25:00 [post_modified] => 2024-09-11 15:43:59 [ID] => 4378 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 534bc3cb-cbc5-4fd5-8cd8-a16c05c73b61 [etat_fiche_online] => en_ligne [date_application] => 11-02-2016 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13315-T1 [keywords] => ASO [pub_scient_inv_dispo] => BMC Biol., 2016 Apr 28, McKey J. et al., LIX1 regulates YAP1 activity and controls the proliferation and differentiation of stomach mesenchymal progenitors, doi: 10.1186/s12915-016-0257-2 [access_to_detailed_offer] => /wp-content/uploads/BIO13315-T1_DE-SANTA-BARBARA.pdf [rare_disease] => false [second_indication] => false [inventors] => FAURE Sandrine [number_application] => European Procedure (Patents) (EPA) - 11 Févr. 2016 - 16 305 159.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal Stromal Tumors (GIST)Therapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 228 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gastrointestinal Stromal Tumors (GIST), Oligonucleotide, Oncology, Target, Target, Validation in vivo [taxonomieurl] => Drug, Gastrointestinal Stromal Tumors (GIST), Oligonucleotide, Oncology, Target, Target, Validation in vivo ) [229] => stdClass Object ( [post] => stdClass Object ( [post_title] => HUMAN MONOCLONAL ANTIBODIES AGAINST OREXIN RECEPTOR TYPE 1 [guid] => https://technology-offers.inserm-transfert.com/offer/human-monoclonal-antibodies-against-orexin-receptor-type-1/ [post_content] => The present invention relates to human monoclonal antibodies against orexin receptor type 1 (OX1R) and uses thereof for the treatment of cancer. [post_date] => 2020-10-02 08:24:59 [post_modified] => 2024-09-11 15:45:14 [ID] => 4377 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cdda3771-d764-45d2-bdc8-ecbdd0ac97f1 [etat_fiche_online] => en_ligne [date_application] => 16-01-2015 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14361-T1 [keywords] => pancreas, colon, liver, prostate [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO14361-T1_COUVINEAU.pdf [rare_disease] => false [second_indication] => false [inventors] => MARTINEAU Pierre,ROBERT Bruno,CHENTOUF Myriam,VOISIN Thierry,NICOLE Pascal [number_application] => European Procedure (Patents) (EPA) - 16 Janv. 2015 - 15 305 038.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Colorectal CancerTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 229 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Colorectal Cancer, Drug, Lead - validation in vivo, Oncology, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Colorectal Cancer, Drug, Lead - validation in vivo, Oncology, Product, Product, Protein ) [230] => stdClass Object ( [post] => stdClass Object ( [post_title] => Sphingosine kinase 2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer [guid] => https://technology-offers.inserm-transfert.com/offer/sphingosine-kinase-2-inhibitors-in-combination-with-immune-checkpoint-blockade-therapy-for-the-treatment-of-cancer/ [post_content] => Immune checkpoint blockade therapy is based on the inhibition of the tumor-mediated suppression of anticancer immune responses. However, the efficacy and effectiveness of said therapy vary greatly across individual patients and among different tumor types. A substantial unmet need is thus to identify novel targets that can enhance the therapeutic efficacy of the immune checkpoint blockade therapy. S1P is produced by sphingosine kinases (i.e. SK1 and SK2) that catalyze the phosphorylation of sphingosine to S1P. SK2 inhibitors were described as suitable for the treatment of cancer. However the role of SK2 in the immune tumor microenvironment has never been investigated. The inventors now showed that genetic deletion of SPHK2 leads to a delay in the melanoma tumor growth and an increase in tumor-infiltrating effector lymphocytes. In particular the increase of tumor-infiltrating effector lymphocytes in the tumor is associated with a decrease in the amount of tumor-infiltrating myeloid-derived suppressor cells. Moreover, the combination of SPHK2 deficiency with immune-checkpoint blockade leads to tumor rejection and increases survival rate. Accordingly, the present invention relates to use of SK2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer. [post_date] => 2020-09-25 13:31:08 [post_modified] => 2024-09-11 15:44:12 [ID] => 4371 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c64ca7bd-3bea-4377-f1a6-5f6d974112e5 [etat_fiche_online] => en_ligne [date_application] => 09-04-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO18120-T1 [keywords] => Combinaison; [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO18120-T1_ANDRIEU-ABADIE.pdf [rare_disease] => false [second_indication] => false [inventors] => ANDRIEU-ABADIE Nathalie,LEVADE Thierry,SEGUI Bruno,GHENASSIA Alexandre [number_application] => European Procedure (Patents) (EPA) - 09 Avr. 2019 - 19 305 461.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 230 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Oncology, Target, Target, Validation in vivo [taxonomieurl] => Drug, Melanoma, Oncology, Target, Target, Validation in vivo ) [231] => stdClass Object ( [post] => stdClass Object ( [post_title] => A Lyn kinase activator for the treatment of BRAF inhibitor-resistant melanoma [guid] => https://technology-offers.inserm-transfert.com/offer/a-lyn-kinase-activator-for-the-treatment-of-braf-inhibitor-resistant-melanoma/ [post_content] => The present invention relates to method and composition for treating melanoma. The inventors have shown that a decrease in LYN expression, in melanoma cells and tumors is related to the acquisition of a resistance to targeted therapies. The have also shown the inhibition of metastatic propensity of melanoma cell by an allosteric activator of LYN. In particular, the present invention relates to a method for predicting whether a subject suffering from a melanoma is or is at risk of having resistant melanoma. The present invention also relates to methods for treating melanoma and resistant melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of an activator of LYN. [post_date] => 2020-09-25 13:31:08 [post_modified] => 2024-09-11 15:40:55 [ID] => 4370 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 93e32c76-1a38-4c67-9c12-5cf78dea0e21 [etat_fiche_online] => en_ligne [date_application] => 07-12-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO18366-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO18366-T1_BALLOTTI.pdf [rare_disease] => false [second_indication] => false [inventors] => BALLOTTI Robert,GAUDEL Céline,BERTOLOTTO Corine [number_application] => European Procedure (Patents) (EPA) - 07 Déc. 2018 - 18 306 642.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 231 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Oncology, Target, Target, Validation in vitro [taxonomieurl] => Drug, Melanoma, Oncology, Target, Target, Validation in vitro ) [232] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mutated strain for the development of attenuated vaccine against Zika virus [guid] => https://technology-offers.inserm-transfert.com/offer/mutated-strain-for-the-development-of-attenuated-vaccine-against-zika-virus-2/ [post_content] => The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barré syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored. [post_date] => 2020-09-14 16:56:02 [post_modified] => 2024-09-11 15:41:53 [ID] => 4357 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 13c455dd-aad9-4f93-a139-459b5bc0a8d5 [etat_fiche_online] => en_ligne [date_application] => 08-07-2016 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO16236-T1 [keywords] => Vaccines, Infectious Diseases, mutant strain, Zika [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO16236-T1_GADEA.pdf [rare_disease] => false [second_indication] => false [inventors] => DESPRES Philippe,GIRARDOT Michael [number_application] => European Procedure (Patents) (EPA) - 08 Juil. 2016 - 16 305 863.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ZikaTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 232 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Identification, Infectious Diseases, Others, Product, Target, Zika [taxonomieurl] => Drug, Identification, Infectious Diseases, Others, Product, Target, Zika ) [233] => stdClass Object ( [post] => stdClass Object ( [post_title] => IL15 antagonist to treat inflammation [guid] => https://technology-offers.inserm-transfert.com/offer/il15-antagonist-to-treat-inflammation/ [post_content] => The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue [post_date] => 2020-09-14 12:43:02 [post_modified] => 2024-09-11 15:42:02 [ID] => 4354 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 397aa02e-2fb9-4172-8bd8-cf42cd72ac8b [etat_fiche_online] => en_ligne [date_application] => 27-06-2013 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO12129-T1 [keywords] => IL-15, Autoimmune Diseases, Rheumatoid Arthritis [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO12129-T1_JACQUES.pdf [rare_disease] => false [second_indication] => false [inventors] => MORTIER Erwan,QUEMENER Agnès,PLET Ariane [number_application] => European Procedure (Patents) (EPA) - 27 Juin 2013 - 13 305 896.6 [technology_engineering] => peptides [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Rheumatoid ArthritisTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 233 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Immunology, Peptide, Peptides, Product, Product, Rheumatoid Arthritis, Screening [taxonomieurl] => Biologic, Drug, Immunology, Peptide, Peptides, Product, Product, Rheumatoid Arthritis, Screening ) [234] => stdClass Object ( [post] => stdClass Object ( [post_title] => Lymphotoxin Alpha Regulates the Immunosuppressive Functions of Regulatory T Cells [guid] => https://technology-offers.inserm-transfert.com/offer/lymphotoxin-alpha-regulates-the-immunosuppressive-functions-of-regulatory-t-cells/ [post_content] => The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT?-/- Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha. [post_date] => 2020-09-14 12:23:01 [post_modified] => 2024-09-11 15:43:01 [ID] => 4353 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5e1ac2f7-3a5e-7ac0-00c5-5b6450488c72 [etat_fiche_online] => en_ligne [date_application] => 13-11-2018 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17326-T1 [keywords] => IBD, Regulatory T Cells, Treg, Auto-immune diseases, CAR-T-Reg [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO17326-T1_Irla.pdf [rare_disease] => false [second_indication] => false [inventors] => IRLA Magali [number_application] => European Procedure (Patents) (EPA) - 14 Nov. 2017 - 17 306 579.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• ImmunologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 234 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Immunology, Method, Protein, Target, Validation in vivo [taxonomieurl] => Biologic, Drug, Immunology, Method, Protein, Target, Validation in vivo ) [235] => stdClass Object ( [post] => stdClass Object ( [post_title] => RANKL to Boost Thymic Regeneration [guid] => https://technology-offers.inserm-transfert.com/offer/rankl-to-boost-thymic-regeneration/ [post_content] => Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoïesis and a prolonged period of T-cell immunodeficiency. Understanding the mechanisms that govern thymic regeneration is of paramount interest for the recovery of a functional immune system notably after bone marrow transplantation (BMT). Here, the inventors show that administration of RANK ligand (RANKL) after total body irradiation and BMT boosts thymic regeneration. Notably, this treatment is also beneficial upon BMT in aged individuals. The inventors show that RANKL can improve thymopoiesis in aged individuals affected by thymic involution. Finally, the inventors show that RANK receptor is conserved in the human thymus. Accordingly, one aspect of the present invention relates to a method of boosting thymic regeneration in a patient suffering from a thymic injury comprising administering to the subject a therapeutically effective amount of a RANKL polypeptide. [post_date] => 2020-09-14 10:12:02 [post_modified] => 2024-09-24 11:15:06 [ID] => 4351 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7c97b5f6-c913-41c9-ae54-e7b132954fd5 [etat_fiche_online] => en_ligne [date_application] => 2018-02-26 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO16458-T1 [keywords] => RANKL, Thymic Regeneration, Bone Marrow Transplantation [pub_scient_inv_dispo] => EMBO Mol Med. 2017 Jun;9(6):835-851. doi: 10.15252/emmm.201607176 [access_to_detailed_offer] => http://technology-offers.inserm-transfert.com/wp-content/uploads/BIO16458-T1_Irla.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => IRLA Magali,LOPES Noella [number_application] => European Procedure (Patents) (EPA) - 27 Févr. 2017 - 17 305 214.3 [technology_engineering] => peptides [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• TransplantationTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 235 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Identification, Immunology, Method, Peptides, Protein, Target, Transplantation [taxonomieurl] => Biologic, Drug, Identification, Immunology, Method, Peptides, Protein, Target, Transplantation ) [236] => stdClass Object ( [post] => stdClass Object ( [post_title] => Sphingosine kinase 1 a new tumor target for enhancing the potency of immune checkpoint inhibitors inhibitor for the treatment of cancer [guid] => https://technology-offers.inserm-transfert.com/offer/sphingosine-kinase-1-a-new-tumor-target-for-enhancing-the-potency-of-immune-checkpoint-inhibitors-inhibitor-for-the-treatment-of-cancer/ [post_content] => The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor. [post_date] => 2020-05-12 09:59:04 [post_modified] => 2024-09-11 15:45:08 [ID] => 4349 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 14aa378d-03e5-43c0-a93f-6e73a2af77f2 [etat_fiche_online] => en_ligne [date_application] => 28-01-2016 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15451-T1 [keywords] => SK1 inhibitor, melanoma, combination, immune checkpoint inhibitor [pub_scient_inv_dispo] => Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Mrad M. et al. Oncotarget 2016 Nov 1;7(44):71873-71886Resistance of Melanoma to Immune Checkpoint Inhibitors Is Overcome by Targeting the Sphingosine kinase-1 Imbert C et al. Nat Commun. 2020 Jan 23;11(1):437 [access_to_detailed_offer] => /wp-content/uploads/BIO15451-T1_LEVADE.pdf [rare_disease] => false [second_indication] => false [inventors] => COLACIOS Céline,ANDRIEU-ABADIE Nathalie,SEGUI Bruno,IMBERT Caroline,MEYER Nicolas [number_application] => European Procedure (Patents) (EPA) - 28 Janv. 2016 - 16 305 084.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 236 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Method, Oncology, Small Molecule, Target, Validation in vivo [taxonomieurl] => Drug, Melanoma, Method, Oncology, Small Molecule, Target, Validation in vivo ) [237] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human/Mouseat Tspan5 (clones TS5-2 and TS5-3) [guid] => https://technology-offers.inserm-transfert.com/?p=4338 [post_content] => This mAb recognizes Tspan5, a member of the Tetraspanin superfamily. It recognizes the human, mouse and rat proteins which are 100% identical. First Tspan5 mAb ever produced. [post_date] => 2021-02-03 18:57:02 [post_modified] => 2024-09-11 16:05:32 [ID] => 4338 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => mpo-be99b14316e44ae57ff0b8938e841064 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00510 [keywords] => Tetraspanin; ADAM10; Notch [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Academic ResearchUses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 237 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, lgG2a, Mouse, Oncology, Other, Others, Western Blot [taxonomieurl] => Academic Research, Central Nervous System, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, lgG2a, Mouse, Oncology, Other, Others, Western Blot ) [238] => stdClass Object ( [post] => stdClass Object ( [post_title] => New biomarker for prognosis and response to corticoid in patients with sepsis [guid] => https://technology-offers.inserm-transfert.com/offer/new-biomarker-for-prognosis-and-response-to-corticoid-in-patients-with-sepsis/ [post_content] => Septic shock is the leading cause of death in intensive care units. Previous studies have highlighted the immunosuppressive protein GILZ (glucocorticoid-induced leucine zipper) as a regulator of innate and adaptive immune responses. To go deeper in the understanding of GILZ protective role during sepsis, the inventors studied in vivo the consequences of a targeted overexpression of GILZ in monocytes and macrophages (M/M) in animal models of sepsis. In addition, they monitored the expression of GILZ in M/M of both patients with septic shock and septic mice. In particular, the inventors show that the overexpression of GILZ limited to M/M leads to an increase survival rate in mice with CLP-induced sepsis. These results provided new evidence for a central role of GILZ in M/M on the pathophysiology of septic shock, and pinpoint the fact that GILZ would be suitable for predicting survival time of patient suffering from sepsis. Moreover these results indicate that determining the level of GILZ expression level in monocytes/macrophages of patients suffering from sepsis is suitable for identifying those patients that will respond or not to treatment with a corticoid. [post_date] => 2020-02-19 13:58:02 [post_modified] => 2024-09-11 15:52:28 [ID] => 4334 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1d0cc8bd-a445-fae3-8a3e-5d07836f9951 [etat_fiche_online] => en_ligne [date_application] => 07-12-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18523-D1 [keywords] => Flow Cytometry, RT-PCR, Immunoassay, Transcriptomics, Treatment Response, Prognosis in Sepsis, Systemic inflammatory response syndrome, Acute respiratory distress syndrome [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GODOT Véronique,TCHERAKIAN Colas,LEVY Yves,ANNANE Djillali [number_application] => European Procedure (Patents) (EPA) - 07 Déc. 2018 - 18306643.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Sepsis / Septic ShockTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 238 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Infectious Diseases, Sepsis / Septic Shock, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Infectious Diseases, Sepsis / Septic Shock, Transcriptomics ) [239] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH AN ACTIVATION OF THE MAPK PATHWAY [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-the-treatment-of-cancers-associated-with-an-activation-of-the-mapk-pathway/ [post_content] => The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor of activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression ofSLITRK6 also paves the way of strategies based on depletion of the residual cancer cells bytargeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drugconjugates binding to SLITRK6 [post_date] => 2020-02-10 10:56:01 [post_modified] => 2024-09-11 15:52:16 [ID] => 4330 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 685ff1f7-e256-4c7e-9a2e-c5546fab3627 [etat_fiche_online] => en_ligne [date_application] => 09-02-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO17032-D1 [keywords] => ELISA, IHC, RT-PCR, Western Blot, Immunoassay, Transcriptomics, Treatment response, Prognosis, Oncology, Solid Tumor, Melanoma
[pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => FAVRE Gilles,POHORECKA Magdalena [number_application] => European Procedure (Patents) (EPA) - 10 Févr. 2017 - 17 305 153.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 239 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, In vitro poc, Oncology, Product, Solid Tumors, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Immunoassay, In vitro poc, Oncology, Product, Solid Tumors, Transcriptomics ) [240] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING MELANOMA [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-melanoma/ [post_content] => The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 correlates with melanoma progression and with a poorer survival rate in metastatic melanoma patients. Then, they have shown that an inhibition of ubiquitin-specific peptidase 14 (USP14) by siRNAs and pharmacological inhibitors (b-AP15, WP1130 and HBX41108), the cell proliferation of melanoma cell drastically decreased. They have also shown that melanoma treatment with pharmacological inhibitors can overcome resistance to drugs targeting oncogenic BRAF. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma by quantifying the expression level of USP14 in a biological sample and to a method of treating melanoma and resistant melanoma by using the inhibitors of USP14. [post_date] => 2020-02-10 10:51:02 [post_modified] => 2024-09-11 15:52:40 [ID] => 4329 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6bd43d19-1712-45b2-820b-977d5ae3be9b [etat_fiche_online] => en_ligne [date_application] => 24-03-2017 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO16432-D1 [keywords] => RT-PCR, Q-PCR, RNA-Seq, Transcriptomics, Prognosis in Cancer, Oncology, Melanoma

[pub_scient_inv_dispo] => Mol Cancer Ther. 2018 Apr 27. pii: molcanther.0919.2017. doi: 10.1158/1535-7163.MCT-17-0919. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DECKERT Marcel,TARTARE-DECKERT Sophie,MALLAVIALLE Aude,DIDIER Robin [number_application] => European Procedure (Patents) (EPA) - 24 Mars 2017 - 17 305 339.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• MelanomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 240 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Melanoma, Oncology, Pre-Analytic Validation, Product, Target, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Melanoma, Oncology, Pre-Analytic Validation, Product, Target, Transcriptomics ) [241] => stdClass Object ( [post] => stdClass Object ( [post_title] => CHIMERIC RECEPTOR FOR USE IN WHOLE-CELL SENSORS FOR DETECTING ANALYTES OF INTEREST [guid] => https://technology-offers.inserm-transfert.com/offer/chimeric-receptor-for-use-in-whole-cell-sensors-for-detecting-analytes-of-interest/ [post_content] => The present invention relates to chimeric receptors that can be used in whole-cell sensors for detecting analytes of interest. The inventors showed that the DNA binding domains and downstream gene expression can be activated via dimerization of an artificial dimerization composed of a single chain variable domain. They demonstrated for the first time that an artificial bacterial receptor using an antibody-like domain can be activated and produce a transcriptional output upon ligand-binding. In particular, the present invention relates to a chimeric receptor polypeptide comprising i) a first DNA binding domain, ii) at least one binding domain selected from the group consisting of heavy chain variable domain, camelid VHHs, or antibody mimetics having specificity for an analyte, and iii) a linker between the DNA binding domain and the binding domain. [post_date] => 2020-02-10 10:36:02 [post_modified] => 2024-09-11 15:52:15 [ID] => 4327 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c5d4735f-885c-4a57-ad41-45f82b128880 [etat_fiche_online] => en_ligne [date_application] => 07-06-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO1550501-D1 [keywords] => ELISA, Flow Cytometry, Technology, Immunoassay, Other, Technology, All therapeutic area
[pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BONNET Jérôme,CHANG Hung Ju [number_application] => European Procedure (Patents) (EPA) - 08 Juin 2017 - 17 305 690.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,other [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• OthersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 241 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Immunoassay, In vitro poc, Method, Other, Others, Others [taxonomieurl] => Biomarker, Immunoassay, In vitro poc, Method, Other, Others, Others ) [242] => stdClass Object ( [post] => stdClass Object ( [post_title] => Prognosis and treatment of patients suffering from prostate cancer [guid] => https://technology-offers.inserm-transfert.com/offer/prognosis-and-treatment-of-patients-suffering-from-prostate-cancer/ [post_content] => The invention relates to methods for predicting the outcome of a patient suffering from prostate cancer and methods for the treatment of prostate cancer. The inventors show that Doublecortin-expressing (DCX+) neural precursors from the central nervous system (CNS) enter the bloodstream, infiltrate prostate tumours and differentiate into neo-neurons that contribute to tumour development. In human primary prostate tumours and transgenic mouse cancer tissues, the density of DCX+ neural progenitors is strongly associated with tumour aggressiveness, invasion and recurrence. In transgenic cancer mice, oscillations of DCX+ neural stem cells in the subventricular zone (SVZ), a neurogenic area of the CNS, were associated with egress of DCX+ cells from the SVZ to the bloodstream. These cells then reach the tumour where they initiate neurogenesis. Selective genetic depletion of DCX+ cells in mice inhibits the early phases of prostate cancer development, whereas orthotopic transplantation of DCX+ cells purified from prostate tumour or brain tissues promotes tumour growth and cancer cell dissemination. These results unveil a unique crosstalk between the CNS and the tumour that drives a process of neurogenesis necessary for prostate cancer development, and indicate a novel neural element of the tumour microenvironment as a potential target for cancer treatment. Thus, the invention relates to a method for predicting the outcome of a patient suffering from prostate cancer and compound targeting DCX+ neural progenitor cells for use in the treatment of prostate cancer. [post_date] => 2020-02-10 10:29:02 [post_modified] => 2024-09-11 15:52:27 [ID] => 4324 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 837d698e-3d97-7ca9-30e1-5b2777b954a2 [etat_fiche_online] => en_ligne [date_application] => 13-04-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO17511-D1 [keywords] => IHC, Flow Cytometry, Immunoassay, Prognosis, Oncology Solid Tumor, Prostate Cancer, Breast Cancer
[pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MAGNON Claire,ROMEO Paul-Henri [number_application] => European Procedure (Patents) (EPA) - 13 Avr. 2018 - 18 305 460.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Prostate CancerTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 242 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Prostate Cancer [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Prostate Cancer ) [243] => stdClass Object ( [post] => stdClass Object ( [post_title] => Stratification of melanoma patients for immune checkpoint inhibitor treatment [guid] => https://technology-offers.inserm-transfert.com/offer/stratification-of-melanoma-patients-for-immune-checkpoint-inhibitor-treatment/ [post_content] => Immune checkpoint inhibitors (ICI) have revolutionized therapy for advanced cancer, however many patients still do not respond to treatment. However, the efficacy and effectiveness of these therapies varies greatly across individual patients and among different tumour types. A substantial unmet need is thus the development of biomarkers of response to ICI, in order to identify, before initiation of treatment, which patients are likely to experience a response to and clinical benefit from such treatments. Here, the inventors analyzed SPHK1 mRNA in tumor biospies by in situ hybridization using the RNAscope technology in a cohort of 22 patients suffering from metastatic melanoma. They showed that elevated expression of sphingosine kinase 1 (SK1), which produces the oncometabolite sphingosine-1-phosphate (S1P) is associated with a poor survival in metastatic melanoma patients treated with to the well-known immune-checkpoint inhibitor anti-PD-1 antibody. Accordingly, the present invention relates to the use of SK1 as biomarker for predicting response to immune-checkpoint inhibitors. [post_date] => 2020-02-10 10:26:02 [post_modified] => 2024-09-11 15:52:15 [ID] => 4323 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a9360e31-1a47-59ac-8734-5b17d6050688 [etat_fiche_online] => en_ligne [date_application] => 28-05-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18047-D1 [keywords] => IHC, RT-PCR, Immunoassay, Transcriptomic, Treatment Response, Prognosis, Oncology, Solid Tumor, Melanoma
[pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => COLACIOS Céline,LEVADE Thierry,SEGUI Bruno,MEYER Nicolas,IMBERT Caroline,LAMANT-ROCHAIX Laurence,ANDRIEU-ABADIE Nathalie [number_application] => European Procedure (Patents) (EPA) - 21 Févr. 2018 - 18305178.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• MelanomaTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 243 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Melanoma, Oncology, Pre-Analytic Validation, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Melanoma, Oncology, Pre-Analytic Validation, Transcriptomics ) [244] => stdClass Object ( [post] => stdClass Object ( [post_title] => New Biomarker for stratifying cancer patients for immune checkpoint inhibitor treatment [guid] => https://technology-offers.inserm-transfert.com/offer/new-biomarker-for-stratifying-cancer-patients-for-immune-checkpoint-inhibitor-treatment/ [post_content] => The present invention relates to use of soluble CD27 as a biomarker to predict the reponse to an immune checkpoint inhibitor treatment. Inventors have worked with two cohorts of patients and have identified a soluble marker, CD27, present in the plasma of patients with renal cell cancer whose pre-treatment concentrations predict the response to anti-PD-1 / PD-L1. This marker appears more as a predictive marker of response to anti-PD1 / PD-L1 treatment, than as a prognostic marker. Indeed, it is not associated with better survival in patients with metastatic renal cell cancer treated with an antiangiogenic agent. This marker is not correlated with conventional clinical markers of severity that classify patients with metastatic renal cancer. [post_date] => 2020-02-10 09:01:02 [post_modified] => 2024-09-11 15:52:55 [ID] => 4320 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => afa39a12-b369-daab-c8c4-5d1c752d4077 [etat_fiche_online] => en_ligne [date_application] => 30-01-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO18516-D1 [keywords] => ELISA, Immunoassay, Treatment Response, Prognosis in Cancer, Renal Cancer, Immune-Checkpoint Inhibitor [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => TARTOUR Eric,OUDARD Stephane,BEN HAMOUDA Nadine,EPAILLARD Nicolas [number_application] => European Procedure (Patents) (EPA) - 30 Janv. 2019 - 19305114.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 244 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Method, Oncology, Pre-Analytic Validation, Solid Tumors [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Method, Oncology, Pre-Analytic Validation, Solid Tumors ) [245] => stdClass Object ( [post] => stdClass Object ( [post_title] => New Biomarker for prognosis and treatment of patients with melanoma [guid] => https://technology-offers.inserm-transfert.com/offer/new-biomarker-for-prognosis-and-treatment-of-patients-with-melanoma/ [post_content] => The present invention relates to a method and composition for treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant. More particularly, inventors have shown that high expression of PTX3 correlates with melanoma invasiveness and with a poorer survival rate in metastatic melanoma patients. PTX3 knockdown inhibited melanoma cell migration, invasion, lung metastasis, and NF?B signaling pathway. An addition of melanoma-derived or recombinant PTX3, or overexpression of PTX3 enhanced motility of low migratory cells. Finally, they found that TLR4 and MYD88 knockdown or targeting inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4FkB-dependent pathway. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by quantifying the expression level of PTX3 in a biological sample and to a method of treating melanoma, aggressive/invasive melanoma, metastatic melanoma or melanoma resistant by using the inhibitors of PTX3. [post_date] => 2020-02-10 08:53:04 [post_modified] => 2024-09-11 15:52:14 [ID] => 4319 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8015b58b-c4ea-f06f-e9b7-5e12eaedaa2a [etat_fiche_online] => en_ligne [date_application] => 30-04-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19137-D1 [keywords] => ELISA, RT-PCR, Immunoassay, Transcriptomics, Treatment Response, Prognosis in Melanoma, Cancer [pub_scient_inv_dispo] => Oncogene. 2019 Jul;38(30):5873-5889. doi: 10.1038/s41388-019-0848-9. Epub 2019 Jun 28. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DECKERT Marcel,RATHORE Moeez,TICHET Mélanie,TARTARE-DECKERT Sophie [number_application] => European Procedure (Patents) (EPA) - 30 Avr. 2019 - 19 305 555.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• MelanomaTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 245 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Melanoma, Oncology, Pre-Analytic Validation, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Melanoma, Oncology, Pre-Analytic Validation, Transcriptomics ) [246] => stdClass Object ( [post] => stdClass Object ( [post_title] => A B cell depleting agent for the treatment of Atherosclerosis or post Myocardial Infarction [guid] => https://technology-offers.inserm-transfert.com/offer/a-b-cell-depleting-agent-for-the-treatment-of-atherosclerosis-or-post-myocardial-infarction-2/ [post_content] => New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated diseases might also benefit from a reduction of cardiovascular risk through limitation of atherosclerotic lesion development or inflammation. CD20-antibody-mediated depletion of mature B lymphocytes impeded monocyte mobilization, limited myocardial injury and improved heart function after acute MI in mice. Results in various animal models; Availability and safety of humanized monoclonal anti-CD20 antibodies in humans. (Zouggari Y. et al., Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al., J Exp Med. 2010 Aug 2;207(8):1579-87.) [post_date] => 2020-01-24 12:37:02 [post_modified] => 2024-09-11 15:43:58 [ID] => 4307 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cf729acd-7e85-4588-b864-179ce89396b7 [etat_fiche_online] => en_ligne [date_application] => 07-01-2009 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO08404-T1 [keywords] => Atherosclerosis; B cell depleting agent; B cell; Anti-CD20 mAb; CD20; Antibody [pub_scient_inv_dispo] => Zouggari Y. et al., Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al., J Exp Med. 2010 Aug 2;207(8):1579-87. [access_to_detailed_offer] => /wp-content/uploads/BIO08404-T1_MALLAT.pdf [rare_disease] => false [second_indication] => true [inventors] => TEDGUI Alain,TEDDER Thomas,AIT-OUFELLA Hafid [number_application] => European Procedure (Patents) (EPA) - 06 Janv. 2009 - 09 290 005.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Myocardial InfarctionTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 246 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Cardiovascular Diseases, Clinical Trial, Drug, Myocardial Infarction, Phase 2, Protein, Target [taxonomieurl] => Antibody, Biologic, Cardiovascular Diseases, Clinical Trial, Drug, Myocardial Infarction, Phase 2, Protein, Target ) [247] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTAGONISTS OF IL-33 FOR USE IN METHODS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN AN ORGAN [guid] => https://technology-offers.inserm-transfert.com/offer/antagonists-of-il-33-for-use-in-methods-for-preventing-ischemia-reperfusion-injury-in-an-organ-2/ [post_content] => Inflammation is a prominent feature of ischemia-reperfusion injury (IRI) characterized by leukocyte infiltration and renal tubular injury. However, the signals that initiate these events remain poorly understood. The inventors identify the nuclear alarmin interleukin (IL)-33 as an initiation factor of tissue injury and also as a major amplification factor of the innate immune response triggered by experimental kidney ischemia-reperfusion in mice. In mice lacking IL-33, IRI is reduced, as attested by early decreased tubular cell injury, and by subsequent decreased infiltration of IFN-?/IL-17A-producing neutrophils and preservation of renal functions. These findings led the inventors to propose that endogenous IL-33 contributes to kidney IRI by promoting iNKT cell recruitment and cytokine production, resulting in neutrophil infiltration and activation at the injury site. Accordingly, the present invention relates to antagonists of IL-33 for use in methods for preventing ischemia reperfusion injury in an organ. [post_date] => 2020-01-22 12:47:01 [post_modified] => 2024-09-11 15:44:10 [ID] => 4297 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8c4bd137-a971-e7f1-2696-5aa656288e33 [etat_fiche_online] => en_ligne [date_application] => 25-01-2018 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17218-T1 [keywords] => ischemia reperfusion injury [pub_scient_inv_dispo] => J Am Soc Nephrol. 2018 Apr;29(4):1272-1288. doi: 10.1681/ASN.2017060650. Epub 2018 Feb 7. [access_to_detailed_offer] => /wp-content/uploads/BIO17218-T1_HERBELIN.pdf [rare_disease] => false [second_indication] => false [inventors] => HERBELIN André,GOMBERT Jean-Marc,THIERRY Antoine,FERHAT Maroua,GIRARD Jean-Philippe [number_application] => European Procedure (Patents) (EPA) - 25 Janv. 2018 - 18305054.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• TransplantationTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 247 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Kidney Transplantation, Target, Target, Transplantation, Validation in vivo [taxonomieurl] => Drug, Immunology, Kidney Transplantation, Target, Target, Transplantation, Validation in vivo ) [248] => stdClass Object ( [post] => stdClass Object ( [post_title] => New method using imaging analysis for assisting with prognosis of DLBCL patients [guid] => https://technology-offers.inserm-transfert.com/offer/new-method-using-imaging-analysis-for-assisting-with-prognosis-of-dlbcl-patients-2/ [post_content] => The present invention relates to a method for assisting with lymphoma prognosis. The prognosis of therapeutic response of patients with lymphoma is difficult. Based on a study of advanced stage DLBCL patients, the inventors showed that medical imaging such as 18F-FDG-PET/CT can provide a prognostic radiomic signature combining metrics reflecting tumor dissemination and tumor burden. In another aspect, the invention relates to a computer software comprising instructions to implement at least a part of a method according to the invention. In yet another aspect, the invention relates to a computer-readable non-transient recording medium on which a software is registered to implement a method according to the invention.Scientific publication(s):J Nucl Med, 2020 Jan, Cottereau AS. Et al., 18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome, doi: 10.2967/jnumed.119.229450 [post_date] => 2020-01-16 10:50:03 [post_modified] => 2024-09-11 15:51:14 [ID] => 4294 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f257dd3d-1727-cf56-3310-5e12fe81e9bc [etat_fiche_online] => en_ligne [date_application] => 31-05-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => 0155030136 [reference_online] => MECA19045-D1 [keywords] => Imaging, Treatment Response, Prognosis in Cancer, Non Hodgkin’s B cell Lymphoma, Diffuse large B-cell lymphoma, DLBCL [pub_scient_inv_dispo] => J Nucl Med. 2020 Jan;61(1):40-45. doi: 10.2967/jnumed.119.229450. Epub 2019 Jun 14. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BUVAT-GUILLEMET Irène,NIOCHE Christophe,COTTEREAU Anne-Ségolène,MEIGNAN Michel [number_application] => European Procedure (Patents) (EPA) - 31 Mai 2019 - 19305697.5 [technology_engineering] => bioinformatic [multidisciplinary_field] => [technological_platform] => imaging [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• LymphomaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 248 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Bioinformatic, Biomarker, Diffuse Large B-Cell Lymphoma, Imaging, Lymphoma, Method, Oncology, Pre-Analytic Validation [taxonomieurl] => Bioinformatic, Biomarker, Diffuse Large B-Cell Lymphoma, Imaging, Lymphoma, Method, Oncology, Pre-Analytic Validation ) [249] => stdClass Object ( [post] => stdClass Object ( [post_title] => SSBP1 as a new target, and biomarker for predicting risk of ocular disease related to mtDNA maintenance such as opic neuropathy or foveopathy [guid] => https://technology-offers.inserm-transfert.com/offer/ssbp1-as-a-new-target-and-biomarker-for-predicting-risk-of-ocular-disease-related-to-mtdna-maintenance-such-as-opic-neuropathy-or-foveopathy-4/ [post_content] => Inventors report heterozygous mutations in mitochondrial single-stranded DNA-binding protein SSBP1 in multiple unrelated families with non-syndromic dominant optic atrophy, associated in half of the cases by a striking occurrence of a foveopathy. SSBP1 is a key protein for the mtDNA replication machinery. Inventors have identified two mutations in SSBP1 in families with dominant optic atrophy and shown that SSBP1 mutation affects mtDNA replication. Patient fibroblasts displayed unstable formation of SSBP1 dimer/tetramer affecting mtDNA replication leading to a decrease of mtDNA copy-number. They provide evidences that SSBP1 deficiency in human results in a novel mtDNA syndrome resulting in an isolated visual defect. The present invention relates to a method for predicting the risk of having or developing ocular disease related to mtDNA maintenance by measuring at least one mutation in SSBP1. The invention relates also to treat ocular disease related to mtDNA maintenance by administering an inhibitor of SSBP1 gene expression or a vector which comprises a nucleic acid molecule encoding for SSBP1.Scientific publication(s):J Clin Invest, 2020 Jan 2, Piro-Mégy C. et al., Dominant mutations in mtDNA maintenance gene SSBP1 cause optic atrophy and foveopathy, doi: 10.1172/JCI128513 [post_date] => 2020-01-16 10:48:02 [post_modified] => 2024-09-11 15:52:18 [ID] => 4293 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 89e2a2ba-98d2-8f1f-c11c-5e132efe144b [etat_fiche_online] => en_ligne [date_application] => 14-06-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19176-D1 [keywords] => ELISA, PCR, RT-PCR, Sequencing, Genomics, Immunoassay, Transcriptomics, Diagnostic, Risk Prediction in mtDNA maintenance related ocular disease, optic neuropathy, Autosomal dominant optic atrophy (ADOA), Foveopathy, Leber’s hereditary optic neuropathy (LHON), glaucoma, retinal macular dystrophy, optic nerve dysfunction, or progressive external ophthalmoplegia (PEO), ptosis [pub_scient_inv_dispo] => J Clin Invest. 2020 Jan 2;130(1):143-156. doi: 10.1172/JCI128513. [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => DELETTRE-CRIBAILLET Cécile,PIRO-MEGY Camille,PEQUIGNOT Marie,SARZI Emmanuelle,SOLA Maria,SPELBRINK Johannes [number_application] => European Procedure (Patents) (EPA) - 14 Juin 2019 - 19305764.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => genomics,immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• OphtalmologyTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 249 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Genomics, Human POC, Immunoassay, Ophtalmology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Genomics, Human POC, Immunoassay, Ophtalmology, Transcriptomics ) [250] => stdClass Object ( [post] => stdClass Object ( [post_title] => Determining whether a patient suffering from lung cancer is eligible to a HER2 inhibitor treatment [guid] => https://technology-offers.inserm-transfert.com/offer/determining-whether-a-patient-suffering-from-lung-cancer-is-eligible-to-a-her2-inhibitor-treatment-2/ [post_content] => Lung cancers consist of two major histological types, non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma. NSCLC consists of squamous cell carcinoma (SCC), adenocarcinoma (AD), large-cell carcinoma, and others. NSCLC accounts for ~85% of all lung cancers, and there are ~80% of NSCLC cases in advanced stage where the prognosis remains poor. Therefore, investigation of the mechanism of initiation, progression, and identification of prognostic markers is still needed for the selection of patients with NSCLC and to provide better individualized treatment.The present invention relates to methods and pharmaceutical compositions for the treatment of lung cancer. The inventors showed that FHIT (also known as bis(5-adenosyl)-triphosphatase) regulates HER2 activity in lung tumor cells and that HER2 inhibitors reduce invasion induced by FHIT inhibition. In particular, the present invention relates to a method of treating lung cancer in a patient in need thereof comprising the steps of i) determining the expression level of FHIT in a tumor tissue sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering to the patient a therapeutically effective amount of at least one HER2 inhibitor when the expression level determined at step i) is lower than the predetermined reference level. [post_date] => 2020-01-16 10:36:02 [post_modified] => 2024-09-11 15:52:19 [ID] => 4289 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => eae38774-1924-4a82-9872-7cc6be799e81 [etat_fiche_online] => en_ligne [date_application] => 22-09-2016 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO16334-D1 [keywords] => RT-PCR, Western Blot, IHC, ELISA, Transcriptomics, Immunoassay, Cancer (Lung / NSCLC) [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => RABY Béatrice,JOUIDA Amina,POLETTE Myriam [number_application] => European Procedure (Patents) (EPA) - 22 Sept. 2016 - 16 306 213.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Lung cancerTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 250 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Human POC, Immunoassay, Lung cancer, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Human POC, Immunoassay, Lung cancer, Oncology, Transcriptomics ) [251] => stdClass Object ( [post] => stdClass Object ( [post_title] => KIR3DL2 as a biomarker and therapeutic target for diagnosis, prognosis and treatment of cutaneous and non-cutaneous peripheral T-cell lymphoma [guid] => https://technology-offers.inserm-transfert.com/offer/kir3dl2-as-a-biomarker-and-therapeutic-target-for-diagnosis-prognosis-and-treatment-of-cutaneous-and-non-cutaneous-peripheral-t-cell-lymphoma-2/ [post_content] => Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon non-Hodgkin’s tumor diseases characterized by an aggressive clinical course and a mostly poor outcome with current treatment strategies. One of the most urgent difficulties is to properly classify these diseases to provide the patient with the most adapted treatment, such as cell-targeted chemotherapy, radiotherapy and/or marrow bone transplantation. Among the cutaneous PTCL, Sézary syndrome and transformed mycosis fungoides are the most prevalent cutaneous T-cell lymphomas. There is a need for targeted therapy. Previous studies demonstrated that treatment of Sézary cells with the Janus kinase (JAK) inhibitor efficiently promotes phospho-STAT3 dephosphorylation and induces Sézary cell apoptosis. Regarding some physiological aspects of Sezary’s syndrome, it has notably been shown that a combination of 4 biomarkers are of special interest, since PSL3, TWIST, KIR3DL2 and NKp46 were shown to be overexpressed in T-cells from Sézary and transformed mycosis fungoides individuals. However, there are confusing data whenever KIR3DL2 should be considered as a relevant biomarker.Killer immunoglobulin-like receptors (KIR) represent a family of receptors that are used by human Natural Killer (NK) cells and T-lymphocyte subsets to specifically recognize MHC class I molecules. KIR3DL2 belongs to the KIR receptor family. KIR3DL2 has been reported to be a candidate for target therapy, since a monoclonal antibody that binds to KIR3DL2 is able to induce an antibody-dependent cellular cytotoxicity (ADCC) against malignant T-cells expressing KIR3DL2.The present invention relates to a ligand molecule that specifically binds to KIR3DL2 at the surface of KIR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma. [post_date] => 2020-01-16 10:28:01 [post_modified] => 2024-09-11 15:52:20 [ID] => 4287 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0d0f77cc-7eee-4c70-ae6c-8f50a60f9f93 [etat_fiche_online] => en_ligne [date_application] => 29-05-2013 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO13042-D1 [keywords] => Diagnostics, Biomarker, RT-PCR, IHC, Western Blot, Transcriptomics, Immunoassay, Cancer (Peripheral T cell Lymphoma) [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => BENSUSSAN Armand,MARIE-CARDINE Anne,GAULARD Philippe [number_application] => International Procedure (PCT) - 29 Mai 2013 - PCT/EP2013/061107 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Hematological tumorTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 251 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Hematological tumor, Human POC, Immunoassay, Oncology, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Hematological tumor, Human POC, Immunoassay, Oncology, Transcriptomics ) [252] => stdClass Object ( [post] => stdClass Object ( [post_title] => Follicular B cell, CD8+ T cell, Treg and dendritic cell density for the prognosis of survival time of a patient suffering from a solid cancer [guid] => https://technology-offers.inserm-transfert.com/offer/follicular-b-cell-cd8-t-cell-treg-and-dendritic-cell-density-for-the-prognosis-of-survival-time-of-a-patient-suffering-from-a-solid-cancer-2/ [post_content] => Lung cancer is the most common cause of cancer related death in the world. Approximately 80% to 90% of cases involve Nonu2013Small-Cell Lung Cancer (NSCLC), which includes adenocarcinoma and squamous cell carcinoma. As many as 30% of patients with stage I disease experience recurrence after surgery. The correlation between tumor-infiltrating immune cells and the prognosis of patients with lung cancer is controversial. A tumor is composed of malignant, stromal, endothelial, and immune cells that form a heterogeneous network and exhibit complex interactions. Spontaneous tumor regressions occurring concomitantly with autoimmune manifestations and the higher incidence of tumors in immunosuppressed patients are indications of the involvement of the immune system in tumor rejection. Mice deficient in immune functions spontaneously develop tumors. The density of tumor-infiltrating lymphocytes (TILs) with cytotoxic and memory phenotypes is highly predictive of good clinical outcome in many solid tumors.It is now well established that immune responses can take place at distance of secondary lymphoid organs, in u201ctertiary lymphoid structuresu201d (TLS) or u201cTertiary Lymphoid Organu201d (TLO). These lymph node-like structures can develop in lung cancer patients. They have been initially named u201cTumor-induced Bronchus-Associated Lymphoid Tissuesu201d (Ti-BALT) as they were never found in the non-tumoral tissues of NSCLC patients. The density of mature DC, a population which was selectively detected in TLS, is associated with a favorable clinical outcome in patients with early-stage NSCLC and in metastatic stage suggesting that lung cancer-associated TLS represent an activation site for tumor-specific T cells.Furthermore, a high density of B cells in TLS (named u201cTLS-B cellsu201d or u201cFollicular B cellsu201d) correlates with long-term survival of patients with early-stage and advanced-stage NSCLC, in accordance with ongoing humoral immune response in TLS. The combination of TLS-B cells and TLS-mature DC allowed the identification of NSCLC patients with the best clinical outcome. The presence of TLS has been reported in other human tumors including, but not limited to, colorectal, breast cancer and melanoma, indicating that ectopic TLS arise in many solid tumors.Thus, the present inventions relates to methods for predicting the survival time of patients suffering from a lung cancer using TLS and cell density as biomarkers of cancer prognosis. In particular, they relate to use as biomarkers of:- the cell density of follicular B cells present in tumor-induced lymphoid structures in a tumor tissue sample;- the cell density of CD8+ cells and DC-LAMP+ dendritic cells present in a tumor tissue sample;- the cell density of regulatory T (Treg) cells, and the cell density of one further population of immune cells selected from the group consisting of TLS-mature DC or TLS-B cells or Tconv cells, CD8+ T cells or CD8+ Granzyme-B+ T cells in said tumor tissue sample obtained from the subject.Scientific Publication(s):Am J Respir Crit Care Med., 2014 April 1, Germain C. et al., Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer, doi: 10.1164ccm.201309-1611OCCancer Res., 2014 February 1, Goc J. et al., Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells, doi: 10.1158/0008-5472.CAN-13-1342 [post_date] => 2020-01-16 10:20:02 [post_modified] => 2024-09-11 15:52:20 [ID] => 4285 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => be568644-1715-457d-800b-217618203c67 [etat_fiche_online] => en_ligne [date_application] => 20-01-2012 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO11338-D1 [keywords] => Cancer (Pan-Cancer - Lung - Colorectal - Breast), Immuno-oncology, IHC, Immunoassay, Oncology [pub_scient_inv_dispo] => Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44. doi: 10.1164ccm.201309-1611OC.Cancer Res. 2014 Feb 1;74(3):705-15. doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => SAUTES-FRIDMAN Catherine,FRIDMAN Wolf Herman (Hervé),REMARK Romain [number_application] => European Procedure (Patents) (EPA) - 20 Janv. 2012 - 12 151 875.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 252 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Solid Tumors [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Solid Tumors ) [253] => stdClass Object ( [post] => stdClass Object ( [post_title] => Diagnosis of GIST [guid] => https://technology-offers.inserm-transfert.com/offer/diagnosis-of-gist-2/ [post_content] => Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, mostly characterized by activating mutations in one of two genes that code for related tyrosine kinases, namely KIT (75-80%) and PDGFRA (5-10%). Mesenchyme-derived cells of the gastrointestinal tract, such as smooth muscle cells (SMCs), demonstrate high plasticity, a quality often associated with high neoplastic risk. Because tumor progression has often been associated with the re-expression of markers of immature tissue, developmental studies have proven to be a reliable source for the identification of new tumoral markers. Thus, genes involved in the development and plasticity of SMCs demonstrate abnormal expression in GISTs. Using a microarray approach, the inventor identified LIX1 as highly expressed at the earliest stages of stomach development. In chicken, LIX1 was first shown to be expressed in the anterior and posterior intestinal portals, the early buds that will invaginate to give rise to the primary intestinal tube. Moreover, the insect homolog of LIX1, is implicated in the Hippo pathway, which has been at the center of many studies regarding the regulation of the balance between cell proliferation and differentiation. Thus, the present invention relates to the diagnosis of GISTs, using LIX1 as a biomarker. In the present invention, the inventors investigate LIX1 function during digestive smooth muscle development. The inventors show that LIX1 is a novel marker of stomach mesenchymal progenitors and that its expression is strong and highly dynamic. The inventors show that LIX1 positively regulates cell proliferation and SMC determination. Finally, the inventors show that LIX1 is expressed in GISTs and that high LIX1 expression is associated with poor patient prognosis.Scientific publication(s):BMC Biol., 2016 Apr 28, McKey J. et al., LIX1 regulates YAP1 activity and controls the proliferation and differentiation of stomach mesenchymal progenitors, doi: 10.1186/s12915-016-0257-2 [post_date] => 2020-01-16 10:15:02 [post_modified] => 2024-09-11 15:51:08 [ID] => 4283 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7ace25ae-9ae0-40c6-a2a9-19140cb5c117 [etat_fiche_online] => en_ligne [date_application] => 11-02-2016 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => 0155030136 [reference_online] => BIO13315-D1 [keywords] => Cancer, Colorectal Cancer, GIST, Gastrointestinal Stromal Tumors, RT-PCR, Transcriptomics [pub_scient_inv_dispo] => BMC Biol. 2016 Apr 28;14:34. doi: 10.1186/s12915-016-0257-2. [access_to_detailed_offer] => /wp-content/uploads/BIO13315-D1_DE-SANTA-BARBARA.pdf [rare_disease] => false [second_indication] => false [inventors] => FAURE Sandrine [number_application] => European Procedure (Patents) (EPA) - 11 Févr. 2016 - 16 305 159.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal Stromal Tumors (GIST)Therapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 253 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Gastrointestinal Stromal Tumors (GIST), Oncology, Pre-Analytic Validation, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Gastrointestinal Stromal Tumors (GIST), Oncology, Pre-Analytic Validation, Transcriptomics ) [254] => stdClass Object ( [post] => stdClass Object ( [post_title] => PD-1 and Tim-3 expression as biomarkers for Predicting survival time and treatement response of a subject suffering from renal cell carcinoma [guid] => https://technology-offers.inserm-transfert.com/offer/pd-1-and-tim-3-expression-as-biomarkers-for-predicting-survival-time-and-treatement-response-of-a-subject-suffering-from-renal-cell-carcinoma-2/ [post_content] => Kidney cancer also called renal cancer, or renal cell carcinoma (RCC) refers to cancer that has arisen from the kidney, and is by far the most common type of kidney cancer. About 9 out of 10 kidney cancers are RCC. Among RCC subtypes, clear cell RCC (ccRCC) is the most common. Incidence of ccRCC is increasing, comprising 80% of localized disease and more than 90% of metastatic disease.Immunotherapy is a new class of cancer treatment that works to harness the innate powers of the immune system to fight cancer. An important part of the immune system is its ability to keep itself from attacking normal cells in the body. To do this, it uses u201ccheckpoints,u201d which are molecules on immune cells that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. But newer drugs that target these checkpoints hold a lot of promise as cancer treatments. Drugs that target PD-1, a protein on immune system cells called programmed cell death 1, T cells that normally helps keep these cells from attacking other cells in the body. By blocking PD-1, the drug boosts the immune response against cancer cells. However, in RCC cancer, the treatment based on the inhibition of PD-1 leads only about 30% clinical responses in cancer patients. There is a need to find a treatment strategy which allows to have few side effects and avoid relapses. Thus, the invention is in the field of oncology. In particular, the invention relates to methods and pharmaceutical compositions for predicting and treating a subject suffering from renal cell carcinoma.Scientific publication(s):Cancer Res., 2016 Nov 21, Granier C. et al., Tim-3 expression on tumor-infiltrating PD-1+CD8+T cells correlates with poor clinical outcome in renal cell carcinoma, pii: canres.0274.2016 [post_date] => 2020-01-16 10:14:01 [post_modified] => 2024-08-28 12:17:41 [ID] => 4282 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 77c7ac83-1a11-4077-ad8a-47c2eafcca02 [etat_fiche_online] => en_ligne [date_application] => 04-01-2016 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO15495-D1 [keywords] => Solid Tumors, Renal Cell Carninoma, IHC, Flow Cytometry, Immunoassay [pub_scient_inv_dispo] => Cancer Res. 2017 Mar 1;77(5):1075-1082. doi: 10.1158/0008-5472.CAN-16-0274. Epub 2016 Nov 21. [access_to_detailed_offer] => /wp-content/uploads/BIO15495-D1_TARTOUR.pdf [rare_disease] => false [second_indication] => false [inventors] => DARIANE Charles,GRANIER Clémence,GEY Alain [number_application] => European Procedure (Patents) (EPA) - 04 Janv. 2016 - 16 305 004.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Solid TumorsTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 254 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Solid Tumors [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Oncology, Pre-Analytic Validation, Solid Tumors ) [255] => stdClass Object ( [post] => stdClass Object ( [post_title] => NGAL as a novel target for the treatment of Chronic Kidney Disease [guid] => https://technology-offers.inserm-transfert.com/offer/ngal-as-a-novel-target-for-the-treatment-of-chronic-kidney-disease-3/ [post_content] => The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, also known as neutrophil gelatinaseu2013associated lipocalin [NGAL]), the most highly upregulated gene in a mouse strain which develop severe renal lesions, is not simply a marker of renal lesions, but also an active player in disease progression. The severity of renal lesions was dramatically reduced in Lcn2u2013/u2013 mice. Lcn2 expression increases upon EGFR activation and Lcn2 mediates its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform. Cell proliferation was dramatically reduced in Lcn2u2013/u2013mice. LCN2 is increased particularly in patients who rapidly progressed to end-stage renal failure. (Viau A. et al., J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004.) [post_date] => 2020-01-08 16:42:02 [post_modified] => 2024-09-11 15:43:33 [ID] => 4276 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 94b3fed8-85f1-48e4-9df8-171f6ff153f2 [etat_fiche_online] => en_ligne [date_application] => 01-10-2010 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO10870-T1 [keywords] => Nephrology; Diagnostics; Biomarker; Chronic Kidne [pub_scient_inv_dispo] => Viau et al, 2010 The Journal of Clinical Investiga [access_to_detailed_offer] => /wp-content/uploads/BIO10870-T1_TERZI.pdf [rare_disease] => false [second_indication] => false [inventors] => BURTIN Martine,EL KAROUI Khalil,VIAU Amandine,NGUYEN Clément [number_application] => European Procedure (Patents) (EPA) - 01 Oct. 2010 - 10 306 077.8 [technology_engineering] => [multidisciplinary_field] => fibrosis [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Genito Urinary SystemTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 255 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Chronic Kidney Disease (Chronic Renal Failure) / End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Drug, Fibrosis, Genito Urinary System, Target, Target, Validation in vivo [taxonomieurl] => Chronic Kidney Disease (Chronic Renal Failure) / End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Drug, Fibrosis, Genito Urinary System, Target, Target, Validation in vivo ) [256] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND COMPOSITIONS FOR TREATING LIVER DISESASES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-compositions-for-treating-liver-disesases-2/ [post_content] => The present invention relates to a method for treating a subject suffering from a liver disease comprising a step of administering said subject with a therapeutically effective amount of an inhibitor of the endoribonuclease activity of IRE1?. Inventors have shown that in livers of tunicamycin-treated BI-1-/- mice aIRE1?-dependent NLRP3 inflammasome activation, an hepatocyte death, a fibrosis and a dysregulated lipid homeostasis that led to liver failure within a week. To test whether the pharmacological inhibition of IRE1? endoribonuclease activity would block the transition to NASH, mice were injected with the small molecule STF-083010 twice a week for 2 weeks towards the end of a 3-month HFD. In BI-1-/- mice, STF-083010 treatment effectively counteracted IRE1? endoribonuclease activity, improving glucose tolerance and rescuing from NASH. The hepatocyte-specific role of IRE1?’s RNase activity in mediating NLRP3 inflammasome activation and programmed cell death was confirmed in primary mouse hepatocytes through knockdown experiments and with STF-083010. [post_date] => 2020-01-07 15:28:02 [post_modified] => 2024-09-11 15:44:11 [ID] => 4272 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 30f3612b-26b3-a1a5-39be-5aaf89a4b126 [etat_fiche_online] => en_ligne [date_application] => 16-02-2018 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17600-T1 [keywords] => [pub_scient_inv_dispo] => Hepatology. 2018 Aug;68(2):515-532. doi: 10.1002/hep.29847. Epub 2018 May 18. [access_to_detailed_offer] => /wp-content/uploads/BIO17600-T1_BAILLY-MAITRE.pdf [rare_disease] => false [second_indication] => false [inventors] => BAILLY-MAITRE Béatrice,TRAN Albert,GUAL Philippe [number_application] => European Procedure (Patents) (EPA) - 16 Févr. 2018 - 18 305 169.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 256 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gastrointestinal Diseases, Liver Disease, Non-Alcoholic Steatohepatitis, Target, Target, Validation in vivo [taxonomieurl] => Drug, Gastrointestinal Diseases, Liver Disease, Non-Alcoholic Steatohepatitis, Target, Target, Validation in vivo ) [257] => stdClass Object ( [post] => stdClass Object ( [post_title] => CD9 as a new biomarker for diagnosing or predicting risk of glomerulonephritis [guid] => https://technology-offers.inserm-transfert.com/offer/cd9-as-a-new-biomarker-for-diagnosing-or-predicting-risk-of-glomerulonephritis/ [post_content] => The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and ?1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritis.Scientific Publication(s):Nat Commun, 2019 Jul 24, Lazareth H. el al., The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progression, doi: 10.1038/s41467-019-11013-2 [post_date] => 2020-01-06 10:37:01 [post_modified] => 2024-09-11 15:51:55 [ID] => 4267 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8bcbd2d1-85a9-f14a-166a-5e130c0d4c2e [etat_fiche_online] => en_ligne [date_application] => 04-06-2019 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO19208-D1 [keywords] => IHC, Immunoassay, Diagnostic, Risk Prediction in Glomerulonephritis [pub_scient_inv_dispo] => Nat Commun. 2019 Jul 24;10(1):3303. doi: 10.1038/s41467-019-11013-2. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => THARAUX Pierre-Louis,HENIQUE-GRECIET Carole,FLAMANT Martin [number_application] => European Procedure (Patents) (EPA) - 04 Juin 2019 - 19 305 721.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Genito Urinary SystemTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 257 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Human POC, Immunoassay [taxonomieurl] => Biomarker, Biomarker, Genito Urinary System, Glomerulonephritis, Human POC, Immunoassay ) [258] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF CD9 AS A BIOMARKER AND AS A BIOTARGET IN GLOMERULONEPHRITIS [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-cd9-as-a-biomarker-and-as-a-biotarget-in-glomerulonephritis-2/ [post_content] => The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and Beta 1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritis. [post_date] => 2019-12-18 09:31:05 [post_modified] => 2024-09-11 15:43:52 [ID] => 4261 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4539ad22-c468-9d70-adc0-5db080286c44 [etat_fiche_online] => en_ligne [date_application] => 04-06-2019 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO19208-T1 [keywords] => [pub_scient_inv_dispo] => Nat Commun. 2019 Jul 24;10(1):3303. doi: 10.1038/s41467-019-11013-2. [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => THARAUX Pierre-Louis,HENIQUE-GRECIET Carole,FLAMANT Martin [number_application] => European Procedure (Patents) (EPA) - 04 Juin 2019 - 19 305 721.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Genito Urinary SystemTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 258 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biomarker, Drug, Genito Urinary System, Glomerulonephritis, Method, Target, Target, Validation in vivo [taxonomieurl] => Biomarker, Drug, Genito Urinary System, Glomerulonephritis, Method, Target, Target, Validation in vivo ) [259] => stdClass Object ( [post] => stdClass Object ( [post_title] => GABA Administration Induces Alpha Cell-Mediated Beta-like Cell Neogenesis [guid] => https://technology-offers.inserm-transfert.com/offer/gaba-administration-induces-alpha-cell-mediated-beta-like-cell-neogenesis-2/ [post_content] => GABA is an inducer of ?-to-?-like cell conversion in vivo. This conversion induces ? cell replacement mechanisms through the mobilization of duct-lining precursor cells that adopt an ? cell identity prior to being converted into ?-like cells, solely upon sustained GABA exposure. Importantly, these neo-generated ?-like cells are functional and can repeatedly reverse chemically induced diabetes in vivo. Similarly, the treatment of transplanted human islets with GABA results in a loss of ? cells and a concomitant increase in ?-like cell counts, suggestive of ?-to-?-like cell conversion processes also in humans. (Cell. 2017 Jan 12;168(1-2):73-85.e11) [post_date] => 2019-12-18 09:31:03 [post_modified] => 2024-09-11 15:43:59 [ID] => 4257 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 182216dc-2947-4d08-841a-44d0cd510cb0 [etat_fiche_online] => en_ligne [date_application] => 27-09-2012 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO11035-T1 [keywords] => Arx; GABA; Pax4; endocrine pancreas; ? cell regeneration [pub_scient_inv_dispo] => Cell. 2017 Jan 12;168(1-2):73-85.e11. doi: 10.1016/j.cell.2016.11.002. Epub 2016 Dec 1. [access_to_detailed_offer] => /wp-content/uploads/BIO11035-T1_COLLOMBAT.pdf [rare_disease] => false [second_indication] => false [inventors] => AL-HASANI Keith,COURTNEY Monica,MANSOURI Ahmed,BEN-OTHMAN Nouha,GJERNES Elisabet [number_application] => European Procedure (Patents) (EPA) - 27 Sept. 2012 - 12 306 172.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 259 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Diabetes, Drug, Lead - validation in vivo, Metabolic Disorders, Product, Small Molecule, Target, Type 1 Diabetes (Juvenile Diabetes) [taxonomieurl] => Diabetes, Drug, Lead - validation in vivo, Metabolic Disorders, Product, Small Molecule, Target, Type 1 Diabetes (Juvenile Diabetes) ) [260] => stdClass Object ( [post] => stdClass Object ( [post_title] => Antibody for the treatment of Myocardial Infarction [guid] => https://technology-offers.inserm-transfert.com/offer/antibody-for-the-treatment-of-myocardial-infarction-2/ [post_content] => The present invention relates to a method for treating MI or AMI in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of an agent capable of depleting CD8 T cells. More particularly, this present invention relates to a method for treating acute myocardial infarction by reducing the size of necrosis and limiting the post ischemic left ventricular remodeling. [post_date] => 2019-12-18 09:31:02 [post_modified] => 2024-09-11 15:41:09 [ID] => 4254 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0cd66896-2f8c-4c5b-a8da-e37c88cba5cf [etat_fiche_online] => en_ligne [date_application] => 12-10-2015 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15275-T1 [keywords] => Cardiovascular, Myocardial infarction, antibody, Cardio-Immunology [pub_scient_inv_dispo] => In progress [access_to_detailed_offer] => /wp-content/uploads/BIO15275-T1_AIT-OUFELLA.pdf [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Myocardial InfarctionTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 260 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Cardiovascular Diseases, Drug, Method, Myocardial Infarction, Protein, Target, Validation in vivo [taxonomieurl] => Antibody, Biologic, Cardiovascular Diseases, Drug, Method, Myocardial Infarction, Protein, Target, Validation in vivo ) [261] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse models of amyloidosis [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-models-of-amyloidosis/ [post_content] => Amyloidosis is a rare disease caused by extracellular deposition of insoluble abnormal fibrils derived from aggregation of a misfolded variant of a normally soluble protein. Apolipoprotein (apo) AII is a major protein of HDL (high density lipoproteins) synthesized in liver. An apo AII variant carrying a mutation in the Stop codon causes an autosomal dominant apoa2-amyloidosis in humans (Yazaki et al, Kidney Int 2001, 60:1658-65). As in humans, our transgenic mice for the mutant human apo a2 gene with a Stop codon to Serine mutation (Stop78->Ser) express a longer hapo AII protein (99 AA instead of 77).Characteristics of transgenic mice:u2022 Spontaneous systemic amyloidosis begins as early as 3-4 months of age and increases as a function of age, with no need for an inflammatory state. Mouse lifespan varies between 6 and 9 months, depending on the gravity of amyloidosis.u2022 Amyloid fibrils stain with Congo red with the characteristic green birefringence under polarized light.u2022 Amyloid fibrils have been characterized by immunohistochemistry with human-apoAII antibodies in kidney, liver, heart spleen, and by electron microscopy in capillaries of liver and heart.u2022 Amyloid fibrils have been isolated from tissues; solubilized amyloid fibril protein was fractionated and the amino acid sequence of full-length hapoAII with a 21 amino acid carboxyl terminal extension was verified. [post_date] => 2019-12-05 14:17:33 [post_modified] => 2024-09-11 16:06:48 [ID] => 4249 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ffbae4f2-ae46-4b61-9fc8-a18f97a2f11a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00462 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Athina-Despina KALOPISSIS [first_name] => Athina-Despina [last_name] => KALOPISSIS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 261 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vivo, Therapeutic ) [262] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F2-3 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f2-3/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 313 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:17:32 [post_modified] => 2024-09-11 16:07:06 [ID] => 4248 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fef3c45f-7a05-4f34-9c19-dc0579811d7f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00412 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 262 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [263] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F2-4 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f2-4/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 347 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:17:31 [post_modified] => 2024-09-11 16:07:07 [ID] => 4247 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fe9f870d-cf7f-45fe-be97-bf09c5adf8e4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00413 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 263 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [264] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M2-0 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m2-0/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 285 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:17:30 [post_modified] => 2024-09-11 16:07:11 [ID] => 4246 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fe0e9eec-00e9-49b1-a2b2-07238548fce9 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00425 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 264 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [265] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human FLI-1 (Friend leukemia virus integration 1) (clone 7.3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-fli-1-friend-leukemia-virus-integration-1-clone-7-3/ [post_content] => Targets : Human FLI-1 and EWS-FLI-1.Applications : Western-blot, Immunoprecipitation, intracellular immunofluorescence [post_date] => 2019-12-05 14:17:29 [post_modified] => 2024-09-11 16:05:59 [ID] => 4245 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fcf2adc1-49cd-48ac-8332-71f6e20542c5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00034 [keywords] => FLI-1 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 265 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Oncology, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Oncology, Other, Western Blot ) [266] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Rat phospholipid scramblase (clone 129.2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-rat-phospholipid-scramblase-clone-129-2/ [post_content] => [post_date] => 2019-12-05 14:17:27 [post_modified] => 2024-09-11 16:05:50 [ID] => 4243 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fb9fb3f3-53ee-4536-9d77-2f87afed9c9a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00284 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc BENHAMOU [first_name] => Marc [last_name] => BENHAMOU [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 266 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot ) [267] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Rat SNAP-25 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-rat-snap-25/ [post_content] => This antibody detects SNAP-25 C-terminal end in Western blots. Pretreatment with botulinum neurotoxin A or E abolishes the signal. [post_date] => 2019-12-05 14:17:25 [post_modified] => 2024-09-11 16:05:48 [ID] => 4241 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fa57ab4d-5345-4f1d-b1a1-e4962ba13057 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00315 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Christian LEVEQUE [first_name] => Christian [last_name] => LEVEQUE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 267 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot [taxonomieurl] => Academic Research, Central Nervous System, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot ) [268] => stdClass Object ( [post] => stdClass Object ( [post_title] => HEK 293 cells expressing human prolactin receptor and LHRE-lucifease reporter gene [guid] => https://technology-offers.inserm-transfert.com/offer/hek-293-cells-expressing-human-prolactin-receptor-and-lhre-lucifease-reporter-gene/ [post_content] => This stable clone of HEK 293 cells has stably incorporated the sequence encoding the long isoform of the human prolactin receptor and a prolactin-responsive reporter gene, the lactogenic hormone response element (LHRE, = repeat of Stat5 DNA binding sequence) fused to the firefly luciferase sequence [post_date] => 2019-12-05 14:17:24 [post_modified] => 2024-09-11 16:06:52 [ID] => 4240 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fa53a280-1de0-4d07-842e-32f2ea052b1c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00002 [keywords] => prolactin ; prolactin receptor ; luciferase ; agonists ; antagonists [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Vincent GOFFIN [first_name] => Vincent [last_name] => GOFFIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 268 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Others ) [269] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD151 (clone TS151) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd151-clone-ts151/ [post_content] => [post_date] => 2019-12-05 14:17:23 [post_modified] => 2024-09-11 16:05:25 [ID] => 4239 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => fa1ff96d-1350-4876-a533-84fb9b3cd055 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00137 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 269 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [270] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F3-1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f3-1/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 356 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:17:22 [post_modified] => 2024-09-11 16:07:08 [ID] => 4238 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f89a178e-d24c-4255-882e-dd7690301201 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00415 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 270 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [271] => stdClass Object ( [post] => stdClass Object ( [post_title] => VHH directed against human DARC [guid] => https://technology-offers.inserm-transfert.com/offer/vhh-directed-against-human-darc/ [post_content] => VHH (i.e. recombinant derivative of peculiar heavy chain only antibodies present in camelids) directed against Duffy antigen receptor for chemokines (DARC). DARC which carries antigens defining the Duffy blood group system, is a human atypical chemokine receptor, the major receptor for Plasmodium vivax merozoite on erythrocytes, a protein implicated in cancer, inflammation, possibly HIV infection and AIDS progression.VHH was obtained afer screening of a library prepared from a dromedary immunized against first extracellular domain of DARC. VHH does recognize DARC on cells and interacts with the Fy6 epitope. It does inhibit P. vivax invasion and chemokine binding (IL8). Its affinity to DARC is in the subnanomolar range. Expression plasmid (6 His) codes for a hemagglutinin tagged VHH. [post_date] => 2019-12-05 14:17:20 [post_modified] => 2024-09-11 16:05:47 [ID] => 4236 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f6f23525-b8d3-4cac-a567-53ff3e8f20f8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00459 [keywords] => VHH ; recombinant antibody fragment ; sdAb ; DARC [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Academic ResearchUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Yves COLIN-ARONOVICZ [first_name] => Yves [last_name] => COLIN-ARONOVICZ [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 271 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Infectious Diseases, Oncology, Other, Other [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Infectious Diseases, Oncology, Other, Other ) [272] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD10 (clones /tK14, K50) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd10-clones-k14-k50/ [post_content] => [post_date] => 2019-12-05 14:17:19 [post_modified] => 2024-09-11 16:05:47 [ID] => 4235 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f6d3bcc7-2ca9-4ad3-bb96-7b5e58720e50 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00117 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 272 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse ) [273] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD1a (clone L119) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1a-clone-l119/ [post_content] => [post_date] => 2019-12-05 14:17:15 [post_modified] => 2024-09-11 16:05:45 [ID] => 4232 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f4faff28-9647-4352-8eef-19e5150ecdc7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00148 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 273 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [274] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human transferrin receptor (clone YDJ1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-transferrin-receptor-clone-ydj1/ [post_content] => [post_date] => 2019-12-05 14:17:13 [post_modified] => 2024-09-11 16:05:44 [ID] => 4229 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f3a813ed-63b2-4211-a0ef-6204e05f3aa4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00073 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 274 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [275] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Mouse I-Ek (Mouse MHC classe II allodeterminants) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-mouse-i-ek-mouse-mhc-classe-ii-allodeterminants-several-clones/ [post_content] => A collection of 17 mouse allospecific monoclonal antibodies raised in the A.TH (Is) anti-A.TL (Ik) combination. [post_date] => 2019-12-05 14:17:11 [post_modified] => 2024-09-11 16:05:43 [ID] => 4228 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f3a813b5-0745-4a0a-95f6-8d74d529f74a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00339 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 275 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse ) [276] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD8 beta subunit (Mouse CD8beta) (clone H37-17.2) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd8-beta-subunit-mouse-cd8beta-clone-h37-17-2/ [post_content] => Thymus-derived CD8+ TCRab+ T cells typically express heterodimericCD8ab consisting of a disulfide-linked a and b chain. CD8 can also be expressed as homodimeric CD8aa, namely on intra-epithelial T lymphocytes, some dendritic cells, NK, NKT and TCRcd+ T cells. Both forms of CD8 bind to the non-polymorphic domain of MHC classIa molecules and associate via CD8a with the intracellularSrc tyrosine kinase p56lck [post_date] => 2019-12-05 14:17:08 [post_modified] => 2024-09-11 16:06:11 [ID] => 4225 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f3421be7-429c-4891-820a-c496d7fa43ef [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00347 [keywords] => CD8beta [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 276 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Proof of concept in vitro, Rat [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Proof of concept in vitro, Rat ) [277] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Rat cleaved SNAP-25 (botulinum neurotoxin A) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-rat-cleaved-snap-25-botulinum-neurotoxin-a/ [post_content] => This antibody detects exclusively SNAP-25 cleaved by botulinum neurotoxin A and not the full length protein. [post_date] => 2019-12-05 14:17:08 [post_modified] => 2024-09-11 16:05:41 [ID] => 4224 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f2d2ea9a-3f2a-47d9-b9e7-ce8165874235 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00313 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Christian LEVEQUE [first_name] => Christian [last_name] => LEVEQUE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 277 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, Central Nervous System, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [278] => stdClass Object ( [post] => stdClass Object ( [post_title] => Real Time NO measurement [guid] => https://technology-offers.inserm-transfert.com/offer/real-time-no-measurement/ [post_content] => Real time constant amperometric detection of NO in tissues/cells.This gaseous neurotransmitter has a very short half-life (*5 s) and is usually studied by using indirect detection.We set up an original method to measure in real-time conditions hypothalamic nitric oxide production after intragastric glucose administration. [post_date] => 2019-12-05 14:17:07 [post_modified] => 2024-09-11 16:07:09 [ID] => 4223 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => f0d27f69-4f98-47ba-aeb0-e840473896ce [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00439 [keywords] => NO ; ROS [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• MusculoskeletalTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe VALET [first_name] => Philippe [last_name] => VALET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 278 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Cardiovascular Diseases, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Musculoskeletal, Proof of concept in vitro [taxonomieurl] => Academic Research, Cardiovascular Diseases, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Musculoskeletal, Proof of concept in vitro ) [279] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Mouse H-2Ks (Mouse MHC class I molecule) (clone H81-104.13) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-mouse-h-2ks-mouse-mhc-class-i-molecule-clone-h81-104-13/ [post_content] => Mouse monoclonal antibody recognizing a private (non-cross-reacting) allodeterminant of the H-2Ks mouse class I molecule. This Monoclonal antibody has been developped in the A.BY anti-A.TL mouse strain combination. [post_date] => 2019-12-05 14:17:02 [post_modified] => 2024-09-11 16:05:40 [ID] => 4219 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ef091001-1e5e-40f6-849a-9f479efd5304 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00350 [keywords] => Mouse H-2Ks ; MHC class I molecule [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 279 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse ) [280] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human CD2 (clone 39C8.14) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-39c8-14/ [post_content] => [post_date] => 2019-12-05 14:17:00 [post_modified] => 2024-09-11 16:05:39 [ID] => 4217 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ee9a485f-50bf-4aa7-9242-6287a118190b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00160 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 280 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [281] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 357-1-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-357-1-1/ [post_content] => [post_date] => 2019-12-05 14:16:59 [post_modified] => 2024-09-11 16:05:39 [ID] => 4216 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ee5cd591-3f2e-4de0-a3d1-8671d1103714 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00291 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 281 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others, Western Blot [taxonomieurl] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others, Western Blot ) [282] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD25 (clone 33B3.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd25-clone-33b3-1/ [post_content] => [post_date] => 2019-12-05 14:16:58 [post_modified] => 2024-09-11 16:05:38 [ID] => 4215 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ee488e9e-0e31-425a-9541-63fa10a1f60c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00174 [keywords] => CD25 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 282 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [283] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human melanoma associated Antigen (clone PNL2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-melanoma-associated-antigen-clone-pnl2/ [post_content] => - this new monoclonal antibody is directed against a new fixative resistant melanocyte/melanoma-associated antigen. - PNL2 labels more than 70% of neoplastic cells in all primary melanomas irrespective of their histologic type. All metastatic melanomas are also stained [post_date] => 2019-12-05 14:16:56 [post_modified] => 2024-09-11 16:05:21 [ID] => 4214 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => edca66c0-fee6-4165-a483-9a193d298d4c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00377 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 283 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology, Others, Proof of concept in vitro, Western Blot [taxonomieurl] => Academic Research, Diagnostic, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology, Others, Proof of concept in vitro, Western Blot ) [284] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human T-cell activation Antigen (clone 8F3.9.3) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-t-cell-activation-antigen-clone-8f3-9-3/ [post_content] => [post_date] => 2019-12-05 14:16:50 [post_modified] => 2024-09-11 16:05:37 [ID] => 4208 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e8d3aa32-905f-4f13-b200-6bb8c76712f7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00101 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 284 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Other, Rat [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Other, Rat ) [285] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Mouse CD4 (Mouse CD4, L3T4) (clone H129-19) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd4-mouse-cd4-l3t4-clone-h129-19/ [post_content] => Rat monoclonal antibody recognizing the CD4 mouse T-cell subset marker. [post_date] => 2019-12-05 14:16:48 [post_modified] => 2024-09-11 16:05:48 [ID] => 4206 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e6c463b1-a6ae-4140-a14c-2a0637dc5f95 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00340 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 285 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Proof of concept in vitro, Proof of concept in vivo, Rat [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Proof of concept in vitro, Proof of concept in vivo, Rat ) [286] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD7 (clone CBC.37) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd7-clone-cbc-37/ [post_content] => This monoclonal antibody is directed against a fixative resistant T-cell associated antigen.Reacts with normal and neoplastic T-cells.This antigen may be lost in some T-cell lymphomas in particular cutaneous T-cell lymphomas. [post_date] => 2019-12-05 14:16:47 [post_modified] => 2024-09-11 16:05:51 [ID] => 4205 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e6c0b626-03c1-41a9-8fe5-8fc6d6027f5a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00388 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 286 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Dermatology, Diagnostic, Human, Immunofluorescence, Immunology, lgG1, Mouse, Oncology, Western Blot [taxonomieurl] => Academic Research, Dermatology, Diagnostic, Human, Immunofluorescence, Immunology, lgG1, Mouse, Oncology, Western Blot ) [287] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD113 (Nectin-3) clone N3.12.4 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd113-nectin-3-clone-n3-12-4/ [post_content] => [post_date] => 2019-12-05 14:16:44 [post_modified] => 2024-09-11 16:06:03 [ID] => 4201 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e458b574-7e82-4bd1-862d-6b2a86ea4d01 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00128 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc LOPEZ [first_name] => Marc [last_name] => LOPEZ [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 287 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot ) [288] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M2-3 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m2-3/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 284 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:16:43 [post_modified] => 2024-09-11 16:07:13 [ID] => 4200 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e39b6496-1ac0-47e9-8ee2-50031fbb46f0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00427 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 288 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [289] => stdClass Object ( [post] => stdClass Object ( [post_title] => Three-dimensional multicellular spheroid cultures [guid] => https://technology-offers.inserm-transfert.com/offer/three-dimensional-multicellular-spheroid-cultures/ [post_content] => When culture in suspension many mammalian cell types can aggregate into 3D-spheroids. These multicellular cultures mimic real tissues or tumours and are useful models for therapeutic screening. [post_date] => 2019-12-05 14:16:41 [post_modified] => 2024-09-11 16:07:09 [ID] => 4198 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e1310caa-2cc2-41a2-a7f6-acbed13a629b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00396 [keywords] => proliferation ; tumour ; cell toxicity ; 3d-cultures ; cell-cell interactions [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Annie MOLLA [first_name] => Annie [last_name] => MOLLA [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 289 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro ) [290] => stdClass Object ( [post] => stdClass Object ( [post_title] => D3H2LN-AT2 human invasive breast cancer cell line expressing the human Angiotensin II-receptor AT2 [guid] => https://technology-offers.inserm-transfert.com/offer/d3h2ln-at2-human-invasive-breast-cancer-cell-line-expressing-the-human-angiotensin-ii-receptor-at2/ [post_content] => D3H2LN-AT2 cell line stably expressing firefly luciferase, GFP and Flagged human AT2 receptor.Empty vector infected cell line is also available. [post_date] => 2019-12-05 14:16:40 [post_modified] => 2024-09-11 16:06:48 [ID] => 4197 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e0a71ccd-fb3f-4d78-80d0-81a64b7dc732 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00457 [keywords] => Breast cancer ; Tumor growth ; Metastasis ; AT2 signalling ; Bioluminescence [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Clara NAHMIAS [first_name] => Clara [last_name] => NAHMIAS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 290 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others ) [291] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human transferrin receptor (clone YDJ5) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-transferrin-receptor-clone-ydj5/ [post_content] => [post_date] => 2019-12-05 14:16:39 [post_modified] => 2024-09-11 16:05:34 [ID] => 4196 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => e091b0fd-4c91-46a0-8e2a-cb27a3234f2b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00074 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 291 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [292] => stdClass Object ( [post] => stdClass Object ( [post_title] => Profiling blood lymphocytes reactivity against cancer cells [guid] => https://technology-offers.inserm-transfert.com/offer/profiling-blood-lymphocytes-reactivity-against-cancer-cells/ [post_content] => In vitro trogocytosis of PKH67-stained cancer cells as a measure of their interactions with bulks of PBMC from patients. This profiling give the quantification of specific interactions of different subsets from PBMC with different cancer cells. [post_date] => 2019-12-05 14:16:38 [post_modified] => 2024-09-11 16:07:08 [ID] => 4194 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => de1b2137-7c8f-41d9-8e4a-0c7fe1938453 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00436 [keywords] => immune reactivity ; trogocytosis ; immunomonitoring ; interactions [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Mary POUPOT [first_name] => Mary [last_name] => POUPOT [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 292 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro ) [293] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human HOX11/TLX1 (clone 16F6) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-hox11-tlx1-clone-16f6/ [post_content] => Mouse monoclonal antibodies recognizing the HOX11 gene product. [post_date] => 2019-12-05 14:16:37 [post_modified] => 2024-09-11 16:05:33 [ID] => 4193 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ddf8ccb6-3b52-4d5c-ae8e-534ca21192c6 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00364 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Theranostic (patients stratification, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Pierre FERRIER [first_name] => Pierre [last_name] => FERRIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 293 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, lgG1, Mouse, Proof of concept in vitro, Proof of concept in vivo, Theranostic (patients stratification, ...), Western Blot [taxonomieurl] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, lgG1, Mouse, Proof of concept in vitro, Proof of concept in vivo, Theranostic (patients stratification, ...), Western Blot ) [294] => stdClass Object ( [post] => stdClass Object ( [post_title] => Tagged Leptin receptors Hek293T cells [guid] => https://technology-offers.inserm-transfert.com/offer/tagged-leptin-receptors-hek293t-cells/ [post_content] => Hek293T cells were transfected with short form human leptin receptors (OBR) tagged individually with either Rluc (pIRESpuro3, Clontech) or YFP (pIEShyg3, Clontech). After antibiotic selection (puromycin and hygromycin), single cell clones were isolated and cultured, then analyzed by microscopy, luminescence measures, western blot and BRET. [post_date] => 2019-12-05 14:16:36 [post_modified] => 2024-09-11 16:06:51 [ID] => 4192 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => db442533-854e-4ea0-80c3-731ba0d42248 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00006 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Ralf JOCKERS [first_name] => Ralf [last_name] => JOCKERS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 294 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Others [taxonomieurl] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Others ) [295] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human CD2 (clone 41F2.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-41f2-1/ [post_content] => [post_date] => 2019-12-05 14:16:35 [post_modified] => 2024-09-11 16:05:32 [ID] => 4191 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => da745166-f2ef-4194-88ba-9613815c6fb7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00162 [keywords] => CD2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 295 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [296] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD25 (clone 18E6.4) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd25-clone-18e6-4/ [post_content] => [post_date] => 2019-12-05 14:16:33 [post_modified] => 2024-09-11 16:05:31 [ID] => 4189 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => da575eea-eb81-44b7-a161-88c886f39923 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00172 [keywords] => CD25 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 296 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [297] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M2-1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m2-1/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 136 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:16:30 [post_modified] => 2024-09-11 16:07:12 [ID] => 4185 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d76bf951-634c-4db6-8283-dfe7810920ed [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00430 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 297 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [298] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat transformed mesothelial cell line F5-3 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-transformed-mesothelial-cell-line-f5-3/ [post_content] => Transformed rat mesothelial cell line (= myofibroblast) isolated from the peritoneal fibrosis observed in a female rat (Fischer F344) after 415 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:16:29 [post_modified] => 2024-09-11 16:06:47 [ID] => 4184 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d6867f94-d599-4ccb-9e28-973edffd8cf2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00458 [keywords] => Mesothelial cells ; Tumor marker ; Tumor invasion process ; Malignant transformation ; Proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 298 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [299] => stdClass Object ( [post] => stdClass Object ( [post_title] => GST and GST fusion protein (clone ND2.1) [guid] => https://technology-offers.inserm-transfert.com/offer/gst-and-gst-fusion-protein-clone-nd2-1/ [post_content] => [post_date] => 2019-12-05 14:16:28 [post_modified] => 2024-09-11 16:05:30 [ID] => 4183 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d582fc31-8638-449c-9aec-f0447e09b541 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00329 [keywords] => GST [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 299 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [300] => stdClass Object ( [post] => stdClass Object ( [post_title] => TP53INP1-deficient mouse [guid] => https://technology-offers.inserm-transfert.com/offer/tp53inp1-deficient-mouse/ [post_content] => This mouse is deficient for TP53INP1 (both isoforms TP53INP1alpha and TP53INP1beta). TP53INP1 is a key stress factor endowed with a tumor suppressor activity as its transcriptional inducer p53. It is involved in the regulation of p53 activity, in the process of autophagy, and in the control of cell redox state. In human cancers, TP53INP1 is either down-regulated (pancreas, stomach) or overexpressed (thyroid, prostate). TP53INP1-deficient mice are highly susceptible to induced tumorigenesis, in association with increased level of Reactive Oxygen Species (ROS) and defects in antioxidant defences. Hence TP53INP1-deficient mice are a new model of chronic oxidative stressed mice prone to develop tumors, like p53-deficient mice. [post_date] => 2019-12-05 14:16:27 [post_modified] => 2024-09-11 16:06:54 [ID] => 4182 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d49c5f3b-d696-4150-99c3-feefe72cacfb [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00468 [keywords] => Tumor suppression ; Oxidative stress [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OncologyTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Alice CARRIER [first_name] => Alice [last_name] => CARRIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 300 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Gastrointestinal Diseases, Genetic Disorders, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Therapeutic [taxonomieurl] => Academic Research, Gastrointestinal Diseases, Genetic Disorders, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Therapeutic ) [301] => stdClass Object ( [post] => stdClass Object ( [post_title] => Adipose tissue selectively invalidated apelin [guid] => https://technology-offers.inserm-transfert.com/offer/adipose-tissue-selectively-invalidated-apelin/ [post_content] => Invalidation of apelin in adipose tissue with an aP2CRE-LoxAPL mouse [post_date] => 2019-12-05 14:16:26 [post_modified] => 2024-09-11 16:06:38 [ID] => 4181 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d3bb2627-1c4a-44be-a375-479ab7b2c7b1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00438 [keywords] => Adipose ; apelin [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Nutritional disorderTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe VALET [first_name] => Philippe [last_name] => VALET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 301 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vivo [taxonomieurl] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vivo ) [302] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 310-1-1) [guid] => [post_content] => [post_date] => 2019-12-05 14:05:53 [post_modified] => 2024-09-11 16:05:29 [ID] => 4180 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d36ca62f-f282-433d-bed1-029de03e7332 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00289 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 302 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others ) [303] => stdClass Object ( [post] => stdClass Object ( [post_title] => Germ free humanized diabetic/obese mice [guid] => https://technology-offers.inserm-transfert.com/offer/germ-free-humanized-diabetic-obese-mice/ [post_content] => These germ free mice are colonized with human microflora and fed a high fat diet which allows the study of the impact of pre and probiotics on the control of metabolic diseases. [post_date] => 2019-12-05 14:05:49 [post_modified] => 2024-09-11 16:06:43 [ID] => 4176 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d2af5e01-6ed1-43cf-ad43-cdd51fa592d1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00405 [keywords] => Germ free ; Diabetes ; Obesity ; High fat diet ; Metabolic syndrome [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Nutritional disorderTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Rémy BURCELIN [first_name] => Rémy [last_name] => BURCELIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 303 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Diabetes, Diagnostic, Gastrointestinal Diseases, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Diabetes, Diagnostic, Gastrointestinal Diseases, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic ) [304] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human FcgRIIA - intracellular domain (clone 93.4) [guid] => https://technology-offers.inserm-transfert.com/offer/human-fcgriia-intracellular-domain-clone-93-4/ [post_content] => [post_date] => 2019-12-05 14:05:48 [post_modified] => 2024-09-11 16:05:29 [ID] => 4175 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d2881d82-29f1-41ad-9b5e-72e8983e82d5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00326 [keywords] => FcgRIIA [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 304 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [305] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD8 ß (clone 1A3.3) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd8-s-clone-1a3-3/ [post_content] => [post_date] => 2019-12-05 14:05:46 [post_modified] => 2024-09-11 16:05:28 [ID] => 4173 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d1e250f5-b5f4-4932-a1e6-9c8c28a0bb2d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00234 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 305 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [306] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 81-2-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-81-2-1/ [post_content] => [post_date] => 2019-12-05 14:05:45 [post_modified] => 2024-09-11 16:05:28 [ID] => 4171 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => d10b4644-218d-4dee-9e5f-d2b0458e1239 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00294 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 306 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others ) [307] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse T lymphoma cell line expressing luciferase - KO99L/Luc [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-t-lymphoma-cell-line-expressing-luciferase-ko99l-luc/ [post_content] => The primary KO99L cell line was established by cultivating tumoral thymocytes from a tPTEN-/- mouse. KO99L cells were transduced with a pLenti-III-luc23 construct to stably express luciferase. Several clones are available. [post_date] => 2019-12-05 14:05:42 [post_modified] => 2024-09-11 16:06:39 [ID] => 4168 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ce5b13d0-a8fb-48b4-9f61-dbc59cfb6b11 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00492 [keywords] => T ALL/LL ; Imaging ; Tumor growth ; Bioluminescence [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Véronique IMBERT [first_name] => Véronique [last_name] => IMBERT [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 307 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro, Proof of concept in vivo [taxonomieurl] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro, Proof of concept in vivo ) [308] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F1-2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f1-2/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 306 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:05:41 [post_modified] => 2024-09-11 16:07:04 [ID] => 4166 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cdcf38fd-8189-4d28-a4b2-5525652c3c33 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00409 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 308 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [309] => stdClass Object ( [post] => stdClass Object ( [post_title] => ApoA2 humanized transgenic mouse - line lambda [guid] => https://technology-offers.inserm-transfert.com/offer/apoa2-humanized-transgenic-mouse-line-lambda/ [post_content] => The mice are hemizygous for the human apolipoprotein A2 (ApoA2) gene expressed under the control of the homologous promoter (-911/+2045). They are humanized because they are deficient in mouse ApoAII following backcrosses with APOA2 Knockout mice (KO-ApoA2 described in Weng W, Breslow JL.; PNAS, 1996). KO-ApoA2 mice have been fully backcrossed into the C57BL/6 background before mating with human ApoAII transgenic mice. ApoAII is expressed only in liver. Its plasma concentration is 70 mg/dl with chow diet (2.5 to 3 times the physiological concentration in humans), and increases up to 110 mg/dl with a high fat diet. In the fed state, mice present dyslipidemia (hypertriglyceridemia and low HDL) characteristic of the Metabolic Syndrome. Plasma HDL are decreased by 64% and triglyceride levels increased up to 20-fold, due to decreased VLDL catabolism (1, 2).In the fasted state, similar reduction in HDL, but normal or mildly increased plasma triglycerides; presence of VLDL-remnants (1). [post_date] => 2019-12-05 14:05:40 [post_modified] => 2024-09-11 16:06:39 [ID] => 4165 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cdad7682-c41b-43ef-bf60-71c3ac0d9711 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00434 [keywords] => ApoA2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Proof of concept in vivoUses:
• Nutritional disorderTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Athina-Despina KALOPISSIS [first_name] => Athina-Despina [last_name] => KALOPISSIS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 309 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Cardiovascular Diseases, In vivo studies, Metabolic Disorders, Nutritional disorder, Proof of concept in vivo [taxonomieurl] => Cardiovascular Diseases, In vivo studies, Metabolic Disorders, Nutritional disorder, Proof of concept in vivo ) [310] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD2 (clone 12E3.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-12e3-1/ [post_content] => [post_date] => 2019-12-05 14:05:37 [post_modified] => 2024-09-11 16:05:27 [ID] => 4162 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cd2c3a6d-d580-4762-9707-a28fb7a22f03 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00155 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 310 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [311] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat-anti TP53INP1, clone E12 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-tp53inp1-clone-e12/ [post_content] => The monoclonal antibody reacts with human and mouse TP53INP1 (both isoforms TP53INP1alpha and TP53INP1beta). TP53INP1 is a key stress factor endowed with a tumor suppressor activity as its transcriptional inducer p53. It is involved in the regulation of p53 activity, in the process of autophagy, and in the control of cell redox state. In human cancers, TP53INP1 is either down-regulated (pancreas, stomach) or overexpressed (thyroid, prostate). [post_date] => 2019-12-05 14:05:33 [post_modified] => 2024-09-11 16:05:25 [ID] => 4158 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => cc50f92e-f0cb-427f-bd1b-4de4f6bd7480 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00465 [keywords] => Tumor suppression ; Oxidative stress [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Alice CARRIER [first_name] => Alice [last_name] => CARRIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 311 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, ELISA (or compatible technique), Gastrointestinal Diseases, Genetic Disorders, Human, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Oncology, Rat [taxonomieurl] => Academic Research, Diagnostic, ELISA (or compatible technique), Gastrointestinal Diseases, Genetic Disorders, Human, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Oncology, Rat ) [312] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD80 (clone B7-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd80-clone-b7-1/ [post_content] => [post_date] => 2019-12-05 14:05:32 [post_modified] => 2024-09-11 16:05:25 [ID] => 4157 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ca33bab2-517a-45fa-b602-02a0fe49c035 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00236 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 312 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [313] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD112 (Nectin-2) clone R2.477.2 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd112-nectin-2-clone-r2-477-2/ [post_content] => [post_date] => 2019-12-05 14:05:30 [post_modified] => 2024-09-11 16:05:51 [ID] => 4155 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c969778b-e419-4955-a777-d95742749622 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00125 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc LOPEZ [first_name] => Marc [last_name] => LOPEZ [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 313 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [314] => stdClass Object ( [post] => stdClass Object ( [post_title] => Conditional TPM3-ALK transgenic mice [guid] => https://technology-offers.inserm-transfert.com/offer/conditional-tpm3-alk-transgenic-mice/ [post_content] => TPM3-ALK (Tropomyosin 3-Anaplastic lymphoma kinase) is oncogenic tyrosine kinase implicated in the pathogenesis of human ALK-positive lymphoma. We have developed novel conditional mouse models for ALK-induced lymphomagenesis, by using the tetracycline regulatory system under the control of the EmuSRalpha enhancer/promoter. The expression of oncogene resulted in the arrest of the differentiation of early B-cells and lymphomagenesis associated with skin keratoacanthoma lesions, likely due to aberrant ALK expression in keratinocytes. The inactivation of the ALK oncogene upon doxycycline or the specific ALK inhibitor (PF-2341066)treatment was sufficient to induce sustained regression of both hematopoietic tumors and skin disease, illustrating the value of these mouse models for the validation of ALK tyrosine kinase inhibitors. [post_date] => 2019-12-05 14:05:29 [post_modified] => 2024-09-11 16:06:42 [ID] => 4154 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c8e591fe-0c90-4940-be1f-032e0e8c176f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00401 [keywords] => ALK tyrosine kinase oncoprotein ; B-lymphoma ; skin hyperplasia ; targeted therapy ; lymphoma regression [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OncologyTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Fabienne MEGGETTO-PRADELLE [first_name] => Fabienne [last_name] => MEGGETTO-PRADELLE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 314 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Dermatology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Therapeutic [taxonomieurl] => Academic Research, Dermatology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Therapeutic ) [315] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F5-2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f5-2/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 412 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:05:27 [post_modified] => 2024-09-11 16:07:10 [ID] => 4152 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c7e79785-6983-4320-8725-6561dd80a5ca [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00431 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 315 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [316] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-erbin (clone RB 181) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-erbin-clone-rb-181/ [post_content] => [post_date] => 2019-12-05 14:05:26 [post_modified] => 2024-09-11 16:05:23 [ID] => 4151 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c7c16a38-7394-4027-b106-8a6d72a55575 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00046 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 316 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Immunoprecipitation, lgG1, Mouse, Oncology, Other [taxonomieurl] => Immunoprecipitation, lgG1, Mouse, Oncology, Other ) [317] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human transferrin receptor (clone YDJ9) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-transferrin-receptor-clone-ydj9/ [post_content] => [post_date] => 2019-12-05 14:05:25 [post_modified] => 2024-09-11 16:05:23 [ID] => 4150 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c7567a74-a454-4cc8-8d3a-d0d2e37fe51e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00076 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 317 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [318] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 314-1-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-314-1-1/ [post_content] => [post_date] => 2019-12-05 14:05:21 [post_modified] => 2024-09-11 16:05:22 [ID] => 4146 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c50cbd7a-cbb0-4ba3-9826-ff4db989890e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00292 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 318 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Other, Others, Western Blot [taxonomieurl] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Other, Others, Western Blot ) [319] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rabbit Polyclonal Anti-Human hCAF1 (CCR4- associated -factor) [guid] => https://technology-offers.inserm-transfert.com/offer/rabbit-polyclonal-anti-human-hcaf1-ccr4-associated-factor/ [post_content] => [post_date] => 2019-12-05 14:05:18 [post_modified] => 2024-09-11 16:05:20 [ID] => 4143 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => c26a2712-16d1-4df8-a7aa-8b01df04c77a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00285 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Muriel LE ROMANCER-CHERIFI [first_name] => Muriel [last_name] => LE ROMANCER-CHERIFI [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 319 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Other, Others, Rabbit, Western Blot [taxonomieurl] => Academic Research, Human, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Other, Others, Rabbit, Western Blot ) [320] => stdClass Object ( [post] => stdClass Object ( [post_title] => GFP-tagged mucin-reporter mouse model [guid] => https://technology-offers.inserm-transfert.com/offer/mucin-reporter/ [post_content] => To follow a gel-forming mucin production, we tagged with a GFP variant a mouse mucin gene. This reporter mouse allow also to follow goblet cell number producing the mucin. [post_date] => 2019-12-05 14:05:17 [post_modified] => 2024-09-11 16:06:48 [ID] => 4141 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bf8b40cc-e0fe-458e-a420-2854493d42a5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00480 [keywords] => mucus ; mucin ; eye ; vagina ; middle hear [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc DESSEYN [first_name] => Jean-Luc [last_name] => DESSEYN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 320 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Therapeutic [taxonomieurl] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Therapeutic ) [321] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD2 (clone 19E3.6.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-19e3-6-1/ [post_content] => [post_date] => 2019-12-05 14:05:15 [post_modified] => 2024-09-11 16:05:19 [ID] => 4140 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bd6ec7ea-4a50-45af-8772-39bb4e87a80d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00157 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 321 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Other, Rat [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Other, Rat ) [322] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD44 (clone 8B2.5) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd44-clone-8b2-5/ [post_content] => [post_date] => 2019-12-05 14:05:10 [post_modified] => 2024-09-11 16:05:16 [ID] => 4135 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => bb3c33cb-6a86-4b4b-9756-54a025419cb3 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00202 [keywords] => CD44 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 322 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [323] => stdClass Object ( [post] => stdClass Object ( [post_title] => TSSP-deficient mice, a model to identify new essential diabetogenic antigens [guid] => https://technology-offers.inserm-transfert.com/offer/tssp-deficient-mice-a-model-to-identify-new-essential-diabetogenic-antigens/ [post_content] => TSSP is a novel protease suspected to edit the peptide repertoire presented by MHC class II molecules in the thymus. Prss16, the gene coding for TSSP is linked to a diabetes susceptibility locus in Human.We found that TSSP-deficient NOD mice are fully protected from spontaneous diabetes and severe insulitis. Disease resistance is due to the intra-thymic deletion of some, yet to characterize, diabetogenic CD4 T cells. Collectively our results show that in the thymus, TSSP prevents the presentation of some self-antigens and consequently impairs central tolerance induction to some self antigens. [post_date] => 2019-12-05 14:05:06 [post_modified] => 2024-09-11 16:06:56 [ID] => 4131 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b2c729e4-df3b-4ae7-be36-00235ff5d3aa [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00435 [keywords] => autoimmunity ; type 1 diabetes ; tolerance ; immunotherapy ; mouse model [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Sylvie GUERDER [first_name] => Sylvie [last_name] => GUERDER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 323 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...) [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...) ) [324] => stdClass Object ( [post] => stdClass Object ( [post_title] => Conditional bioluminescent TMP3-ALK cell line [guid] => https://technology-offers.inserm-transfert.com/offer/conditional-bioluminescent-tmp3-alk-cell-line/ [post_content] => Overexpression and activation of TMP3-ALK tyrosine kinase fusion protein is a causal oncogenic event in the development of Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic ALK-positive tumors. Thus, the development of ALK specific tyrosine kinase inhibitors is a current therapeutic challenge. Animal models are essential to assess, in vivo, the efficiency of ALK-oncogene inhibitors and to identify new and/or additional therapeutic targets in the ALK tumorigenesis pathway. Using the tertracyclin system to allow conditional and concomitant TMP3-ALK and luciferase expression, we have developed a unique transplant model for bioluminescent TMP3-ALK-induced fibroblastic tumors in athymic nude mice. The reversible TPM3-ALK expression allowed us to demonstrate that this oncogene is essential for the tumor growth and its maintenance. In addition, we showed that this model could be used to precisely assess tumor growth inhibition upon ALK chemical inactivation. As proof of principle, we used the general tyrosine kinase inhibitor herbimycin A to inhibit ALK oncoprotein activity. This transplant model for TPM3-ALK-induced tumors represents a valuable tool not only to accurately and rapidly evaluate in vivo ALK-targeted therapies but also to gain insight into the mechanism of ALK-positive tumor development. [post_date] => 2019-12-05 14:05:06 [post_modified] => 2024-09-11 16:07:27 [ID] => 4130 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b2b84ca1-f547-4d3c-bb2c-367087617cad [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00433 [keywords] => ALK tyrosine kinase oncogenesis ; bioluminescence imaging ; tetracycline system ; tumour regression ; targeted therapy [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Fabienne MEGGETTO-PRADELLE [first_name] => Fabienne [last_name] => MEGGETTO-PRADELLE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 324 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others ) [325] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human Antigens H and Y (red blood cell-related) (clone BNH.9) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-antigens-h-and-y-red-blood-cell-related-clone-bnh-9/ [post_content] => [post_date] => 2019-12-05 14:05:05 [post_modified] => 2024-09-11 16:05:14 [ID] => 4129 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b1db40bf-29b0-4a6b-8366-b241aeea0213 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00022 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 325 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse [taxonomieurl] => Academic Research, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse ) [326] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD11b (clone FN2H3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd11b-clone-fn2h3/ [post_content] => [post_date] => 2019-12-05 14:05:04 [post_modified] => 2024-09-11 16:06:31 [ID] => 4128 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b16f3af2-28cc-4dd1-ac92-43c04c2955de [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00134 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 326 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [327] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human LAT (Linker for Activation of T cells) (clone LAT. 10-17) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-lat-linker-for-activation-of-t-cells-clone-lat-10-17/ [post_content] => - This antibody recognizes the LAT-adaptor protein expressed on T-cells, mast cells and megacaryocytes.- Suitable for use on paraffin sections [post_date] => 2019-12-05 14:04:59 [post_modified] => 2024-09-11 16:05:04 [ID] => 4125 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => b003c2ef-db88-4f37-b2ce-692d56e5dbe7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00389 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 327 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunology, lgG1, Mouse, Oncology, Western Blot [taxonomieurl] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunology, lgG1, Mouse, Oncology, Western Blot ) [328] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti mouse CCL5 monoclonal antibody (clone 2E9) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-mouse-ccl5-monoclonal-antibody-clone-2e9/ [post_content] => Mouse monoclonal antibody directed against mouse CCL5. Antibody was produced by immunising CCL5 KO mice with recombinant CCL5. [post_date] => 2019-12-05 14:04:58 [post_modified] => 2024-09-11 16:06:00 [ID] => 4124 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => afcd9051-1fea-4804-81ac-f584390aa2ee [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00320 [keywords] => CCL5, cytokines [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jacqueline MARVEL [first_name] => Jacqueline [last_name] => MARVEL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 328 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, lgG2b, Mouse, Mouse, Oncology, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, lgG2b, Mouse, Mouse, Oncology, Western Blot ) [329] => stdClass Object ( [post] => stdClass Object ( [post_title] => Selective antiestrogen binding site (AEBS) ligands in the diphenyl methane series [guid] => https://technology-offers.inserm-transfert.com/offer/selective-antiestrogen-binding-site-aebs-ligands-in-the-diphenyl-methane-series/ [post_content] => We can offer and produce selective AEBS lignads for research purpose only.These compounds are potent inducers of breast cancer cell differentiation and death [post_date] => 2019-12-05 14:04:56 [post_modified] => 2024-09-11 16:07:16 [ID] => 4122 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => af52d458-566e-473d-93b5-d6be7a470fde [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00455 [keywords] => AEBS ; sterol ; oxysterol ; apoptosis ; autophagy [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Others [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OncologyTherapy Area:
• OthersType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc POIROT [first_name] => Marc [last_name] => POIROT [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 329 [terms] => Array ( [0] => Others ) [taxonomie] => Academic Research, Oncology, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Oncology, Proof of concept in vitro, Therapeutic ) [330] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human FcgRIIA/B (CD32 clone 6C4) [guid] => https://technology-offers.inserm-transfert.com/offer/human-fcgriia-b-cd32-clone-6c4/ [post_content] => [post_date] => 2019-12-05 14:04:54 [post_modified] => 2024-09-11 16:06:10 [ID] => 4119 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => add97158-1f27-4490-9237-44c75da46d42 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00323 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 330 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology ) [331] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone B9.7) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-b9-7/ [post_content] => [post_date] => 2019-12-05 14:04:53 [post_modified] => 2024-09-11 16:05:11 [ID] => 4118 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => add8e971-8618-4bd4-9235-4957ad1d2e88 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00228 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 331 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [332] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M3-1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m3-1/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 265 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:04:51 [post_modified] => 2024-09-11 16:07:14 [ID] => 4116 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => acf1b863-1e08-45c3-b23e-63eb2f4947d0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00428 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 332 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [333] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD52 (clone O97) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd52-clone-o97/ [post_content] => [post_date] => 2019-12-05 14:04:50 [post_modified] => 2024-09-11 16:05:54 [ID] => 4115 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ace97d62-958e-403c-8d5e-21290385cc71 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00211 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Laurence BOUMSELL [first_name] => Laurence [last_name] => BOUMSELL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 333 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [334] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD245 (clone DY12) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd245-clone-dy12/ [post_content] => [post_date] => 2019-12-05 14:04:49 [post_modified] => 2024-09-11 16:06:02 [ID] => 4114 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => acd4df47-8cbd-4189-bc55-8c80995b217e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00169 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 334 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [335] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD151 (clone TS151r) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd151-clone-ts151r/ [post_content] => Recognizes CD151 not associated with integrins. [post_date] => 2019-12-05 14:04:48 [post_modified] => 2024-09-11 16:05:25 [ID] => 4112 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ac614853-24b7-48f3-bf5e-30ec8d9357fc [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00138 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 335 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [336] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD55 (clone JS11) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd55-clone-js11/ [post_content] => [post_date] => 2019-12-05 14:04:46 [post_modified] => 2024-09-11 16:05:07 [ID] => 4111 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ac5be608-5193-4114-8fd1-5662b58d9eda [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00213 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 336 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [337] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD90 (Mouse Thy-1, monomorphic) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd90-mouse-thy-1-monomorphic-several-clones/ [post_content] => A collection of rat monoclonal antibodies recognizing monomorphic determinants of the mouse Thy-1 moecule (CD90) located in two spatially distinct epitope regions:Epitope B : H154-161 (IgG2c) ; H154-190, H154-11 (IgM) ; H140-61, H140-150 (IgG2b)Epitope C : H154-236, H154-57, H155-124, H154-262 (IgG2c), H154-177, H154-200 (IgG2b) [post_date] => 2019-12-05 14:04:43 [post_modified] => 2024-09-11 16:05:08 [ID] => 4108 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => abd11167-539f-4945-9eb8-904f5a02099d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00354 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 337 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat [taxonomieurl] => Academic Research, Central Nervous System, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat ) [338] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD1a (clone L404) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1a-clone-l404/ [post_content] => [post_date] => 2019-12-05 14:04:42 [post_modified] => 2024-09-11 16:05:07 [ID] => 4107 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => ab6727e2-1952-4d56-88fd-b55dcf98d3e5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00149 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 338 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [339] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Rat FCeRIß (high-affinity IgE receptor subunit) clone 30.9 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-rat-fceris-high-affinity-ige-receptor-subunit-clone-30-9/ [post_content] => [post_date] => 2019-12-05 14:04:42 [post_modified] => 2024-09-11 16:05:53 [ID] => 4106 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a939f605-4d41-420d-91fc-596cc7e2c994 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00108 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc BENHAMOU [first_name] => Marc [last_name] => BENHAMOU [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 339 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Other [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Other ) [340] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat-anti TP53INP1, clone F8 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-tp53inp1-clone-f8/ [post_content] => The monoclonal antibody reacts with human and mouse TP53INP1 (both isoforms TP53INP1alphau0192nand TP53INP1beta). TP53INP1 is a key stress factor endowed with a tumor suppressor activity as its transcriptional inducer p53. It is involved in the regulation of p53 activity, in the process of autophagy, and in the control of cell redox state. In human cancers, TP53INP1 is either down-regulated (pancreas, stomach) or overexpressed (thyroid, prostate). [post_date] => 2019-12-05 14:04:39 [post_modified] => 2024-09-11 16:05:52 [ID] => 4104 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a88221fe-1447-4c05-9400-c2f36639a0ba [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00466 [keywords] => Tumor suppression ; Oxidative stress [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Alice CARRIER [first_name] => Alice [last_name] => CARRIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 340 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, ELISA (or compatible technique), Gastrointestinal Diseases, Genetic Disorders, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Oncology, Rat, Western Blot [taxonomieurl] => Academic Research, Diagnostic, ELISA (or compatible technique), Gastrointestinal Diseases, Genetic Disorders, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Oncology, Rat, Western Blot ) [341] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M3-2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m3-2/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 263 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:04:39 [post_modified] => 2024-09-11 16:07:14 [ID] => 4103 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a853579a-f8be-4961-ab54-6dafeb27a4a5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00429 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 341 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [342] => stdClass Object ( [post] => stdClass Object ( [post_title] => Highly differentiated human hepatocytes in primary culture [guid] => https://technology-offers.inserm-transfert.com/offer/highly-differentiated-human-hepatocytes-in-primary-culture/ [post_content] => Hepatocytes are isolated from human liver and cultured in a system that allows to maintain a highly differentiated phenotype for several weeks.In these conditions, hepatocytes are sensitive to hepatitis C virus infection and permissive to viral genome replication. [post_date] => 2019-12-05 14:04:36 [post_modified] => 2024-09-11 16:07:07 [ID] => 4101 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a769a480-00c1-4140-a068-7cd4cb0a0ee4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00321 [keywords] => hepatocyte; drug metabolism; HCV [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OncologyTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick MAUREL [first_name] => Patrick [last_name] => MAUREL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 342 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Oncology, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Oncology, Therapeutic ) [343] => stdClass Object ( [post] => stdClass Object ( [post_title] => Anti-KIAA0753 rat monoclonal antibody 17D4 [guid] => https://technology-offers.inserm-transfert.com/offer/anti-kiaa0753-rat-monoclonal-antibody-17d4/ [post_content] => This antibody recognizes the human KIAA0753 protein (also named OFIP or MNR). The epitope is located at the carboxy terminus of the protein, between residues 885 and 967. It detects endogenous KIAA0753 in various cell lines using immunoblot and immunofluorescence techniques. [post_date] => 2019-12-05 14:04:35 [post_modified] => 2024-09-11 16:05:06 [ID] => 4100 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a7092b69-f381-d2b9-8634-5b893f09006e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00504 [keywords] => Cilia ; Centrosome ; Ciliopathy ; Microtubule [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Theranostic (patients stratification, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Olivier ROSNET [first_name] => Olivier [last_name] => ROSNET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 343 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Genetic Disorders, Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Others, Rat, Theranostic (patients stratification, ...), Western Blot [taxonomieurl] => Academic Research, Diagnostic, Genetic Disorders, Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Others, Rat, Theranostic (patients stratification, ...), Western Blot ) [344] => stdClass Object ( [post] => stdClass Object ( [post_title] => ApoA2 humanized transgenic mouse - line beta [guid] => https://technology-offers.inserm-transfert.com/offer/apoa2-humanized-transgenic-mouse-line-beta/ [post_content] => The mice are hemizygous for the human apolipoprotein A2 (ApoA2) gene expressed under the control of the homologous promoter (-911/+2045). They are humanized because they are deficient in mouse ApoAII following backcrosses with APOA2 Knockout mice (KO-ApoA2 described in ref. 1). KO-ApoA2 mice have been fully backcrossed into the C57BL/6 background before mating with human ApoAII transgenic mice. ApoAII is expressed only in liver. Its plasma concentration is 20-30 mg/dl with chow diet (physiological concentration in humans), and increases up to 50 mg/dl with a high fat diet. Mice present with normal plasma HDL levels and normal lipoprotein profile in the fed and fasted states (2). [post_date] => 2019-12-05 14:04:32 [post_modified] => 2024-09-11 16:06:38 [ID] => 4096 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a3b8799f-2459-480b-be4f-a7c9ffedd514 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00403 [keywords] => ApoA2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Nutritional disorderTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Athina-Despina KALOPISSIS [first_name] => Athina-Despina [last_name] => KALOPISSIS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 344 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Cardiovascular Diseases, In vivo studies, Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Cardiovascular Diseases, In vivo studies, Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic ) [345] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD25 (clone 27E4.6) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd25-clone-27e4-6/ [post_content] => [post_date] => 2019-12-05 14:04:29 [post_modified] => 2024-09-11 16:05:02 [ID] => 4093 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a2d0ff5e-efd2-472d-bf6e-9670db7ef2e5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00173 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 345 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [346] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F2-0 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f2-0/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 347 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:04:28 [post_modified] => 2024-09-11 16:07:05 [ID] => 4092 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => a1d9e69d-23ec-4618-b9ba-bfcb4fd11590 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00410 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 346 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [347] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 233-1-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-233-1-1/ [post_content] => [post_date] => 2019-12-05 14:04:23 [post_modified] => 2024-09-11 16:05:00 [ID] => 4087 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9f628f21-acb9-4fda-8a17-d9f1c8fa299d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00296 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 347 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others ) [348] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD1a (clone 10D12.2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1a-clone-10d12-2/ [post_content] => [post_date] => 2019-12-05 14:04:23 [post_modified] => 2024-09-11 16:05:00 [ID] => 4086 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9f5b4df9-eb7f-46cc-acbb-196a3541bd7b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00145 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 348 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [349] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rabbit polyclonal Anti-VGLUT3 serum [guid] => https://technology-offers.inserm-transfert.com/offer/rabbit-polyclonal-anti-vglut3-serum/ [post_content] => [post_date] => 2019-12-05 14:04:20 [post_modified] => 2024-09-11 16:04:58 [ID] => 4083 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9da71efa-45fb-4364-bd9a-72f25459f567 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00080 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bruno GIROS [first_name] => Bruno [last_name] => GIROS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 349 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Rabbit [taxonomieurl] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Rabbit ) [350] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD11a/CD18 (Mouse LFA-1 alpha/beta conformational determinants) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd11a-cd18-mouse-lfa-1-alpha-beta-conformational-determinants-several-clones/ [post_content] => Two rat monoclonal anti-mouse LFA-1 recognizing two spatially distinct conformational determinants, the expression of which requires the CD11a/CD18 subunits pairing. Epitope B : H154-266 (IgG2a) ; Epitope E : H155-78 (IgG1) [post_date] => 2019-12-05 14:04:18 [post_modified] => 2024-09-11 16:05:23 [ID] => 4081 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9cdb20f6-3d7c-405c-9b57-da5958f62587 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00356 [keywords] => mouse LFA-1 ; CD11a/CD18 ; Activating anti-LFA-1 monoclonal ; Marker of immune synapse [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 350 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Proof of concept in vitro, Rat [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Proof of concept in vitro, Rat ) [351] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD1b (clone 4A7.6.5) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1b-clone-4a7-6-5/ [post_content] => [post_date] => 2019-12-05 14:04:13 [post_modified] => 2024-09-11 16:04:56 [ID] => 4077 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9b53dedd-f827-4bcc-8858-33c8ce66283f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00151 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 351 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [352] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human Interferon -g (IFNg) (clone 29.12C10) [guid] => [post_content] => sandwich ELISA, ELISPOT [post_date] => 2019-12-05 14:02:32 [post_modified] => 2024-09-11 16:04:56 [ID] => 4076 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9b42a6ad-bd78-41c6-b322-f0e5f4a85a57 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00330 [keywords] => IFNg; Interferon [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 352 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [353] => stdClass Object ( [post] => stdClass Object ( [post_title] => High-throughput screening for small psycho-active molecules in zebrafish embryos [guid] => https://technology-offers.inserm-transfert.com/offer/high-throughput-screening-for-small-psycho-active-molecules-in-zebrafish-embryos/ [post_content] => Here, we describe a simple, behaviour-based approach to identify in vivo novel psycho-active molecules in zebrafish embryos. Using an automated behaviour recording system, we have developed a protocol that makes it possible to distil drug-induced behaviour changes into a series of quantifiable parameters, which allow inferring the psycho-activity of tested molecules. [post_date] => 2019-12-05 14:02:31 [post_modified] => 2024-09-11 16:07:16 [ID] => 4075 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9ac3544e-ab40-405f-aa22-3b281dbae0b0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00406 [keywords] => Zebrafish ; Small molecules ; Psycho-active molecule ; High-throughput in vivo screening ; Vertebrate model [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Others [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• OthersType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Nadia SOUSSI-YANICOSTAS [first_name] => Nadia [last_name] => SOUSSI-YANICOSTAS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 353 [terms] => Array ( [0] => Others ) [taxonomie] => Academic Research, Central Nervous System, In vivo studies, Others, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Central Nervous System, In vivo studies, Others, Proof of concept in vivo, Therapeutic ) [354] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD3 (clone IP8) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd3-clone-ip8/ [post_content] => [post_date] => 2019-12-05 14:02:30 [post_modified] => 2024-09-11 16:04:55 [ID] => 4074 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 9a3e9bbb-a276-4840-890b-da5d03a3db51 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00190 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 354 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [355] => stdClass Object ( [post] => stdClass Object ( [post_title] => Nomenclature of rare diseases, including all genetic diseases [guid] => https://technology-offers.inserm-transfert.com/offer/nomenclature-of-rare-diseases-including-all-genetic-diseases/ [post_content] => Comprehensive inventory of 5,000 rare diseases, indexed with ICD10, OMIM, genes (HGNC nomenclature), swissprot, genatlas, class of prevalence, class of age of onset, class of age of death, mode of inheritance, clinical signs, all published classifications, description in 250 words in five languages (English, French, Italian, German, Spanish)You also may find the products catalogs of this Institute at :http://www.orphadata.org/cgi-bin/docs/CataloguePdt-Industry.pdfhttp://www.orphadata.org/cgi-bin/docs/CataloguePdt-Academia.pdf [post_date] => 2019-12-05 14:02:29 [post_modified] => 2024-09-04 13:45:17 [ID] => 4073 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 99616c44-6fdb-48c8-9583-605195716eaf [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00310 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Others [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Genetic DisordersTherapy Area:
• OthersType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Natalia MARTIN [first_name] => Natalia [last_name] => MARTIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 355 [terms] => Array ( [0] => Others ) [taxonomie] => Academic Research, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...) [taxonomieurl] => Academic Research, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...) ) [356] => stdClass Object ( [post] => stdClass Object ( [post_title] => Labeled mouse Escherichia coli (GFP or DSRed) [guid] => https://technology-offers.inserm-transfert.com/offer/labeled-mouse-escherichia-coli-gfp-or-dsred/ [post_content] => An E. coli was isolated from the mouse feces and transformed with a plasmid expressing either the GFP or the DSRed under an E coli specific promoter. this bacteria can be followed into the body and DSRed labelled bacteria can be sorted by FACS analysis [post_date] => 2019-12-05 14:02:28 [post_modified] => 2024-09-11 16:07:12 [ID] => 4071 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 96e8ffe0-47a3-4cfd-aaac-783d78e7ad22 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00463 [keywords] => Bacterial translocation ; Intestinal permeability ; Inflammation ; Phagocytosis ; Biomarkers [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Biosamples [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• Nutritional disorderTherapy Area:
• BiosamplesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Rémy BURCELIN [first_name] => Rémy [last_name] => BURCELIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 356 [terms] => Array ( [0] => Biosamples ) [taxonomie] => Academic Research, Diagnostic, Gastrointestinal Diseases, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vitro, Proof of concept in vivo [taxonomieurl] => Academic Research, Diagnostic, Gastrointestinal Diseases, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vitro, Proof of concept in vivo ) [357] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD316/EWI-2 (clone 8A12) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd316-ewi-2-clone-8a12/ [post_content] => Clone 8A12 is the only published mAb to CD316. [post_date] => 2019-12-05 14:02:25 [post_modified] => 2024-09-11 16:05:51 [ID] => 4069 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 967ed2cd-716a-4077-8b29-fb37d9eb8e08 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00194 [keywords] => CD316 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 357 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot ) [358] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD30 (clone BY88) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd30-clone-by88/ [post_content] => [post_date] => 2019-12-05 14:02:21 [post_modified] => 2024-09-11 16:06:05 [ID] => 4065 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 94f68728-19dc-4b7b-b4f9-98ea1f735318 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00191 [keywords] => CD30 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 358 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [359] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human plasminogen kringle 1 (clone CPL-15) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-plasminogen-kringle-1-clone-cpl-15/ [post_content] => [post_date] => 2019-12-05 14:02:19 [post_modified] => 2024-09-11 16:04:52 [ID] => 4062 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 93ee9987-82db-4a22-b7f7-6b9c0ccf75f1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00023 [keywords] => Fibrinolysis; plasmin; kringle 1 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eduardo ANGLES-CANO [first_name] => Eduardo [last_name] => ANGLES-CANO [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 359 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [360] => stdClass Object ( [post] => stdClass Object ( [post_title] => RBL-2H3 Rat mast cell line : In vitro degranulation assay for evaluation of IgE-reactivity towards environmental allergens in allergic patient serum [guid] => https://technology-offers.inserm-transfert.com/offer/rbl-2h3-rat-mast-cell-line-in-vitro-degranulation-assay-for-evaluation-of-ige-reactivity-towards-environmental-allergens-in-allergic-patient-serum/ [post_content] => Rat mast cell line (RBL-2H3) transfected with the cDNAs encoding the three subunits (alpha, beta, gamma) of the human high affinity IgE receptor. The transfected cell line binds human IgE, which does not bind to rodent receptor. It enablesto perform degranulation assays with serum from allergic patients for its reactivity towards environmental allergens. [post_date] => 2019-12-05 14:02:17 [post_modified] => 2024-08-28 12:24:41 [ID] => 4060 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 92f8901c-0d1c-407a-a33d-3e3b138da816 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00394 [keywords] => allergy ; mast cell ; human IgE [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Ulrich BLANK [first_name] => Ulrich [last_name] => BLANK [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 360 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), Others, Proof of concept in vitro [taxonomieurl] => Academic Research, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), Others, Proof of concept in vitro ) [361] => stdClass Object ( [post] => stdClass Object ( [post_title] => hu-UCP3 transgenic mice (moderate overexpr.) resistant to high fat-induced obesity [guid] => https://technology-offers.inserm-transfert.com/offer/transgenic-mice-with-human-ucp3-moderate-overexpression-show-resistance-to-high-fat-induced-obesity/ [post_content] => Uncoupling protein (UCP) 3 is a mitochondrial inner membrane protein expressed predominantly in glycolytic skeletal muscles.Transgenic mice were created with a 16 kb region encompassing the human UCP3 gene. Changes in body weight, adiposity and glucose or insulin tolerance were assessed in mice fed chow and high-fat diets. Mitochondrial uncoupling was investigated on permeabilised muscle fibres. Indirect calorimetry was used to determine whole-body energy expenditure and substrate utilisation. [post_date] => 2019-12-05 14:02:16 [post_modified] => 2024-09-11 16:06:54 [ID] => 4059 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 92d1f826-3a67-46ac-bd4a-8b768bd1d95b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00452 [keywords] => Obesity ; uncoupling protein ; glucose tolerance ; skeletal muscle ; sexual dimorphism [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Nutritional disorderTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Geneviève TAVERNIER [first_name] => Geneviève [last_name] => TAVERNIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 361 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Musculoskeletal, Nutritional disorder [taxonomieurl] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Musculoskeletal, Nutritional disorder ) [362] => stdClass Object ( [post] => stdClass Object ( [post_title] => ApoA2 humanized transgenic mouse - line delta [guid] => https://technology-offers.inserm-transfert.com/offer/apoa2-humanized-transgenic-mouse-line-delta/ [post_content] => The mice are hemizygous for the human apolipoprotein A2 (ApoA2) gene expressed under the control of the homologous promoter (-911/+2045). They are humanized because they are deficient in mouse ApoAII following backcrosses with APOA2 Knockout mice (KO-ApoA2 described in ref. 1). KO-ApoA2 mice have been fully backcrossed into the C57BL/6 background before mating with human ApoAII transgenic mice. ApoAII is expressed only in liver. Its plasma concentration is 50 mg/dl with chow diet (1.5 to 2 times the physiological concentration in humans), and increases up to 70 mg/dl with a high fat diet.In the fed state, plasma HDL levels are decreased by 45% (compared to C57BL/6 mice) and triglycerides are increased up to 10-fold, due to decreased VLDL catabolism. In the fasted state, mice display a 34% reduction in HDL and normal triglyceridemia (2). [post_date] => 2019-12-05 14:02:14 [post_modified] => 2024-09-11 16:06:39 [ID] => 4057 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 911111e3-b9fe-4bec-a852-549e0acc3cfc [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00423 [keywords] => ApoA2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Nutritional disorderTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Athina-Despina KALOPISSIS [first_name] => Athina-Despina [last_name] => KALOPISSIS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 362 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Cardiovascular Diseases, In vivo studies, Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Cardiovascular Diseases, In vivo studies, Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic ) [363] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD28 (clone CD28.1.25.6) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd28-clone-cd28-1-25-6/ [post_content] => [post_date] => 2019-12-05 14:02:13 [post_modified] => 2024-09-11 16:05:43 [ID] => 4056 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 905bd890-1814-43a6-944c-16a1b682fdb7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00186 [keywords] => CD28 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 363 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [364] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human melanoma associated Antigen (clone KBA.62) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-melanoma-associated-antigen-clone-kba-62/ [post_content] => - Anti-melanoma associated antigen reactive on paraffin sections.- KBA.62 is useful in ascertaining the immunomorphological diagnosis of malignant melanoma in routinely processed paraffin sections.- Staining is localised predominantly to the cell membrane with little or no cytoplasmic reactivity. Negative staining is observed in the majority of human non-melanocytic neoplasms. [post_date] => 2019-12-05 14:02:12 [post_modified] => 2024-09-11 16:05:21 [ID] => 4055 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8f153ebf-2a34-4249-bd59-d4473eccd24c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00385 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 364 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Human, lgG2a, Mouse, Oncology, Others [taxonomieurl] => Academic Research, Diagnostic, Human, lgG2a, Mouse, Oncology, Others ) [365] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rabbit polyclonal Anti-phospho-NCF1/p47Phox (Ser345) antibody [guid] => https://technology-offers.inserm-transfert.com/offer/detection-of-nadph-oxidase-hyperactivation-by-the-rabbit-anti-human-phospho-ser345-antibody/ [post_content] => Detection of NADPH oxidase hyperactivation by the Rabbit anti-Human phospho-NCF1/p47Phox (phospho-Ser345) antibody [post_date] => 2019-12-05 14:02:06 [post_modified] => 2024-09-11 16:05:51 [ID] => 4050 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8b74b94d-49b5-4a98-b88d-89ae7373eb68 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00001 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jamel EL BENNA [first_name] => Jamel [last_name] => EL BENNA [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 365 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Rabbit, Western Blot [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Rabbit, Western Blot ) [366] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD5 (clone CBF.60) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd5-clone-cbf-60/ [post_content] => [post_date] => 2019-12-05 14:02:00 [post_modified] => 2024-09-11 16:04:50 [ID] => 4045 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8936487b-2df8-44b9-9862-73e4b88d7c56 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00116 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 366 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [367] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human TCR alpha, beta (clone IP26) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-tcr-alpha-beta-clone-ip26/ [post_content] => [post_date] => 2019-12-05 14:01:58 [post_modified] => 2024-09-11 16:05:13 [ID] => 4043 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 883becb2-8efc-4bfc-b434-28ec3e131d38 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00113 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 367 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [368] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD111 (Nectin-1) clone R1.302.12 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd111-nectin-1-clone-r1-302-12/ [post_content] => Nectin-1 Cross reactive with monkey, not with rat and mouse [post_date] => 2019-12-05 14:01:57 [post_modified] => 2024-09-11 16:05:26 [ID] => 4042 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8740f936-ad0c-4b09-aac3-988739d0eb31 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00124 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc LOPEZ [first_name] => Marc [last_name] => LOPEZ [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 368 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [369] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 8-1-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-8-1-1/ [post_content] => [post_date] => 2019-12-05 14:01:57 [post_modified] => 2024-09-11 16:04:49 [ID] => 4041 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 873a62c9-b308-4594-b604-62671f3d32c5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00288 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 369 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others, Western Blot [taxonomieurl] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others, Western Blot ) [370] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD16 (clone CRET 16) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd16-clone-cret-16/ [post_content] => [post_date] => 2019-12-05 14:01:56 [post_modified] => 2024-09-11 16:05:37 [ID] => 4040 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 87177f6a-7f44-4475-8ce0-26734f494ff4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00139 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 370 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse ) [371] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human FcgRIIIA/B (clone 7.5.4) [guid] => https://technology-offers.inserm-transfert.com/offer/human-fcgriiia-b-clone-7-5-4/ [post_content] => [post_date] => 2019-12-05 14:01:55 [post_modified] => 2024-09-11 16:04:49 [ID] => 4039 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8695ff66-d2d8-4fb7-8264-6baad717f425 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00327 [keywords] => FcgRIIIA/B [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 371 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [372] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Mouse & anti-Rat CD90.1 (Mouse Thy-1.1) (clone H171-146) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-mouse-anti-rat-cd90-1-mouse-thy-1-1-clone-h171-146/ [post_content] => Monoclonal antibody raised in (A.TLxA.TH)F1 hybrid mouse (expressing the Thy-1b allele) immunized with T hybridoma cells [derived from BALB/c T cells (Thy-1b allele) fused with the BW5147 AKR thymoma (Thy-1a allele)]. [post_date] => 2019-12-05 14:01:54 [post_modified] => 2024-09-11 16:04:48 [ID] => 4038 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 862eeccf-25ed-4db9-9254-222241d23be0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00352 [keywords] => Thy-1.1 ; Mouse & rat ; activating MAb [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 372 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Proof of concept in vitro [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Proof of concept in vitro ) [373] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Mouse medullary epithelial cells (thymus) (clone H210-95) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-medullary-epithelial-cells-thymus-clone-h210-95/ [post_content] => [post_date] => 2019-12-05 14:01:51 [post_modified] => 2024-09-11 16:04:47 [ID] => 4035 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 8516c265-d2fd-41eb-b1a1-fe8cd0d06099 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00100 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 373 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse, Rat, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse, Rat, Western Blot ) [374] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human transferrin receptor (clone YDJ10) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-transferrin-receptor-clone-ydj10/ [post_content] => [post_date] => 2019-12-05 14:01:50 [post_modified] => 2024-09-11 16:04:47 [ID] => 4034 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 841dbf12-a16a-4036-8902-8b776a210579 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00077 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 374 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [375] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD45RA (clone DBB.42) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd45ra-clone-dbb-42/ [post_content] => This antibody reacts on paraffin sections with B-cells.It also reacts with large granular lymphocytes. [post_date] => 2019-12-05 14:01:49 [post_modified] => 2024-09-11 16:04:46 [ID] => 4033 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 836b4411-af11-4887-bca0-e14e91380746 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00391 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 375 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Human, Immunofluorescence, Immunology, lgG1, Mouse, Oncology, Western Blot [taxonomieurl] => Academic Research, Diagnostic, Human, Immunofluorescence, Immunology, lgG1, Mouse, Oncology, Western Blot ) [376] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD99 & Anti-CD99R (clone O662) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd99-anti-cd99r-clone-o662/ [post_content] => [post_date] => 2019-12-05 14:01:48 [post_modified] => 2024-09-11 16:05:40 [ID] => 4032 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 82ef201d-9559-4679-aeda-cde01ce075d8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00244 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 376 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [377] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD8 a (clone 21C11.5) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd8-a-clone-21c11-5/ [post_content] => [post_date] => 2019-12-05 14:01:47 [post_modified] => 2024-09-11 16:04:46 [ID] => 4031 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 82886559-482c-478d-9d0c-f9dd57336bd8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00233 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 377 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [378] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F1-1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f1-1/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 292 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:01:45 [post_modified] => 2024-09-11 16:07:04 [ID] => 4030 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 827f2fa3-78b8-4f04-afef-79ffd6a17bf1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00407 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 378 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [379] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD113 (Nectin-3) clone N3.81.6 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd113-nectin-3-clone-n3-81-6/ [post_content] => [post_date] => 2019-12-05 14:01:44 [post_modified] => 2024-09-11 16:05:45 [ID] => 4029 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 822fccab-a0ba-4cb8-a82d-7d33d625b19e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00129 [keywords] => CD113; Nectin-3 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc LOPEZ [first_name] => Marc [last_name] => LOPEZ [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 379 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse ) [380] => stdClass Object ( [post] => stdClass Object ( [post_title] => EX VIVO CULTURE SYSTEM FOR SCREENING COMPOUNDS TARGETING LEUKAEMIA-INITIATING CELLS [guid] => https://technology-offers.inserm-transfert.com/offer/ex-vivo-culture-system-for-screening-compounds-targeting-leukaemia-initiating-cells/ [post_content] => A novel, ex vivo niche-based hypoxic culture system for maintaining Leukaemia Initiating Cells (LICs) from patients and an associated method to quantify their dynamics. [post_date] => 2019-12-05 14:01:43 [post_modified] => 2024-09-11 16:07:07 [ID] => 4028 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 81f97f51-0d8a-4422-b11a-831acc25d40a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00483 [keywords] => Leukaemia Initiating Cells (LICs) ; Acute Myeloid Leukaemia (AML) ; Stem cells Niche ; Self-renewal [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Emmanuel GRIESSINGER [first_name] => Emmanuel [last_name] => GRIESSINGER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 380 [terms] => Array ( [0] => Know How ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [381] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD59 (clone P282) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd59-clone-p282/ [post_content] => [post_date] => 2019-12-05 14:01:42 [post_modified] => 2024-09-11 16:05:06 [ID] => 4027 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 81752e4d-31f0-4262-b346-bfb1debcd21e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00215 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 381 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [382] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD106 (clone STA) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd106-clone-sta/ [post_content] => [post_date] => 2019-12-05 14:01:39 [post_modified] => 2024-09-11 16:05:07 [ID] => 4023 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 800b8026-763f-495c-8a92-9ac44a7b4e88 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00123 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 382 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [383] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD7 (clone 1I21) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd7-clone-1i21/ [post_content] => [post_date] => 2019-12-05 14:01:36 [post_modified] => 2024-09-11 16:04:45 [ID] => 4021 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7f485b01-7f5d-4b89-aa30-e5c3c61a8713 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00220 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 383 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [384] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD24 (Mouse, P31) (clones H193-4 ; H194-563) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd24-mouse-p31-clones-h193-4-h194-563/ [post_content] => Rat monoclonal antibody recognizing a glycosyl-phosphatidylinositol-anchored glycoconjugate of 28-33 kDa (P31) expressed in developing mouse brain. [post_date] => 2019-12-05 14:01:34 [post_modified] => 2024-09-11 16:04:44 [ID] => 4019 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7f1cb207-6c7a-43de-86ba-2956b4f55444 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00345 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 384 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Proof of concept in vitro, Rat [taxonomieurl] => Academic Research, Central Nervous System, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Proof of concept in vitro, Rat ) [385] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 214-1-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-214-1-1/ [post_content] => [post_date] => 2019-12-05 14:01:30 [post_modified] => 2024-09-11 16:04:42 [ID] => 4014 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7cd75dcb-7ea6-4cbc-9b21-c97604f39b14 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00297 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 385 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot ) [386] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human HOX11L2/TLX3 (clones 34H9 & 10A5) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-hox11l2-tlx3-clones-34h9-10a5/ [post_content] => Mouse monoclonal antibodies recognizing the Hox11L2 gene product. [post_date] => 2019-12-05 14:01:29 [post_modified] => 2024-09-11 16:04:41 [ID] => 4013 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7cbb8070-f433-49d5-b594-76ddd166d023 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00363 [keywords] => human T-ALL ; oncogene ; HOX11L2/TLX3 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Theranostic (patients stratification, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Pierre FERRIER [first_name] => Pierre [last_name] => FERRIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 386 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, lgG1, Mouse, Proof of concept in vitro, Proof of concept in vivo, Theranostic (patients stratification, ...), Western Blot [taxonomieurl] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, lgG1, Mouse, Proof of concept in vitro, Proof of concept in vivo, Theranostic (patients stratification, ...), Western Blot ) [387] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD2 (clone 6F10.3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd2-clone-6f10-3/ [post_content] => [post_date] => 2019-12-05 14:01:27 [post_modified] => 2024-09-11 16:04:41 [ID] => 4011 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7c56164d-f589-418f-85a5-682def15cc0e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00154 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 387 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [388] => stdClass Object ( [post] => stdClass Object ( [post_title] => Staining of human tissues for multi-color confocal microscopy analysis [guid] => https://technology-offers.inserm-transfert.com/offer/staining-of-human-tissues-for-multi-color-confocal-microscopy-analysis/ [post_content] => This proposition describes a technique that allowed us to successfully stain human tissues with fluorochrome labelled antibodies for confocal and two-photon microscopy. Tissues are cut using either a microtome or a vibratome, fixed in parapholmaldeide and permebilized. This techinique is relatively complex and does not work for all the antibodies tested, the know-how to optimize the staining is relevant. The method can be of interest for partners interested in multi-parameter morphological analysis of human tissues. [post_date] => 2019-12-05 14:01:26 [post_modified] => 2024-09-04 13:45:09 [ID] => 4010 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7c469e55-9993-4248-ab0f-4a68c0a9170c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00445 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Theranostic (patients stratification, ...)Uses:
• OncologyTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Salvatore VALITUTTI [first_name] => Salvatore [last_name] => VALITUTTI [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 388 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Proof of concept in vitro, Theranostic (patients stratification, ...) [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Proof of concept in vitro, Theranostic (patients stratification, ...) ) [389] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD32 (clone 3D3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd32-clone-3d3/ [post_content] => Isotype IgG1, kHost : BALB/c mouseTarget species: FcgRIIA/B [post_date] => 2019-12-05 14:01:23 [post_modified] => 2024-09-11 16:06:15 [ID] => 4008 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7b424144-0514-4742-ae5b-63242b9a6010 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00195 [keywords] => CD32 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 389 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [390] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD7 (clone 46B3.5) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd7-clone-46b3-5/ [post_content] => [post_date] => 2019-12-05 14:01:21 [post_modified] => 2024-09-11 16:04:40 [ID] => 4005 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7a07198c-766d-4758-b3e2-fdf1a17de107 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00219 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 390 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [391] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone 10D11.5) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-10d11-5/ [post_content] => [post_date] => 2019-12-05 14:01:20 [post_modified] => 2024-09-11 16:04:40 [ID] => 4004 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 78c9ffd2-0a48-4369-8727-fef531019794 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00232 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 391 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [392] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-erbin (clone RB 99) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-erbin-clone-rb-99/ [post_content] => [post_date] => 2019-12-05 14:01:17 [post_modified] => 2024-09-11 16:04:39 [ID] => 4001 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 784601d9-307d-4837-91c9-b9eff49cbbe4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00045 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 392 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology, Other [taxonomieurl] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology, Other ) [393] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human transferrin receptor (clone YDJ8) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-transferrin-receptor-clone-ydj8/ [post_content] => [post_date] => 2019-12-05 14:01:16 [post_modified] => 2024-09-11 16:04:39 [ID] => 4000 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7819fb93-0985-4ed8-aea8-48fd0f0a4365 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00075 [keywords] => transferrin [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 393 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Central Nervous System, Human, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [394] => stdClass Object ( [post] => stdClass Object ( [post_title] => Tailor made high-fat diet fed diabetic mice [guid] => https://technology-offers.inserm-transfert.com/offer/tailor-made-high-fat-diet-fed-diabetic-mice/ [post_content] => We can provide mice a nutritional model of mice which become either type 2 diabetic without obesity, or obese and diabetic or mainly obese. [post_date] => 2019-12-05 14:01:14 [post_modified] => 2024-09-11 16:06:52 [ID] => 3998 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 77a3c127-0486-454a-9d16-2f16748dd71d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00404 [keywords] => incretins ; high fat diet ; diabetes ; obesity ; nutritionnal [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Nutritional disorderTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Rémy BURCELIN [first_name] => Rémy [last_name] => BURCELIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 394 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Diagnostic, Gastrointestinal Diseases, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Gastrointestinal Diseases, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Proof of concept in vivo, Therapeutic ) [395] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Mouse CD26 (Mouse dipeptidyl peptidase IV, DPP IV) (clone H207-1082) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd26-mouse-dipeptidyl-peptidase-iv-dpp-iv-clone-h207-1082/ [post_content] => Rat monoclonal antibody recognizing the cell surface antigen DPP IV (CD26) involved in T cell activation and in the processing of a variety of biologically-active peptide. [post_date] => 2019-12-05 14:01:11 [post_modified] => 2024-09-11 16:05:42 [ID] => 3996 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 7717294f-7027-4b05-8428-67d5482524c9 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00344 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Metabolic DisordersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 395 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Metabolic Disorders, Mouse, Proof of concept in vitro, Rat, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Metabolic Disorders, Mouse, Proof of concept in vitro, Rat, Western Blot ) [396] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD45 (clone CBE.77) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd45-clone-cbe-77/ [post_content] => [post_date] => 2019-12-05 14:01:09 [post_modified] => 2024-09-11 16:04:38 [ID] => 3995 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 76eaf105-7baa-489f-9bab-ced1db6cf7f1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00205 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 396 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Western Blot [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Western Blot ) [397] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD25 (clone 33B7.3) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd25-clone-33b7-3/ [post_content] => [post_date] => 2019-12-05 14:01:07 [post_modified] => 2024-09-11 16:04:37 [ID] => 3993 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 75370252-6ca3-4a80-b4a5-a8040b76ee42 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00175 [keywords] => CD25 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 397 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [398] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD113 (Nectin-3) clone N3.2.9 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd113-nectin-3-clone-n3-2-9/ [post_content] => [post_date] => 2019-12-05 14:01:06 [post_modified] => 2024-09-11 16:05:44 [ID] => 3992 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 74a70a8c-dc69-4a4d-83e4-1481523ffef4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00127 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc LOPEZ [first_name] => Marc [last_name] => LOPEZ [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 398 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Other [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Other ) [399] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse model for multiple sclerosis mediated by CD8 T cells [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-model-for-multiple-sclerosis-mediated-by-cd8-t-cells/ [post_content] => we generated mice in which the model antigen influenza hemagglutinin (HA) is selectively expressed as a neo-self antigen in oligodendrocytes, referred as MOG-HA mice. In these mice upon adoptive transfer of preactivated HA-specific CD8 T cells led to inflammatory lesions in the CNS, These lesions, associating CD8 T cell infiltration with focal loss of oligodendrocytes, and subsequent demyelination [post_date] => 2019-12-05 14:01:04 [post_modified] => 2024-09-11 16:06:47 [ID] => 3991 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 738e981a-680a-46c7-b0a4-0be4c8b22a4e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00009 [keywords] => Multiple Sclerosis ; CNS inflammation ; CD8 T cells ; Autoimmunity ; Immunology [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Roland LIBLAU [first_name] => Roland [last_name] => LIBLAU [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 399 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Central Nervous System, Diagnostic, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Others, Therapeutic [taxonomieurl] => Academic Research, Central Nervous System, Diagnostic, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Others, Therapeutic ) [400] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human CD2 (clone 39B2.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-39b2-1/ [post_content] => [post_date] => 2019-12-05 14:01:03 [post_modified] => 2024-09-11 16:04:36 [ID] => 3990 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 73649733-2a65-44da-8b64-f6b3aa744150 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00159 [keywords] => CD2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 400 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [401] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human CD2 (clone 39H7.2) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-39h7-2/ [post_content] => [post_date] => 2019-12-05 14:01:00 [post_modified] => 2024-09-11 16:04:35 [ID] => 3987 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 70dd82d9-4a36-445e-9ef5-1fe5fa8ab62e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00161 [keywords] => CD2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 401 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [402] => stdClass Object ( [post] => stdClass Object ( [post_title] => LGI1-null mouse: a model for epilepsy [guid] => https://technology-offers.inserm-transfert.com/offer/lgi1-null-mouse-a-model-for-epilepsy/ [post_content] => LGI1 (leucine-rich, glioma-inactivated 1) mutations are responsible for an inherited focal epileptic syndrome with onset in adolescence. LGI1-related epilepsy mutations result from a loss of function. We have used a strategy of conditional knockout to model the haploinsufficiency observed in the human genetic condition. According to Mendelian ratios, we have obtained LGI1+/- and LGI1-/- mice which are undistinguishable from wild type littermates at birth. At age P10, LGI1-/- mice start to have spontaneous frequent seizures monitored by EEG-video. The complete loss of LGI1 leads to premature death in the null-mutant mice around P15-P18 apparently from seizures. Morphological modifications (mossy fiber sprouting, gliosis, neuronal loss) subsequent to seizures are observed in the hippocampus of the LGI1-/- mice.THIS MODEL IS AVAILABLE THROUGH EMMA [post_date] => 2019-12-05 14:00:59 [post_modified] => 2024-09-11 16:06:45 [ID] => 3986 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 706621f2-c73f-48cb-9315-543488d273b6 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00390 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Central Nervous SystemTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Stéphanie BAULAC [first_name] => Stéphanie [last_name] => BAULAC [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 402 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Central Nervous System, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro, Proof of concept in vivo, Theranostic (patients stratification, ...), Therapeutic [taxonomieurl] => Academic Research, Central Nervous System, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro, Proof of concept in vivo, Theranostic (patients stratification, ...), Therapeutic ) [403] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD9 (clone TS9) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd9-clone-ts9/ [post_content] => [post_date] => 2019-12-05 14:00:56 [post_modified] => 2024-09-11 16:05:29 [ID] => 3983 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6d26cf72-0e87-4018-86ea-3cda825407f2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00242 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 403 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [404] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD20 (clone CRET 20) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd20-clone-cret-20/ [post_content] => [post_date] => 2019-12-05 14:00:56 [post_modified] => 2024-09-11 16:04:34 [ID] => 3982 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6c097e31-ad61-4c4e-9ba2-590dafd18fc1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00164 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 404 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [405] => stdClass Object ( [post] => stdClass Object ( [post_title] => Anti-KIAA0753 rat monoclonal antibody 5H3 [guid] => https://technology-offers.inserm-transfert.com/offer/anti-kiaa0753-rat-monoclonal-antibody-5h3/ [post_content] => This antibody recognizes the human KIAA0753 protein (also named OFIP or MNR). The epitope is located at the carboxy terminus of the protein, between residues 763 and 884. It detects endogenous KIAA0753 in various cell lines using immunoblot and immunofluorescence techniques. [post_date] => 2019-12-05 14:00:55 [post_modified] => 2024-09-11 16:06:14 [ID] => 3981 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6be7a379-481e-bc3c-ca89-5b893e08e48a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00503 [keywords] => Cilia ; Centrosome ; Ciliopathy [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Theranostic (patients stratification, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Olivier ROSNET [first_name] => Olivier [last_name] => ROSNET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 405 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Genetic Disorders, Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Others, Rat, Theranostic (patients stratification, ...), Western Blot [taxonomieurl] => Academic Research, Diagnostic, Genetic Disorders, Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Others, Rat, Theranostic (patients stratification, ...), Western Blot ) [406] => stdClass Object ( [post] => stdClass Object ( [post_title] => New production system for human recombinant Leptin [guid] => https://technology-offers.inserm-transfert.com/offer/new-production-system-for-human-recombinant-leptin/ [post_content] => Leptin is an adipocyte-derived pleiotropic hormone that modulates a large number of physiological functions, including control of body weight and regulation of the immune system. In this work, we show that a recombinant strain of the food-grade lactic acid bacterium Lactococcus lactis (LL-lep) can produce and efficiently secrete human leptin. The secreted leptin is a fully biologically active hormone, as demonstrated by its capacity to stimulate a STAT3 reporter gene in HEK293 cells transfected with the Ob-Rb leptin receptor. The immunomodulatory activity of leptin-secreting L.lactis was evaluated in vivo by coexpression with the human papillomavirus type 16 E7 protein. In C57BL/6 mice immunized intranasally with a recombinant L.lactis strain coproducing leptin and E7 antigen, the adaptive immune response was significantly higher than in mice immunized with recombinant L. lactis producing only E7 antigen, demonstrating adjuvanticity of leptin. We then analyzed the effects of intranasally administered LL-lep in obese ob/ob mice. We observed that dailyadministration of LL-lep to these mice significantly reduced body weight gain and food intake. These results demonstrate that leptin can be produced and secreted in an active form by L. lactis and that leptin-producing L. lactis regulates in vivo antigen-specific immune responses, as well as body weight and food consumption. [post_date] => 2019-12-05 14:00:54 [post_modified] => 2024-09-11 16:06:59 [ID] => 3980 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6b811a5f-6147-4891-a629-86e6ee415686 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00308 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Nucleic acids [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Nucleic acidsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Tarik ISSAD [first_name] => Tarik [last_name] => ISSAD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 406 [terms] => Array ( [0] => Nucleic acids ) [taxonomie] => Academic Research, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Others [taxonomieurl] => Academic Research, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Nutritional disorder, Others ) [407] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F2-5 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f2-5/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 347 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:00:53 [post_modified] => 2024-09-11 16:07:08 [ID] => 3979 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6a978b78-49ba-4732-8742-e8c4c18e5b1c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00414 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 407 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [408] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelioma cell line F5-T1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelioma-cell-line-f5-t1/ [post_content] => Neoplastic rat cell line isolated from tumor masses (peritoneal mesothelioma) collected in the peritoneal cavity of a female rat (F344) after 392 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:00:52 [post_modified] => 2024-09-11 16:07:16 [ID] => 3978 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 69fe3b9d-a768-4289-8c8d-37ce4e4e05d7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00421 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 408 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Proof of concept in vitro, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Proof of concept in vitro, Proof of concept in vivo, Therapeutic ) [409] => stdClass Object ( [post] => stdClass Object ( [post_title] => Primary cultures of mice proximal tubular cells [guid] => https://technology-offers.inserm-transfert.com/offer/primary-cultures-of-mice-proximal-tubular-cells/ [post_content] => Proximal tubular cells are isolated by magnetic sorting coupled with microbeads-conjugated anti-Prominin-1 antibodies. Prominin-1 colocalizes with Megalin in normal and pathological kidneys.Proximal tubular cells are well-differentiated and keep a proliferative potential after dozens of passages in culture. [post_date] => 2019-12-05 14:00:50 [post_modified] => 2024-10-03 13:15:02 [ID] => 3976 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6813cc0d-764d-4f65-a4b9-18b6647ee75d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00486 [keywords] => Proximal tubule ; Primary culture [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Genito Urinary SystemTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Pierre GALICHON [first_name] => Pierre [last_name] => GALICHON [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 409 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Genito Urinary System, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro [taxonomieurl] => Academic Research, Genito Urinary System, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro ) [410] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD112(Nectin-2) clone R2.525.2 [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd112nectin-2-clone-r2-525-2/ [post_content] => [post_date] => 2019-12-05 14:00:49 [post_modified] => 2024-09-11 16:06:04 [ID] => 3975 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 6697cce2-25bb-40bb-97bc-90d5f193142a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00126 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marc LOPEZ [first_name] => Marc [last_name] => LOPEZ [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 410 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [411] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD44 (clone BJ18) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd44-clone-bj18/ [post_content] => [post_date] => 2019-12-05 14:00:46 [post_modified] => 2024-09-11 16:05:39 [ID] => 3972 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 65d06a61-aaf4-4513-8bd0-127c6d0b9840 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00204 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 411 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [412] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD27 (clone O323) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd27-clone-o323/ [post_content] => [post_date] => 2019-12-05 14:00:46 [post_modified] => 2024-09-11 16:05:50 [ID] => 3971 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 65ae9def-3997-4316-a768-63173cc76dae [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00180 [keywords] => CD27 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 412 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [413] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Mouse Tcr Alpha 2 (V2aT) clone B20.1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-tcr-alpha-2-v2at-clone-b20-1/ [post_content] => [post_date] => 2019-12-05 14:00:44 [post_modified] => 2024-09-11 16:05:16 [ID] => 3970 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 65ac8f25-9c85-4501-b35f-b64697ec5b63 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00110 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bernard MALISSEN [first_name] => Bernard [last_name] => MALISSEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 413 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat ) [414] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F1-3 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f1-3/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 307 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:00:42 [post_modified] => 2024-09-11 16:07:05 [ID] => 3968 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 648a47af-7dc6-4b78-8c38-dbdf4978c7c5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00408 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 414 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [415] => stdClass Object ( [post] => stdClass Object ( [post_title] => Technique to isolate live renal proximal tubular cells from any mouse strain [guid] => https://technology-offers.inserm-transfert.com/offer/technique-to-isolate-live-renal-proximal-tubular-cells-from-any-mouse-strain/ [post_content] => We isolate renal proximal tubular cells using the proximal tubular marker Prominin-1.We use a 4°C, enzyme free protocole allowing high quality subsequent analyses (e.g. transcriptome), and obtention of primary cultures. [post_date] => 2019-12-05 14:00:42 [post_modified] => 2024-10-03 13:15:02 [ID] => 3967 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 641cd59e-d536-47ae-ac61-25821a5b3d17 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00488 [keywords] => proximal tubule ; renal primary culture ; ex vivo [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Genito Urinary SystemTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Pierre GALICHON [first_name] => Pierre [last_name] => GALICHON [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 415 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Genito Urinary System, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro, Proof of concept in vivo [taxonomieurl] => Academic Research, Genito Urinary System, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro, Proof of concept in vivo ) [416] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone B9.8) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-b9-8/ [post_content] => [post_date] => 2019-12-05 14:00:41 [post_modified] => 2024-09-11 16:04:33 [ID] => 3966 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 61727ba9-bfbb-4d3d-82bf-d25ca6083ea4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00229 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 416 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [417] => stdClass Object ( [post] => stdClass Object ( [post_title] => tissue specific invalidation of apelin (Lox-APL) [guid] => https://technology-offers.inserm-transfert.com/offer/tissue-specific-invalidation-of-apelin-lox-apl/ [post_content] => mouse exhibiting a Lox-APL transgene leading to a tissue specific invalidation. [post_date] => 2019-12-05 14:00:38 [post_modified] => 2024-09-11 16:06:53 [ID] => 3963 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5fe8707b-d6a4-4694-8538-3d9d223fb976 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00437 [keywords] => apelin ; diabetes ; obesity [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• MusculoskeletalTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe VALET [first_name] => Philippe [last_name] => VALET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 417 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Cardiovascular Diseases, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Musculoskeletal [taxonomieurl] => Academic Research, Cardiovascular Diseases, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Musculoskeletal ) [418] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD63 (clone TS63) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd63-clone-ts63/ [post_content] => [post_date] => 2019-12-05 14:00:36 [post_modified] => 2024-09-11 16:05:30 [ID] => 3961 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5fc4318f-a144-4450-8798-eb58fef6e770 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00217 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 418 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [419] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-schwann cell (clone 224-58) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-schwann-cell-clone-224-58/ [post_content] => Positive staining observed on human, rabbit, rat and mouse peripheral nerve sections or Schwann cell cultures. No staining on chick. [post_date] => 2019-12-05 14:00:35 [post_modified] => 2024-09-11 16:04:32 [ID] => 3960 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5faf976c-b61a-433f-835f-64ce87c5fde1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00072 [keywords] => schwann cells [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bernard ZALC [first_name] => Bernard [last_name] => ZALC [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 419 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other [taxonomieurl] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other ) [420] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD48 (clone BJ40) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd48-clone-bj40/ [post_content] => [post_date] => 2019-12-05 14:00:34 [post_modified] => 2024-09-11 16:05:54 [ID] => 3959 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5f2247fe-93b7-4935-9df6-814e22c3a115 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00207 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 420 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [421] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelioma cell line F4-T2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelioma-cell-line-f4-t2/ [post_content] => Neoplastic rat cell line isolated from tumor masses (peritoneal mesothelioma) collected in the peritoneal cavity of a male rat (F344) after 387 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:00:33 [post_modified] => 2024-09-11 16:07:15 [ID] => 3958 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5ed7eb26-27f5-48bf-9613-05508932eb49 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00419 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 421 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Proof of concept in vitro, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Proof of concept in vitro, Proof of concept in vivo, Therapeutic ) [422] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human Thyroglobulin (clone THYR 5.52) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-thyroglobulin-clone-thyr-5-52/ [post_content] => This antibody can be used on paraffin sections after retrieval antigen procedure. The best retrieval technique is the heating in microwave oven (2 X10 minutes) in 10mM citrate buffer, pH6 [post_date] => 2019-12-05 14:00:32 [post_modified] => 2024-09-11 16:05:22 [ID] => 3957 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5ed7d78b-10aa-4b9f-b87a-954055531115 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00384 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 422 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunoprecipitation, lgG1, Mouse, Oncology, Western Blot [taxonomieurl] => Academic Research, Diagnostic, ELISA (or compatible technique), Human, Immunoprecipitation, lgG1, Mouse, Oncology, Western Blot ) [423] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rabbit polyclonal Anti-VGLUT1 serum [guid] => https://technology-offers.inserm-transfert.com/offer/rabbit-polyclonal-anti-vglut1-serum/ [post_content] => [post_date] => 2019-12-05 14:00:31 [post_modified] => 2024-09-11 16:04:31 [ID] => 3956 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5ebd1cdc-0d59-40a7-8389-7633ba477764 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00078 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bruno GIROS [first_name] => Bruno [last_name] => GIROS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 423 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Rabbit [taxonomieurl] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Rabbit ) [424] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD28 (clone CD28.2.45.6) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd28-clone-cd28-2-45-6/ [post_content] => [post_date] => 2019-12-05 14:00:30 [post_modified] => 2024-09-11 16:06:00 [ID] => 3955 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5e8d734f-7c30-480c-9dac-98fc985363be [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00182 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 424 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [425] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD80 (clone 2D10.4) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd80-clone-2d10-4/ [post_content] => [post_date] => 2019-12-05 14:00:29 [post_modified] => 2024-09-11 16:06:03 [ID] => 3954 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5e6a86ea-7248-460b-bd15-54d978161033 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00235 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 425 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [426] => stdClass Object ( [post] => stdClass Object ( [post_title] => 3D Cell Omics - Clinical Proteomics Platform [guid] => https://technology-offers.inserm-transfert.com/offer/3d-cell-omics-clinical-proteomics-platform/ [post_content] => For your Clinical investigations, they propose to apply 3D culture cell methods to further your knowledge of disease, pathways, targets and drugs effects. 3D Cell Omics offers :- Technology that mimics the tumor microenvironment- Study of drug effects on different cell line, - Drug following by mass spectrometry imaging,- Biomarkers hunting,- Large scale proteins identification and relative quantification.3D Cell Omics will assist you throughout all steps of your project from culture of your cell lines to the data analysis. - Maintenance of cell lines- Access to innovative technologies : creation of mixed spheroid, invasion computation software, 3D organs Bioprinting, exosome isolation and count u2026- Data processing and statistical analysis for identifications and relative quantification of markers.For more information : http:/www.laboratoire-prism.fr/index.php/platforms/3d-cellomics [post_date] => 2019-12-05 14:00:29 [post_modified] => 2024-09-11 16:07:05 [ID] => 3953 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5c753057-33fa-1b34-9ce2-5bb613b202f7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00507 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel SALZET [first_name] => Michel [last_name] => SALZET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 426 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Others [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Others ) [427] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD315/Anti-CD9P-1/EWI-F (clone 1F11) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd315-anti-cd9p-1-ewi-f-clone-1f11/ [post_content] => Clone 1F11 is the only published mAb to CD315 [post_date] => 2019-12-05 14:00:26 [post_modified] => 2024-09-11 16:05:52 [ID] => 3952 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5c6acb6f-6a28-44ed-a672-aa0387f4fc39 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00193 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 427 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [428] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 (clone IBB.18) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-clone-ibb-18/ [post_content] => [post_date] => 2019-12-05 14:00:24 [post_modified] => 2024-09-11 16:04:31 [ID] => 3950 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 58cbcd09-966f-410f-92f7-b87b8de32739 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00223 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 428 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [429] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 (clone L533) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-clone-l533/ [post_content] => [post_date] => 2019-12-05 14:00:23 [post_modified] => 2024-09-11 16:04:31 [ID] => 3949 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 57e65e52-0afa-4ea4-9479-d2ee1004c218 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00224 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 429 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [430] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD2 (clone 13E1.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-13e1-1/ [post_content] => [post_date] => 2019-12-05 14:00:21 [post_modified] => 2024-09-11 16:04:30 [ID] => 3948 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 56bf995e-d870-46ba-b4fe-23b7c6990c23 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00156 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 430 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [431] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Mouse I-As (Mouse MHC class II molecule) (clone H83-82.6) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-mouse-i-as-mouse-mhc-class-ii-molecule-clone-h83-82-6/ [post_content] => Monoclonal antibody raised in the A.TL anti-A.TH mouse strain combination. Recognizes an allodeterminant expressed on the mouse MHC class II molecule I-As (corresponding to the former Ia.12 serologic specificity). [post_date] => 2019-12-05 14:00:20 [post_modified] => 2024-09-11 16:04:30 [ID] => 3947 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 555e0a21-e233-4f7b-a3d9-42044e49d343 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00351 [keywords] => MHC class II molecule [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 431 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse ) [432] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M4-1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m4-1/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 307 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:00:19 [post_modified] => 2024-09-11 16:07:15 [ID] => 3946 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5540441c-3a36-4124-a1e4-83efe7574fb6 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00432 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 432 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [433] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-human Protein S (PROS1) mAbs [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-protein-s-pros1-mabs/ [post_content] => These mouse monoclonal antibodies are directed against human PROS1, an anti-coagulation factor. They are very specific and recognize 70-kDa protein. [post_date] => 2019-12-05 14:00:18 [post_modified] => 2024-09-11 16:04:29 [ID] => 3945 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 54a6ef76-8913-4e33-863b-87fad3ac5696 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00484 [keywords] => Protein S ; Coagulation factor [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• Cardiovascular DiseasesTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Habib BOUKERCHE [first_name] => Habib [last_name] => BOUKERCHE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 433 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Cardiovascular Diseases, Diagnostic, Human, Immunofluorescence, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Cardiovascular Diseases, Diagnostic, Human, Immunofluorescence, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [434] => stdClass Object ( [post] => stdClass Object ( [post_title] => Cardiac overexpression of the human beta3-adrenergic receptor. [guid] => https://technology-offers.inserm-transfert.com/offer/cardiac-overexpression-of-the-human-beta3-adrenergic-receptor/ [post_content] => Mice with a cardiac ovexpression of the human beta3-adrenergic receptor were produced by microinjection of a construct with A or C isoform gene under the control of the alpha myosin heavy chain promoter. Phenotypic analyses comprised beta3-AR mRNA and protein determinations, histological studies, electrocardiogram, contractility and cyclic nucleotide measurements.Transgenic mice that ovexepressed the A form were cryopreserved while transgenic mice that ovexepressed the C form are already alive. [post_date] => 2019-12-05 14:00:14 [post_modified] => 2024-09-11 16:06:41 [ID] => 3941 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 53ebf36e-9eb9-46f0-a2b9-0047d3f53e71 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00451 [keywords] => adrenergic ; heart ; secreening [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Geneviève TAVERNIER [first_name] => Geneviève [last_name] => TAVERNIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 434 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Cardiovascular Diseases, Industry Research (screening, tox.studies, bioreactor, ...), Others [taxonomieurl] => Academic Research, Cardiovascular Diseases, Industry Research (screening, tox.studies, bioreactor, ...), Others ) [435] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD14 (clone 10G3.3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd14-clone-10g3-3/ [post_content] => [post_date] => 2019-12-05 14:00:12 [post_modified] => 2024-09-11 16:04:28 [ID] => 3939 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 539cfc30-4a72-4e10-9a0d-afc8e406ce34 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00136 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 435 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [436] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD100 (clone BD18) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd100-clone-bd18/ [post_content] => [post_date] => 2019-12-05 14:00:11 [post_modified] => 2024-09-11 16:04:28 [ID] => 3938 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 527241aa-4a02-4b7c-bde3-9d9e978b3b58 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00120 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 436 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [437] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M1-1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m1-1/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 257 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 14:00:10 [post_modified] => 2024-09-11 16:07:10 [ID] => 3937 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 5222a626-22fa-40c6-8876-6c1a398579e1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00424 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 437 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [438] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD1a (clone 10H3.9.3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1a-clone-10h3-9-3/ [post_content] => [post_date] => 2019-12-05 14:00:08 [post_modified] => 2024-09-11 16:04:27 [ID] => 3935 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 518e6203-b261-4719-917b-8108f66e1e34 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00146 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 438 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [439] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD5 (clone A50) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd5-clone-a50/ [post_content] => [post_date] => 2019-12-05 14:00:07 [post_modified] => 2024-09-11 16:04:27 [ID] => 3934 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 511ff3e2-da4e-4871-888c-bb702e9bc5cd [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00210 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 439 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [440] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human CD2 (clone 22E3.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd2-clone-22e3-1/ [post_content] => [post_date] => 2019-12-05 14:00:06 [post_modified] => 2024-09-11 16:04:26 [ID] => 3933 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 50a12201-b437-4fde-a936-c1ef83312a4b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00158 [keywords] => CD2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 440 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [441] => stdClass Object ( [post] => stdClass Object ( [post_title] => HT29-MTX cells : intestinal model of goblet cells [guid] => https://technology-offers.inserm-transfert.com/offer/ht29-mtx-cells-intestinal-model-of-goblet-cells/ [post_content] => HT29MTX10-6 and HT29MTX10-5 cell populations were isolated from the colon cancer cell line by stepwise adaptation to 10-6 M and 10-5 M Methotrexate (MTX), respectively. HT29MTX cells form a homogeneous population of polarized goblet cells that secrete mucins of gastric immunoreactivity. A mucus gel becomes visible on the surface of the cell layer at postconfluency. These cells maintain their ability to differentiate under normal culture conditions (without MTX).This cell line is available through CelluloNet in Lyon [post_date] => 2019-12-05 14:00:04 [post_modified] => 2024-09-11 16:06:56 [ID] => 3931 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4fe8de12-7944-407f-bc51-9dc19a7ce978 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00309 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Thecla LESUFFLEUR [first_name] => Thecla [last_name] => LESUFFLEUR [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 441 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Gastrointestinal Diseases, Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Academic Research, Gastrointestinal Diseases, Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [442] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone B9.4) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-b9-4/ [post_content] => [post_date] => 2019-12-05 14:00:01 [post_modified] => 2024-09-11 16:04:26 [ID] => 3930 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4fb87d24-2134-4d1c-8e3a-6ddfac615e42 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00227 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 442 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse ) [443] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone B9.3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-b9-3/ [post_content] => [post_date] => 2019-12-05 13:59:58 [post_modified] => 2024-09-11 16:04:25 [ID] => 3927 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4e700caf-9c0c-4af9-bf30-a5ed5f1f7a2b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00226 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 443 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [444] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human Follicular Dendritic Cells (clone CNA.42) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-follicular-dendritic-cells-clone-cna-42/ [post_content] => Follicular dendritic cells (FDCs) are large cells in germinal centers (GCs) of primary and lymphoid tissues. They present non-processed antigen and switch off apoptosis of B cells through a selection process resulting in selection of memory B cells. They express many B cell markers such as CD21 (long isoform), CD23 and CD35.The hybridoma CNA.42 recognizes a unique carbohydrate epitope found on FDCs from a variety of species.It has been shown to be a useful reagent for both flow cytometry and IHC analysis. [post_date] => 2019-12-05 13:59:56 [post_modified] => 2024-09-11 16:06:11 [ID] => 3925 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4d8e3a25-4b23-467f-b356-df9214464421 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00166 [keywords] => FDC [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 444 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse, Western Blot [taxonomieurl] => Academic Research, Human, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse, Western Blot ) [445] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human FcgRIIIA/B (clone 7.5.4Sw50 - switch variant) [guid] => https://technology-offers.inserm-transfert.com/offer/human-fcgriiia-b-clone-7-5-4sw50-switch-variant/ [post_content] => [post_date] => 2019-12-05 13:59:55 [post_modified] => 2024-09-11 16:04:24 [ID] => 3923 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4c74b010-f693-4182-a7e2-95ff8577df8d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00328 [keywords] => FcgRIIIA/B [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 445 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Other, Western Blot ) [446] => stdClass Object ( [post] => stdClass Object ( [post_title] => BMP6 -/- mice [guid] => https://technology-offers.inserm-transfert.com/offer/bmp6-mice/ [post_content] => Targeted disruption of BMP6 in mice causes a rapid and massive accumulation of iron in the liver, the acinar cells of the exocrine pancreas, the heart and the renal convoluted tubes. Despite their severe iron overload, the livers of Bmp6-deficient mice have low levels of phosphorylated Smad 1, Smad 5 and Smad 8, and these Smads are not significantly translocated to the nucleus. In addition, hepcidin synthesis is markedly reduced. This indicates that Bmp6 is critical for iron homeostasis and that it is functionally nonredundant with other members of the Bmp subfamily. Notably, Bmp6-deficient mice retain their capacity to induce hepcidin in response to inflammation. [post_date] => 2019-12-05 13:59:54 [post_modified] => 2024-09-11 16:06:40 [ID] => 3922 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4c716c19-daf1-493b-a892-5968a11e7ed2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00319 [keywords] => BMP6 ; iron ; anemia ; hemochromatosis ; inflammation [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Metabolic DisordersTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Marie-Paule ROTH [first_name] => Marie-Paule [last_name] => ROTH [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 446 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Inflammation, Metabolic Disorders, Proof of concept in vivo, Therapeutic [taxonomieurl] => Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Inflammation, Metabolic Disorders, Proof of concept in vivo, Therapeutic ) [447] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human plasminogen kringle 4 (lysine-binding site) and APO (A) kringle IV-10 (clone A10.2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-plasminogen-kringle-4-lysine-binding-site-and-apo-a-kringle-iv-10-clone-a10-2/ [post_content] => [post_date] => 2019-12-05 13:59:53 [post_modified] => 2024-09-11 16:04:24 [ID] => 3921 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4c38bee4-1211-4fcc-ac0f-b96e694f7b69 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00024 [keywords] => Kringles; plasminogen-prothrombin [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eduardo ANGLES-CANO [first_name] => Eduardo [last_name] => ANGLES-CANO [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 447 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [448] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CDw75 (clone DNA.7) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cdw75-clone-dna-7/ [post_content] => [post_date] => 2019-12-05 13:59:52 [post_modified] => 2024-09-11 16:04:23 [ID] => 3920 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4b12471c-ee5e-4d9b-97dc-1e1330b9540d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00245 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 448 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse, Western Blot [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse, Western Blot ) [449] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-erbin (clone RB.24.1.1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-erbin-clone-rb-24-1-1/ [post_content] => [post_date] => 2019-12-05 13:59:51 [post_modified] => 2024-09-11 16:04:23 [ID] => 3919 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4ad9668b-7d2e-438d-85c5-c07a9ea0806f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00044 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 449 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology, Other [taxonomieurl] => Academic Research, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Oncology, Other ) [450] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Mouse H-2Dd (Mouse MHC class I & Human HLA-B7, HLA-B27) (clone H81-257) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-mouse-h-2dd-mouse-mhc-class-i-human-hla-b7-hla-b27-clone-h81-257/ [post_content] => Mouse alloantibody recognizing the mouse MHC classI H-2Dd molecule. raised in the A.BY (KbIbDb) anti-A.TL (KsIkDd) strain combination. [post_date] => 2019-12-05 13:59:50 [post_modified] => 2024-09-11 16:04:23 [ID] => 3918 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4a324f9d-7e88-40ea-9f89-8686c6e028d4 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00348 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 450 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse ) [451] => stdClass Object ( [post] => stdClass Object ( [post_title] => MS-5-Omi/HTRA2-mCherry cells [guid] => https://technology-offers.inserm-transfert.com/offer/ms-5-omi-htra2-mcherry-cells/ [post_content] => Murine stromal MS-5 cells were transduced with a retroviral pBabe vector to stably express the Omi/HTRA2-mCherry protein. OMI/HTRA2 is a marker of intact polarized mitochondria that is rapidly degraded following mitochondrial outer membrane permeabilization (MOMP). [post_date] => 2019-12-05 13:59:48 [post_modified] => 2024-09-11 16:06:40 [ID] => 3916 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 48b1583b-2932-4a48-8efa-3439d7883c5d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00494 [keywords] => Stromal cells ; LTC-IC ; Omi-mCherry ; Mitochondrial transfer [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Véronique IMBERT [first_name] => Véronique [last_name] => IMBERT [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 451 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro ) [452] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone 8E1.7) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-8e1-7/ [post_content] => [post_date] => 2019-12-05 13:59:46 [post_modified] => 2024-09-11 16:04:22 [ID] => 3914 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 47fb2514-aa55-419b-a31a-4f7b056f0b97 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00231 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 452 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [453] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone B9.2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-b9-2/ [post_content] => [post_date] => 2019-12-05 13:59:46 [post_modified] => 2024-09-11 16:04:21 [ID] => 3913 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 478c0769-0fc6-4f32-a416-911f1bbe5a48 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00225 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 453 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [454] => stdClass Object ( [post] => stdClass Object ( [post_title] => DBA/1-Abca1tm1Jdm/J mice [guid] => https://technology-offers.inserm-transfert.com/offer/dba-1-abca1tm1jdm-j-mice/ [post_content] => The mutant ABC1 allele was generated by homologous recombination, by using a targeting vector containing a neomycin resistance and herpes simplex virus thymidine kinase genes to disrupt exons 17 and 22 of the Abca1 gene. This portion of the gene encodes the entire N-terminal ATP-binding cassette. The construct was electroporated into DBA/1LacJ-derived 252 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J blastocysts to generate chimeric animals.This disruption leads to a null mutation, as demonstrated by the lack of expression of ABC1 mRNA and protein.Analysis of heterozygous intercrosses showed that the mutant allele is transmitted at mendelian frequency, with high lethality in ABC1-null pups during the first few weeks after birth. Autopsies revealed deep perivisceral hemorrhages in null animals but not in wild-type pups. No gross morphological defect was detected. Mating of homozygous mutant females produced no litters, irrespective of male genotype, because of impaired placental development, which is consistent with the high level of ABC1 expression in this organ.Pups that survive beyond birth have no detectable ABCA1 gene transcript in the tissues.This mouse model is deposited at The Jackson Laboratory (Jax stock#003897). [post_date] => 2019-12-05 13:59:43 [post_modified] => 2024-09-11 16:06:42 [ID] => 3910 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 46306ce7-664e-4377-8683-56b4e86d0f78 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00472 [keywords] => ABC1 ; DBA [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Metabolic DisordersTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Giovanna CHIMINI [first_name] => Giovanna [last_name] => CHIMINI [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 454 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Cardiovascular Diseases, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders [taxonomieurl] => Cardiovascular Diseases, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders ) [455] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 578-2-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-578-2-1/ [post_content] => [post_date] => 2019-12-05 13:59:41 [post_modified] => 2024-09-11 16:04:20 [ID] => 3908 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 461481e0-5ac8-471a-92c6-dbb20b9d397f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00293 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 455 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others ) [456] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD101 (clone BB27) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd101-clone-bb27/ [post_content] => [post_date] => 2019-12-05 13:59:39 [post_modified] => 2024-09-11 16:05:53 [ID] => 3906 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 453b2502-13d9-42e8-a3e4-46227fb07cad [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00122 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 456 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [457] => stdClass Object ( [post] => stdClass Object ( [post_title] => Urinary peptidome analysis [guid] => https://technology-offers.inserm-transfert.com/offer/urinary-peptidome-analysis/ [post_content] => In collaboration with Mosaiques Diagnostics we can analyse biofluid proteomes for your needs using capillary electrophoresis coupled to mass spectrometry.This equipment is available in our institute. We have ample experience with this approach both in human and animal biofluids, mainly urine. [post_date] => 2019-12-05 13:59:37 [post_modified] => 2024-09-11 16:07:04 [ID] => 3904 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 43ec47f3-ca51-4aa9-9898-eb99c8c8556c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00450 [keywords] => Bodyfluid ; Biomarker ; Proteomics
[pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• Genito Urinary SystemTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Joost SCHANSTRA [first_name] => Joost [last_name] => SCHANSTRA [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 457 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Cardiovascular Diseases, Diagnostic, Genito Urinary System [taxonomieurl] => Academic Research, Cardiovascular Diseases, Diagnostic, Genito Urinary System ) [458] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD74 (clone DND.53) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd74-clone-dnd-53/ [post_content] => [post_date] => 2019-12-05 13:59:36 [post_modified] => 2024-09-11 16:04:19 [ID] => 3903 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 43a96a3c-4a08-4a70-bd05-fda09b1455ec [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00222 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 458 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse ) [459] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD31 (clone IP28) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd31-clone-ip28/ [post_content] => [post_date] => 2019-12-05 13:59:34 [post_modified] => 2024-09-11 16:04:19 [ID] => 3901 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 4256d922-623d-484a-86cf-e5c0744ae6db [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00192 [keywords] => CD31 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 459 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [460] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD7 (clone 13C7.4) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd7-clone-13c7-4/ [post_content] => [post_date] => 2019-12-05 13:59:33 [post_modified] => 2024-09-11 16:04:18 [ID] => 3900 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 41a4246c-cca5-4d76-a93b-de4d34863d1b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00218 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 460 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [461] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human CD25 (clone 39C6.5) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd25-clone-39c6-5/ [post_content] => [post_date] => 2019-12-05 13:59:26 [post_modified] => 2024-09-11 16:04:17 [ID] => 3894 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3f9a3213-a9d1-4006-8ad6-86cc4eb308cf [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00177 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 461 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Other [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Other ) [462] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F3-2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f3-2/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 356 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 13:59:26 [post_modified] => 2024-09-11 16:07:09 [ID] => 3893 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3f873e01-2f07-4ed7-9a2c-3a9abe1b7a00 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00416 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 462 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [463] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelioma cell line M5-T2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelioma-cell-line-m5-t2/ [post_content] => Neoplastic rat cell line isolated from tumor masses (peritoneal mesothelioma) collected in the peritoneal cavity of a male rat (F344) after 387 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 13:59:25 [post_modified] => 2024-09-11 16:07:17 [ID] => 3892 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3eb485c7-c4ec-4056-8d2a-9326e2299d01 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00418 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 463 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Proof of concept in vivo, Therapeutic ) [464] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Poly(Glu60,Ala40) (GA) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-polyglu60ala40-ga-several-clones/ [post_content] => Synthetic linear bipolymer of glutamic acid (60%) and Alanine (40%). Average m.w. 360.000 [post_date] => 2019-12-05 13:59:21 [post_modified] => 2024-09-11 16:04:15 [ID] => 3888 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3d781b60-770c-4e6d-ab2b-f411fea227fc [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00337 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 464 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Proof of concept in vitro [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Proof of concept in vitro ) [465] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD18 (clone O501) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd18-clone-o501/ [post_content] => [post_date] => 2019-12-05 13:59:20 [post_modified] => 2024-09-11 16:04:15 [ID] => 3887 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3d5d8fb4-6bbb-46d2-9515-ba9641d64783 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00144 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 465 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [466] => stdClass Object ( [post] => stdClass Object ( [post_title] => Animal models of fibrosis [guid] => https://technology-offers.inserm-transfert.com/offer/animal-models-of-fibrosis/ [post_content] => UUO: This model is induced in mice or rats by unilateral ureteral ligation (UUO) of the left ureter. The animals rapidly develop, within a few days, severe tubulo-interstitial renal fibrosis with an inflammatory cell infiltrate in the affected kidney. SNX: This model consists at reducing the renal mass by 83%. This induces hyperfiltration and induces over a period of around 6 months significant fibrotic lesions in C57bl/6j mice and in 2 months in Swiss mice. In rats the model is somewhat faster as it induces renal fibrosis in 3 months. [post_date] => 2019-12-05 13:59:19 [post_modified] => 2024-09-04 13:45:07 [ID] => 3886 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3d2c51de-5890-442f-89c7-f2f0e3ca87b3 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00449 [keywords] => Chronic kidney disease ; Fibrosis ; In vivo drug evaluation [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Joost SCHANSTRA [first_name] => Joost [last_name] => SCHANSTRA [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 466 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Cardiovascular Diseases, Genito Urinary System, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Others, Proof of concept in vitro [taxonomieurl] => Academic Research, Cardiovascular Diseases, Genito Urinary System, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Others, Proof of concept in vitro ) [467] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD11a (clone 25.5.2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd11a-clone-25-5-2/ [post_content] => [post_date] => 2019-12-05 13:59:18 [post_modified] => 2024-09-11 16:04:14 [ID] => 3885 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3c47401e-f930-4763-8a3e-f89f6274a77c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00131 [keywords] => CD11a [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 467 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [468] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Poly(Glu60,Ala30,Tyr10) (GAT) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-polyglu60ala30tyr10-gat-several-clones/ [post_content] => Synthetic polypeptide polymer [post_date] => 2019-12-05 13:59:17 [post_modified] => 2024-09-11 16:04:14 [ID] => 3884 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3b8d6c13-d1f2-4bf8-bc96-3768846b3a6a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00336 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 468 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other ) [469] => stdClass Object ( [post] => stdClass Object ( [post_title] => Screening and characterization of new histone deacetylase inhibitors (HDACi) using BRET based assay [guid] => https://technology-offers.inserm-transfert.com/offer/screening-and-characterization-of-new-histone-deacetylase-inhibitors-hdaci-using-bret-based-assay/ [post_content] => Using BRET technology, we designed a method to measure histone acetylation in living cells. Cells are transfected with a vector coding for a bromodomain fused to renilla luciferase (Rluc-BrD) and with a vector coding for histone H3 fused to yellow fluorescent protein (YFP). In the presence of HDACi, Rluc-BrD and YFP-histone H3 interact and generate an increase of BRET signal. [post_date] => 2019-12-05 13:59:15 [post_modified] => 2024-09-11 16:07:04 [ID] => 3882 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3afc93b2-6402-45dd-b419-c51f35a1d65a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00422 [keywords] => BRET ; screening ; HDAC ; inhibitors [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Christophe BLANQUART [first_name] => Christophe [last_name] => BLANQUART [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 469 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Cardiovascular Diseases, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Proof of concept in vitro [taxonomieurl] => Academic Research, Cardiovascular Diseases, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Proof of concept in vitro ) [470] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD44 (clone 9C1.7) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd44-clone-9c1-7/ [post_content] => [post_date] => 2019-12-05 13:59:14 [post_modified] => 2024-09-11 16:04:13 [ID] => 3881 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3a2c4e5f-2047-4c8f-8b98-fec35818c423 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00203 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 470 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [471] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD4 (clone O516) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd4-clone-o516/ [post_content] => [post_date] => 2019-12-05 13:59:12 [post_modified] => 2024-09-11 16:04:12 [ID] => 3879 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3949e630-98e5-4e51-9cee-88449099606d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00200 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 471 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [472] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Mouse TLR2 (mouse Toll-like receptor 2) (clone 8C5.4) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-tlr2-mouse-toll-like-receptor-2-clone-8c5-4/ [post_content] => Rat monoclonal antibody recognizing the mouse TLR-2 [post_date] => 2019-12-05 13:59:11 [post_modified] => 2024-09-11 16:04:12 [ID] => 3878 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 390e6e29-ec8e-4cc8-a182-356ae741537e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00342 [keywords] => TLR2 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Infectious DiseasesTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 472 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, lgG2a, Mouse, Proof of concept in vitro, Rat, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, lgG2a, Mouse, Proof of concept in vitro, Rat, Western Blot ) [473] => stdClass Object ( [post] => stdClass Object ( [post_title] => Directory of research activities in the field of rare diseases and orphan drugs in Europe [guid] => https://technology-offers.inserm-transfert.com/offer/directory-of-research-activities-in-the-field-of-rare-diseases-and-orphan-drugs-in-europe/ [post_content] => Directory of 5,000 ongoing academic research projects funded at national or European level in 36 countries, classified by disease and health product if relevant, by type of research, by stage of developement, by country/city/institutionYou also may find the products catalogs of this Institute at :http://www.orphadata.org/cgi-bin/docs/CataloguePdt-Industry.pdfhttp://www.orphadata.org/cgi-bin/docs/CataloguePdt-Academia.pdf [post_date] => 2019-12-05 13:59:10 [post_modified] => 2024-09-04 13:45:16 [ID] => 3877 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 38a126a2-278b-470a-86d1-efd80a79b916 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00311 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Others [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Genetic DisordersTherapy Area:
• OthersType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Natalia MARTIN [first_name] => Natalia [last_name] => MARTIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 473 [terms] => Array ( [0] => Others ) [taxonomie] => Academic Research, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Therapeutic [taxonomieurl] => Academic Research, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Therapeutic ) [474] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD18 (clone 6.7) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd18-clone-6-7/ [post_content] => [post_date] => 2019-12-05 13:59:09 [post_modified] => 2024-09-11 16:05:43 [ID] => 3876 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3801a26d-f10e-cd71-820f-5b768f8e583f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00497 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 474 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [475] => stdClass Object ( [post] => stdClass Object ( [post_title] => HG5LN cell line [guid] => https://technology-offers.inserm-transfert.com/offer/hg5ln-cell-line/ [post_content] => HG5LN were generated by transfection of cervical cancer HeLa cells with the (GAL4RE)5-betaGlobin-Luciferase-SV40-Neomycin plasmid. [post_date] => 2019-12-05 13:59:08 [post_modified] => 2024-09-11 16:06:51 [ID] => 3875 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 37885f45-434c-4a5b-874b-8199dfcf58f2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00318 [keywords] => luciferase, pharmaceutical and environmental chemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OncologyTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 475 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology ) [476] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD56 (clone CRET 56) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd56-clone-cret-56/ [post_content] => [post_date] => 2019-12-05 13:59:04 [post_modified] => 2024-09-11 16:04:11 [ID] => 3870 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 345626a9-9cd4-456c-bb6d-3bd6a271eb47 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00214 [keywords] => CD56 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 476 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse ) [477] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Mouse Tcr Vbeta2T (clone B20.6) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-tcr-vbeta2t-clone-b20-6/ [post_content] => [post_date] => 2019-12-05 13:59:03 [post_modified] => 2024-09-11 16:05:17 [ID] => 3869 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3396260f-bf3a-4d1e-b619-c876fd143f38 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00112 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bernard MALISSEN [first_name] => Bernard [last_name] => MALISSEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 477 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat ) [478] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD25 (clone BC96) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd25-clone-bc96/ [post_content] => [post_date] => 2019-12-05 13:59:00 [post_modified] => 2024-09-11 16:05:23 [ID] => 3867 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 328adef7-5625-4509-989e-243a1673b8d2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00178 [keywords] => CD25 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 478 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [479] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD2 (clones 0275, 20) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd2-clones-0275-20/ [post_content] => [post_date] => 2019-12-05 13:58:57 [post_modified] => 2024-09-11 16:04:10 [ID] => 3863 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3210fb47-c3ef-4783-a012-bdbfd0e5d3ce [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00163 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 479 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [480] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Mouse CD71 (Mouse transferrin receptor) (clones H129-20 & H129-121) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd71-mouse-transferrin-receptor-clones-h129-20-h129-121/ [post_content] => Recognize the extracellular domain of the dimeric mouse transferrin receptor (Mr 200 000). [post_date] => 2019-12-05 13:58:56 [post_modified] => 2024-09-11 16:04:09 [ID] => 3862 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 317bd7fb-d9dd-4c95-9577-144a871126c0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00341 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 480 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Proof of concept in vitro, Rat, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2b, Mouse, Proof of concept in vitro, Rat, Western Blot ) [481] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-histone H1zero (clone 27E8E10) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-histone-h1zero-clone-27e8e10/ [post_content] => [post_date] => 2019-12-05 13:58:55 [post_modified] => 2024-09-11 16:05:09 [ID] => 3861 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3105ea93-7a73-49c8-ba99-66e77681cdeb [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00286 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Saadi KHOCHBIN [first_name] => Saadi [last_name] => KHOCHBIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 481 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others, Western Blot ) [482] => stdClass Object ( [post] => stdClass Object ( [post_title] => HELN hER alpha cell line [guid] => https://technology-offers.inserm-transfert.com/offer/heln-er-alpha-cell-line/ [post_content] => HELN were generated by transfection of cervical cancer HeLa cells with the ERE-betaGlobin-Luciferase-SV40-Neomycin plasmid. HELN hER alpha cells were generated by transfection of HELN cells with the plasmid pSG5-human ERalpha-puromycin. [post_date] => 2019-12-05 13:58:54 [post_modified] => 2024-09-11 16:07:20 [ID] => 3860 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 30c5f9a6-6343-435b-b330-b4962180dc42 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00316 [keywords] => hER alpha, luciferase, pharmaceutical and environmental estrogens [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Women healthTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 482 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Women health [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Women health ) [483] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD28 (clone CD28.4.75.24) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd28-clone-cd28-4-75-24/ [post_content] => [post_date] => 2019-12-05 13:58:53 [post_modified] => 2024-09-11 16:04:09 [ID] => 3859 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 309589f4-3385-48d3-a104-6ec978679ceb [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00184 [keywords] => CD28 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 483 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgM, Mouse ) [484] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F2-2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f2-2/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 271 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 13:58:52 [post_modified] => 2024-09-11 16:06:46 [ID] => 3858 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 3044833b-52ec-478e-aafd-2b0925a044e6 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00460 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 484 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [485] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD82b (clone TS82b) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd82b-clone-ts82b/ [post_content] => [post_date] => 2019-12-05 13:58:50 [post_modified] => 2024-09-11 16:05:31 [ID] => 3855 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2e988c12-cf25-48dd-82ed-a59d33614f10 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00239 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 485 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [486] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse T lymphoma cell line - KO99L [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-t-lymphoma-cell-line-ko99l/ [post_content] => The murine primary KO99L cell line was established by cultivating tumoral thymocytes from a tPTEN-/- mouse. Mice carrying a T cell-specific deletion of PTEN develop invasive T-cell lymphomas and die within 10-15 weeks. KO99L cells display an abnormal constitutive activation of the PI3K/Akt/mTOR pathway that supports their enhanced proliferation and deregulated metabolism, as well as their resistance to cell death. This cell line also displayed an amplification of c-Myc . [post_date] => 2019-12-05 13:58:49 [post_modified] => 2024-09-11 16:06:41 [ID] => 3854 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2d4e1ca8-b521-4955-9c61-7f2dda43160e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00493 [keywords] => T-ALL/LL ; PI3K/Akt/mTor ; c-myc [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Véronique IMBERT [first_name] => Véronique [last_name] => IMBERT [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 486 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro, Proof of concept in vivo [taxonomieurl] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Others, Proof of concept in vitro, Proof of concept in vivo ) [487] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD28 (clone CD28.6.1.1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd28-clone-cd28-6-1-1/ [post_content] => [post_date] => 2019-12-05 13:58:47 [post_modified] => 2024-09-11 16:05:38 [ID] => 3852 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2cbbb9ba-05c4-4c13-b54f-c00c01e5d8cf [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00187 [keywords] => CD28 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 487 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot ) [488] => stdClass Object ( [post] => stdClass Object ( [post_title] => Establishment of redifferentiated cells after treatment of neoplastic invasive cell lines with curcumin [guid] => https://technology-offers.inserm-transfert.com/offer/establishment-of-redifferentiated-cells-after-treatment-of-neoplastic-invasive-cell-lines-with-curcumin/ [post_content] => When undifferentiated, invasive neoplastic cell lines are treated with an optimal time / concentration combination of curcumin (under conditions producing dramatic cell death), a small proportion of surviving cells can undergo a process of redifferentiation. These clones of redifferentiated cells, together with the original tumor cells, could represent interesting biological tools for both academic research (onco-immunology, genetics / epigenetics) and industry research (for example design of cancer vaccines). [post_date] => 2019-12-05 13:58:44 [post_modified] => 2024-09-11 16:07:10 [ID] => 3849 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2c2972aa-0e4a-45c9-8557-f5464dfef57c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00495 [keywords] => Redifferentiation ; Neoplastic cells ; Epithelial cells ; Phytochemicals [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OncologyTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 488 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, Diagnostic, Genetic Disorders, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Genetic Disorders, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Proof of concept in vitro, Therapeutic ) [489] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD53 (clone TS53) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd53-clone-ts53/ [post_content] => [post_date] => 2019-12-05 13:58:43 [post_modified] => 2024-09-11 16:05:30 [ID] => 3848 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2b709b79-5204-4302-b7c0-97a1a697ed0f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00212 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 489 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [490] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human Ferroportin polyclonal Antibodies [guid] => https://technology-offers.inserm-transfert.com/offer/human-ferroportin-polyclonal-antibodies/ [post_content] => Rabbit Polyclonal antibodies raised against 3 differents portions of the iron exporter Human Ferroportin 1 = Solute Carrier Family 40 (Iron-Regulated Transporter) Member 1 (SLC40A1): 1- Named anti-HuFPN1 : intracellular loop; residues 224-303 (79aa)2- Named anti-HuFPN2 : extracellular loop; residues 395-450 (55aa)3- Named anti-HuFPN3 : C terminal sequence; residues 541-571 (30aa) [post_date] => 2019-12-05 13:58:42 [post_modified] => 2024-09-11 16:04:07 [ID] => 3847 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2b61a936-1e0c-46a6-91cc-97d0bcd9895c [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00469 [keywords] => Iron ; Ferropotin [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Proof of concept in vitroUses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Francois CANONNE-HERGAUX [first_name] => Francois [last_name] => CANONNE-HERGAUX [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 490 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Inflammation, Metabolic Disorders, Other, Others, Proof of concept in vitro, Rabbit, Western Blot [taxonomieurl] => Academic Research, Human, Immunology, Inflammation, Metabolic Disorders, Other, Others, Proof of concept in vitro, Rabbit, Western Blot ) [491] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F1-0 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f1-0/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 277 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 13:58:40 [post_modified] => 2024-09-11 16:07:03 [ID] => 3845 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2aed31e1-6318-4bfd-91bd-daa30361836f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00420 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 491 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [492] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD81 (clone TS81) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd81-clone-ts81/ [post_content] => [post_date] => 2019-12-05 13:58:37 [post_modified] => 2024-09-11 16:05:31 [ID] => 3842 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 297952cb-61bd-41bb-a281-38ad1985eea7 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00238 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 492 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot [taxonomieurl] => Academic Research, Flow Cytometry, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Western Blot ) [493] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD11a (clone 2H8.3) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd11a-clone-2h8-3/ [post_content] => [post_date] => 2019-12-05 13:58:36 [post_modified] => 2024-09-11 16:04:05 [ID] => 3841 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 28b7cdfd-6128-476d-ab71-41201d39a46a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00132 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 493 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [494] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 142-1-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-142-1-1/ [post_content] => [post_date] => 2019-12-05 13:58:32 [post_modified] => 2024-09-11 16:04:04 [ID] => 3837 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 27076209-e951-49d3-abf7-e964e938f700 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00295 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 494 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others ) [495] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelioma cell line M5-T1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelioma-cell-line-m5-t1/ [post_content] => Neoplastic rat cell line isolated from tumor masses (peritoneal mesothelioma) collected in the peritoneal cavity of a male rat (F344) after 378 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 13:58:31 [post_modified] => 2024-09-11 16:07:17 [ID] => 3836 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 25ece7ec-d1c1-4d15-affa-b7cd5932df2f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00417 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 495 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Proof of concept in vivo, Therapeutic ) [496] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human Interferon -g (IFNg) (clone 29.51A10) [guid] => https://technology-offers.inserm-transfert.com/offer/human-interferon-g-ifng-clone-29-51a10/ [post_content] => sandwich ELISA; ELISPOT [post_date] => 2019-12-05 13:58:30 [post_modified] => 2024-09-11 16:04:03 [ID] => 3835 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 257a60d7-71af-4746-97cc-63d05188ddbe [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00331 [keywords] => Interferon-g; (IFNg) [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 496 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [497] => stdClass Object ( [post] => stdClass Object ( [post_title] => Transgenic mouse model for myotonic dystrophy: DMSXL carrying >1000 CTG repeats [guid] => https://technology-offers.inserm-transfert.com/offer/transgenic-mice-model-for-myotonic-dystrophy-type-1-dm1-dmsxl/ [post_content] => This transgenic mice model (DMSXL) contains large human genomic DNA sequence carrying the DMPK gene with very large repeat (>1200 CTG). They show intergenerational and somatic instability biased towards expansions. Homozygous mice, expressing enough toxic RNA carrying CUG expansion display a clear phenotype and some DM1 features: Growth retardation, muscle weakness, myotonia, splicing defects in muscle heart and brain, especially at young ages. Brain, muscles and heart abnormalities are under characterisation. [post_date] => 2019-12-05 13:58:29 [post_modified] => 2024-09-11 16:06:55 [ID] => 3833 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2494b812-80b7-43d3-8690-68524981e037 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00399 [keywords] => mice model; myotonic dystrophy type 1; DM1 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Geneviève GOURDON [first_name] => Geneviève [last_name] => GOURDON [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 497 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Central Nervous System, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Musculoskeletal, Others, Proof of concept in vivo [taxonomieurl] => Academic Research, Central Nervous System, Genetic Disorders, Industry Research (screening, tox.studies, bioreactor, ...), Musculoskeletal, Others, Proof of concept in vivo ) [498] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD28 (clone CD28.5.86.14) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd28-clone-cd28-5-86-14/ [post_content] => [post_date] => 2019-12-05 13:58:26 [post_modified] => 2024-09-11 16:04:02 [ID] => 3831 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2425fc24-935e-4a07-852c-eb166db316c1 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00185 [keywords] => CD28 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 498 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [499] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD90.2 (Mouse Thy-1.2) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd90-2-mouse-thy-1-2-several-clones/ [post_content] => A collection of rat monoclonal antibodies recognizing Thy-1-2-associated epitopesH154-530 ; H140-226 ; H154-18 ; H154-470 ; H154-238 (all IgM,kappa) and H129-93 (IgG2c,K).Do not react with Thy-1.1 [post_date] => 2019-12-05 13:58:24 [post_modified] => 2024-09-11 16:04:02 [ID] => 3829 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 23e9e2d1-fd25-4d67-93e3-a4cea707d94a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00353 [keywords] => Mouse Thy-1.2 ; CD90.2 ; Thy-1 epitope region A [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 499 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat [taxonomieurl] => Academic Research, Central Nervous System, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat ) [500] => stdClass Object ( [post] => stdClass Object ( [post_title] => Monoclonal anti-Human FcgRIIA/B / CD32 antibody (clone 2B2) [guid] => https://technology-offers.inserm-transfert.com/offer/human-fcgriia-b-clone-2b2/ [post_content] => [post_date] => 2019-12-05 13:58:23 [post_modified] => 2024-09-11 16:05:46 [ID] => 3828 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 23d57e6a-b2eb-4ed8-a136-dfef1d8092aa [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00324 [keywords] => FcgRIIA/B [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 500 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other ) [501] => stdClass Object ( [post] => stdClass Object ( [post_title] => mouse anti-human CD43-CBF78 (clone CBF.78) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd43-cbf78-clone-cbf-78/ [post_content] => this antibody is suitable for use on paraffin sections.It reacts with T-cells. [post_date] => 2019-12-05 13:58:20 [post_modified] => 2024-09-11 16:04:01 [ID] => 3825 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 22a1fc29-8e0f-4c9d-96f3-4395e77362b3 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00392 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 501 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Human, Immunofluorescence, Immunology, Immunoprecipitation, lgG1, Mouse, Oncology, Western Blot [taxonomieurl] => Academic Research, Diagnostic, Human, Immunofluorescence, Immunology, Immunoprecipitation, lgG1, Mouse, Oncology, Western Blot ) [502] => stdClass Object ( [post] => stdClass Object ( [post_title] => Scavenger Receptor BI Knockout mouse [guid] => https://technology-offers.inserm-transfert.com/offer/scavenger-receptor-bi-knockout-mouse/ [post_content] => The class B, type I scavenger receptor (Srb1 or Scarb1) is a cell surface HDL receptor. It plays a key role in determining the levels of plasma lipoprotein cholesterol (primarily HDL) and the accumulation of cholesterol stores in the adrenal gland. Homozygous females are infertile if the diet is not supplemented with probucol; homozygous males are fertile. A cross between heterozygotes will generate homozygous pups at a normal mendelian ratio if the breeding pair are fed with a probucol supplemented diet. [post_date] => 2019-12-05 13:58:19 [post_modified] => 2024-09-11 16:06:51 [ID] => 3824 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2289c18e-e73a-4827-9601-0d2460aeee56 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00307 [keywords] => SR-BI ; atherosclerosis ; HDL-cholesterol ; Plasmodium [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Infectious DiseasesTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => [first_name] => [last_name] => [wp_capabilities] => [wp_user_level] => [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 502 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Cardiovascular Diseases, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Proof of concept in vivo [taxonomieurl] => Academic Research, Cardiovascular Diseases, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Proof of concept in vivo ) [503] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Mouse I-Ak (Mouse MHC classe II allodeterminants) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-mouse-i-ak-mouse-mhc-classe-ii-allodeterminants-several-clones/ [post_content] => A collection of 17 mouse allospecific monoclonal antibodies raised in the A.TH (Is) anti-A.TL (Ik) combination. [post_date] => 2019-12-05 13:58:17 [post_modified] => 2024-09-11 16:03:59 [ID] => 3822 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 2174fbe9-e736-4a4e-8a12-02655f55830f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00338 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Michel PIERRES [first_name] => Michel [last_name] => PIERRES [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 503 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse, Proof of concept in vitro, Proof of concept in vivo, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse, Mouse, Proof of concept in vitro, Proof of concept in vivo, Western Blot ) [504] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD1b (clone O249) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1b-clone-o249/ [post_content] => [post_date] => 2019-12-05 13:58:15 [post_modified] => 2024-09-11 16:05:38 [ID] => 3821 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 20cc8471-b489-4c3a-a124-a101b691924b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00152 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 504 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [505] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD81 (clone MT81) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd81-clone-mt81/ [post_content] => [post_date] => 2019-12-05 13:58:14 [post_modified] => 2024-09-11 16:05:33 [ID] => 3820 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 20795328-f39e-41c1-a5f9-807f54cbcb3f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00237 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Infectious DiseasesTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 505 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Mouse, Other, Rat, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Mouse, Other, Rat, Western Blot ) [506] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human ADAM10 (a disintegrin and metalloprotease domain 10) (clone 11G2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-adam10-a-disintegrin-and-metalloprotease-domain-10-clone-11g2/ [post_content] => Mammalian disintegrin-metalloproteasem Kuzbanian protein homolog, CDw156, Disintegrin and metalloproteinase domain-containing protein 10 [post_date] => 2019-12-05 13:58:13 [post_modified] => 2024-09-11 16:05:28 [ID] => 3819 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1fcec250-fb7b-4e9d-a35c-28aae591c4bc [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00070 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 506 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Flow Cytometry, Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot [taxonomieurl] => Academic Research, Central Nervous System, Flow Cytometry, Human, Immunofluorescence, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Western Blot ) [507] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD21 (clone DR53) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd21-clone-dr53/ [post_content] => [post_date] => 2019-12-05 13:58:12 [post_modified] => 2024-09-11 16:03:59 [ID] => 3818 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1fad2356-e3a3-41fa-a550-08d4a1029fbc [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00165 [keywords] => CD21 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Georges DELSOL [first_name] => Georges [last_name] => DELSOL [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 507 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [508] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-human plasmin-Antiplasmin complexes (clone CPL-12) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-plasmin-antiplasmin-complexes-clone-cpl-12/ [post_content] => [post_date] => 2019-12-05 13:58:09 [post_modified] => 2024-09-11 16:03:57 [ID] => 3815 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1f3245c0-3275-431a-9a14-08e8a40fe6fa [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00010 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eduardo ANGLES-CANO [first_name] => Eduardo [last_name] => ANGLES-CANO [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 508 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [509] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rabbit Polyclonal Anti-VGLUT2 serum [guid] => https://technology-offers.inserm-transfert.com/offer/rabbit-polyclonal-anti-vglut2-serum/ [post_content] => [post_date] => 2019-12-05 13:58:07 [post_modified] => 2024-09-11 16:03:57 [ID] => 3813 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1de9f985-4ec2-4212-91fd-5ca1d28c3601 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00079 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bruno GIROS [first_name] => Bruno [last_name] => GIROS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 509 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Rabbit [taxonomieurl] => Academic Research, Central Nervous System, Industry Research (screening, tox.studies, bioreactor, ...), Other, Other, Rabbit ) [510] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD11a (clone 8F2.7) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd11a-clone-8f2-7/ [post_content] => [post_date] => 2019-12-05 13:58:05 [post_modified] => 2024-09-11 16:03:56 [ID] => 3811 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1d0d25b6-5879-4751-ae27-18d342e278f5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00133 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 510 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [511] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD8 a (clone 4D12.1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd8-a-clone-4d12-1/ [post_content] => [post_date] => 2019-12-05 13:58:04 [post_modified] => 2024-09-11 16:03:56 [ID] => 3810 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1b71dfd3-22b0-49c1-9a2d-c73cb8ad476b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00230 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 511 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [512] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human Interferon -g (IFNg) (clone 16.32E12) [guid] => https://technology-offers.inserm-transfert.com/offer/human-interferon-g-ifng-clone-16-32e12/ [post_content] => sandwich ELISA, ELISPOT [post_date] => 2019-12-05 13:58:00 [post_modified] => 2024-09-11 16:03:54 [ID] => 3808 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1a707af9-3ab6-4cae-b582-6744986c4fdb [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00332 [keywords] => Interferon -g; (IFNg) [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 512 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [513] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD100 (clone BB16) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd100-clone-bb16/ [post_content] => [post_date] => 2019-12-05 13:57:59 [post_modified] => 2024-09-11 16:03:54 [ID] => 3807 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 19a1f8fd-aadf-4721-87b6-c4acf656364f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00119 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 513 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [514] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD26 (clone BA5b) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd26-clone-ba5b/ [post_content] => [post_date] => 2019-12-05 13:57:56 [post_modified] => 2024-09-11 16:05:05 [ID] => 3804 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 1854fa00-0571-4371-81b0-0dee604a7abf [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00179 [keywords] => CD26 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 514 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [515] => stdClass Object ( [post] => stdClass Object ( [post_title] => CPT1 expressing yeast strains [guid] => https://technology-offers.inserm-transfert.com/offer/cpt1-expressing-yeast-strains/ [post_content] => Saccharomyces cerevisiae expressing under the GAL promoter either the wild-type rat liver CPT1, mutated rat liver CPT1 or chimeric CPT. CPT1A activity is inhibited by malonyl-CoA, its allosteric inhibitor. [post_date] => 2019-12-05 13:57:56 [post_modified] => 2024-09-11 16:07:27 [ID] => 3803 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 17980089-f9dd-403d-be50-53cdc4863b7e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00005 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Carina PRIP-BUUS [first_name] => Carina [last_name] => PRIP-BUUS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 515 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro, Proof of concept in vivo, Therapeutic [taxonomieurl] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Proof of concept in vitro, Proof of concept in vivo, Therapeutic ) [516] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-lano (LAP and no PDZ) protein (clone 353-1-1) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-lano-lap-and-no-pdz-protein-clone-353-1-1/ [post_content] => [post_date] => 2019-12-05 13:57:52 [post_modified] => 2024-09-11 16:03:51 [ID] => 3799 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 130f1345-bd30-4626-bd7d-40e73522c81a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00290 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Paul BORG [first_name] => Jean-Paul [last_name] => BORG [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 516 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Others ) [517] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD29 (clone K20) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd29-clone-k20/ [post_content] => [post_date] => 2019-12-05 13:57:49 [post_modified] => 2024-09-11 16:05:50 [ID] => 3796 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 118d50cc-9d6c-4887-8bfc-aaaffd961ae5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00188 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 517 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Mouse ) [518] => stdClass Object ( [post] => stdClass Object ( [post_title] => HELN ER beta cell line [guid] => https://technology-offers.inserm-transfert.com/offer/heln-er-beta-cell-line/ [post_content] => HELN were generated by transfection of cervical cancer HeLa cells with the ERE-betaGlobin-Luciferase-SV40-Neomycin plasmid. HELN hER beta cells were generated by transfection of HELN cells with the plasmid pSG5-human ERbeta-puromycin. Lignée cellulaire de cancer du col de l?utérus HeLa (ER négative) transfectée premièrement par le plasmide de la luciférase firefly sous le contrôle d?un élément de réponse au récepteur des oestrogènes ERE, secondairement par un plasmide d?expression du récepteur des oestrogènes humain beta [post_date] => 2019-12-05 13:57:47 [post_modified] => 2024-09-11 16:07:19 [ID] => 3794 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0ff3e23f-8b5c-42c3-a4bf-fc3a6d6af81e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00317 [keywords] => hER beta, luciferase, pharmaceutical and environmental estrogens [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• Women healthTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Patrick BALAGUER [first_name] => Patrick [last_name] => BALAGUER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 518 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Women health [taxonomieurl] => Industry Research (screening, tox.studies, bioreactor, ...), Oncology, Women health ) [519] => stdClass Object ( [post] => stdClass Object ( [post_title] => Human FcgRIIA/B (clone 3D3) [guid] => https://technology-offers.inserm-transfert.com/offer/human-fcgriia-b-clone-3d3/ [post_content] => [post_date] => 2019-12-05 13:57:46 [post_modified] => 2024-09-11 16:03:50 [ID] => 3793 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0fdc9d39-54ac-4b6a-9b2e-7d3e463ff6d0 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00325 [keywords] => FcgRIIA [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Luc TEILLAUD [first_name] => Jean-Luc [last_name] => TEILLAUD [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 519 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other ) [520] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD1a (clone O10) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1a-clone-o10/ [post_content] => [post_date] => 2019-12-05 13:57:45 [post_modified] => 2024-09-11 16:06:05 [ID] => 3792 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0fce93cb-6092-4717-afc3-8ea388014a70 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00147 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 520 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Other, Other [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Other, Other ) [521] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Rat cleaved SNAP-25 (botulinum neurotoxin E) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-rat-cleaved-snap-25-botulinum-neurotoxin-e/ [post_content] => This antibody detects exclusively SNAP-25 cleaved by botulinum neurotoxin E and not the full-length protein [post_date] => 2019-12-05 13:57:44 [post_modified] => 2024-09-11 16:03:49 [ID] => 3791 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0fb44206-8306-4862-a327-2208a7d63fcd [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00314 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• Central Nervous SystemTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Christian LEVEQUE [first_name] => Christian [last_name] => LEVEQUE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 521 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Central Nervous System, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot [taxonomieurl] => Academic Research, Central Nervous System, Diagnostic, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Other, Western Blot ) [522] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD1c (clone L161) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1c-clone-l161/ [post_content] => [post_date] => 2019-12-05 13:57:43 [post_modified] => 2024-09-11 16:06:09 [ID] => 3789 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0e49a423-ef25-4135-b212-522738720e63 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00153 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 522 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [523] => stdClass Object ( [post] => stdClass Object ( [post_title] => Microbiota dependent spontaneous colorectal cancer [guid] => https://technology-offers.inserm-transfert.com/offer/microbiota-dependent-spontaneous-colorectal-cancer/ [post_content] => 100% of the animals spontaneously tumor in the distal part of the colon after 7 month of age, or within 5 weeks after bone marrow transfer. The mutation affect the immune system and not the stromal cells. Tumor development is totally prevented in the absence of microbiota. [post_date] => 2019-12-05 13:57:38 [post_modified] => 2024-09-11 16:06:46 [ID] => 3784 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0d3bfa27-f5cb-441b-898f-68c98480f82b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00491 [keywords] => microbiota ; Colorectal cancer [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• Colorectal CancerTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Julien MARIE [first_name] => Julien [last_name] => MARIE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 523 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Academic Research, Colorectal Cancer, Diagnostic, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Inflammation, Metabolic Disorders, Oncology, Proof of concept in vivo, Theranostic (patients stratification, ...), Therapeutic [taxonomieurl] => Academic Research, Colorectal Cancer, Diagnostic, Immunology, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Inflammation, Metabolic Disorders, Oncology, Proof of concept in vivo, Theranostic (patients stratification, ...), Therapeutic ) [524] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-mouse Tcr Vbeta10T (clone B21.1) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-tcr-vbeta10t-clone-b21-1/ [post_content] => [post_date] => 2019-12-05 13:57:37 [post_modified] => 2024-09-11 16:03:46 [ID] => 3783 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0ca8f31c-1aa5-4cb8-9a70-9738bcef2c6f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00111 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bernard MALISSEN [first_name] => Bernard [last_name] => MALISSEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 524 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat [taxonomieurl] => Academic Research, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat ) [525] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD9 (clone 4.1F12) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd9-clone-4-1f12/ [post_content] => [post_date] => 2019-12-05 13:57:36 [post_modified] => 2024-09-11 16:05:55 [ID] => 3782 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0c92b2bd-d5a7-4cb8-bcf0-f92a3b9687d5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00241 [keywords] => 1) Charrin S, Latil M, Soave S, Polesskaya A, Chrétien F, Boucheix C, Rubinstein E. Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81. Nat Commun. 2013 Apr 9;4:1674. doi: 10.1038
comms2675.
2) Silvie O, Charrin S, , Billard M, Franetich JF, Clark K, van Gemert GJ, Sauerwein RW, Dautry F, Boucheix C, Mazier D, Rubinstein E. Cholesterol contributes to the organization of tetraspanin-enriched microdomains and to CD81-dependent infection by malaria sporozoites. J. Cell Science, 2006, 119, 1992-2002.
3) Rubinstein E, Ziyyat A, Prenant M, Wrobel E, Wolf JP, Levy S, Le Naour F, Boucheix C. Reduced fertility of female mice lacking CD81. Dev Biol., 2006, 290:351-8.
4) Le Naour F, Rubinstein E, Jasmin C, Prenant M, Boucheix C. Severely reduced female fertility in CD9-deficient mice. Science 2000, 287, 319-321. [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Eric RUBINSTEIN [first_name] => Eric [last_name] => RUBINSTEIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 525 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Flow Cytometry, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat, Western Blot [taxonomieurl] => Academic Research, Flow Cytometry, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat, Western Blot ) [526] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD38 (clone BB51) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd38-clone-bb51/ [post_content] => [post_date] => 2019-12-05 13:57:35 [post_modified] => 2024-09-11 16:05:39 [ID] => 3781 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0c05e1fb-a36f-419c-ac02-162d03dddc43 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00197 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 526 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [527] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD45 (clone O509) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd45-clone-o509/ [post_content] => [post_date] => 2019-12-05 13:57:33 [post_modified] => 2024-09-11 16:03:45 [ID] => 3779 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0bbb44dc-543e-4ac1-b480-249489eaa984 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00206 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 527 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [528] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line M2-2 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-m2-2/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a male rat (Fischer F344) after 270 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 13:57:32 [post_modified] => 2024-09-11 16:07:12 [ID] => 3777 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0a465acb-04de-49c6-b87a-d705d653b7f2 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00426 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 528 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [529] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD2R (clone G144) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd2r-clone-g144/ [post_content] => [post_date] => 2019-12-05 13:57:30 [post_modified] => 2024-09-11 16:03:45 [ID] => 3776 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0a084edd-962e-40e6-94ec-c68c3ff77626 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00189 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 529 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [530] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat-anti TP53INP1, clone A1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-tp53inp1-clone-a1/ [post_content] => The monoclonal antibody reacts with human and mouse TP53INP1 (both isoforms TP53INP1alpha and TP53INP1beta). TP53INP1 is a key stress factor endowed with a tumor suppressor activity as its transcriptional inducer p53. It is involved in the regulation of p53 activity, in the process of autophagy, and in the control of cell redox state. In human cancers, TP53INP1 is either down-regulated (pancreas, stomach) or overexpressed (thyroid, prostate). [post_date] => 2019-12-05 13:57:27 [post_modified] => 2024-09-11 16:03:44 [ID] => 3774 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 08a7aa2d-01a5-4f9c-bf01-ebd60a4c7a22 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00467 [keywords] => Tumor suppression ; Oxidative stress [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Alice CARRIER [first_name] => Alice [last_name] => CARRIER [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 530 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, ELISA (or compatible technique), Gastrointestinal Diseases, Genetic Disorders, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Oncology, Rat [taxonomieurl] => Academic Research, Diagnostic, ELISA (or compatible technique), Gastrointestinal Diseases, Genetic Disorders, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Oncology, Rat ) [531] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD49d (clone O403) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd49d-clone-o403/ [post_content] => [post_date] => 2019-12-05 13:57:26 [post_modified] => 2024-09-11 16:05:40 [ID] => 3773 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 08179c34-3b29-46c1-96bc-70f9258b4480 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00208 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 531 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [532] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD1a (clone L547) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd1a-clone-l547/ [post_content] => [post_date] => 2019-12-05 13:57:26 [post_modified] => 2024-09-11 16:03:43 [ID] => 3772 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 07b3696a-70c8-4e7b-ae3a-6cc9bc6e536a [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00150 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Armand BENSUSSAN [first_name] => Armand [last_name] => BENSUSSAN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 532 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [533] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat Anti-Human CD25 (clone 36A1.2) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd25-clone-36a1-2/ [post_content] => [post_date] => 2019-12-05 13:57:25 [post_modified] => 2024-09-11 16:03:43 [ID] => 3771 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 06a3659b-efad-448d-973b-0e6568c1d127 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00176 [keywords] => CD25 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 533 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [534] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse Jam-1 (JAM-A, F11 Receptor) (clone H202-106) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-jam-1-jam-a-f11-receptor-clone-h202-106/ [post_content] => [post_date] => 2019-12-05 13:57:23 [post_modified] => 2024-09-11 16:05:11 [ID] => 3769 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 05aa6a8b-0b1b-40c5-bf2a-1b2f210ed41d [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00368 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 534 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Rat [taxonomieurl] => Academic Research, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse, Rat ) [535] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse anti-Human CD5 (clone C1.1E4) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd5-clone-c1-1e4/ [post_content] => [post_date] => 2019-12-05 13:57:22 [post_modified] => 2024-09-11 16:03:42 [ID] => 3768 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 051d40ad-5a66-47a2-8982-f107170104a3 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00209 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 535 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse [taxonomieurl] => Academic Research, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), lgG1, Mouse ) [536] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rabbit CPT1A antibody (polyclonal) [guid] => https://technology-offers.inserm-transfert.com/offer/rabbit-cpt1a-antibody-polyclonal/ [post_content] => A polyclonal antibody raised in rabbit against the rat liver carnitine palmitoyltransferase 1. This antibody is very specific, has an efficient titer and detects CPT1A protein in different species (rat, mouse, human, pig). It can be used for western-blotting, Blue-Native PAGE, immunoprecipitation and immunohistochemistry studies. [post_date] => 2019-12-05 13:57:20 [post_modified] => 2024-09-11 16:05:27 [ID] => 3766 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 03aef2c7-c44a-4542-a534-7ea945dd31cb [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00004 [keywords] => CPT1A [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• DiagnosticUses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Carina PRIP-BUUS [first_name] => Carina [last_name] => PRIP-BUUS [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 536 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Immunofluorescence, Immunoprecipitation, Metabolic Disorders, Nutritional disorder, Oncology, Other, Other, Proof of concept in vitro, Proof of concept in vivo, Rabbit, Western Blot [taxonomieurl] => Academic Research, Diagnostic, Immunofluorescence, Immunoprecipitation, Metabolic Disorders, Nutritional disorder, Oncology, Other, Other, Proof of concept in vitro, Proof of concept in vivo, Rabbit, Western Blot ) [537] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Human CD25 (clone 11H2.16) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-human-cd25-clone-11h2-16/ [post_content] => [post_date] => 2019-12-05 13:57:18 [post_modified] => 2024-09-11 16:03:41 [ID] => 3764 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 037743fd-6d4d-4f1e-b511-dedfb3b54fc5 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00171 [keywords] => CD25 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 537 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), lgG2a, Rat ) [538] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-histone H1zero (clone 34B10H4) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-histone-h1zero-clone-34b10h4/ [post_content] => [post_date] => 2019-12-05 13:57:17 [post_modified] => 2024-09-11 16:05:09 [ID] => 3763 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 02d8e69d-c4c4-460c-8a00-fe993e775ec8 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00287 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Saadi KHOCHBIN [first_name] => Saadi [last_name] => KHOCHBIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 538 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Immunofluorescence, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot [taxonomieurl] => Academic Research, Immunofluorescence, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Other, Others, Western Blot ) [539] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human FLT3 (FMS-like tyrosine kinase 3) CD135 (clone SF1.340) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-flt3-fms-like-tyrosine-kinase-3-cd135-clone-sf1-340/ [post_content] => Flt-3/Flk-2 Antibody (SF1.340) is a mouse monoclonal IgG1 (kappa light chain) [post_date] => 2019-12-05 13:57:16 [post_modified] => 2024-09-11 16:06:16 [ID] => 3762 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 01f1fadb-82c9-4d6e-9667-e706e9a78b2f [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00036 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Theranostic (patients stratification, ...)Uses:
• OncologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Olivier ROSNET [first_name] => Olivier [last_name] => ROSNET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 539 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Diagnostic, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Oncology, Other, Theranostic (patients stratification, ...) [taxonomieurl] => Academic Research, Diagnostic, Human, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Oncology, Other, Theranostic (patients stratification, ...) ) [540] => stdClass Object ( [post] => stdClass Object ( [post_title] => Stable human prolactin receptor Ba/F3 cell [guid] => https://technology-offers.inserm-transfert.com/offer/stable-human-prolactin-receptor-ba-f3-cell/ [post_content] => Ba/F3 cells are mouse pro-B lymphocytes that are dependent on IL-3 for survival/growth. We stably transfeted them with expression vector encoding the long isoform of the human prolactin receptor. Their survival/growth can now be shifted to prolactin in the absence of IL-3. [post_date] => 2019-12-05 13:57:15 [post_modified] => 2024-09-11 16:06:52 [ID] => 3761 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 01ba256e-0017-4af4-84d0-ebf27d29cb51 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00003 [keywords] => prolactin ; prolactin receptor ; luciferase ; agonists ; antagonists [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Vincent GOFFIN [first_name] => Vincent [last_name] => GOFFIN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 540 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Others [taxonomieurl] => Academic Research, Industry Research (screening, tox.studies, bioreactor, ...), Others ) [541] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse Anti-Human CD18 (clone 41.23.2) [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-anti-human-cd18-clone-41-23-2/ [post_content] => [post_date] => 2019-12-05 13:57:12 [post_modified] => 2024-09-11 16:03:39 [ID] => 3759 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 010ecabf-eb5b-47db-bd54-af86f97e26fa [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00143 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel OLIVE [first_name] => Daniel [last_name] => OLIVE [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 541 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other [taxonomieurl] => Academic Research, Human, Immunofluorescence, Immunology, Immunoprecipitation, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other ) [542] => stdClass Object ( [post] => stdClass Object ( [post_title] => Mouse model FoxP3-EGFP [guid] => https://technology-offers.inserm-transfert.com/offer/mouse-model-foxp3-egfp/ [post_content] => The targeting vector was designed to insert (from 5' to 3') an internal ribosomal entry site (IRES) fused to an enhanced green fluorescent protein (EGFP) and a self-excising loxP-flanked ACN cassette into exon 11 of the X-linked forkhead box P3 (Foxp3) gene. The ACN cassette contained a neomycin resistance (Neo) gene and a testes-specific angiotensin-converting enzyme promoter-driven Cre recombinase gene (tACE-Cre). The construct was electroporated into C57BL/6-derived Bruce-4 embryonic stem (ES) cells. Correctly targeted ES cells were injected into FVB blastocysts and chimeric males were bred to C57BL/6J females. The resulting Foxp3GFP mice were maintained on a C57BL/6J background.This reporter mouse model is deposited at The Jackson Laboratory (Jax stock#018628). [post_date] => 2019-12-05 13:57:11 [post_modified] => 2024-09-11 16:06:37 [ID] => 3758 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 00c10a70-aa0f-4944-8c36-b8a27bb36e77 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00482 [keywords] => FoxP3 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Laboratory Animals [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• Laboratory AnimalsType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Bernard MALISSEN [first_name] => Bernard [last_name] => MALISSEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 542 [terms] => Array ( [0] => Laboratory Animals ) [taxonomie] => Immunology, Industry Research (screening, tox.studies, bioreactor, ...) [taxonomieurl] => Immunology, Industry Research (screening, tox.studies, bioreactor, ...) ) [543] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat anti-Mouse CD11a/CD18 (Mouse LFA-1 heavy chain, CD11a) (several clones) [guid] => https://technology-offers.inserm-transfert.com/offer/rat-anti-mouse-cd11a-cd18-mouse-lfa-1-heavy-chain-cd11a-several-clones/ [post_content] => A collection of 8 rat monoclonal antibodies recognizing the heavy chain (CD11a) of the mouse CD11a/CD18 heterodimer LFA-1. The correponding epitopes organize themselves in 3 spatially distinct structural regions of CD11a :Epitope region A : defined by 6 Monoclonal antibodies (H129-37, H68-98,H35-89, H154-595,H85-326, & H155-141); Epitope region C : defined by the monoclonal antibody H129-296 ; and Epitope region D : defined by the monoclonal antibody H154-163. [post_date] => 2019-12-05 13:57:10 [post_modified] => 2024-09-11 16:03:39 [ID] => 3757 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 00a926e2-0c0f-439d-8b05-08c7dc3fd82b [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00355 [keywords] => CD11a ; CD18 [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Antibodies [parent_category] => 215 [inserm_tags_to_put] =>

• Industry Research (screening, tox.studies, bioreactor, ...)Uses:
• ImmunologyTherapy Area:
• AntibodiesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Philippe NAQUET [first_name] => Philippe [last_name] => NAQUET [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 543 [terms] => Array ( [0] => Antibodies ) [taxonomie] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat [taxonomieurl] => Academic Research, ELISA (or compatible technique), Immunofluorescence, Immunology, Immunoprecipitation, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Mouse, Other, Rat ) [544] => stdClass Object ( [post] => stdClass Object ( [post_title] => Xenograft models to study stem and chemoresistant cells, and to assess the in vivo efficacy of new anti-cancer agents [guid] => https://technology-offers.inserm-transfert.com/offer/xenograft-models-to-study-stem-and-chemoresistant-cells-and-to-assess-the-in-vivo-efficacy-of-new-anti-cancer-agents/ [post_content] => We have recently contributed to establish a robust xenotransplantation model (NSG, NRG) to study the leukemic engraftment as well as the stem cell biology in acute leukemias. Others and we also suggest that these highly immunocompromised mice represent a powerful in vivo model to screen new therapeutic strategies (kinase inhibitors, epigentic agents, metabolic agents) and to mimic the chemoresistance and minimal residual disease observed in leukemic patients after chemotherapy.The study of the in vivo chemoresistance is crucial to improve therapeutic outcome of leukemia patients. [post_date] => 2019-12-05 13:57:09 [post_modified] => 2024-09-11 16:07:02 [ID] => 3756 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 0099f22e-2241-497e-b32b-fd6ab40ba380 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00453 [keywords] => preclinical model ; stem cell ; cancer ; hematology ; metabolism [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Know How [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Know HowType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Jean-Emmanuel SARRY [first_name] => Jean-Emmanuel [last_name] => SARRY [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 544 [terms] => Array ( [0] => Know How ) [taxonomie] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Oncology, Others, Proof of concept in vivo, Theranostic (patients stratification, ...), Therapeutic [taxonomieurl] => Academic Research, In vivo studies, Industry Research (screening, tox.studies, bioreactor, ...), Metabolic Disorders, Oncology, Others, Proof of concept in vivo, Theranostic (patients stratification, ...), Therapeutic ) [545] => stdClass Object ( [post] => stdClass Object ( [post_title] => Rat mesothelial cell line F2-1 [guid] => https://technology-offers.inserm-transfert.com/offer/rat-mesothelial-cell-line-f2-1/ [post_content] => Transformed rat mesothelial cell line isolated from the peritoneal fluid of a female rat (Fischer F344) after 298 days of induction with crocidolite (blue asbestos) injected intraperitoneously. [post_date] => 2019-12-05 13:57:07 [post_modified] => 2024-09-11 16:07:06 [ID] => 3755 ) [post_meta] => stdClass Object ( [object] => [application] => [idSugar] => 005f7b19-fc6e-4792-8697-783103ab5950 [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => [bd_referent_id] => [contact_email] => [contact_phone] => [reference_online] => RT00411 [keywords] => mesothelial cells ; tumor marker ; tumor invasion process ; malignant transformation ; proliferation rate [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Cell Lines [parent_category] => 215 [inserm_tags_to_put] =>

• TherapeuticUses:
• OthersTherapy Area:
• Cell LinesType of research tool:

[tags_order_view] => stdClass Object ( [uses] => Uses [thera_area] => Therapy Area [researchtools] => Type of research tool ) ) [user] => stdClass Object ( [nickname] => Daniel POULIQUEN [first_name] => Daniel [last_name] => POULIQUEN [wp_capabilities] => stdClass Object ( [um_researcher] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 545 [terms] => Array ( [0] => Cell Lines ) [taxonomie] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic [taxonomieurl] => Academic Research, Diagnostic, Immunology, Industry Research (screening, tox.studies, bioreactor, ...), Infectious Diseases, Oncology, Others, Proof of concept in vitro, Therapeutic ) [546] => stdClass Object ( [post] => stdClass Object ( [post_title] => Methods for expanding a population of alveolar macrophages in a long term culture [guid] => https://technology-offers.inserm-transfert.com/offer/methods-for-expanding-a-population-of-alveolar-macrophages-in-a-long-term-culture/ [post_content] => The present invention relates to methods for expanding a population of alveolar macrophages in a long term culture. In particular, an object of the present invention relates to a method of expanding a population of alveolar macrophages in a long term culture comprising culturing the population of alveolar macrophages in a culture medium supplemented with an amount of GM-CSF. The population of alveolar macrophages as prepared by the method of the present invention is particularly suitable for the treatment of pulmonary diseases such as Pulmonary Alveolar Proteinosis (PAP) but also for treatment of various diseases such as autoimmune diseases, or transplantation. [post_date] => 2015-12-08 13:56:28 [post_modified] => 2024-09-11 15:44:41 [ID] => 3753 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => fc95a841-47cd-4b21-bc07-3ea229c276de [etat_fiche_online] => en_ligne [date_application] => 08-12-2015 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13284-T1 [keywords] => alveolar macrophages; GM-CSF; cancers, infectious diseases, autoimmune diseases, inflammatory diseases, degenerative diseases, pulmonary diseases [pub_scient_inv_dispo] => Science. 2016 Feb 12;351(6274):aad5510. doi: 10.1126/science.aad5510. Epub 2016 Jan 21. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GEIRSDOTTIR Laufey,MOLAWI Kaaweh [number_application] => European Procedure (Patents) (EPA) - 08 Déc. 2015 - 15 306 959.6 [technology_engineering] => cell_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• TransplantationTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 546 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cell therapy, Cell therapy, Drug, Hit - validation in vivo, Immunology, Lung transplantation, Method, Product, Transplantation [taxonomieurl] => Biologic, Cell therapy, Cell therapy, Drug, Hit - validation in vivo, Immunology, Lung transplantation, Method, Product, Transplantation ) [547] => stdClass Object ( [post] => stdClass Object ( [post_title] => Recombinant flagellin for preventing and treating respiratoryinfections / COPD-AE [guid] => https://technology-offers.inserm-transfert.com/offer/recombinant-flagellin-for-preventing-and-treating-respiratoryinfections-copd-ae/ [post_content] => The present invention relates to the use of an optimized truncated flagellin (TLR5 agonist devoided of toxic effect) for preventing or treating respiratory tract infection. Both preventive and currative effects in the absence of any antibiotic have been demonstrated in a mouse model of infection with S. Pneumoniae. Action mechanism of this immunomodulator includes neutrophil infiltration into airways, upregulation of IL6, TNFa, CXCL1, CXCL2 and CCL20 genes and complete restoration of lung architecture within one week after treatment. Promising data obtained with this novel immunomodulator in combination with antibiotics in various mouse models (infection and superinfection/lung inflammation) open new doors in the field of prevention and treatment of nosocomial infections. [post_date] => 2010-06-25 13:56:28 [post_modified] => 2024-09-11 15:42:39 [ID] => 3752 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => f96c8b4b-ccf3-45f1-bb59-c27ee9524190 [etat_fiche_online] => en_ligne [date_application] => 25-06-2010 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO10412-T1 [keywords] => Infectious diseases, bacterial infection, viral infection, superinfection, COPD acute exhacerbation, lung, flagellin, TLR, TLR-5, immunomodulator, antibiotics, nosocomial infections, prevention, treatment, Antibiotic combination, Innate immune system modulation, respiratory system, Streptococcus pneumoniae, vaccine, Leishmaniasis, adjuvant [pub_scient_inv_dispo] => Infect. Immunol, 2010 Oct;78(10):4226-33 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CHABALGOITY Jose A. [number_application] => International Procedure (PCT) - 25 Juin 2010 - PCT/IB2010/001911 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Infectious DiseasesTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 547 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Infectious Diseases, Lead - validation in vivo, Product, Product, Protein, Recombinant protein [taxonomieurl] => Biologic, Drug, Infectious Diseases, Lead - validation in vivo, Product, Product, Protein, Recombinant protein ) [548] => stdClass Object ( [post] => stdClass Object ( [post_title] => Transoesophageal device using high intensity focused ultrasounds for cardiac thermal ablation [guid] => https://technology-offers.inserm-transfert.com/offer/transoesophageal-device-using-high-intensity-focused-ultrasounds-for-cardiac-thermal-ablation/ [post_content] => The present invention relates to a probe comprising: a piezoelectric therapy transducer having an acoustic axis BB’, and an imaging transducer having an imaging plane, said therapy transducer and imaging transducer being mounted in a head itself connected to a guide means wherein: the therapy transducer has a spherical concave front face for emitting ultrasonic waves focused on a focal point, a rear surface , a length d1, a width t and is a 1D annular phased array transducer and; the imaging transducer is a multiplane transducer having a rotation axis corresponding to the acoustic axis of the therapy transducer whereby the focal point of the therapy transducer is comprised in the imaging plane of the imaging transducer, said imaging transducer being fixed to the therapy transducer. (IEEE Trans Ultrason Ferroelectr Freq Control. 2013 Sep;60(9):1868-83. doi: 10.1109/TUFFC.2013.2772.) [post_date] => 2011-04-05 13:56:27 [post_modified] => 2024-09-11 15:42:51 [ID] => 3751 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => f487adaa-c2cd-4a26-84a3-50ed6fc08c0f [etat_fiche_online] => en_ligne [date_application] => 05-04-2011 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => MECA11013-T1 [keywords] => Cardiac thermal Ablation, atrial fibrillation, High Intensity Focused Ultrasound, Rhythm abnormalities, Ultrasound, [pub_scient_inv_dispo] => IEEE Trans Ultrason Ferroelectr Freq Control. 2013 Sep;60(9):1868-83. doi: 10.1109/TUFFC.2013.2772. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CHAPELON Jean-Yves,CONSTANCIEL Elodie [number_application] => European Procedure (Patents) (EPA) - 05 Avr. 2011 - 11 305 392.0 [technology_engineering] => ultrasound [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• Atrial FibrillationTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 548 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Atrial Fibrillation, Cardiovascular Diseases, Device, Devices, Method, Prototype validated, Ultrasound, Validated in a relevant environment [taxonomieurl] => Atrial Fibrillation, Cardiovascular Diseases, Device, Devices, Method, Prototype validated, Ultrasound, Validated in a relevant environment ) [549] => stdClass Object ( [post] => stdClass Object ( [post_title] => Pyk2-based gene therapy gene therapy attenuates cognitive deficits associated to Alzheimer’s Disease [guid] => https://technology-offers.inserm-transfert.com/offer/pyk2-based-gene-therapy-gene-therapy-attenuates-cognitive-deficits-associated-to-alzheimers-disease-2/ [post_content] => In the present invention it is shown that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent memory tasks and LTP. Inventors clearly provide evidence for multiple roles of Pyk2 in spine morphology and post synaptic structure. Thus, the inventors used direct overexpression of PYK2 by AAV-mediated gene transfer into the brain of Alzheimer’s mouse models and found that overexpression of PYK2 in this models improves synaptic properties and spine density deficits wich is also accompanied by a rescue of spatial memory. Accordingly it was demonstrated that PYK2 may restore cognitive functions in neurodegenerative diseases. Thus the present invention relates to methods and pharmaceutical compositions for the treatment of neurodegenerative disease. In particular the present invention relates to a method of treating neurodegenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for PYK2 polypeptide. [post_date] => 2017-03-24 13:56:27 [post_modified] => 2024-09-11 15:44:25 [ID] => 3749 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => f2627c3a-446d-0477-6ecb-5b0fc08ed436 [etat_fiche_online] => en_ligne [date_application] => 24-03-2017 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17059-T3 [keywords] => neurodegenerative disease - cognitif deficits [pub_scient_inv_dispo] => Exp Neurol. 2018 May 24. pii: S0014-4886(18)30160-2. doi: 10.1016/j.expneurol.2018.05.020 [access_to_detailed_offer] => /wp-content/uploads/BIO17059-T3_GIRAULT.pdf [rare_disease] => false [second_indication] => false [inventors] => GIRAULT Jean-Antoine,BRITO Veronica Ines,GINES Silvia,GIRALT Albert [number_application] => European Procedure (Patents) (EPA) - 24 Mars 2017 - 17305340.6 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Alzheimer’s diseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 549 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Alzheimer’s disease, Biologic, Central Nervous System, Drug, Gene Therapy, Gene therapy, Lead - validation in vivo, Method, Product [taxonomieurl] => Alzheimer’s disease, Biologic, Central Nervous System, Drug, Gene Therapy, Gene therapy, Lead - validation in vivo, Method, Product ) [550] => stdClass Object ( [post] => stdClass Object ( [post_title] => Medical device for olfactory stimulation [guid] => https://technology-offers.inserm-transfert.com/offer/medical-device-for-olfactory-stimulation/ [post_content] => The invention relates to a new medical device for olfactory stimulation of a patient. This device delivers a plurality of scents with precise flow rates and duration, preferably according to preprogrammed flexible sequences.The aim of the present invention is to provide a new solution to treat diseases requiring a cerebral wakefulness, in particular apnea in premature newborn infants or neonates and sleep apnea in adults which could supplement, or even replace the existing pharmacological treatments to avoid undesirable effects, and prevent apneic episodes by stimulating the whole cardio-respiratory system of the newborn. From a broader perspective, the use of DM could contribute to the overall objective of the maturation of the autonomic nervous system of premature newborn as well as to the limbic and cognitive structures. [post_date] => 2016-02-02 13:56:26 [post_modified] => 2024-09-11 15:41:10 [ID] => 3747 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => eb581796-b2a1-463d-ae8f-1f60ad890157 [etat_fiche_online] => en_ligne [date_application] => 02-02-2016 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 18 [reference_online] => MECA15483-T1 [keywords] => Respiratory, medical device [pub_scient_inv_dispo] => https:/clinicaltrials.gov/ct2/showCT02851979 [access_to_detailed_offer] => /wp-content/uploads/MECA15483-T1_VIRET.pdf [rare_disease] => false [second_indication] => false [inventors] => THEVENET Marc [number_application] => European Procedure (Patents) (EPA) - 02 Févr. 2016 - 16 153 961.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• Respiratory DiseaseTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 550 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Device, Devices, Pilote clinical trial, Product, Respiratory Disease, Sleep Apnea, System completed and qualified in an operational environment [taxonomieurl] => Device, Devices, Pilote clinical trial, Product, Respiratory Disease, Sleep Apnea, System completed and qualified in an operational environment ) [551] => stdClass Object ( [post] => stdClass Object ( [post_title] => Targeting Myeloperoxidase Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia [guid] => https://technology-offers.inserm-transfert.com/offer/targeting-myeloperoxidase-overcomes-cytarabine-resistance-in-human-acute-myeloid-leukemia/ [post_content] => Chemotherapy commonly alters cellular redox balance and increases the oxidative state. Recent studies have reported that chemoresistant cells have an increased reactive oxygen species (ROS) content in hematological malignancies. Here the inventors demonstrate that chemoresistant acute myeloid leukemia (AML) cells have a decreased level of mitochondrial and cytosolic ROS associated with an overexpression of myeloperoxidase (MPO), a heme protein that converts chloride and hydrogen peroxide to hypochlorous acid (HOCl). They also show that high MPO-expressing AML cells are less sensitive to AraC in vitro and in vivo. Targeting MPO expression and enzyme activity sensitizes to AraC treatment by triggering sustained oxidative stress in the high MPO expressing AML cells. Thus the present invention relates to use of myeloperoxidase (MPO) inhibitors for the treatment of chemoresistant acute myeloid leukemia (AML) [post_date] => 2018-07-24 13:56:25 [post_modified] => 2024-09-11 15:42:00 [ID] => 3745 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => e7c754de-d12b-b558-1761-5b8018f82ffa [etat_fiche_online] => en_ligne [date_application] => 24-07-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO18285-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO18285-T1_SARRY.pdf [rare_disease] => false [second_indication] => true [inventors] => SARRY Jean-Emmanuel,HOSSEINI Seyed Mohsen,RECHER Christian [number_application] => International Procedure (PCT) - 24 Juil. 2018 - PCT/IB2018/001013 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• LeukemiasTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 551 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Acute Myelocytic Leukemia (AML), Drug, Leukemias, Method, Oncology, Target [taxonomieurl] => Acute Myelocytic Leukemia (AML), Drug, Leukemias, Method, Oncology, Target ) [552] => stdClass Object ( [post] => stdClass Object ( [post_title] => Lipid antisens oligonucleotide targeting Fxyd2 as a therapeutic agent for pain management [guid] => https://technology-offers.inserm-transfert.com/offer/lipid-antisens-oligonucleotide-targeting-fxyd2-as-a-therapeutic-agent-for-pain-management/ [post_content] => The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct administration into the peripheral nervous system (PNS) of a patient (e.g., formulated for intrathecal administration).The invention also relates to an inhibitor of FXYD2 wherein said inhibitor reduces the expression and/or activity of FXYD2 in a subject in need thereof and targets at least the region comprising or consisting of the nucleotides 219-229 of SEQ ID NO: 3. Inventors have shown that targeting a region of FXYD2 can be used to inhibit and/or reduce the expression and/or activity of FXYD2. They have designed and synthesized an antisense oligonucleotide (SEQ ID NO: 4) targeting the rat and human FXYD2 gene. The have performed intrathecal injection of FXYD2 optimized ASO in two rat models of pain (neuropathic and inflammatory pain). They have shown that FXYD2 ASO efficiently reduces its expression in rat Dorsal root ganglion (DRG). The have demonstrated that FXYD2 ASO dramatically reduces neuropathic pain in the Spinal Nerve Ligation (SNL) rat model and analgesic effect of FXYD2 ASO on neuropathic pain is greater than that of Ziconotide, the current market leader. They also have shown that FXYD2 ASO dramatically reduces inflammatory pain in Complete Freund’s Adjuvant (CFA)-induced rat model. [post_date] => 2014-07-09 13:56:25 [post_modified] => 2024-09-11 15:42:37 [ID] => 3744 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => e4fc0ddc-9ded-4715-acf8-bd9a6449d77a [etat_fiche_online] => en_ligne [date_application] => 09-07-2014 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO14109-T1 [keywords] => [pub_scient_inv_dispo] => Sci Rep. 2016 Nov 2;6:36407. doi: 10.1038/srep36407.PLoS One. 2012;7(1):e29852. doi: 10.1371/journal.pone.0029852. Epub 2012 Jan 13. [access_to_detailed_offer] => /wp-content/uploads/BIO14109-T1_CARROLL.pdf [rare_disease] => false [second_indication] => false [inventors] => PATTYN Alexandre,VENTEO Stéphanie,VENTEO Stéphanie [number_application] => European Procedure (Patents) (EPA) - 09 Juil. 2014 - 14 306 114.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Neuropathic PainTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 552 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antisense Oligonucleotide, Central Nervous System, Drug, Lead - validation in vivo, Neuropathic Pain, Oligonucleotide, Product, Target [taxonomieurl] => Antisense Oligonucleotide, Central Nervous System, Drug, Lead - validation in vivo, Neuropathic Pain, Oligonucleotide, Product, Target ) [553] => stdClass Object ( [post] => stdClass Object ( [post_title] => PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF BRAIN INJURIES OR DEMYELINATING DISORDERS [guid] => https://technology-offers.inserm-transfert.com/offer/pharmaceutical-compositions-for-use-in-the-treatment-of-brain-injuries-or-demyelinating-disorders/ [post_content] => The invention is in the field of neuroregenerative medicine. Controlling the fate of neural stem cells represents a key therapeutic strategy in neuroregenerative medicine. The inventors used in silico genomic approaches, searchable platform-independent expression database/connectivity map (SPIED/CMAP) strategy, to identify small molecules that are predicted to regulate transcriptional changes associated with neurogenesis in the subventricular zone (SVZ) neurogenic niche. The approach was validated by demonstrating that two of the identified small molecules, inhibiting PI3K/Akt and GSK3beta respectively, were able to differentially direct the fate of NSCs in vivo, to promote oligodendrogenesis and neurogenesis, in the postnatal and adult SVZ. The present invention thus relates to methods and pharmaceutical composition for use in the treatment of brain injuries or demyelinating disorders, and in particular to PI3K or GSK3beta inhibitors for use in treating brain injuries, such as perinatal hypoxia/ischemia, or demyelinating disorders such as periventricular leukomalacias or multiple sclerosis. [post_date] => 2017-03-28 13:56:23 [post_modified] => 2024-09-11 15:41:19 [ID] => 3741 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => ddf21fc5-3c3f-4238-8ff7-51409d4d5760 [etat_fiche_online] => en_ligne [date_application] => 28-03-2017 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17098-T1 [keywords] => neuroregenerative medicine; brain injuries; demyelinating disorders [pub_scient_inv_dispo] => Pharmacogenomic identification of small molecules for lineage specific manipulation of subventricular zone germinal activity. Azim K. et al. PLoS Biol. 2017 Mar 28;15(3) [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => RAINETEAU Olivier,AZIM Kasum,BUTT Arthur Morgan [number_application] => European Procedure (Patents) (EPA) - 28 Mars 2017 - 17 305 356.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Central Nervous SystemTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 553 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Central Nervous System, Drug, Method, Small Molecule, Target, Validation in vivo [taxonomieurl] => Central Nervous System, Drug, Method, Small Molecule, Target, Validation in vivo ) [554] => stdClass Object ( [post] => stdClass Object ( [post_title] => Apelin analogs for the treatment of Heart Failure [guid] => https://technology-offers.inserm-transfert.com/offer/apelin-analogs-for-the-treatment-of-heart-failure/ [post_content] => The invention related to metabolically stable Apelin analogs and their use for the prevention or the treatment of diseases mediated by the apelin receptor in particular of cardiovascular disease (heart failure, hypertension, pulmonary hypertension, kidney failure) and inappropriate vasopressin secretions (SIADH). FASEB J. 2017 Feb;31(2):687-700. 4. [post_date] => 2014-12-23 13:56:23 [post_modified] => 2024-09-11 15:43:40 [ID] => 3740 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => d891ef15-2baa-4b88-a4da-5ea7bba5784b [etat_fiche_online] => en_ligne [date_application] => 23-12-2014 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13310-T1 [keywords] => Hypertension; Pulmonary Hypertension, Apelin; Syndrome of inappropriate antidiuretic hormone secretion [pub_scient_inv_dispo] => FASEB J. 2017 Feb;31(2):687-700. doi: 10.1096/fj.201600784R. Epub 2016 Nov 4. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ITURRIOZ Xavier,BONNET Dominique [number_application] => European Procedure (Patents) (EPA) - 23 Déc. 2014 - 14 307 170.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Chronic Heart FailureTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 554 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cardiovascular Diseases, Chronic Heart Failure, Drug, Hit - validation in vivo, Peptide, Product, Product [taxonomieurl] => Biologic, Cardiovascular Diseases, Chronic Heart Failure, Drug, Hit - validation in vivo, Peptide, Product, Product ) [555] => stdClass Object ( [post] => stdClass Object ( [post_title] => Nano-sized drug delivery structure [guid] => https://technology-offers.inserm-transfert.com/offer/nano-sized-drug-delivery-structure/ [post_content] => The present invention relates to a nano-sized drug delivery structure for delayed and controlled diffusion of at least one drug active, in particular into an aqueous medium, said drug delivery structure comprising at least one support material; one multilayered structure overlaying and/or surrounding at least partially said support material and comprising at least two layers of oppositely charged materials; and one drug active agent immobilized on one or more material(s) of one or more inner layer(s) of the said multilayered structure. The invention also relates to a process for preparing the nano-sized drug delivery structure, to the use of said structure in a pharmaceutical composition and to such a pharmaceutical composition [post_date] => 2016-04-26 13:56:22 [post_modified] => 2024-09-11 15:41:51 [ID] => 3738 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => d730586d-6a63-48cd-91c5-eb7939f20dc8 [etat_fiche_online] => en_ligne [date_application] => 26-04-2016 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => CHIM15575-T1 [keywords] => Drug Delivery -Nano-size drug delivery [pub_scient_inv_dispo] => J R Soc Interface. 2018 Feb;15(139). pii: 20170949. doi: 10.1098sif.2017.0949. [access_to_detailed_offer] => /wp-content/uploads/CHIM15575-T1_PUVIRAJESINGHE.pdf [rare_disease] => false [second_indication] => false [inventors] => CRASTER Richard,GUENNEAU Sébastien,ZHI Zheng-Liang [number_application] => European Procedure (Patents) (EPA) - 26 Avr. 2016 - 16 305 485.1 [technology_engineering] => biomaterials [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 555 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biomaterials, Drug, Method, Oncology, Others [taxonomieurl] => Biomaterials, Drug, Method, Oncology, Others ) [556] => stdClass Object ( [post] => stdClass Object ( [post_title] => ROCK inhibitors to treat diabetic retinopathy [guid] => https://technology-offers.inserm-transfert.com/offer/rock-inhibitors-to-treat-diabetic-retinopathy/ [post_content] => In diabetic retinopathy, the exact mechanisms leading to retinal capillary closure and to retinal barriers breakdown remain imperfectly understood. Rho-associated kinase (ROCK), an effector of the small GTPase Rho, involved in cytoskeleton dynamic regulation and cell polarity is activated by hyperglycemia. In both GK rat and in human type 2 diabetic retinas, ROCK-1 is activated and associated with non-apoptotic membrane blebbing in retinal vessels and in retinal pigment epithelium (RPE) that respectively form the inner and the outer barriers. Activation of ROCK-1 induces focal vascular constrictions, endoluminal blebbing and subsequent retinal hypoxia. In RPE cells, actin cytoskeleton remodeling and membrane blebs in RPE cells contributes to outer barrier breakdown. Diabetes-induced cell blebbing may contribute to ischemic maculopathy and represent an intervention target.The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor. [post_date] => 2019-12-05 13:56:21 [post_modified] => 2024-09-11 15:41:23 [ID] => 3737 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => d6caf47d-25a6-44fc-b187-b0bbb2afb31e [etat_fiche_online] => en_ligne [date_application] => [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO15371-T1 [keywords] => Diabetic Retinopathy - Drug repositionning - ROCK inhibitor-Fasudil [pub_scient_inv_dispo] => Sci Rep. 2017 Aug 18;7(1):8834. doi: 10.1038/s41598-017-07329-y. [access_to_detailed_offer] => /wp-content/uploads/BIO15371-T1_BEHAR-COHEN.pdf [rare_disease] => false [second_indication] => true [inventors] => CRISANTI-LASSIAZ Patricia [number_application] => European Procedure (Patents) (EPA) - 13 Oct. 2015 - 15 306 618.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OphtalmologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 556 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Lead - validation in vivo, Method, Ophtalmology, Product, Small Molecule [taxonomieurl] => Drug, Lead - validation in vivo, Method, Ophtalmology, Product, Small Molecule ) [557] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR CARDIAC REGENERATION [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-cardiac-regeneration/ [post_content] => The adult mammalian heart regeneration is largely prevented by the limited proliferative capacity of the resident cardiomyocytes (CMs). Here, the inventors identify Ephrin-B1 as a new critical regulator of adult CM proliferation. CM-specific transgenic repression of Ephrin-B1 promotes adult CM cell cycle reentry until division both in vitro and in vivo upon stimulation only, thus leading to substantial cardiac tissue regeneration through atypical CM proliferation and contractile function improvement to compensate for ageing stress, and apex resection. Cardiac deletion of efnb1 after myocardial infarction also improves considerably cardiac function and survival in mice. Together, these findings highlight Ephrin-B1 as a promising original target for future therapeutic strategies in cardiac regenerative medicine. Accordingly, the present invention relates to methods and pharmaceutical composition for cardiac regeneration based on use of Ephrin-B1 inhibitors. [post_date] => 2017-11-27 13:56:21 [post_modified] => 2024-09-11 15:40:52 [ID] => 3736 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => d69aad9b-de93-efb2-c451-5aa656aaa2c4 [etat_fiche_online] => en_ligne [date_application] => 27-11-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15226-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => SENARD Jean-Michel,GUILBEAU-FRUGIER Céline,KARSENTY Clément,GALES Céline,SEGUELAS Françoise,CAUQUIL Marie [number_application] => European Procedure (Patents) (EPA) - 27 Nov. 2017 - 17 306 641.6 [technology_engineering] => [multidisciplinary_field] => ageing [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Myocardial InfarctionTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 557 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Ageing, Cardiovascular Diseases, Drug, Myocardial Infarction, Target, Target, Validation in vivo [taxonomieurl] => Ageing, Cardiovascular Diseases, Drug, Myocardial Infarction, Target, Target, Validation in vivo ) [558] => stdClass Object ( [post] => stdClass Object ( [post_title] => Apelin analogs for the treatment of dysfunction associated with aging [guid] => https://technology-offers.inserm-transfert.com/offer/apelin-analogs-for-the-treatment-of-dysfunction-associated-with-aging/ [post_content] => The inventors show that apelin plays a role in energy metabolism and particularly in energetic mechanisms in mitochondria. They show that apelin treatment increases complete fatty acid oxidation (FAO), glucose transport, mitochondrial oxidative capacity and biogenesis in muscle of insulin-resistant mice. Furthermore, they show that skeletal muscle appears as the major tissue target for apelin action, where it mediates increased fuel consumption. Thus apelin could be used in diseases related to problems in energetic mechanism in mitochondria.Using apelin KO mice and wild type mice chronically-treated by apelin, the inventors identified that markers of sarcopenia like myostatin and myogenin were respectively down or up regulated in old mice. Thus, apelin should be used to treat dysfunction associated with aging and particularly in sarcopenia.Thus, the invention relates to an APJ receptor agonist or an apelinomimetic for use in the treatment or the prevention of a dysfunction associated with aging. [post_date] => 2011-11-28 13:56:21 [post_modified] => 2024-09-11 15:41:23 [ID] => 3735 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => d4deb34c-7fc2-4ccf-9ba9-383a6a8ff283 [etat_fiche_online] => en_ligne [date_application] => 28-11-2011 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO11315-T1 [keywords] => Myology - Apelin - Peptide - [pub_scient_inv_dispo] => Nat Med. 2018 Sep;24(9):1360-1371. doi: 10.1038/s41591-018-0131-6. Epub 2018 Jul 30 [access_to_detailed_offer] => /wp-content/uploads/BIO11315-T1_VALET.pdf [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => ageing [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MusculoskeletalTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 558 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Ageing, Biologic, Drug, Lead - validation in vivo, Musculoskeletal, Peptide, Product, Sarcopenia, Target [taxonomieurl] => Ageing, Biologic, Drug, Lead - validation in vivo, Musculoskeletal, Peptide, Product, Sarcopenia, Target ) [559] => stdClass Object ( [post] => stdClass Object ( [post_title] => Direct pulmonary delivery of oseltamivir carboxylate for the treatment of influenza infections [guid] => https://technology-offers.inserm-transfert.com/offer/direct-pulmonary-delivery-of-oseltamivir-carboxylate-for-the-treatment-of-influenza-infections/ [post_content] => The present application relates to antiviral compounds and to their use for the treatment and/or prevention of viral infections.More particularly, the present invention relates to Sulconazole and Sulconazole derivatives for their use in treating and/or preventing viral infections. Sulconazole and its derivatives demonstrated an effective anti-adenoviral activity used at 5 µM in-vitro. Moreover, these compounds demonstrated an increased activity compared to the lead compound Cidofovir (standard clinical drug used against adenovirus infection). [post_date] => 2016-05-25 13:56:20 [post_modified] => 2024-09-11 15:41:43 [ID] => 3733 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => d2d96a5a-b006-46aa-95ea-d11fd7254f96 [etat_fiche_online] => en_ligne [date_application] => 25-05-2016 [date] => [bd_referent] => Stephane THUMELIN [bd_referent_id] => [contact_email] => stephane.thumelin@inserm-transfert.fr [contact_phone] => 0612174727 [reference_online] => BIO16197-T1 [keywords] => Infectious diseases, antivirals,pulmonary formulation [pub_scient_inv_dispo] => J Control Release. 2018 Feb 10;271:118-126. doi: 10.1016/j.jconrel.2017.12.021. Epub 2017 Dec 22. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MARCHAND Sandrine [number_application] => European Procedure (Patents) (EPA) - 25 Mai 2016 - 16 305 605.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• Infectious DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 559 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Infectious Diseases, Method [taxonomieurl] => Infectious Diseases, Method ) [560] => stdClass Object ( [post] => stdClass Object ( [post_title] => NEW MOLECULES FOR NEURODEGENERATIVE PATHOLOGIES : INDIRECT ?-SECRETASE INHIBITORS [guid] => https://technology-offers.inserm-transfert.com/offer/new-molecules-for-neurodegenerative-pathologies-indirect-%ce%b2-secretase-inhibitors/ [post_content] => The present invention is directed to novel compounds and pharmaceutically acceptable salts or solvates thereof, and their use. [post_date] => 2018-07-11 13:56:20 [post_modified] => 2024-09-11 15:42:24 [ID] => 3732 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => cf9800d3-e3fe-e946-aa51-5b80114f3df0 [etat_fiche_online] => en_ligne [date_application] => 11-07-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => CHIM17092-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/CHIM17092-T1_MELNYK.pdf [rare_disease] => false [second_indication] => false [inventors] => MELNYK Patricia,DESCAMPS Florian,EVRARD Caroline,CARATO Pascal,VINGTDEUX Valérie,RENAULT Nicolas,SERGEANT Nicolas,EL BAKALI Jamal,GAY Marion,TAUTOU Marie [number_application] => European Procedure (Patents) (EPA) - 11 Juil. 2018 - 18 305 932.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Alzheimer’s diseaseTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 560 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Alzheimer’s disease, Central Nervous System, Drug, Product, Product, Small Molecule [taxonomieurl] => Alzheimer’s disease, Central Nervous System, Drug, Product, Product, Small Molecule ) [561] => stdClass Object ( [post] => stdClass Object ( [post_title] => Reduction of carcinomatosis risk using icodextrin as a carrier solution of intraperitoneal oxaliplatin chemotherapy [guid] => https://technology-offers.inserm-transfert.com/offer/reduction-of-carcinomatosis-risk-using-icodextrin-as-a-carrier-solution-of-intraperitoneal-oxaliplatin-chemotherapy/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of peritoneal carcinomatosis. In particular, the present invention relates to a method for the prophylactic treatment of peritoneal carcinomatosis in a patient in need thereof comprising administering to the patient a therapeutically effective combination of at least one dextrin polysaccharide and at least one chemotherapeutic agent. [post_date] => 2016-02-04 13:56:19 [post_modified] => 2024-09-11 15:41:50 [ID] => 3730 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => cf193c57-3b36-4be7-89f2-ca4d1f689462 [etat_fiche_online] => en_ligne [date_application] => 04-02-2016 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO15407-T1 [keywords] => Peritoneal carcinomatosis, dextrin polysaccharide [pub_scient_inv_dispo] => Eur J Surg Oncol. 2017 Jun;43(6):1088-1094. doi: 10.1016/j.ejso.2016.12.009. Epub 2017 Jan 9. [access_to_detailed_offer] => /wp-content/uploads/BIO15407-T1_POCARD.pdf [rare_disease] => false [second_indication] => false [inventors] => [number_application] => European Procedure (Patents) (EPA) - 04 Févr. 2016 - 16 305 126.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 561 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Method, Oncology [taxonomieurl] => Drug, Method, Oncology ) [562] => stdClass Object ( [post] => stdClass Object ( [post_title] => M-CSF for preventing or treating myeloid cytopenia and related complications following hematopoetic stem cell transplantation [guid] => https://technology-offers.inserm-transfert.com/offer/m-csf-for-preventing-or-treating-myeloid-cytopenia-and-related-complications-following-hematopoetic-stem-cell-transplantation/ [post_content] => The invention relates to a method for preventing or treating myeloid cytopenia and related complications such as infections in patients undergoing hematopoietic stem cell transplantation (HSCT). The approach is based on the priming of the hematopoietic stem cell graft with M-CSF following HSCT. [post_date] => 2013-04-09 13:56:19 [post_modified] => 2024-09-11 15:41:48 [ID] => 3728 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => cb8371b5-2d8e-456d-998e-6a8d8b4e0e03 [etat_fiche_online] => en_ligne [date_application] => 09-04-2013 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13024-T1 [keywords] => Hematopoetic stem cells; transplantation; HSCT; cell therapy; regenerative medicine; cytopenia; infectious diseases, protein; polypeptide; bacterial infections; fungal infections [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => [number_application] => European Procedure (Patents) (EPA) - 09 Avr. 2013 - 13 305 464.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Infectious DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 562 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Infectious Diseases, Lead - validation in vivo, Method, Product [taxonomieurl] => Drug, Infectious Diseases, Lead - validation in vivo, Method, Product ) [563] => stdClass Object ( [post] => stdClass Object ( [post_title] => Modulator of WIP1 levels to treat Wolfram syndrome [guid] => https://technology-offers.inserm-transfert.com/offer/modulator-of-wip1-levels-to-treat-wolfram-syndrome/ [post_content] => The present invention relates to novel therapeutic ways for treating Wolfram Syndrome (WS) by targeting the neuronal calcium sensor 1 (NCS1). The present invention provides a NCS1-encoding polynucleotide for use in therapy, particularly for use in the treatment of WS, and also relates to an inhibitor of the proteasome for use in the treatment of Wolfram Syndrome. Finally, the present invention also concerns a method for predicting the severity of wolfram syndrome in a patient by measuring the NCS1 level in a sample obtained from said subject, wherein the lower said level of NCS1 is, the higher the patient is predisposed to having severe Wolfram Syndorme. [post_date] => 2016-03-23 13:56:18 [post_modified] => 2024-09-11 15:41:59 [ID] => 3725 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => ca7319d7-b25a-4a72-b03a-2664566897ba [etat_fiche_online] => en_ligne [date_application] => 23-03-2016 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO15148-T1 [keywords] => Wolfram Syndrome [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO15148-T1_DELPRAT.pdf [rare_disease] => true [second_indication] => false [inventors] => DELETTRE-CRIBAILLET Cécile,ANGEBAULT Claire [number_application] => European Procedure (Patents) (EPA) - 23 Mars 2016 - 16 305 330.9 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OphtalmologyTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 563 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Gene therapy, Ophtalmology, Target, Target, Validation in vivo [taxonomieurl] => Drug, Gene therapy, Ophtalmology, Target, Target, Validation in vivo ) [564] => stdClass Object ( [post] => stdClass Object ( [post_title] => A Checkpoint kinase 1 inhibitor sensitises cancer cells to dihydroorotate dehydrogenase inhibition [guid] => https://technology-offers.inserm-transfert.com/offer/a-checkpoint-kinase-1-inhibitor-sensitises-cancer-cells-to-dihydroorotate-dehydrogenase-inhibition/ [post_content] => The present invention relates to the field of cancer treatment. In this study, the inventors sought to investigate whether this antiproliferative effect of DHODH inhibitors could be enhanced by combining Chk1 kinase inhibition. They show that the effect of the DHODH inhibitor teriflunomide was amplified when cells were subsequently exposed to PF477736 Chk1 inhibitor. Flow cytometry analyses revealed substantial accumulations of cells in S and G2/M phases, followed by increased cytotoxicity which was characterised by caspase 3-dependent induction of cell death. Associating PF477736 with teriflunomide significantly sensitised SUM159 and HCC1937 human triple negative breast cancer cell line to dihydroorotate dehydrogenase inhibition. More, the combination of the DHODH inhibitor with the Chk1 inhibitor in a significant lower dose allow to minimize the off-target effects of the Chk1 inhibitor. Altogether these results suggest that combining DHODH and Chk1 inhibitions may be a strategy worth considering as a potential alternative to conventional chemotherapies. Thus, the present invention relates to an inhibitor of DHODH and an inhibitor of Chk1 for use in the treatment of a cancer in a subject in need thereof. [post_date] => 2017-07-13 13:56:18 [post_modified] => 2024-09-11 15:41:51 [ID] => 3723 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => c8e93af8-e411-4442-9de3-27e160c3fe58 [etat_fiche_online] => en_ligne [date_application] => 13-07-2017 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17261-T1 [keywords] => combination; DHODH; Chk1 inhibitor [pub_scient_inv_dispo] => Oncotarget. 2017 Jul 12;8(56):95206-95222. doi: 10.18632/oncotarget.19199. eCollection 2017 Nov 10. [access_to_detailed_offer] => /wp-content/uploads/BIO17261-T1_SARDET.pdf [rare_disease] => false [second_indication] => true [inventors] => SARDET Claude,ARNOULD Stéphanie,RODIER Genevieve [number_application] => European Procedure (Patents) (EPA) - 13 Juil. 2017 - 17 305 941.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 564 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Breast Cancer, Drug, Method, Oncology, Product, Small Molecule [taxonomieurl] => Breast Cancer, Drug, Method, Oncology, Product, Small Molecule ) [565] => stdClass Object ( [post] => stdClass Object ( [post_title] => A microRNA switch regulates the rise in hypothalamic GnRH production before puberty [guid] => https://technology-offers.inserm-transfert.com/offer/a-microrna-switch-regulates-the-rise-in-hypothalamic-gnrh-production-before-puberty/ [post_content] => A method for diagnosing a reproduction-related disorder in an individual, comprising:a) measuring the level of a miR200 nucleic acid and/or miR155 nucleic acid in a sample from an individual;b) comparing the level value of a miR200 nucleic acid and/or miR155 nucleic acid measured at step a) to a reference level value of the said miR200 acid nucleic and/or miR155nucleic acid. [post_date] => 2016-04-20 13:56:16 [post_modified] => 2024-09-11 15:40:38 [ID] => 3718 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => b9d954ca-49e4-4260-bf4f-2730d5787ba2 [etat_fiche_online] => en_ligne [date_application] => 20-04-2016 [date] => [bd_referent] => Myriam GAMBERONI [bd_referent_id] => [contact_email] => myriam.gamberoni@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 36 [reference_online] => BIO16167-T1 [keywords] => Reproduction-related disorder, miRNA [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MESSINA Andrea [number_application] => European Procedure (Patents) (EPA) - 20 Avr. 2016 - 16 305 459.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Women healthTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 565 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Oligonucleotide, Target, Target, Validation in vitro, Women health, Women infertility [taxonomieurl] => Drug, Oligonucleotide, Target, Target, Validation in vitro, Women health, Women infertility ) [566] => stdClass Object ( [post] => stdClass Object ( [post_title] => Novel target candidate for the prevention and treatment of respiratory infections / COPD-AE [guid] => https://technology-offers.inserm-transfert.com/offer/novel-target-candidate-for-the-prevention-and-treatment-of-respiratory-infections-copd-ae/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the prevention and treatment of respiratory bacterial infections and more particularly of superinfection and acute exacerbation of chronic obstructive pulmonary disease with a therapeutically effective amount of an antagonist of IL-20 cytokines. Proof of concept has been achieved in mouse models with a mAb targeting IL20R [post_date] => 2014-11-24 13:56:16 [post_modified] => 2024-09-20 16:50:02 [ID] => 3717 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => b9552c1f-418d-481e-885d-dc718d72446c [etat_fiche_online] => en_ligne [date_application] => 2014-11-24 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => +33622908798 [reference_online] => BIO13400-T1 [keywords] => Infectious diseases, Respiratory, IL-20, COPD acute exacerbation, antibacterials [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO13400-T1_GOSSET.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => PEREZ-CRUZ Magdiel,KONE Bachirou,PICHAVANT Muriel [number_application] => European Procedure (Patents) (EPA) - 24 Nov. 2014 - 14 306 868.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Infectious DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 566 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Infectious Diseases, Target, Target, Validation in vivo [taxonomieurl] => Drug, Infectious Diseases, Target, Target, Validation in vivo ) [567] => stdClass Object ( [post] => stdClass Object ( [post_title] => A wearable healthcare and lifestyle device [guid] => https://technology-offers.inserm-transfert.com/offer/a-wearable-healthcare-and-lifestyle-device/ [post_content] => A wearable healthcare and lifestyle device acting as a personal assistant regarding the exposure to light (UV, light below and above 460 nm, infrared), physical activity, and sleep patterns of a user, and as a personal advisor in relationship with his lifestyle and noticeably his sleep and circadian rhythms.The device named Lightmonitor could be used :- By researchers to investigate the influence of light (flux, duration, exposure) on: sleep and circadian disorders, seasonal or non-seasonal depression, metabolism disorders, memory troubles, physical activity disorders.- By researchers to assess photic strategies in the treatment of: troubles of sleep circadian rhythm, and sleep, for example in people having neurodegenerative pathologies or affective disorders.- By physicians as a diagnostic tool to assess a patient’s lifestyle in order to propose recommendations to improve sleep in shift workers or adolescents, improve sleep hygiene in the general population, increase physical activity,or prevent premature aging of the eye.- By physicians for monitoring patients in the course of light therapy treatments. They could assess whether adolescents, shift workers, patients have followed their recommendations to treat their circadian sleep disorder, or SAD, or insomnia.- By clinicians in applications wherein particular specific wavelengths of the light spectrum, have an impact on health. They could monitor the exposure to light of patients given photosensitizing medications or suffering from cancer, from age-related macular degeneration or other eye diseases.- By everyone as a mean to control systems in buildings or any other built environments in order to satisfy one’s health and comfort related requirements. The device would control blinds, lights, heaters, based on their activity, their biological clock,u2026. [post_date] => 2015-09-02 13:56:15 [post_modified] => 2024-08-28 12:19:03 [ID] => 3716 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => b8b7d167-20a9-4a5d-b26b-37705f16da8d [etat_fiche_online] => en_ligne [date_application] => 02-09-2015 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => MECA14091-T1 [keywords] => wearable device; circadian rhythms; light type exposure (UV, light below and above 460 nm, infrared); Lightmonitor [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => DUMORTIER Dominique [number_application] => European Procedure (Patents) (EPA) - 02 Sept. 2015 - 15 306 351.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• OthersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 567 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Component/subsystem validated, Device, Devices, Others, Product, Validated in lab [taxonomieurl] => Component/subsystem validated, Device, Devices, Others, Product, Validated in lab ) [568] => stdClass Object ( [post] => stdClass Object ( [post_title] => Product combination for the treatment of filovirus infections [guid] => https://technology-offers.inserm-transfert.com/offer/product-combination-for-the-treatment-of-filovirus-infections/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. Although several antivirals have shown efficacy against Ebola virus infection in vitro or in animal models, few of them have been yet assessed in human beings with Ebola virus disease. The inventors aimed at identifying novel antivirals showing efficacy against Ebola virus infection. Gemcitabine and obatoclax were identified and their synergistic effects with favipiravir were demonstrated. In particular, the present invention relates to a method of treating a filovirus infection in a subject in need thereof comprising administering to the subject a therapeutically effective combination of favipiravir and Obatoclax. The present invention also relates to a method of treating a filovirus infection in a subject in need thereof comprising administering to the subject a therapeutically effective combination of favipiravir and gemcitabine. [post_date] => 2016-05-23 13:56:15 [post_modified] => 2024-09-11 15:41:41 [ID] => 3715 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => b7521cd0-91a6-42bd-9509-8f9fbb88518b [etat_fiche_online] => en_ligne [date_application] => 23-05-2016 [date] => [bd_referent] => Stephane THUMELIN [bd_referent_id] => [contact_email] => stephane.thumelin@inserm-transfert.fr [contact_phone] => 0612174727 [reference_online] => BIO16121-T1 [keywords] => Infectious diseases, antivirals, virus, Ebola, [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => [number_application] => European Procedure (Patents) (EPA) - 23 Mai 2016 - 16 305 590.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• EbolaTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 568 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Candidate drug, Drug, Ebola, Infectious Diseases, Method, Small Molecule [taxonomieurl] => Candidate drug, Drug, Ebola, Infectious Diseases, Method, Small Molecule ) [569] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED CARDIOMETABOLIC DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-pharmaceutical-compositions-for-the-treatment-of-age-related-cardiometabolic-diseases/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. In particular, the present invention relates to a method of treating an age-related cardiometabolic disease in an elderly subject in need thereof comprising administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor. [post_date] => 2017-04-05 13:56:15 [post_modified] => 2024-09-11 15:43:39 [ID] => 3713 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => b2b91ba2-72fb-4e93-aec7-68e79f310f3a [etat_fiche_online] => en_ligne [date_application] => 05-04-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15415-T1 [keywords] => [pub_scient_inv_dispo] => Circulation. 2018 Aug 21;138(8):809-822. doi: 10.1161/CIRCULATIONAHA.117.031358. [access_to_detailed_offer] => /wp-content/uploads/BIO15415-T1_DERUMEAUX.pdf [rare_disease] => false [second_indication] => false [inventors] => CZIBIK Gabor,SAWAKI Daigo,YOSHIMITSU Takehiko [number_application] => European Procedure (Patents) (EPA) - 06 Avr. 2016 - 16 305 397.8 [technology_engineering] => [multidisciplinary_field] => fibrosis [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Chronic Heart FailureTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 569 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Cardiovascular Diseases, Chronic Heart Failure, Drug, Fibrosis, Target, Target, Validation in vivo [taxonomieurl] => Cardiovascular Diseases, Chronic Heart Failure, Drug, Fibrosis, Target, Target, Validation in vivo ) [570] => stdClass Object ( [post] => stdClass Object ( [post_title] => Factor H fragment for use as an anti-angiogenic agent [guid] => https://technology-offers.inserm-transfert.com/offer/factor-h-fragment-for-use-as-an-anti-angiogenic-agent/ [post_content] => The invention relates to a complement factor H fragment for use in the therapy and/or prophylaxis of a disease involving neovascularization.POC in vivo in a choroidal neovascularization model [post_date] => 2015-12-30 13:56:13 [post_modified] => 2024-09-11 15:41:48 [ID] => 3708 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 9f7d43aa-3590-4491-8dca-17d8ee746714 [etat_fiche_online] => en_ligne [date_application] => 30-12-2015 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO14280-T1 [keywords] => Dry AMD - neovascularization [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => ABACHE Toufik,DINET Virginie,JORIEUX Sylvie [number_application] => France (NP) - 30 Déc. 2015 - 15 63465 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OphtalmologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 570 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Hit - validation in vivo, Macular Degeneration, Method, Ophtalmology, Product, Synthetic peptide [taxonomieurl] => Drug, Hit - validation in vivo, Macular Degeneration, Method, Ophtalmology, Product, Synthetic peptide ) [571] => stdClass Object ( [post] => stdClass Object ( [post_title] => PTGDRs, CXCR4 and Basophils in Systemic Lupus Erythematosus [guid] => https://technology-offers.inserm-transfert.com/offer/ptgdrs-cxcr4-and-basophils-in-systemic-lupus-erythematosus/ [post_content] => The present invention relates to PTGDRs, CXCR4 and Basophils to treat in Systemic Lupus Erythematosus. In particular, the present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE. [post_date] => 2015-02-13 13:56:12 [post_modified] => 2024-09-18 18:55:02 [ID] => 3706 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 9c65115b-d792-4219-a695-0e430e581ad2 [etat_fiche_online] => en_ligne [date_application] => 2015-02-13 [date] => [bd_referent] => Nathan POMORSKI [bd_referent_id] => [contact_email] => nathan.pomorski@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14401-T1 [keywords] => Lupus, PTGDRs, CXCR4 [pub_scient_inv_dispo] => Nat Commun. 2018 Feb 20;9(1):725. doi: 10.1038/s41467-018-03129-8. [access_to_detailed_offer] => https://technology-offers.inserm-transfert.com/wp-content/uploads/BIO14401-PTGDRs-CXCR4-and-Basophils-in-Systemic-Lupus-Erythematosus.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => PELLEFIGUES Christophe [number_application] => European Procedure (Patents) (EPA) - 13 Févr. 2015 - 15 305 222.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Systemic Lupus ErythematosusTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 571 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Immunology, Product, Small Molecule, Systemic Lupus Erythematosus, Target, Validation in vivo [taxonomieurl] => Drug, Immunology, Product, Small Molecule, Systemic Lupus Erythematosus, Target, Validation in vivo ) [572] => stdClass Object ( [post] => stdClass Object ( [post_title] => PPAR-gamma agonist as target for the treatment of Rapidly Progressive GlomeruloNephritis [guid] => https://technology-offers.inserm-transfert.com/offer/ppar-gamma-agonist-as-target-for-the-treatment-of-rapidly-progressive-glomerulonephritis/ [post_content] => This study demonstrates the pivotal role of the local PPAR-gamma agonist system in maintaining podocyte quiescence and orchestrating the global glomerular tolerance to a severe immune-complex-mediated disease. PPAR-gamma agonist was found to be a downstream effector of the NRF2 pathway, unveiling the critical protective role of both NRF2 activity and PPAR-gamma. We also provide proof of principle that delayed PPAR-gamma agonism could display therapeutic action on glomerular function and structure in a severe model of Rapidly Progressive GlomeruloNephritis. (J Am Soc Nephrol. 2016 Jan;27(1):172-88. doi: 10.1681/ASN.2014111080. Epub 2015 May 21.) [post_date] => 2014-11-04 13:56:11 [post_modified] => 2024-09-11 15:43:32 [ID] => 3703 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 9391e6fa-ae3c-4183-b9eb-a00d04f5c352 [etat_fiche_online] => en_ligne [date_application] => 04-11-2014 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13363-T1 [keywords] => Rapidly Progressive GlomeruloNephritis [pub_scient_inv_dispo] => J Am Soc Nephrol. 2016 Jan;27(1):172-88. doi: 10.1681/ASN.2014111080. Epub 2015 May 21. [access_to_detailed_offer] => /wp-content/uploads/BIO13363-T1_THARAUX.pdf [rare_disease] => true [second_indication] => true [inventors] => BOLLÉE Guillaume,HENIQUE-GRECIET Carole [number_application] => International Procedure (PCT) - 04 Nov. 2014 - PCT/IB2014/002603 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Genito Urinary SystemTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 572 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Genito Urinary System, Glomerulonephritis, Target, Target, Validation in vivo [taxonomieurl] => Drug, Genito Urinary System, Glomerulonephritis, Target, Target, Validation in vivo ) [573] => stdClass Object ( [post] => stdClass Object ( [post_title] => Gene therapy coding for anti-Tau Nanobody to treat rare tauopathies [guid] => https://technology-offers.inserm-transfert.com/offer/gene-therapy-coding-for-anti-tau-nanobody-to-treat-rare-tauopathies/ [post_content] => The invention relates to generation, optimization and characterisation of VHH targeted against Tau MTBD (microtubule-binding domain) with high affinity, obtained by screening from a naïve synthetic library. The inventors optimized version of a lead VHH which is able to inhibit Tau aggregation in vitro and in HEK 293 aggregation-reporting cellular model, providing a new tool in Tau immunotherapies. Accordingly the invention relates to new VHH antibody that specifically binds with high affinity Tau species, especially the epitope region involved in Tau aggregation. These specific antibodies can be used for the therapy of tauopathy disorders such as Progressive supranuclear palsy (PSP). [post_date] => 2018-12-13 13:56:11 [post_modified] => 2024-09-11 15:42:21 [ID] => 3702 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 9119f3ba-46c6-e471-9d44-5c408f574c6c [etat_fiche_online] => en_ligne [date_application] => 13-12-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO18023-T1 [keywords] => Tauopathy - Progressive supranuclear palsy [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO18023-T1_BUEE.pdf [rare_disease] => false [second_indication] => false [inventors] => BUEE Luc,DUPRE Elian,LANDRIEU Isabelle,ARRIAL Alexis,RAIN Jean-christophe,DANIS Clément [number_application] => European Procedure (Patents) (EPA) - 13 Déc. 2018 - 18 306 684.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Central Nervous SystemTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 573 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Central Nervous System, Drug, Lead - validation in vitro, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Central Nervous System, Drug, Lead - validation in vitro, Product, Product, Protein ) [574] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF ENHANCING THE POTENCY OF INCRETIN-BASED DRUGS IN SUBJECTS IN NEED THEREOF [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-enhancing-the-potency-of-incretin-based-drugs-in-subjects-in-need-thereof/ [post_content] => The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileummicrobiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen. [post_date] => 2017-12-05 13:56:10 [post_modified] => 2024-09-11 15:44:07 [ID] => 3698 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 880b1386-5cd8-453d-bbd5-0686bacb0f8b [etat_fiche_online] => en_ligne [date_application] => 05-12-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO16235-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BURCELIN Rémy,COLLET Xavier,CHRISTENSEN Jeffrey,GRASSET Estelle,TERCE François [number_application] => European Procedure (Patents) (EPA) - 06 Déc. 2016 - 16306623.6 [technology_engineering] => [multidisciplinary_field] => microbiota [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 574 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Diabetes, Drug, Metabolic Disorders, Microbiota, Product, Target, Type 2 Diabetes, Validation in vivo [taxonomieurl] => Biologic, Diabetes, Drug, Metabolic Disorders, Microbiota, Product, Target, Type 2 Diabetes, Validation in vivo ) [575] => stdClass Object ( [post] => stdClass Object ( [post_title] => Ex-vivo active immunotherapy against infectious diseases and tumoral antigens for mimicking natural production by B cells of immunoglobulin [guid] => https://technology-offers.inserm-transfert.com/offer/ex-vivo-active-immunotherapy-against-infectious-diseases-and-tumoral-antigens-for-mimicking-natural-production-by-b-cells-of-immunoglobulin/ [post_content] => The present invention concerns lentiviral vectors enabling the expression of membrane-anchored and secreted antibodies by B cells. This invention results from the development of a new method for adoptive transfer of B-cells transduced with a lentiviral vector (LV) conditionally expressing the secreted or the membrane-anchored form (BCR) of a transgenic immunoglobulin of interest, depending on the maturation status of transduced B-cells. Engineered B-cells producing an ectopic immunoglobulin of interest for ex vivo active immunotherapy, allow long-term memory immune response. [post_date] => 2015-07-09 13:56:10 [post_modified] => 2024-09-11 15:41:30 [ID] => 3697 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 871d7931-2ea9-459d-b109-2cefa84a8cf9 [etat_fiche_online] => en_ligne [date_application] => 09-07-2015 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15066-T1 [keywords] => infectious diseases, Oncology, lentivirus, vectors, multicistronic, BCR, immunoprophylaxis, ex-vivo therapy; FAM2; immunotherapy [pub_scient_inv_dispo] => Mol Ther. 2015 Nov;23(11):1734-1747. doi: 10.1038/mt.2015.148. Epub 2015 Aug 18. [access_to_detailed_offer] => /wp-content/uploads/BIO15066-T1_COSSET.pdf [rare_disease] => false [second_indication] => false [inventors] => DEFRANCE Thierry,FUSIL Floriane,VERHOEYEN Els [number_application] => European Procedure (Patents) (EPA) - 09 Juil. 2015 - 15 306 132.0 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hepatitis cTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 575 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Gene Therapy, Gene therapy, Hepatitis c, Hit - validation in vivo, Infectious Diseases, Product, Product [taxonomieurl] => Biologic, Drug, Gene Therapy, Gene therapy, Hepatitis c, Hit - validation in vivo, Infectious Diseases, Product, Product ) [576] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS OF TREATING HEART FAILURE [guid] => https://technology-offers.inserm-transfert.com/offer/methods-of-treating-heart-failure/ [post_content] => Worldwide, 1% to 2% of the general adult population have heart failure (HF), which is accompanied by reduced quality of life, high morbidity, mortality, and significant financial costs. Recently, the potential role of the gut in the pathophysiology of heart failure (HF) has recently begun to attract increased attention. In this context, the inventors demonstrated that treatment with Lactobbacillus reuteri ameliorates mice survival following myocardial infarction and that said treatment prevented the decrease of both cardiac function, (estimated by the % of ejection fraction) and cardiac remodeling. Moreover, the inventors show that ligands of aryl hydrocarbon receptor (AHR) that comprise some metabolites produced by Lactobacillus reuteri are also particularly suitable for the treatment of heart failure. Accordingly, the present invention relates to methods of treating heart failure in a subject in need thereof comprising administering to the subject an effective amount of Lactobacillus reuteri or at least one ligand of AHR. [post_date] => 2017-12-13 13:56:09 [post_modified] => 2024-09-11 15:40:54 [ID] => 3695 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 82da5f83-db70-63bd-4fa2-5aa6572ffc2a [etat_fiche_online] => en_ligne [date_application] => 13-12-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17568-T1 [keywords] => Microbiota, probiotic [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => HEYMES Christophe,BURCELIN Rémy [number_application] => European Procedure (Patents) (EPA) - 13 Déc. 2017 - 17 306 764.6 [technology_engineering] => [multidisciplinary_field] => microbiota [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Chronic Heart FailureTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 576 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Cardiovascular Diseases, Chronic Heart Failure, Drug, Hit - validation in vivo, Method, Microbiota, Product [taxonomieurl] => Biologic, Cardiovascular Diseases, Chronic Heart Failure, Drug, Hit - validation in vivo, Method, Microbiota, Product ) [577] => stdClass Object ( [post] => stdClass Object ( [post_title] => System for treatment by photodynamic therapy and method for preparation of such system [guid] => https://technology-offers.inserm-transfert.com/offer/system-for-treatment-by-photodynamic-therapy-and-method-for-preparation-of-such-system/ [post_content] => System for treatment by photodynamic therapy comprising:- an illuminating device including a light emitting surface for illuminating an internal surface to be treated with a light adapted to activate a photosensitizer compound, the light emitting surface emitting light with a distribution of light power comprising fractions of light power decreasing from a maximum at the light emitting surface, the light emitting surface having a determined illumination profile that provides respective illuminated areas for a plurality of the fractions of light power,- a positioning system adapted to position in real-time the light emitting surface within a reference frame,- an electronic unit connected to the positioning system and adapted to monitor in real-time a dose of light energy delivered to the internal surface based on the illumination profile and the position of the light emitting surface. [post_date] => 2015-01-19 13:56:09 [post_modified] => 2024-09-11 15:40:37 [ID] => 3694 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 829274f2-e1e5-4769-b58d-7616845bb7ff [etat_fiche_online] => en_ligne [date_application] => 19-01-2015 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 45 [reference_online] => MECA14369-T1 [keywords] => illuminating device; photodynamic therapy [pub_scient_inv_dispo] => https:/clinicaltrials.gov/ct2/showecordCT02662504 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MUNCK Camille,SCHERPEREEL Arnaud,MORDON Serge,LESAGE Jean-Claude [number_application] => European Procedure (Patents) (EPA) - 19 Janv. 2015 - 15 305 052.1 [technology_engineering] => imaging [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• Malignant MesotheliomaTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 577 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Clinical safety and effectiveness trials, Device, Devices, Imaging, Malignant Mesothelioma, Oncology, Product, System completed and qualified in an operational environment [taxonomieurl] => Clinical safety and effectiveness trials, Device, Devices, Imaging, Malignant Mesothelioma, Oncology, Product, System completed and qualified in an operational environment ) [578] => stdClass Object ( [post] => stdClass Object ( [post_title] => Antibody Protecting from BSCB leakage induced CNS damages [guid] => https://technology-offers.inserm-transfert.com/offer/antibody-protecting-from-bscb-leakage-induced-cns-damages/ [post_content] => The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis. [post_date] => 2013-05-21 13:56:08 [post_modified] => 2024-09-11 15:42:55 [ID] => 3693 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 7f361f0e-c43e-4efe-496a-5b97b813be23 [etat_fiche_online] => en_ligne [date_application] => 21-05-2013 [date] => [bd_referent] => Gregoire SERRA [bd_referent_id] => [contact_email] => gregoire.serra@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13193-T2 [keywords] => Ischemic stroke - Hemorrhagic stroke - Neurodegenerative diseases - Multiple Sclerosis -
[pub_scient_inv_dispo] => Brain. 2016 Sep;139(Pt 9):2406-19. doi: 10.1093/brain/aww172. Epub 2016 Jul 19Neuropharmacology. 2013 Apr;67:267-71. doi: 10.1016/j.neuropharm.2012.11.023. Epub 2012 Dec 3.Stroke. 2011 Aug;42(8):2315-22. doi: 10.1161/STROKEAHA.110.606293. Epub 2011 Jun 16.J Neurochem. 2010 Apr;113(2):447-53. doi: 10.1111/j.1471-4159.2010.06598.x. Epub 2010 Jan 18. [access_to_detailed_offer] => /wp-content/uploads/BIO13193-T2_VIVIEN.pdf [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => antibodies_nanobodies [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Multiple sclerosisTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 578 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibodies nanobodies, Antibody, Biologic, Central Nervous System, Drug, Lead - validation in vivo, Multiple sclerosis, Product, Product, Protein [taxonomieurl] => Antibodies nanobodies, Antibody, Biologic, Central Nervous System, Drug, Lead - validation in vivo, Multiple sclerosis, Product, Product, Protein ) [579] => stdClass Object ( [post] => stdClass Object ( [post_title] => USE OF FZD7 INHIBITORS FOR THE TREATMENT OF RETINAL NEOVASCULARIZATION [guid] => https://technology-offers.inserm-transfert.com/offer/use-of-fzd7-inhibitors-for-the-treatment-of-retinal-neovascularization/ [post_content] => Retinal ischemia and abnormal blood vessels growth are major determinants in the pathogenesis of retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (DR). The present study used mice model of oxygen-induced retinopathy (OIR) to investigate the role of Fzd7 during initial vaso-obliteration (VO) and subsequent hypoxia-induced neovascularization (NV) phases. In particular, the inventors performed two blocking strategies: a monoclonal antibody (mAbFzd7) directed against Fzd7 and a soluble Fzd7 receptor (CRD domain). In vivo intravitreal microinjection of mAbFzd7 or CRD receptor in mice after 5 days of exposure to 75% oxygen (P12) resulted in a significant decrease of pathological neovascularization in the treated eye compared to the control eye. Collectively, the results established that Fzd7 acts as an important regulator of retinal neovascularization and offers a promising anti-angiogenic strategy for the treatment of ischemic retinopathies. Accordingly, the present invention relates to use of Fzd7 inhibitors for the treatment of retinal neovascularization. [post_date] => 2018-04-04 13:56:08 [post_modified] => 2024-09-11 15:41:46 [ID] => 3692 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 78030886-5b3c-3230-9157-5b18e1cc787d [etat_fiche_online] => en_ligne [date_application] => 04-04-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17121-T1 [keywords] => ischemic retinopathy; retinal neovascularization [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO17121-T1_DUFFOURCQ.pdf [rare_disease] => false [second_indication] => false [inventors] => DUFOURCQ Pascale,BATS Marie-Lise,COUFFINHAL Thierry,PEGHAIRE Claire,DUPLAA Cécile [number_application] => International Procedure (PCT) - 04 Avr. 2018 - PCT/IB2018/000444 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OphtalmologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 579 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Drug, Method, Ophtalmology, Protein, Target, Validation in vivo [taxonomieurl] => Antibody, Biologic, Drug, Method, Ophtalmology, Protein, Target, Validation in vivo ) [580] => stdClass Object ( [post] => stdClass Object ( [post_title] => Pyk2-based gene therapy attenuates cognitive deficits associated to Huntington’s Disease [guid] => https://technology-offers.inserm-transfert.com/offer/pyk2-based-gene-therapy-attenuates-cognitive-deficits-associated-to-huntingtons-disease/ [post_content] => In the present invention it is shows that the inactivation of the Pyk2 gene does not alter hippocampal development but prevents hippocampal-dependent memory tasks and LTP. Inventors clearly provide evidence for multiple roles of Pyk2 in spine morphology and post synaptic structure. Thus, the inventors used direct overexpression of PYK2 by AAV-mediated gene transfer into the brain of Huntington’s mouse model and found that overexpression of PYK2 in this model improves synaptic plasticity and spine density deficits wich is also accompanied by a rescue of spatial memory. Accordingly it was demonstrate that PYK2 may restore cognitive functions in neurodegenerative diseases. Thus the present invention relates to a method of treating neurodegenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for PYK2 polypeptide. [post_date] => 2017-03-24 13:56:05 [post_modified] => 2024-09-11 15:44:24 [ID] => 3685 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 69418a64-7eb7-4dd3-a14c-2da1efcdc342 [etat_fiche_online] => en_ligne [date_application] => 24-03-2017 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17059-T1 [keywords] => neurodegenerative disease - cognitif deficits [pub_scient_inv_dispo] => Nat Commun. 2017 May 30;8:15592. doi: 10.1038comms15592. [access_to_detailed_offer] => /wp-content/uploads/BIO17059-T1_GIRAULT.pdf [rare_disease] => true [second_indication] => false [inventors] => GIRAULT Jean-Antoine,BRITO Veronica Ines,GINES Silvia,GIRALT Albert [number_application] => European Procedure (Patents) (EPA) - 24 Mars 2017 - 17305340.6 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Huntington's DiseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 580 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Central Nervous System, Drug, Gene Therapy, Gene therapy, Huntington's Disease, Lead - validation in vivo, Method, Product [taxonomieurl] => Biologic, Central Nervous System, Drug, Gene Therapy, Gene therapy, Huntington's Disease, Lead - validation in vivo, Method, Product ) [581] => stdClass Object ( [post] => stdClass Object ( [post_title] => SLITRK6 as a target for cancers associated with activation of the MAPK pathway [guid] => https://technology-offers.inserm-transfert.com/offer/slitrk6-as-a-target-for-cancers-associated-with-activation-of-the-mapk-pathway/ [post_content] => The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor of activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression of SLITRK6 also paves the way of strategies based on depletion of the residual cancer cells by targeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drug conjugates binding to SLITRK6. [post_date] => 2017-02-10 13:56:05 [post_modified] => 2024-09-11 15:45:15 [ID] => 3684 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 68bef3a3-e385-40ac-8aa6-2d56162e4506 [etat_fiche_online] => en_ligne [date_application] => 10-02-2017 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17032-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO17032-T1_FAVRE.pdf [rare_disease] => false [second_indication] => false [inventors] => FAVRE Gilles,POHORECKA Magdalena [number_application] => European Procedure (Patents) (EPA) - 10 Févr. 2017 - 17 305 153.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 581 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Drug, Melanoma, Oncology, Protein, Target, Target, Validation in vivo [taxonomieurl] => Antibody, Biologic, Drug, Melanoma, Oncology, Protein, Target, Target, Validation in vivo ) [582] => stdClass Object ( [post] => stdClass Object ( [post_title] => Fonctionalized microparticules as vaccination adjuvant and Ag vector for the development of therapeutic vaccines against cancer [guid] => https://technology-offers.inserm-transfert.com/offer/fonctionalized-microparticules-as-vaccination-adjuvant-and-ag-vector-for-the-development-of-therapeutic-vaccines-against-cancer/ [post_content] => The invention relates to microparticules fonctionalized with alphagalactosylceramide for sustained iNKT cell activation. Delivering of alphagalactosylceramide (a natural iNKT agonist presented by DC to iNKT cells) through functionalized microparticules allows to prevent the iNKT anergy observed with non vectorized alphagalactosylceramide. Such approach reopens the doors of the use of alphagalactosylceramide in the treatment of cancer, more particularly the treatment of lung cancer for which alphagalactosylceramide had shown promising short term efficacy. [post_date] => 2013-02-20 13:56:04 [post_modified] => 2024-09-11 15:41:44 [ID] => 3681 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 5f2f4d50-ab18-4b93-b32d-e5eed7dc188e [etat_fiche_online] => en_ligne [date_application] => 20-02-2013 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO12320-T1 [keywords] => Vaccine, therapeutic vaccine, antigen, adjuvant, microparticules, lung, oncology, cancer, DC, iNKT, alpha-GalCer, alphagalacotsylceramide [pub_scient_inv_dispo] => Oncoimmunology. 2017 Aug 18;6(9):e1339855. doi: 10.1080/2162402X.2017.1339855. eCollection 2017. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => MACHO-FERNANDEZ Elodie,FAVEEUW Christelle,CRUZ-RICONDO Luis Javier [number_application] => United States Of America (PSP) - 20 Févr. 2013 - 61/766,789 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 582 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Lead - validation in vivo, Oncology, Product, Product [taxonomieurl] => Drug, Lead - validation in vivo, Oncology, Product, Product ) [583] => stdClass Object ( [post] => stdClass Object ( [post_title] => Increasing Tfr1 palmitoylation as a novel therapeutic strategy for Neurodegeneration with brain iron accumulation [guid] => https://technology-offers.inserm-transfert.com/offer/increasing-tfr1-palmitoylation-as-a-novel-therapeutic-strategy-for-neurodegeneration-with-brain-iron-accumulation/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration with brain iron accumulation (NBIA). In particular, the present invention relates to a method of treating neurodegeneration with brain iron accumulation comprising administering to the subject a therapeutically effective amount of a drug increasing TfR1 palmitoylation. [post_date] => 2016-12-20 13:56:03 [post_modified] => 2024-09-11 15:41:20 [ID] => 3679 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 59cd4fe4-f624-409b-9267-980af374a26f [etat_fiche_online] => en_ligne [date_application] => 20-12-2016 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO16340-T1 [keywords] => Neurology - Neurodegeneration - Small molecule - Brain Iron Accumulation [pub_scient_inv_dispo] => Am J Hum Genet. 2018 Feb 1;102(2):266-277. doi: 10.1016/j.ajhg.2018.01.003. [access_to_detailed_offer] => /wp-content/uploads/BIO16340-T1_ROTIG.pdf [rare_disease] => true [second_indication] => true [inventors] => ROTIG Agnès,DRECOURT Anthony [number_application] => European Procedure (Patents) (EPA) - 20 Déc. 2016 - 16 306 740.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Central Nervous SystemTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 583 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Central Nervous System, Drug, Method, Small Molecule, Target, Validation in vitro [taxonomieurl] => Central Nervous System, Drug, Method, Small Molecule, Target, Validation in vitro ) [584] => stdClass Object ( [post] => stdClass Object ( [post_title] => Treatment of bone mineral density related diseases [guid] => https://technology-offers.inserm-transfert.com/offer/treatment-of-bone-mineral-density-related-diseases/ [post_content] => The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis, osteogenesis imperfecta) [post_date] => 2007-12-07 13:56:03 [post_modified] => 2024-09-11 15:43:31 [ID] => 3677 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 5859ff01-259b-4638-b9e5-c2639641329d [etat_fiche_online] => en_ligne [date_application] => 07-12-2007 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO07572-T1 [keywords] => osteogenesis imperfecta [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => CORMIER-DAIRE Valérie [number_application] => European Procedure (Patents) (EPA) - 07 Déc. 2007 - 07 301643.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Osteoporosis / Post Menopausal OsteoporosisTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 584 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Metabolic Disorders, Osteoporosis / Post Menopausal Osteoporosis, Target, Target, Validation in vivo [taxonomieurl] => Drug, Metabolic Disorders, Osteoporosis / Post Menopausal Osteoporosis, Target, Target, Validation in vivo ) [585] => stdClass Object ( [post] => stdClass Object ( [post_title] => Method for the treatment of disease associated with angiogenesis [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-the-treatment-of-disease-associated-with-angiogenesis/ [post_content] => The present invention relates to a method of treating disease associated with angiogenesis using an N-Methyl-D-aspartate receptor (NMDA) antagonist. More specifically, it concerns use of an NMDA receptor antagonist, for the treatment of disease associated with angiogenesis such as tumor angiogenesis, ocular neovascular disease, Age-related macular degeneration (AMD). [post_date] => 2015-11-30 13:56:02 [post_modified] => 2024-09-11 15:45:14 [ID] => 3676 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 58507c9f-77c8-4a0a-89ce-6103b39f5e18 [etat_fiche_online] => en_ligne [date_application] => 30-11-2015 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO13165-T1 [keywords] => NMDAR antagonist - Target - Angiogenesis [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO13165-T1_COHEN-KAMINSKI.pdf [rare_disease] => false [second_indication] => true [inventors] => BRU-MERCIER Gilles,DUMAS Sébastien [number_application] => European Procedure (Patents) (EPA) - 30 Nov. 2015 - 15 306 894.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 585 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Method, Oncology, Target, Validation in vitro [taxonomieurl] => Drug, Method, Oncology, Target, Validation in vitro ) [586] => stdClass Object ( [post] => stdClass Object ( [post_title] => TRPV2 as a new therapeutic target to modulate Blood Brain Barrier properties [guid] => https://technology-offers.inserm-transfert.com/offer/trpv2-as-a-new-therapeutic-target-to-modulate-blood-brain-barrier-properties/ [post_content] => The present invention relates to a method for modulating blood-brain barrier (BBB) in a subject comprising a step of administering said subject with a therapeutically effective amount of a modulator of transient receptor potential vanilloid-2 (TRPV2). For the first time, inventors have shown that TRPV2 is present in endothelial cells of BBB. More particularly, Inventor’s results show that cannabidiol (CBD), at extracellular concentrations close to those observed in plasma of patients treated by CBD, and induces proliferation, migration, tubulogenesis and TEER increase in human brain endothelial cells, suggesting TRPV2 as a potent target for modulating the human BBB. [post_date] => 2019-02-04 13:56:02 [post_modified] => 2024-09-11 15:42:36 [ID] => 3675 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 53c84512-368d-d3a0-85ae-5dc0578d6cd4 [etat_fiche_online] => en_ligne [date_application] => 04-02-2019 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO18544-T1 [keywords] => BBB dysfunction - TRPV2 agonist [pub_scient_inv_dispo] => [access_to_detailed_offer] => /t/wp-content/uploads/BIO18544-T1_DECLEVES.pdf.pdf [rare_disease] => false [second_indication] => false [inventors] => DECLEVES Xavier,CISTERNINO Salvatore,SAUBAMEA Bruno,LUO Huilong [number_application] => European Procedure (Patents) (EPA) - 04 Févr. 2019 - 19 305 131.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Central Nervous SystemTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 586 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Central Nervous System, Drug, Target, Target, Validation in vitro [taxonomieurl] => Central Nervous System, Drug, Target, Target, Validation in vitro ) [587] => stdClass Object ( [post] => stdClass Object ( [post_title] => ANTIBODIES SPECIFIC TO GLYCOPROTEIN (GP) OF EBOLAVIRUS AND USES FOR THE TREATMENT AND DIAGNOSIS OF EBOLA VIRUS INFECTION [guid] => https://technology-offers.inserm-transfert.com/offer/antibodies-specific-to-glycoprotein-gp-of-ebolavirus-and-uses-for-the-treatment-and-diagnosis-of-ebola-virus-infection/ [post_content] => The present invention relates to antibodies or fragments thereof that specifically bind to glycoprotein (GP) of Ebola virus, and to their use for treating and diagnosing Ebola virus disease. [post_date] => 2015-03-06 13:56:02 [post_modified] => 2024-09-11 15:41:43 [ID] => 3674 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 5113a51c-b83c-4782-b596-a2fefc40122e [etat_fiche_online] => en_ligne [date_application] => 06-03-2015 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14444-T1 [keywords] => neutralizing monoclonal antibody [pub_scient_inv_dispo] => J Infect Dis. 2015 Oct 1;212 Suppl 2:S372-8. doi: 10.1093/infdis/jiv303. Epub 2015 Aug 1. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => VOLCHKOV Viktor [number_application] => United States Of America (PSP) - 09 Févr. 2015 - 62/113,597 [technology_engineering] => antibodies_nanobodies [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• EbolaTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 587 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibodies nanobodies, Antibody, Biologic, Drug, Ebola, Hit - validation in vitro, Infectious Diseases, Product, Product, Protein [taxonomieurl] => Antibodies nanobodies, Antibody, Biologic, Drug, Ebola, Hit - validation in vitro, Infectious Diseases, Product, Product, Protein ) [588] => stdClass Object ( [post] => stdClass Object ( [post_title] => Lipopeptide compound for the treatment of pain disorder [guid] => https://technology-offers.inserm-transfert.com/offer/lipopeptide-compound-for-the-treatment-of-pain-disorder/ [post_content] => The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain. [post_date] => 2017-04-27 13:56:01 [post_modified] => 2024-09-11 15:42:21 [ID] => 3673 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 503f42e5-1fa2-4793-aa6f-e587398946b6 [etat_fiche_online] => en_ligne [date_application] => 27-04-2017 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO16070-T1 [keywords] => Pain - Lipopeptide [pub_scient_inv_dispo] => Nat Commun. 2017 Nov 3;8(1):1314. doi: 10.1038/s41467-017-01403-9. [access_to_detailed_offer] => /wp-content/uploads/BIO16070-T1_CENAC.pdf [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Central Nervous SystemTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 588 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Central Nervous System, Drug, Hit - validation in vivo, Product, Product [taxonomieurl] => Central Nervous System, Drug, Hit - validation in vivo, Product, Product ) [589] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD TO RESTORE OR IMPROVE COGNITIVE FUNCTIONS [guid] => https://technology-offers.inserm-transfert.com/offer/method-to-restore-or-improve-cognitive-functions/ [post_content] => The present invention relates to the field of memory and cognitive functions. Here the inventors show that memory stimulations induce autophagy in the mouse hippocampus, while local pharmacological and genetic modulations of hippocampal autophagy strongly influence memory acquisition. More, the inventors observe that hippocampal autophagy declines during aging and they find that restoring autophagy specifically in the hippocampus of aged mice, following autophagy inducers (such as TAT-Beclin-1), can significantly reverse age-related memory decline. Their results reveal a novel physiological role of autophagy in regulating hippocampal-dependent memory functions, and demonstrate the potential therapeutic benefits of modulating autophagy in order to prevent and/or reverse the deleterious effects of aging on cognitive function. The present invention relates to an activator of the autophagy for use in the restoration and/or improvement of cognitive functions in a subject in need thereof. [post_date] => 2018-10-04 13:56:00 [post_modified] => 2024-09-11 15:41:19 [ID] => 3672 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 4ea76865-8ce2-aef3-b860-5bf284964291 [etat_fiche_online] => en_ligne [date_application] => 04-10-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17325-T1 [keywords] => Autophagy [pub_scient_inv_dispo] => Curr Biol. 2019 Feb 4;29(3):435-448.e8. doi: 10.1016/j.cub.2018.12.021. [access_to_detailed_offer] => /wp-content/uploads/BIO17325-T1_OURY.pdf [rare_disease] => false [second_indication] => false [inventors] => OURY Franck,CODOGNO Patrice [number_application] => European Procedure (Patents) (EPA) - 04 Oct. 2018 - 18 306 307.2 [technology_engineering] => [multidisciplinary_field] => ageing [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 589 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Ageing, Biologic, Drug, Method, Peptide, Product [taxonomieurl] => Ageing, Biologic, Drug, Method, Peptide, Product ) [590] => stdClass Object ( [post] => stdClass Object ( [post_title] => CB1 receptor antagonist for the treatment of liver fibrosis [guid] => https://technology-offers.inserm-transfert.com/offer/cb1-receptor-antagonist-for-the-treatment-of-liver-fibrosis/ [post_content] => CB1 were highly induced in human cirrhotic samples and in liver fibrogenic cells. Treatment with specific CB1 antagonist decreased the wound-healing response to acute liver injury and inhibited progression of fibrosis in three mouse models of chronic liver injury. Similar changes are observed in CB1-deficient mice as compared to wild-type mice. CB1 promotes pro-fibrogenic effects. (Julien et al., Gastroenterology. 2005 Mar;128(3):742-55. ; Teixeira-Clerc et al., Nat Med. 2006 Jun;12(6):671-6. ; Mallat et al., Br J Pharmacol. 2011 Aug;163(7):1432-40.) [post_date] => 2004-03-09 13:56:00 [post_modified] => 2024-09-11 15:41:08 [ID] => 3670 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 4cbd1bbd-e0e3-42d0-bd8a-caa2d704707f [etat_fiche_online] => en_ligne [date_application] => 09-03-2004 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO03318-T1 [keywords] => Cannabinoid receptors; CB1; CB1 antagonist [pub_scient_inv_dispo] => Julien et al., Gastroenterology. 2005 Mar;128(3):742-55. ; Teixeira-Clerc et al., Nat Med. 2006 Jun;12(6):671-6. ; Mallat et al., Br J Pharmacol. 2011 Aug;163(7):1432-40. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => TRAN-VAN-NHIEU Jeanne,MALLAT Ariane,JULIEN Boris,GRENARD Pascale [number_application] => European Procedure (Patents) (EPA) - 09 Mars 2004 - 04 290 633.9 [technology_engineering] => [multidisciplinary_field] => fibrosis [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Gastrointestinal DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 590 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Fibrosis, Gastrointestinal Diseases, Liver Disease, Liver Fibrosis, Target, Target, Validation in vivo [taxonomieurl] => Drug, Fibrosis, Gastrointestinal Diseases, Liver Disease, Liver Fibrosis, Target, Target, Validation in vivo ) [591] => stdClass Object ( [post] => stdClass Object ( [post_title] => ALLELE-SPECIFIC SILENCING THERAPY FOR DYNAMIN 2-RELATED DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/allele-specific-silencing-therapy-for-dynamin-2-related-diseases/ [post_content] => The invention relates to an allele specific siRNA able to silence the expression of only one allele of a heterozygous DNM2 gene, for treating diseases caused by heterozygous mutation and/or overexpression of Dynamin 2. [post_date] => 2016-11-29 13:55:59 [post_modified] => 2024-09-11 15:42:49 [ID] => 3667 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 47c2c832-90de-a9fb-52b1-5d309eb3c932 [etat_fiche_online] => en_ligne [date_application] => 29-11-2016 [date] => [bd_referent] => Gregoire SERRA [bd_referent_id] => [contact_email] => gregoire.serra@inserm-transfert.fr [contact_phone] => [reference_online] => BIO17148-T1 [keywords] => Centronuclear Myopathies - [pub_scient_inv_dispo] => EMBO Mol Med. 2018 Feb;10(2):239-253. doi: 10.15252/emmm.201707988. [access_to_detailed_offer] => /wp-content/uploads/BIO17148-T1_BITOUN.pdf [rare_disease] => true [second_indication] => false [inventors] => BITOUN Marc,PRUDHON Bernard,TROCHET Delphine [number_application] => European Procedure (Patents) (EPA) - 29 Nov. 2016 - 16306575.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Genetic DisordersTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 591 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Gene Therapy, Genetic Disorders, Hit - validation in vivo, Product, Product, Rnai gene therapy [taxonomieurl] => Biologic, Drug, Gene Therapy, Genetic Disorders, Hit - validation in vivo, Product, Product, Rnai gene therapy ) [592] => stdClass Object ( [post] => stdClass Object ( [post_title] => Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) for the treatment of melanomas [guid] => https://technology-offers.inserm-transfert.com/offer/inhibition-of-nicotinamide-phosphoribosyltransferase-nampt-for-the-treatment-of-melanomas/ [post_content] => The present invention relates to a method for treating a subject suffering from melanoma resistant by administering to said subject an inhibitor of NAMPT. Using a global metabolic profiling, inventors have showed that in addition to glycolysis, the BRAF inhbitor, PLX4032, promoted a complex metabolic rewiring of melanoma cells, including protein catabolism and fatty acid synthesis. Importantly, they observed that PLX4032 reduced the levels of nicotinamide adenine dinucleotide (NAD+), an important redox co-factor in numerous metabolic processes, including glycolysis, tricarboxylic acid cycle (TCA) cycle, glutamate metabolism and fatty acid betaoxidation. Pharmacological or genetic inhibition of NAMPT impaired melanoma cell growth, whereas the overexpression of NAMPT dampened the antiproliferative effect of PLX4032. In vivo, the inhibition of NAMPT also prevented the xenograft development of PLX4032-sensitive and -resistant melanoma cells, identifying NAMPT as a potential target for BRAFi-resistant melanomas. [post_date] => 2018-01-04 13:55:58 [post_modified] => 2024-09-11 15:40:57 [ID] => 3665 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 43db30c1-0772-6f01-d41b-5abca551f9ab [etat_fiche_online] => en_ligne [date_application] => 04-01-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17393-T1 [keywords] => NAMPT inhibitor - BRAF-resistance [pub_scient_inv_dispo] => Genes Dev. 2018 Mar 22. doi: 10.1101/gad.305854.117 [access_to_detailed_offer] => /wp-content/uploads/BIO17393-T1_BERTOLOTTO-BALLOTTI.pdf [rare_disease] => false [second_indication] => false [inventors] => BERTOLOTTO Corine,BALLOTTI Robert,OHANNA Mickaël [number_application] => European Procedure (Patents) (EPA) - 04 Janv. 2018 - 18 305 002.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 592 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Oncology, Small Molecule, Target, Target, Validation in vivo [taxonomieurl] => Drug, Melanoma, Oncology, Small Molecule, Target, Target, Validation in vivo ) [593] => stdClass Object ( [post] => stdClass Object ( [post_title] => Neuroglobin gene therapy for use in the treatment or prevention of a mitochondrial ophthalmic disease associated with respiratory chain complex [guid] => https://technology-offers.inserm-transfert.com/offer/neuroglobin-gene-therapy-for-use-in-the-treatment-or-prevention-of-a-mitochondrial-ophthalmic-disease-associated-with-respiratory-chain-complex/ [post_content] => Mitochondrial dysfunction is responsible for hereditary optic neuropathies. We wished to determine whether preserving mitochondrial bioenergetics could prevent optic neuropathy in a reliable model of glaucoma. DBA/2J mice exhibit elevated intraocular pressure, progressive degeneration of their retinal ganglion cells, and optic neuropathy that resembles glaucoma. The inventors established that glaucoma in these mice is directly associated with mitochondrial dysfunction: respiratory chain activity was compromised in optic nerves 5 months before neuronal loss began, and the amounts of some mitochondrial proteins were reduced in retinas of glaucomatous mice. One of these proteins is neuroglobin, thus the inventors investigated whether gene therapy aimed at restoring neuroglobin levels in the retina via ocular administration of an adeno-associated viral vector could reduce neuronal degeneration. The approach of treating 2-month-old mice impeded glaucoma development: few neurons died and respiratory chain activity and visual cortex activity were comparable to those in young, asymptomatic mice. When the treatment was performed in 8-month-old mice, the surviving neurons acquired new morphologic and functional properties, leading to the preservation of visual cortex activity and respiratory chain activity. The beneficial effects of neuroglobin in DBA/2J retinas confirm this protein to be a promising candidate for treating glaucoma. [post_date] => 2013-09-30 13:55:58 [post_modified] => 2024-09-11 15:41:45 [ID] => 3663 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 4267c3e2-168a-4462-b2e3-6d9e5ea3cb76 [etat_fiche_online] => en_ligne [date_application] => 30-09-2013 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO14389-T1 [keywords] => Ophthalmology - Gene Therapy - Neuroglobine - Mitochondrial Diseases [pub_scient_inv_dispo] => Mol Ther. 2014 Jun;22(6):1096-1109. doi: 10.1038/mt.2014.44. Epub 2014 Mar 13.Mol Ther Methods Clin Dev. 2017 Apr 27;5:200-220. doi: 10.1016/j.omtm.2017.04.008. eCollection 2017 Jun 16 [access_to_detailed_offer] => /wp-content/uploads/BIO14389-T1_CORRAL-DEBRINSKI.pdf [rare_disease] => false [second_indication] => false [inventors] => DEBEIR Thomas,LECHAUVE Christophe,SAHEL José Alain [number_application] => International Procedure (PCT) - 30 Sept. 2013 - PCT/IB2013/002461 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OphtalmologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 593 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Glaucoma, Lead - validation in vivo, Ophtalmology, Product, Product [taxonomieurl] => Drug, Glaucoma, Lead - validation in vivo, Ophtalmology, Product, Product ) [594] => stdClass Object ( [post] => stdClass Object ( [post_title] => Ox1R agonists for the treatment of autoimmunity diseases [guid] => https://technology-offers.inserm-transfert.com/offer/ox1r-agonists-for-the-treatment-of-autoimmunity-diseases/ [post_content] => [post_date] => 2014-06-24 13:55:57 [post_modified] => 2024-09-11 15:41:40 [ID] => 3660 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 3d6bf15a-0915-4786-9d45-faa1a97627ed [etat_fiche_online] => en_ligne [date_application] => 24-06-2014 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14095-T1 [keywords] => [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/Licensing-opportunity-Immunology-Therapeutic-June2018_Couvineau.pdf [rare_disease] => false [second_indication] => false [inventors] => MESSAL Nassima,OGIER-DENIS Eric,VOISIN Thierry,TRETON Xavier [number_application] => European Procedure (Patents) (EPA) - 24 Juin 2014 - 14 305 990.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• Gastrointestinal DiseasesTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 594 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target [taxonomieurl] => Gastrointestinal Diseases, Inflammatory Bowel Disease / Crohn's Disease, Target ) [595] => stdClass Object ( [post] => stdClass Object ( [post_title] => Enhancement of 5-Fluorouracil cytotoxicity by Pyridoxal 5’-phosphate and Folinic acid in tandem [guid] => https://technology-offers.inserm-transfert.com/offer/enhancement-of-5-fluorouracil-cytotoxicity-by-pyridoxal-5-phosphate-and-folinic-acid-in-tandem/ [post_content] => The invention relates to methods and pharmaceutical compositions for treating cancer in a subject in need thereof. The inventors thought that low activity of serine hydroxymethyl transferase (SHMT) due to poor pyridoxal 5’-phosphate (PLP) availability within cancer cells would result in insufficient growth inhibition in cancer cells exposed to 5-fluorouracil (FUra), as well as to FUra in combination with N5-formyl tetra hydro pteroylglutamate (5-HCOH4PteGlu; folinic acid). Cancer cell lines grown in vitro were exposed to FUra as a single agent and to FUra with folinic acid, in combination with high concentration PLP. The inventors demonstrated synergistic and additive interactions upon cytotoxicity of FUra by folinic acid and PLP combined in HT29, HCT116, and L1210 cancer cells. Murine studies of parenteral administration of pyridoxamine in high doses showed that intracellular PLP is augmented to levels close or greater than the Kd reported for binding of cofactor to SHMT, which suggests that modulation of the fluoropyrimidines by vitamin B6 could be achieved in vivo. Thus, the present invention relates to an antitumor pharmaceutical combination comprising (i) a fluoropyrimidine, (ii) a B6 vitamer, and optionally (iii) a folate, and the use of said combination in the treatment of cancer in a subject in need thereof. [post_date] => 2018-05-30 13:55:56 [post_modified] => 2024-09-11 15:41:49 [ID] => 3658 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 30923cfd-91a9-3404-2e10-5b2a6fc7a308 [etat_fiche_online] => en_ligne [date_application] => 30-05-2018 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17660-T1 [keywords] => combination [pub_scient_inv_dispo] => J Pharmacol Exp Ther. 2018 Aug;366(2):238-243. doi: 10.1124/jpet.118.249367. Epub 2018 Jun 1. [access_to_detailed_offer] => /wp-content/uploads/BIO17660-T1_MACHOVER.pdf [rare_disease] => false [second_indication] => false [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Colorectal CancerTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 595 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Colorectal Cancer, Drug, Lead - validation in vitro, Method, Oncology, Product, Small Molecule [taxonomieurl] => Colorectal Cancer, Drug, Lead - validation in vitro, Method, Oncology, Product, Small Molecule ) [596] => stdClass Object ( [post] => stdClass Object ( [post_title] => Anti-KIT mAb for the treatment of cancer (AML, GIST) [guid] => https://technology-offers.inserm-transfert.com/offer/anti-kit-mab-for-the-treatment-of-cancer-aml-gist/ [post_content] => The invention relates to two isolated human neutralizing antibodies that binds to an undisclosed Tyrosine Kinase Receptor, which further induces internalization and degradation of oncogenic forms of this Receptor. The invention is based on the generation and characterization of two neutralizing scFv-Fc which interfered with ligand binding and consequently, inhibited ligand-dependant Tyrosine Kinase Receptor phosphorylation and downstream signalling. These antibodies reduced the viability of erythroleukemic cell line UT-7, after 3 days of treatment. These anti-TK Receptor scFv-Fc also reduced cell viability of two mast cell leukemia cell lines bearing activating mutations of the TK Receptor.Inhibition was due to intensive internalization and degradation of oncogenic forms of the TK Receptor upon antibody treatment. These fully human antibodies thus represent new therapeutic tools useful for targeting diseases associated with Receptor or Ligand overexpression as well as for targeting oncogenic TK Receptor signalling in cancer such as AML or GIST, and to bypass Tyrosine Kinase Inhibition resistance of certain mutants. [post_date] => 2013-11-05 13:55:56 [post_modified] => 2024-09-11 15:42:29 [ID] => 3655 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 27e9051d-044f-4763-996f-36d24ba2f0ee [etat_fiche_online] => en_ligne [date_application] => 05-11-2013 [date] => [bd_referent] => Myriam GAMBERONI [bd_referent_id] => [contact_email] => myriam.gamberoni@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 36 [reference_online] => BIO13274-T1 [keywords] => scFv-Fc, fully human, TK Receptor degradation [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CREPIN Ronan [number_application] => European Procedure (Patents) (EPA) - 05 Nov. 2013 - 13 306 519.3 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 596 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Drug, Hit - validation in vivo, Oncology, Product, Product [taxonomieurl] => Biologic, Drug, Hit - validation in vivo, Oncology, Product, Product ) [597] => stdClass Object ( [post] => stdClass Object ( [post_title] => Inhibition of USP14 impairs melanoma cell survival and overcomes resistance to MAPK-targeting therapies [guid] => https://technology-offers.inserm-transfert.com/offer/inhibition-of-usp14-impairs-melanoma-cell-survival-and-overcomes-resistance-to-mapk-targeting-therapies/ [post_content] => The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 correlates with melanoma progression and with a poorer survival rate in metastatic melanoma patients. Then, they have shown that when ubiquitin-specific peptidase 14 (USP14) is inhibited by siRNAs and pharmacological inhibitors (b-AP15, WP1130 and HBX41108), the cell proliferation of melanoma cell drastically decreased. They have also shown that melanoma treatment with pharmacological inhibitors can overcome resistance to drugs targeting oncogenic BRAF. Accordingly, the invention relates to a method for predicting the survival time of a subject suffering from melanoma by quantifying the expression level of USP14 in a biological sample and to a method of treating melanoma and resistant melanoma by using the inhibitors of USP14. Targeting the proteasome-associated deubiquitinating enzyme USP14 induces melanoma cell death and overcomes resistance to MAPK-targeting therapies in vitro/in vivo. [post_date] => 2017-03-24 13:55:55 [post_modified] => 2024-09-11 15:41:00 [ID] => 3654 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 26c5b72d-4a7b-44d8-b280-e20be5c4a194 [etat_fiche_online] => en_ligne [date_application] => 24-03-2017 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO16432-T1 [keywords] => ubiquitin-proteasome, deubiquitinase, USP14, MAPK-targeting therapies [pub_scient_inv_dispo] => Mol Cancer Ther. 2018 Apr 27. pii: molcanther.0919.2017. doi: 10.1158/1535-7163.MCT-17-0919. [Epub ahead of print] [access_to_detailed_offer] => /wp-content/uploads/BIO16432-T1_DECKERT.pdf [rare_disease] => false [second_indication] => false [inventors] => DECKERT Marcel,TARTARE-DECKERT Sophie,MALLAVIALLE Aude,DIDIER Robin [number_application] => European Procedure (Patents) (EPA) - 24 Mars 2017 - 17 305 339.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• MelanomaTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 597 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Melanoma, Oncology, Target, Target, Validation in vivo [taxonomieurl] => Drug, Melanoma, Oncology, Target, Target, Validation in vivo ) [598] => stdClass Object ( [post] => stdClass Object ( [post_title] => OPTICAL FIBER MODE SCRAMBLER [guid] => https://technology-offers.inserm-transfert.com/offer/optical-fiber-mode-scrambler/ [post_content] => The invention relates to a fiber optic mode scrambler component and method of making the same.This scrambler converts a Gaussian intensity profile of a laser beam passing through an optical fiber into a top-hat profile at the distal end of the optical fiber.This invention aims to provide an optical fiber mode scrambler device adapted to provide a significant mode scrambling of an optical fiber associated to it.Applied for homogeneous illumination of fiber-optic textiles used for photodynamic therapy. [post_date] => 2016-02-05 13:55:55 [post_modified] => 2024-09-11 15:40:36 [ID] => 3652 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 251af32e-3402-498f-93bf-cb14f15a38a9 [etat_fiche_online] => en_ligne [date_application] => 05-02-2016 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 45 [reference_online] => MECA15328-T1 [keywords] => Fiber Mode Scrambler ; photodynamic therapy; laser based medical tools connected to optical fibers [pub_scient_inv_dispo] => Published patent WO/2017/134194 on 10.08.2017 [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => BETROUNI Nacim,DELEPORTE Pascal [number_application] => European Procedure (Patents) (EPA) - 05 Févr. 2016 - 16 305 141.0 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 598 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Component/subsystem validated, Device, Devices, Oncology, Product, Validated in lab [taxonomieurl] => Component/subsystem validated, Device, Devices, Oncology, Product, Validated in lab ) [599] => stdClass Object ( [post] => stdClass Object ( [post_title] => VDAC1 inhibition for the treatment of peripheral demyelination [guid] => https://technology-offers.inserm-transfert.com/offer/vdac1-inhibition-for-the-treatment-of-peripheral-demyelination/ [post_content] => Here the inventors show, using in vivo imaging and viral approaches, that calcium released by mitochondrial VDAC1 directly induces Schwann cell demyelination via MAPK and c-jun activation after sciatic nerve injury and more importantly in diabetic neuropathy. Moreover, reduction of mitochondrial calcium release by VDAC1 silence or/and drug blocking strongly reduces the number of demyelinating Schwann cell in vivo and improve nerve conduction and neuromuscular activity in diabetic and Charcot-Marie Tooth disease models.Accordingly the present invention relates to a method of treating a peripheral demyelinating disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an inhibitor of VDAC1 activity or expression. [post_date] => 2015-05-20 13:55:54 [post_modified] => 2024-09-11 15:44:26 [ID] => 3650 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 233e9b2a-72a7-4c40-8f4e-9b6dc928bee9 [etat_fiche_online] => en_ligne [date_application] => 20-05-2015 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO15042-T1 [keywords] => Demyelinating neuropathies (CMT, ALS, Diabetic neuropathy,Tangier disease, Metachromatic leukodystrophy, Fabry’sdisease, hypothyroïd neuropathies, ... )
VDAC inhibitor - peptide
[pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO15042-T1_TRICAUD.pdf [rare_disease] => true [second_indication] => false [inventors] => [number_application] => [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Central Nervous SystemTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 599 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Central Nervous System, Drug, Synthetic peptide, Target, Target, Validation in vivo [taxonomieurl] => Central Nervous System, Drug, Synthetic peptide, Target, Target, Validation in vivo ) [600] => stdClass Object ( [post] => stdClass Object ( [post_title] => Non-invasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies [guid] => https://technology-offers.inserm-transfert.com/offer/non-invasive-imaging-of-tumor-pd-l1-expression-using-radiolabeled-anti-pd-l1-antibodies/ [post_content] => The present invention relates to a method for identifying patients sufferingfrom or suspected to suffer from a cancer involving a solid tumor [post_date] => 2015-04-07 13:55:53 [post_modified] => 2024-09-11 15:40:35 [ID] => 3648 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 1c23cc76-209b-4ebf-9a00-c340a8eaa0d1 [etat_fiche_online] => en_ligne [date_application] => 07-04-2015 [date] => [bd_referent] => Myriam GAMBERONI [bd_referent_id] => [contact_email] => myriam.gamberoni@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 36 [reference_online] => BIO15048-T1 [keywords] => PD-L1; imaging; radiolabel [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => [number_application] => European Procedure (Patents) (EPA) - 07 Avr. 2015 - 15305510.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 600 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Basic principles observed, Basic research, Drug, Oncology, Product [taxonomieurl] => Basic principles observed, Basic research, Drug, Oncology, Product ) [601] => stdClass Object ( [post] => stdClass Object ( [post_title] => Anti Notch3 antibody for CADASIL treatment [guid] => https://technology-offers.inserm-transfert.com/offer/anti-notch3-antibody-for-cadasil-treatment/ [post_content] => The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. [post_date] => 2014-09-18 13:55:51 [post_modified] => 2024-09-11 15:42:23 [ID] => 3644 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 11ad3853-160e-46db-aaf5-b8793488b5c9 [etat_fiche_online] => en_ligne [date_application] => 18-09-2014 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO11607-T1 [keywords] => Neurology - Neurovascular -CADASIL - monoclonal antibody [pub_scient_inv_dispo] => Brain. 2013 Jun;136(Pt 6):1830-45. doi: 10.1093/brain/awt092. Epub 2013 May 6.Ann Neurol. 2016 Mar;79(3):387-403. doi: 10.1002/ana.24573. Epub 2016 Feb 10. [access_to_detailed_offer] => /wp-content/uploads/BIO11607-T1_JOUTEL.pdf [rare_disease] => true [second_indication] => false [inventors] => [number_application] => Denmark (NP) - 25 Sept. 2014 - PA201400547 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Central Nervous SystemTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 601 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Antibody, Biologic, Central Nervous System, Drug, Lead - validation in vivo, Product, Product, Protein [taxonomieurl] => Antibody, Biologic, Central Nervous System, Drug, Lead - validation in vivo, Product, Product, Protein ) [602] => stdClass Object ( [post] => stdClass Object ( [post_title] => Device for monitoring the density of a sample and associated method [guid] => https://technology-offers.inserm-transfert.com/offer/device-for-monitoring-the-density-of-a-sample-and-associated-method/ [post_content] => The invention concerns the field of measuring the density of a sample, notably for evaluating the relative amount of the first component and the second component in the sample.For this, optical measuring of the index is known but such kind of measurement implies drying the sample. There is therefore a need for a device that can be used in vivo and that can achieve a plurality of different measurement.Such versatility is provided by a device comprising:- a first detector adapted to measure the sample absorption of a first light beam comprised between 200 nanometers and 300 nanometers,- a second detector adapted to measure the sample absorption of the second light beam comprised between 700 nanometers and 3500 nanometers, and- a calculator adapted to obtain the relative amount by using the first and second measured absorptions.Applications would include pathological cases of dense cells and amyloids usually due to undesired protein aggregates. In the case of sickle cell disease, dense subpopulations can lead to exaggerated effects on the cell function. A range of densities can also be expected for cancer cells. Other proteins aggregates form amyloids such as for transthyretin, or proteins in Alzheimer’s disease. [post_date] => 2016-10-06 13:55:51 [post_modified] => 2024-09-11 15:40:34 [ID] => 3643 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 1130a58b-db13-4fbc-86dd-8f9390f65350 [etat_fiche_online] => en_ligne [date_application] => 06-10-2016 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 45 [reference_online] => MECA16210-T1 [keywords] => Oncology; Hematology [pub_scient_inv_dispo] => Publication WO/2018/065547 on 12.04.2018 [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => KIGER Laurent [number_application] => European Procedure (Patents) (EPA) - 06 Oct. 2016 - 16 306 317.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• OncologyTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 602 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Device, Devices, Oncology, Product, Validated in lab [taxonomieurl] => Device, Devices, Oncology, Product, Validated in lab ) [603] => stdClass Object ( [post] => stdClass Object ( [post_title] => Apelin receptor agonist for the treatment of post-operative cognitive dysfunction [guid] => https://technology-offers.inserm-transfert.com/offer/apelin-receptor-agonist-for-the-treatment-of-post-operative-cognitive-dysfunction/ [post_content] => The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist. [post_date] => 2016-02-15 13:55:51 [post_modified] => 2024-09-11 15:41:22 [ID] => 3641 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 0eda1fc9-4a47-4c3e-a39e-ff821fc044ad [etat_fiche_online] => en_ligne [date_application] => 15-02-2016 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO15529-T1 [keywords] => Neurology - Cognitive dysfunction - Apelin receptor agonist - peptide [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/BIO15529-T1_VALET.pdf [rare_disease] => false [second_indication] => false [inventors] => FRANCES Bernard,VINEL Claire,DRAY Cédric,LABASTE François,MINVILLE Vincent [number_application] => European Procedure (Patents) (EPA) - 15 Févr. 2016 - 16 305 170.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Cognitive disordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 603 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Biologic, Central Nervous System, Cognitive disorders, Drug, Lead - validation in vivo, Method, Peptide, Product [taxonomieurl] => Biologic, Central Nervous System, Cognitive disorders, Drug, Lead - validation in vivo, Method, Peptide, Product ) [604] => stdClass Object ( [post] => stdClass Object ( [post_title] => Protease nexin-1 inhibitor for the treatment of haemorrhagic disease [guid] => https://technology-offers.inserm-transfert.com/offer/protease-nexin-1-inhibitor-for-the-treatment-of-haemorrhagic-disease/ [post_content] => The thrombogram of FVIII-KO mice displays a prolonged time to peak and a reduced peak thrombin. The addition of the neutralizing anti-protease nexin-1 (PN-1) antibody enhances thrombin generation in PRP from haemophilia mice. The thrombogram of patient with haemophilia displays prolonged lag time and time to peak and a reduced peak thrombin and a reduced endogenous thrombin potential. As observed with the addition of recombinant FVIII, the neutralizing anti-PN-1 antibody enhances thrombin generation in PRP from patients with haemophilia A. Anti-PN-1 antibody improves thrombin generation in mild and moderate haemophilia patients but not in severe haemophilia patients. These findings establish a requirement for PN-1 inhibition as a specific anticoagulant in platelets and demonstrated that blocking PN-1 have a role in haemorrhagic disease treatment. [post_date] => 2015-04-15 13:55:50 [post_modified] => 2024-09-11 15:43:33 [ID] => 3639 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 09eab879-9439-40c4-928e-6b640fc7e46d [etat_fiche_online] => en_ligne [date_application] => 15-04-2015 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO15008-T1 [keywords] => Protease nexin-1; Haemophilia [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => true [second_indication] => false [inventors] => LENTING Petrus,DENIS Cécile,CHRISTOPHE Olivier [number_application] => European Procedure (Patents) (EPA) - 13 Avr. 2015 - 15 305 544.7 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Hematological DisordersTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 604 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Hematological Disorders, Hemorrhage, Target, Target, Validation in vitro [taxonomieurl] => Drug, Hematological Disorders, Hemorrhage, Target, Target, Validation in vitro ) [605] => stdClass Object ( [post] => stdClass Object ( [post_title] => G quadruplex ligands to treat infectious diseases [guid] => https://technology-offers.inserm-transfert.com/offer/porphyrin-derivatives-as-g-quadruplex-ligands-against-viral-infections-such-as-hiv/ [post_content] => The present inventions relate to - metallated porphyrin derivatives as ligands of G quadruplex and their use as anti-viral agents. Porphyrin derivatives candidates inhibits HIV replication with IC 50 around 100 nM in vitro. More specifically, this application is related to the use of porphyrin derivatives as G-quadruplex ligands to inhibit viral infections, such as HIV, more particularly to inhibit HIV-1 replication cycle;-methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one G4 forming sequence oligonucleotide;- novel candidates for treating viral infections such as HIV, Epstein Barr virus, HPV (Papillomavirus), SARS coronavirus, Ebola virus, Marburg virus, Zika, Herpes (HHV) , Hepatitis B, Hepatitis C, Kaposi’s sarcoma-associated herpesvirus (KSHV). In particular, the invention relates to novel compound derivatives that are shown to be G-quadruplex ligands and are thus useful for treating the above infections. Also the invention relates to the process of preparation of the novel compound derivatives. [post_date] => 2015-10-30 13:55:50 [post_modified] => 2024-09-11 15:41:28 [ID] => 3638 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 09267cb5-fab4-4b99-a5ef-1ae7ef5e3342 [etat_fiche_online] => en_ligne [date_application] => 30-10-2015 [date] => [bd_referent] => Soraya SIN-MONNOT [bd_referent_id] => [contact_email] => Soraya.SIN-MONNOT@inserm-transfert.fr [contact_phone] => [reference_online] => CHIM14143-T1 [keywords] => Virology, HIV, G4-Quadruplex, Ebola [pub_scient_inv_dispo] => Biochimie. 2015 Nov;118:173-5. doi: 10.1016/j.biochi.2015.09.009. Epub 2015 Sep 10.Review Nucleic Acids Res. 2014 Nov 10;42(20):12352-66. doi: 10.1093ar/gku999. Epub 2014 Oct 20.Dalton Trans. 2019 May 7;48(18):6091-6099. doi: 10.1039/c8dt04703k. [access_to_detailed_offer] => /wp-content/uploads/CHIM14143-T1_AMRANE.pdf [rare_disease] => false [second_indication] => false [inventors] => ANDREOLA Marie-Aline,MERGNY Jean-Louis,PRATVIEL Geneviève [number_application] => European Procedure (Patents) (EPA) - 30 Oct. 2015 - 15 306 737.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Infectious DiseasesTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 605 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Drug, Infectious Diseases, Lead - validation in vitro, Product, Product, Small Molecule [taxonomieurl] => Drug, Infectious Diseases, Lead - validation in vitro, Product, Product, Small Molecule ) [606] => stdClass Object ( [post] => stdClass Object ( [post_title] => TREK1/TREK2 As Targets For The Treatment Of Migraine [guid] => https://technology-offers.inserm-transfert.com/offer/trek1-trek2-as-targets-for-the-treatment-of-migraine/ [post_content] => Inventors have found that the MT mutation puts an alternative start codon in frame which leads to the translation of a second TRESK fragment. Surprisingly, the 2 gene products, termed MT1 and MT2, have differential dominant negative effects: MT1 targets TRESK while MT2 targets TREK1 and TREK2, members of another subfamily of K2P channels. Furthermore, they have shown that by co-assembling with and inhibiting TREK1 and TREK2, MT2 increases TG excitability. This resolves the contradictory lack of effects of TRESKC110R which targets only TRESK and not TREK1 or TREK2. Together their results demonstrate that alternative translation initiation is a mechanism initiated by the TRESK-MT mutation which leads to two protein fragments with dominant negative effects on distinct channel targets. The present invention relates to a method for treating migraine in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of agonists of: TREK1, TREK2, TRESK-TREK1, TRESK-TREK2 or TREK1-TREK2. [post_date] => 2017-07-29 13:55:49 [post_modified] => 2024-09-11 15:41:21 [ID] => 3636 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 05091425-193f-4e6b-b9a2-1939611df7a8 [etat_fiche_online] => en_ligne [date_application] => 29-07-2017 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO17200-T1 [keywords] => Pain - Migraine - Repositionning [pub_scient_inv_dispo] => Neuron. 2018 Dec 12. pii: S0896-6273(18)31048-1. doi: 10.1016/j.neuron.2018.11.039 [access_to_detailed_offer] => /wp-content/uploads/BIO17200-T1_SANDOZ.pdf [rare_disease] => false [second_indication] => true [inventors] => SANDOZ Guillaume,ROYAL Perrine,LESAGE Florian,VERKEST Clément,BARON-VAN EVERCOOREN Anne [number_application] => European Procedure (Patents) (EPA) - 29 Juin 2017 - 17 305 813.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Chronic painTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 606 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Central Nervous System, Chronic pain, Drug, Small Molecule, Target, Target, Validation in vivo [taxonomieurl] => Central Nervous System, Chronic pain, Drug, Small Molecule, Target, Target, Validation in vivo ) [607] => stdClass Object ( [post] => stdClass Object ( [post_title] => PLGA MICROPARTICLES LOADED WITH A FLUOROQUINOLONE FORTHE TREATMENT OF RESPIRATORY DISEASES [guid] => https://technology-offers.inserm-transfert.com/offer/plga-microparticles-loaded-with-a-fluoroquinolone-forthe-treatment-of-respiratory-diseases/ [post_content] => This invention relates to:- PLGA (poly lactic-co-glycolic acid, i.e. a copolymer of poly lactic acid (PLA) and poly glycolic acid) microparticles loaded with a fluoroquinolone with high mucosal permeability,- the method of preparation thereof and- applications thereof.The invention could notably be used in the treatment of pulmonary infections, such as bacterial bronchitis, bronchiolitis and pneumonia. Fluoroquinolones constitute a family of antibacterial agents. Fluoroquinolones are indicated for the treatment of several bacterial infections.Several bacterial infections include but are not limited to, respiratory infections such as bacterial bronchitis, bronchiolitis, pneumonia, tuberculosis, tonsillitis pharyngitis, otitis and sinusitis, septicaemia, typhoid fever, joint and bone infections, soft tissue and skin infections, gastrointestinal infections and urogenital infections.More particularly, fluoroquinolones are known to have an activity against a wide range of gram-positive and gram-negative organisms.The inventors have found and demonstrated that the PLGA microparticles loaded with a fluoroquinolone with high mucosal permeability of the present invention enable to improve the fluoroquinolone efficiency against bacterial agents in comparison to free fluoroquinolones.They have also demonstrated that a pulmonary administration of the PLGA microparticles loaded with a fluoroquinolone with high mucosal permeability of the present invention, results in a prolonged release of the fluoroquinolone within the lung and in much higher fluoroquinolone concentrations in pulmonary system, in particular in lung epithelial lining fluid (ELF).They have also demonstrated that specific PLGA microparticles loaded with a fluoroquinolone, in term of nature of PLGA, PLGA particle size and fluoroquinolone content enable to reduce the frequency of administrations, to increase anti-infectious treatment efficiency while reducing systemic toxicity. Indeed, the PLGA microparticles loaded with a fluoroquinolone with high mucosal permeability of the present invention have fluoroquinolone sustained-release of at least 72 hours. [post_date] => 2016-07-13 13:55:49 [post_modified] => 2024-09-11 15:40:33 [ID] => 3635 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 03dda8d1-b3b1-4a0b-ab03-98386e79b6f6 [etat_fiche_online] => en_ligne [date_application] => 13-07-2016 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 45 [reference_online] => BIO16043-T1 [keywords] => aerosol; PLGA microparticles; fluoroquinolone; bacterial infections; pulmonary infections [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DA COSTA GASPAR Marisa [number_application] => European Procedure (Patents) (EPA) - 13 Juil. 2016 - 16 305 907.4 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• Respiratory DiseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 607 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Animal POC, Device, Experimental proof of concept, Method, Others, Product, Respiratory Disease [taxonomieurl] => Animal POC, Device, Experimental proof of concept, Method, Others, Product, Respiratory Disease ) [608] => stdClass Object ( [post] => stdClass Object ( [post_title] => Soluble APPs?-based Gene Therapy in Alzheimer’s Disease [guid] => https://technology-offers.inserm-transfert.com/offer/soluble-apps%ce%b1-based-gene-therapy-in-alzheimers-disease/ [post_content] => The present invention relates to a method of treating Alzheimer’s disease by administration to the subject of a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for a polypeptide which is a soluble member of the APP (amyloid precursor protein) family. [post_date] => 2014-06-12 13:55:49 [post_modified] => 2024-09-11 15:41:57 [ID] => 3634 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 03ad3c5b-4b29-49a2-9769-84a1bc6ac697 [etat_fiche_online] => en_ligne [date_application] => 12-06-2014 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => BIO15161-T1 [keywords] => soluble amyloid precursor protein (APPs?) [pub_scient_inv_dispo] => Acta Neuropathol. 2016 Feb;131(2):247-266. doi: 10.1007/s00401-015-1498-9. Epub 2015 Nov 4. [access_to_detailed_offer] => /wp-content/uploads/BIO15161-T1_CARTIER.pdf [rare_disease] => false [second_indication] => false [inventors] => FOL Romain,BRAUDEAU Jérôme,ABEL Tobias,BUCHHOLZ Christian,MUELLER Ulrike [number_application] => European Procedure (Patents) (EPA) - 12 Juin 2015 - 15 305 904.3 [technology_engineering] => gene_therapy [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Alzheimer’s diseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 608 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Alzheimer’s disease, Biologic, Central Nervous System, Drug, Gene Therapy, Gene therapy, Lead - validation in vivo, Method, Product [taxonomieurl] => Alzheimer’s disease, Biologic, Central Nervous System, Drug, Gene Therapy, Gene therapy, Lead - validation in vivo, Method, Product ) [609] => stdClass Object ( [post] => stdClass Object ( [post_title] => Apelin for the treatment of type 2 diabetes [guid] => https://technology-offers.inserm-transfert.com/offer/apelin-for-the-treatment-of-type-2-diabetes/ [post_content] => Use of Apelin in humans has a positive effect on insulin sensitivity with a good tolerance and a good safety. Thus, a first object of the invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.(Eur J Pharmacol. 2015 Sep 15;763(Pt B):149-59. doi: 10.1016/j.ejphar.2015.05.017. Review.) [post_date] => 2015-03-25 13:55:48 [post_modified] => 2024-09-11 15:44:00 [ID] => 3632 ) [post_meta] => stdClass Object ( [object] => [application] => Therapeutic [idSugar] => 024c579b-78d2-45d1-921e-76ae66243fd4 [etat_fiche_online] => en_ligne [date_application] => 25-03-2015 [date] => [bd_referent] => Aymeric EMPEREUR [bd_referent_id] => [contact_email] => aymeric.empereur@inserm-transfert.fr [contact_phone] => [reference_online] => BIO14414-T1 [keywords] => Apelin, APJ receptor [pub_scient_inv_dispo] => Eur J Pharmacol. 2015 Sep 15;763(Pt B):149-59. doi: 10.1016/j.ejphar.2015.05.017. Review. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => CAZALS Laurent,GOURDY Pierre,CASTAN-LAURELL Isabelle [number_application] => European Procedure (Patents) (EPA) - 24 Mars 2015 - 15 305 422.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Therapeutic [parent_category] => 195 [inserm_tags_to_put] =>

• DrugField of development:
• Metabolic DisordersTherapy Area:
• TargetType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => aymeric.empereur@inserm-transfert.fr [first_name] => Aymeric [last_name] => Empereur [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => [bd_referent] => [contact_description] => [contact_email] => [contact_phone] => ) [comteur] => 609 [terms] => Array ( [0] => Therapeutic ) [taxonomie] => Clinical Trial, Diabetes, Drug, Metabolic Disorders, Phase 2, Target, Type 2 Diabetes [taxonomieurl] => Clinical Trial, Diabetes, Drug, Metabolic Disorders, Phase 2, Target, Type 2 Diabetes ) [610] => stdClass Object ( [post] => stdClass Object ( [post_title] => CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair [guid] => https://technology-offers.inserm-transfert.com/offer/ctip-fusion-to-cas9-enhances-transgene-integration-by-homology-dependent-repair/ [post_content] => The present invention relates to nuclease protein fusions for enhancing genome editing by homology-directed transgene integration (HDI).The inventors found that the rate of HDI mediated by the CRISPR-Cas9 system may be substantially improved by providing the Cas9 nuclease in the form of a fusion protein with at least the N-terminal domain of the CtIP protein. CtIP proteins are involved in the early steps of homologous recombination. In addition, the inventors identified the subdomains of the N-terminal domain of the CtIP protein that are important for improving the HDI rate.Thus, the invention relates to fusion proteins comprising a Cas9 protein, a tetramerization domain of a CtIP protein and a dimerization domain of a CtIP protein. Particularly, the inventors have tested these fusion proteins HEK293 cells, RG37DR cells and Sprague-Dawley rats. [post_date] => 2017-03-10 13:55:41 [post_modified] => 2024-09-11 15:58:02 [ID] => 3631 ) [post_meta] => stdClass Object ( [object] => [application] => Research [idSugar] => e1191819-9b31-4f64-ac88-8b98f6db7f2b [etat_fiche_online] => en_ligne [date_application] => 10-03-2017 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 18 [reference_online] => BIO16366-R1 [keywords] => CRISPR-Cas9; gene therapy; Genome editing; Efficient transgene integration by homology-dependent repair (HDR) [pub_scient_inv_dispo] => Nat Commun. 2018 Mar 19;9(1):1133. doi: 10.1038/s41467-018-03475-7. [access_to_detailed_offer] => /wp-content/uploads/BIO16366-R1_CONCORDET.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => CONCORDET Jean-Paul,ANEGON Ignacio,LOPEZ Bernard,GIOVANNANGELI Carine,CHARPENTIER Marine [number_application] => European Procedure (Patents) (EPA) - 10 Mars 2017 - 17 305 260.6 [technology_engineering] => gene_editing [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• Research toolField of development:
• Genetic DisordersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 610 [terms] => Array ( [0] => Research ) [taxonomie] => Gene editing, Genetic Disorders, Method, Research tool [taxonomieurl] => Gene editing, Genetic Disorders, Method, Research tool ) [611] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHOD AND APPARATUS FOR ACQUIRING A SPATIAL MAP OF AUDITORY PERCEPTION OF A SUBJECT [guid] => https://technology-offers.inserm-transfert.com/offer/method-and-apparatus-for-acquiring-a-spatial-map-of-auditory-perception-of-a-subject/ [post_content] => This method for acquiring a spatial map of auditory perception of a subject comprises a plurality of successive test sequences, each test sequence comprising steps of:a) calibration of the subject’s position, by displaying instructions to the subject, using a head-mounted visual display system worn by the subject, in order to acquire a reference position of the subject, the subject’s position being measured using a video motion capture system by measuring the spatial coordinates of a first optical marker worn by the subject,b) choosing spatial coordinates of a target location of a sound source, said target location being located around the subject, c) emitting a predefined sound, using a sound source placed at said target location,d) in response to acquisition instructions generated by the subject using an acquisition interface, acquiring an estimated location of said sound source, by using the video motion capture system to measure the spatial coordinates of a second optical marker held and pointed by the subject towards a perceived location of the sound source. [post_date] => 2017-05-26 13:55:41 [post_modified] => 2024-09-11 15:57:58 [ID] => 3630 ) [post_meta] => stdClass Object ( [object] => [application] => Research [idSugar] => d3a1f4f4-a830-41be-a6eb-caea3a81cb61 [etat_fiche_online] => en_ligne [date_application] => 26-05-2017 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 45 [reference_online] => MECA15572-R1 [keywords] => 3D-map of auditory perception [pub_scient_inv_dispo] => [access_to_detailed_offer] => /wp-content/uploads/MECA15572-R1_FARNE.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => GAVEAU Valérie,BELLE Anaël,SALEMME Roméo,PAVANI Francesco,KOUN Eric [number_application] => European Procedure (Patents) (EPA) - 27 Mai 2016 - 16 305 621.1 [technology_engineering] => imaging [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• DeviceField of development:
• Central Nervous SystemTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 611 [terms] => Array ( [0] => Research ) [taxonomie] => Alpha prototype validated, Central Nervous System, Device, Devices, Electromechanical medical device, Imaging, Method, Validated in lab [taxonomieurl] => Alpha prototype validated, Central Nervous System, Device, Devices, Electromechanical medical device, Imaging, Method, Validated in lab ) [612] => stdClass Object ( [post] => stdClass Object ( [post_title] => Method for universal detection and quantification of mycoplasma (Mollicutes) 16S rDNA by quantitative polymerase chain reaction amplifying a 1.5 kilobase fragment [guid] => https://technology-offers.inserm-transfert.com/offer/method-for-universal-detection-and-quantification-of-mycoplasma-mollicutes-16s-rdna-by-quantitative-polymerase-chain-reaction-amplifying-a-1-5-kilobase-fragment/ [post_content] => The present invention relates to a method for detecting mycoplasma 16S rDNA 1.5 kilobase fragment amplified quantitative polymerase chain reaction (qPCR).The method according to the invention is suitable for the detection of potentially any Prokaryote contamination, especially mycoplasma contamination, in cell cultures.Another possible application can be its use in diagnosis and follow up of contamination in human, livestock, plants, food, or water for example. [post_date] => 2016-04-14 13:55:41 [post_modified] => 2024-09-11 15:57:30 [ID] => 3629 ) [post_meta] => stdClass Object ( [object] => [application] => Research [idSugar] => 6b6ee477-f2c2-4316-984d-73f376d7cf88 [etat_fiche_online] => en_ligne [date_application] => 14-04-2016 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 18 [reference_online] => BIO15302-R1 [keywords] => qPCR; mycoplasma [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => 0 [second_indication] => 0 [inventors] => JEAN Audrey,GROSJEAN Isabelle,BLANQUIER Bariza,GERLIER Denis [number_application] => European Procedure (Patents) (EPA) - 14 Avr. 2016 - 16 305 435.6 [technology_engineering] => nucleic_acids [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• Research toolField of development:
• Infectious DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 612 [terms] => Array ( [0] => Research ) [taxonomie] => Infectious Diseases, Method, Nucleic acids, Research tool [taxonomieurl] => Infectious Diseases, Method, Nucleic acids, Research tool ) [613] => stdClass Object ( [post] => stdClass Object ( [post_title] => CRISPR barcoding: method and kit for labeling and detecting a population of endonuclease-treated cells [guid] => https://technology-offers.inserm-transfert.com/offer/crispr-barcoding-method-and-kit-for-labeling-and-detecting-a-population-of-endonuclease-treated-cells/ [post_content] => The invention relates to methods, compositions and kits for labelling and detecting endonuclease-treated cells, and most preferably eukaryotic cells.The CRISPR-barcoding system could be used as an alternative tool to the classical lentiviral DNA barcode libraries, ensuring the detection of thousands of distinct barcodes through qPCR or deep-sequencing.This barcoding approach enables tracing of the mutated cells immediately after DNA editing without the need to derive clones, thus providing a unique means to investigate the effects of different kinds of genomic modifications, regardless of their potential impact on cell growth, in a broad range of functional assays.This strategy represents a high-resolution tracking of single specific cancer cells allowing to identify even rare pre-existing resistant subclones potentially involved in mechanisms of acquired resistance to therapy. The main proofs of concept reported are related to cancer models, nevertheless this technology can be implemented in different fields of biological research. [post_date] => 2015-10-22 13:55:40 [post_modified] => 2024-09-11 15:57:11 [ID] => 3625 ) [post_meta] => stdClass Object ( [object] => [application] => Research [idSugar] => 1e0a2085-59af-4624-8ce9-2f4109999153 [etat_fiche_online] => en_ligne [date_application] => 22-10-2015 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 18 [reference_online] => BIO14199-R1 [keywords] => CRISPR-Cas9; barcoding; Gene editing [pub_scient_inv_dispo] => CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.Modeling intratumor heterogeneity through CRISPR-barcodes. Mol Cell Oncol. 2016; 3(6): e1227894.CRISPR-Cas9 editing of the genome for cancer modeling. Methods. 2017 May 15;121-122:130-137. doi: 10.1016/j.ymeth.2017.03.007. Epub 2017 Mar 10. [access_to_detailed_offer] => /wp-content/uploads/BIO14199-R1_GRUMOLATO.pdf [rare_disease] => 0 [second_indication] => 0 [inventors] => [number_application] => [technology_engineering] => gene_editing [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• Research toolField of development:
• OncologyTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 613 [terms] => Array ( [0] => Research ) [taxonomie] => Gene editing, Method, Oncology, Others, Research tool [taxonomieurl] => Gene editing, Method, Oncology, Others, Research tool ) [614] => stdClass Object ( [post] => stdClass Object ( [post_title] => METHODS AND KITS FOR DETECTING PROTEIN-PROTEIN INTERACTIONS [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-kits-for-detecting-protein-protein-interactions/ [post_content] => The present invention relates to methods and kits for detection protein-protein interactions.In particular, the present invention relates to a method for detecting the binding between a first polypeptide (A) and a second polypeptide (B) in a cell comprising:i) providing a cell that expresses:(a) a polypeptide (GFP1-9) comprising an amino acid sequence having at least 90% of identity with the amino acid sequence selected from the group consisting of SEQ ID NO:1-4(b) a first fusion protein wherein the polypeptide (A) is fused to a polypeptide (GFP10) having an amino an amino acid sequence having at least 90% of identity with the amino acid sequence selected from the group consisting of SEQ ID NO:5-7(c) a second fusion protein wherein the polypeptide (B) is fused to a polypeptide (GFP11) having an amino an amino acid sequence having at least 90% of identity with the amino acid sequence selected from the group consisting of SEQ ID NO:8-9 and(d) an intrabody specific for the complex formed by the self-assembly of the first, second and third polypeptides (a), (b) and (c)ii) detecting the fluorescence wherein when the fluorescence is detected it is concluded that the polypeptide (A) binds to polypeptide (B) and wherein the fluorescence is not detected it is concluded that the polypeptides (A) does not bind to polypeptide (B). [post_date] => 2015-06-24 13:55:39 [post_modified] => 2024-09-11 15:57:03 [ID] => 3624 ) [post_meta] => stdClass Object ( [object] => [application] => Research [idSugar] => 02bd32a7-475b-4b91-bbbc-1227431a3bfc [etat_fiche_online] => en_ligne [date_application] => 24-06-2015 [date] => [bd_referent] => Stephanie OLAS [bd_referent_id] => [contact_email] => stephanie.olas@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 18 [reference_online] => BIO15012-R1 [keywords] => protein-protein interaction; screening; GTPase; split-GFP [pub_scient_inv_dispo] => Sci Rep. 2013 Oct 4;3:2854. doi: 10.1038/srep02854. [access_to_detailed_offer] => http:/ [rare_disease] => 0 [second_indication] => 0 [inventors] => KORAÏCHI Faten,FAVRE Gilles [number_application] => European Procedure (Patents) (EPA) - 24 Juin 2015 - 15 305 971.2 [technology_engineering] => biomaterials [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Research [parent_category] => 195 [inserm_tags_to_put] =>

• Research toolField of development:
• OthersTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 614 [terms] => Array ( [0] => Research ) [taxonomie] => Biomaterials, Method, Others, Others, Research tool [taxonomieurl] => Biomaterials, Method, Others, Others, Research tool ) [615] => stdClass Object ( [post] => stdClass Object ( [post_title] => Diagnosis of latent Mycobacterium Tuberculosis infection [guid] => https://technology-offers.inserm-transfert.com/offer/diagnosis-of-latent-mycobacterium-tuberculosis-infection/ [post_content] => Tuberculosis (TB), caused by M. tuberculosis infection, continues to be one of the most prevalent infectious diseases worldwide. The WHO has also estimated that one third of the world population would be infected with latent M. tuberculosis (LTBI), where individuals are do not exhibit active disease but are with a high risk of reactivation. Primary infection leads to active TB in less than 10% of infected individuals, as the immune system is usually able to contain, but not eliminate, the infection, leading to LTBI. Latency can persist throughout lifetime, but weakness of the immune system, due to therapeutical treatments (in AIDS, organ transplant casesu2026), malnutrition or old age of the host, can lead to reactivation. The situation is aggravated by the high rate of M. tuberculosis- HIV co-infection. Interferon gamma release assays (IGRAs) represent the most novel TB infection diagnostic assays and have been well received in most developed countries, but current tests are not able to discriminate active TB and LTBI. The lack of a gold standard for diagnosing LTBI has thus remained a main hurdle.Thus, the present invention relates to a mixture of peptides derived from the M. tuberculosis antigen Rv2626c that, unlike current commercial tests, discriminates latent TB individuals from patients with tuberculosis active disease and from healthy subjects.In addition, the present invention also relates to a combination of these peptides with the antigens CFP-10 and ESAT-6 (which only discriminate M. tuberculosis infection, either latent or active) this combination being able, in one test, to discriminate between the three groups of individuals: healthy subjects, individuals with LTBI and patients with active TB.Scientific Publication(s):EBioMedicine., 2015 May 30, Peña D. et al., A Mycobacterium tuberculosis Dormancy Antigen Differentiates Latently Infected Bacillus Calmette-Guérin-vaccinated Individuals, doi: 10.1016/j.ebiom.2015.05.026. [post_date] => 2014-08-29 13:54:56 [post_modified] => 2024-09-11 15:52:10 [ID] => 3623 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => fe340553-fb97-40d7-81f6-fa62e1ec8c5d [etat_fiche_online] => en_ligne [date_application] => 29-08-2014 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO13394-D1 [keywords] => Tuberculosis, TB, pneumology, lung, mycobacterium, antigen, Rv2626c, Mycobacterium Tuberculosis; ELISA, IFNg Relase Assay, Immunoassay [pub_scient_inv_dispo] => EBioMedicine. 2015 May 30;2(8):884-90. doi: 10.1016/j.ebiom.2015.05.026. eCollection 2015 Aug. [access_to_detailed_offer] => /wp-content/uploads/BIO13394-D1_IOVANNA.pdf [rare_disease] => false [second_indication] => false [inventors] => CHULUYAN Hector Eduardo,GARCIA Veronica Edith,GHERARDI Maria Magdalena,PASQUINELLI Virginia,PENA Delfina,ROVETTA Ana Inés [number_application] => European Procedure (Patents) (EPA) - 29 Août 2014 - 14 306 329.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• TuberculosisTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 615 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biologic, Biomarker, Immunoassay, Infectious Diseases, Peptide, Pre-Analytic Validation, Product, Recombinant Peptide, Tuberculosis [taxonomieurl] => Biologic, Biomarker, Immunoassay, Infectious Diseases, Peptide, Pre-Analytic Validation, Product, Recombinant Peptide, Tuberculosis ) [616] => stdClass Object ( [post] => stdClass Object ( [post_title] => MAIT cell and iNKT cell phenotypes as biomarkers for Diagnosis, prediction or prognosis of Type 1 Diabetes [guid] => https://technology-offers.inserm-transfert.com/offer/mait-cell-and-inkt-cell-phenotypes-as-biomarkers-for-diagnosis-prediction-or-prognosis-of-type-1-diabetes/ [post_content] => Type 1 diabetes (TID) is an autoimmune disease that results from the selective destruction of insulin-producing ?-cells in pancreatic islets. The diagnosis of TID is commonly preceded by a long prodromal period which includes seroconversion to islet autoantibody positivity and subtle metabolic disturbances. Thus there is still a need for improved methods of assessing status, risk or prognosis of T1D. It is hypothesized that gut microbiota may affect T1D incidence via the modulation of the host innate immune system. In particular, the literature describes a decreased diversity in the intestinal microbiota in at risk children with seroconversions who progressed to T1D compared to those who did not progress during the study observation period. Because this observation takes place in the time window between the first seroconversion and much before the T1D diagnosis, it suggests that an event linked to the intestinal microbiota could contribute to the progression of islet autoimmunity towards clinical T1D. Moreover, this decrease of intestinal microbiota diversity seems to be associated with an increased intestinal permeability in at risk children who have at least two autoantibodies. Recently published data also show modification of glycolipids in the stools of at risk children.Thus, the present invention relates to methods and kits of assessing status, risk or prognosis of T1D. The inventors have observed different alterations of iNKT and MAIT cells quantity, frequency and markers in T1D patients compared to controls and also in children with recent onset T1D compared to control children or children with established T1D. The present invention relates to a method of assessing status, risk or prognosis of T1D in a subject using iNKT and MAIT cells as biomarkersScientific publication(s):Nat Immunol., 2017 Dec, Rouxel O. et al., Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes, doi: 10.1038i.3854 [post_date] => 2016-03-22 13:54:53 [post_modified] => 2024-09-11 15:52:09 [ID] => 3613 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => bcc7463b-1371-4960-8c41-99f24a80a897 [etat_fiche_online] => en_ligne [date_application] => 22-03-2016 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO15256-D1 [keywords] => Type 1 Diabetes [pub_scient_inv_dispo] => Nat Immunol. 2017 Dec;18(12):1321-1331. doi: 10.1038i.3854. Epub 2017 Oct 9. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => DA SILVA Jennifer,BEAUDOIN Lucie,NEL Isabelle [number_application] => European Procedure (Patents) (EPA) - 22 Mars 2016 - 16 305 319.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Metabolic DisordersTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 616 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Diabetes, Immunoassay, Metabolic Disorders, Pre-Analytic Validation, Type 1 Diabetes (Juvenile Diabetes) [taxonomieurl] => Biomarker, Biomarker, Diabetes, Immunoassay, Metabolic Disorders, Pre-Analytic Validation, Type 1 Diabetes (Juvenile Diabetes) ) [617] => stdClass Object ( [post] => stdClass Object ( [post_title] => Free ?-hemoglobin as biomarker for diagnosing and stratifiying severity of ?-thalassemia and other hemoglobin-related disorders [guid] => https://technology-offers.inserm-transfert.com/offer/free-%ce%b1-hemoglobin-as-biomarker-for-diagnosing-and-stratifiying-severity-of-%ce%b2-thalassemia-and-other-hemoglobin-related-disorders/ [post_content] => The normal development of red blood cells requires a coordinated synthesis of the hemoglobin (Hb) subunits, the ?- and ?-globins in the case of adult hemoglobin (Hb A). Unlike the ?-hemoglobin chains (?-Hb) which are soluble and form homologous tetramers, the free ?-hemoglobin chains (?-Hb) are highly instable, may form precipitates and act as active oxidants.The molecular chaperone of ?-Hb, the « Alpha-Hemoglobin Stabilizing Protein » (AHSP) was reported to specifically bind to ?-Hb to form a stable soluble heterodimer but not to the ?-Hb or to tetrameric Hb A. Hence the role of AHSP could be to prevent free ?-Hb from aggregation until the encounter of other ?, ? or ? chains. In the red blood cell of ?-thalassemic patients, AHSP acts as a scavenger against the pool of free ?-chain but may be overwhelmed by a defective production or level of availability of ?-like chains. The free ?-chain pool may thus reflect the severity of a ?-thalassemia syndrome.Currently, the diagnosis of ?-thalassemia is still based on the hematological parameters of the patients and the molecular diagnosis is obtained by PCR techniques to identify point mutations for most at-risk populations. The severity of the ?-thalassemia also depends on the nature of the mutation. More generally one may need to consider the overall imbalance between the ? and ? family of globin chains. Currently, the only technique to quantify the relative excess of free ?-Hb is to carry out globin biosynthesis in vitro in the presence of a radioactive amino-acid. Therefore, there is a need for a method for easily diagnosing and/or staging a hemoglobin-related disorder without using molecular or radioactive technique. Thus, the invention relates to a method for diagnosing and/or staging a hemoglobin-related disorder, such as ?-thalassemias, in a subject in need thereof. The invention also relates a method for monitoring a treatment against said hemoglobin-related disorder in a subject in need thereof.Scientific publication(s):Am J Hematol., 2017 Oct, Vasseur C. et al., Elevated soluble ?-hemoglobin pool in sickle cell anemia, doi: 10.1002/ajh.24835BJH, 2017 Apr, Vasseur C. et al., Red blood cells free ?-hemoglobin pool: a biomarker to monitor the ?-thalassemia intermedia variability. The ALPHAPOOL StudyAm J Hematol., 2011 Feb, Vasseur C. et al., Evaluation of the free ?-hemoglobin pool in red blood cells: a new test providing a scale of ?-thalassemia severity, doi: 10.1002/ajh.21918 [post_date] => 2009-04-24 13:54:53 [post_modified] => 2024-09-11 15:52:12 [ID] => 3612 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => bc6d5649-c1d0-4d91-9bc0-f9bca642bfc8 [etat_fiche_online] => en_ligne [date_application] => 24-04-2009 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO08398-D1 [keywords] => Anemia, Thalassemia, Sickle Cell Disease, Hemoglobin-related disorders, ELISA, HTRF, Immunoassay [pub_scient_inv_dispo] => Am J Hematol. 2017 Oct;92(10):E593-E595. doi: 10.1002/ajh.24835. Epub 2017 Jul 24.Br J Haematol. 2017 Oct;179(1):142-153. doi: 10.1111/bjh.14800. Epub 2017 Jun 23.Am J Hematol. 2011 Feb;86(2):199-202. doi: 10.1002/ajh.21918. [access_to_detailed_offer] => /wp-content/uploads/BIO08398-D1_BAUDIN-CREUZA.pdf [rare_disease] => false [second_indication] => false [inventors] => GALACTEROS Frédéric,VASSEUR Corinne [number_application] => European Procedure (Patents) (EPA) - 24 Avr. 2009 - 09 305 352.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Hematological DisordersTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 617 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Hematological Disorders, Immunoassay, Pre-Analytic Validation, Thalassemia [taxonomieurl] => Biomarker, Biomarker, Hematological Disorders, Immunoassay, Pre-Analytic Validation, Thalassemia ) [618] => stdClass Object ( [post] => stdClass Object ( [post_title] => A 7 protein signature for Stratifying patients with Rheumatoid Arthritis for TNFa blocking agent treatment [guid] => https://technology-offers.inserm-transfert.com/offer/a-7-protein-signature-for-stratifying-patients-with-rheumatoid-arthritis-for-tnfa-blocking-agent-treatment/ [post_content] => Rheumatoid arthritis (RA) is a chronic, auto-immune and inflammatory polyarthritis which induces joint damage and disability. Thanks to the better understanding of RA pathophysiology, several anti-cytokines targeted against TNFa, IL-1b, IL-6 or IL-6 receptor and several cellular immunotherapies (anti-CD20 or CTLA-4Ig) have been successfully introduced for RA treatment. Studies have led to the recognition of TNFa as one of the cornerstone cytokines involved in synovial inflammatory process. Such results have provided the basis for the development of TNFa blocking agents (TBAs) for the treatment of RA. Five TNFa blocking agents (TBAs) are currently used for RA treatment, one corresponding to a recombinant soluble form of TNF receptor, TNFRSF1B (etanercept), four others corresponding to an anti-TNFa monoclonal antibody: infliximab, adalimumab (ADA), certolizumab and golimumab.The number of biological agents in RA is continuously increasing and various clinical trials with a TBA / methotrexate combination have shown efficacy in 60-70 % of RA patients. However, clinicians observe that around 30 to 40% of treated patients fail to respond to TBAs. Moreover, TNFa blocking agents may have side effects, they are costly and the efficacy of any given TBA in a given patient is unpredictable.Taking into account the risk of these treatments, the increasing number of available therapeutic molecules in RA, the variability of the response to the various treatment, and to optimize the drug prescription, identification of predictive markers of TBA / methotrexate combination may be highly desirable.Thus, the invention relates to methods and means for predicting rheumatoid arthritis treatment response, using a signature of 7 protein expression in a blood sample.Scientific publication(s):Theranostics, 2015 Aug 9, Obry A. et al., Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response, doi: 10.7150/thno [post_date] => 2013-06-10 13:54:53 [post_modified] => 2024-09-11 15:52:11 [ID] => 3611 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => b6c458e6-c7c9-488a-8442-161c751f8195 [etat_fiche_online] => en_ligne [date_application] => 10-06-2013 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO12348-D1 [keywords] => Rheumatoid Arthritis; anti-TNFa treatment; Auto-Immune disease; ELISA; Immunoassay [pub_scient_inv_dispo] => Theranostics. 2015 Aug 9;5(11):1214-24. doi: 10.7150/thno.12403. eCollection 2015. [access_to_detailed_offer] => /wp-content/uploads/BIO12348-D1_VITTECOQ.pdf [rare_disease] => false [second_indication] => false [inventors] => COSETTE Pascal,LE LOET Xavier,BOYER Olivier,HARDOUIN Julie,LEQUERRE Thierry,OBRY Antoine [number_application] => European Procedure (Patents) (EPA) - 10 Juin 2013 - 13 305 778.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Rheumatoid ArthritisTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 618 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Immunology, Pre-Analytic Validation, Rheumatoid Arthritis [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Immunology, Pre-Analytic Validation, Rheumatoid Arthritis ) [619] => stdClass Object ( [post] => stdClass Object ( [post_title] => Predicting the risk of having hepatocellular carcinoma in cirrhosis patients [guid] => https://technology-offers.inserm-transfert.com/offer/predicting-the-risk-of-having-hepatocellular-carcinoma-in-cirrhosis-patients/ [post_content] => Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA / filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E +) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient. [post_date] => 2017-03-21 13:54:51 [post_modified] => 2024-09-11 15:52:06 [ID] => 3604 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 8aa7c310-bbcb-44ea-a86f-fce7d72e84cc [etat_fiche_online] => en_ligne [date_application] => 21-03-2017 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO16372-D1 [keywords] => ELISA, Flow Cytometry, Immunoassay, Risk Prediction in Cirrhosis, Hepatocellular Carcinoma [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => RAUTOU Pierre-Emmanuel,BOULANGER-ROBERT Chantal [number_application] => European Procedure (Patents) (EPA) - 21 Mars 2017 - 17 305 316.6 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Liver CancerTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 619 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Immunoassay, Liver Cancer, Oncology, Pre-Analytic Validation [taxonomieurl] => Biomarker, Biomarker, Immunoassay, Liver Cancer, Oncology, Pre-Analytic Validation ) [620] => stdClass Object ( [post] => stdClass Object ( [post_title] => NGAL as a biomarker for Predicting the evolution and treatment of chronic kidney disease [guid] => https://technology-offers.inserm-transfert.com/offer/ngal-as-a-biomarker-for-predicting-the-evolution-and-treatment-of-chronic-kidney-disease/ [post_content] => The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, also known as neutrophil gelatinaseu2013associated lipocalin [NGAL]), the most highly upregulated gene in a mouse strain which develop severe renal lesions, is not simply a marker of renal lesions, but also an active player in disease progression. The severity of renal lesions was dramatically reduced in Lcn2u2013/u2013 mice. Lcn2 expression increases upon EGFR activation and Lcn2 mediates its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform. Cell proliferation was dramatically reduced in Lcn2u2013/u2013mice. LCN2 is increased particularly in patients who rapidly progressed to end-stage renal failure.Scientific Publication(s):J Clin Invest., 2010 November 1, Viau A. et al., Lipocalin 2 is essential for chronic kidney disease progression in mice and humans, doi: 10.1172/JCI42004 [post_date] => 2010-10-01 13:54:51 [post_modified] => 2024-09-11 15:52:12 [ID] => 3603 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 895c4814-24c7-4c05-bf52-7561465e82c7 [etat_fiche_online] => en_ligne [date_application] => 01-10-2010 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO10870-D1 [keywords] => Nephrology; Diagnostics; Biomarker; Chronic Kidney Disease; NGAL; Lipocalin 2; EGFR; renal failure [pub_scient_inv_dispo] => J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004. [access_to_detailed_offer] => /wp-content/uploads/BIO10870-D1_TERZI.pdf [rare_disease] => false [second_indication] => false [inventors] => BURTIN Martine,EL KAROUI Khalil,VIAU Amandine,NGUYEN Clément [number_application] => European Procedure (Patents) (EPA) - 01 Oct. 2010 - 10 306 077.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay,transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Genito Urinary SystemTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 620 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Chronic Kidney Disease (Chronic Renal Failure) / End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Genito Urinary System, Human POC, Immunoassay, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Chronic Kidney Disease (Chronic Renal Failure) / End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Genito Urinary System, Human POC, Immunoassay, Transcriptomics ) [621] => stdClass Object ( [post] => stdClass Object ( [post_title] => SUPERCARBA selective medium for the detection of carbapenem-resistant bacteria [guid] => https://technology-offers.inserm-transfert.com/offer/supercarba-selective-medium-for-the-detection-of-carbapenem-resistant-bacteria/ [post_content] => Carbapenemase-producing bacteria isolates are increasingly identified throughout the world. Their early detection is becoming a major issue in the field of clinical microbiology in order to prevent their spread and preserve the efficacy of carbapenems which are becoming the antibiotics of last resort for treating severe infections. Moreover, carbapenemases are usually associated to many other non-beta-lactam resistant determinants giving rise to multidrug and pandrug resistance. Therefore, due to current population exchange and travel, early recognition of carbapenemase producers is becoming mandatory whatever the antibiotic policy or rate of multidrug-resistant nosocomial infections. The vast majoriry of acquired carbapenemases belong to three of the four known classes of beta-lactamases, namely Ambler class A, Ambler class B (metallo-beta-lactamases (MBLs)) and Ambler class D (oxacillinases (OXAs)). These three classes of carbapenemases confer clinical resistance to carbapenems. Consequently, carbapenemase-producing bacteria isolates from these three classes have been involved in nosocomial outbreaks. In particular, although OXA-48-like enzymes remain susceptible to extended-spectrum cephalosporins, they confer resistance to penicillins and reduced susceptibility to carbapenems, thereby making the clinical laboratory detection of OXA-48-like producing isolates difficult. In fact, it has been identified in multidrug-resistant isolates, which often accumulate multiple resistance mechanisms, including production of extended-spectrum beta-lactamases (ESBLs). Most carbapenemase producers co-express ESBLs, but several OXA-48- like producing isolates that do not carry ESBL genes may remain susceptible to extended-spectrum cephalosporins.Thus, the present invention relates to a selective culture medium and a method for detecting carbapenem-resistant bacteria, in particular carbapenemase producers, in a test sample.Scientific publication(s):Diagn Microbiol Infect Dis, 2013 Feb, Girlich D. et al., Comparison of the SUPERCARBA, CHROMagar KPC, and Brilliance CRE screening media for detection of Enterobacteriaceae with reduced susceptibility to carbapenems, doi: 10.1016/j.diagmicrobio.2012.10.006J Clin Microbiol., 2012 Aug, Nordmann P. et al., Detection of carbapenemase producers in Enterobacteriaceae by use of a novel screening medium, doi: 10.1128/JCM.06477-11 [post_date] => 2011-07-05 13:54:49 [post_modified] => 2024-09-11 15:51:52 [ID] => 3598 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 6f2fc33f-5a52-5905-fce4-5aaaa9799d03 [etat_fiche_online] => en_ligne [date_application] => 05-07-2011 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO10913-D1 [keywords] => Carbapenem-Resistant Bacteria; Culture Medium [pub_scient_inv_dispo] => Diagn Microbiol Infect Dis. 2013 Feb;75(2):214-7. doi: 10.1016/j.diagmicrobio.2012.10.006. Epub 2012 Nov 9.J Clin Microbiol. 2012 Aug;50(8):2761-6. doi: 10.1128/JCM.06477-11. Epub 2012 Feb 22. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => GIRLICH Delphine,POIREL Laurent [number_application] => European Procedure (Patents) (EPA) - 05 Juil. 2011 - 11 305 860.6 [technology_engineering] => [multidisciplinary_field] => resistance [technological_platform] => other [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gram-Negative Bacterial InfectionsTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 621 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Enterobacteriaceae infections, Gram-Negative Bacterial Infections, Infectious Diseases, Marketed, Method, Other, Resistance [taxonomieurl] => Biomarker, Enterobacteriaceae infections, Gram-Negative Bacterial Infections, Infectious Diseases, Marketed, Method, Other, Resistance ) [622] => stdClass Object ( [post] => stdClass Object ( [post_title] => New antibodies recognising HEV capsid forms for HEV diagnosis [guid] => https://technology-offers.inserm-transfert.com/offer/new-antibodies-recognising-hev-capsid-forms-for-hev-diagnosis/ [post_content] => Hepatitis E virus (HEV) is the leading cause of enterically transmitted viral hepatitis globally, and is responsible for 20 million infections and 70,000 deaths every year. Though HEV infection is usually self-resolving, severe forms or chronic infections have been described, mainly in immunocompromised patients. A high rate of mortality has also been reported among pregnant women. The diagnosis of hepatitis E is based on the detection of anti-HEV antibodies and/or viral RNA in patient serum. HEV is a quasi-enveloped, positive-sense RNA virus expressing three open reading frames (ORFs). In particular, ORF2 encodes the ORF2 viral capsid protein, which is involved in particle assembly, binding to host cells and eliciting neutralizing antibodies. Although HEV is a non-enveloped virus in bile and feces, patient serum and cell culture-produced particles have been described to be associated with cellular lipids, as for Hepatitis A virus.The growth of HEV in cell culture has been proven to be very difficult. Notably, the exact sequence of infectious particle-associated ORF2 protein is unknown. In addition, the ultrastructure of particles has never been robustly studied by immune electron microscopy.The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i protein is thus the subject matter of the present invention as well as antibodies specific for the protein and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.Scientific publication(s):Gastroenterology, 2017 Sep 25, Montpellier C. et al., Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein, doi: 10.1053/j.gastro.2017.09.020 [post_date] => 2017-01-30 13:54:49 [post_modified] => 2024-09-11 15:52:07 [ID] => 3597 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 699d1650-b637-4b18-8a84-2c4b08f5a674 [etat_fiche_online] => en_ligne [date_application] => 30-01-2017 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO17006-D1 [keywords] => ELISA, Western Blot, Immunoassay, Diagnostic, Prognosis in Hepatitis E Virus (HEV) [pub_scient_inv_dispo] => Gastroenterology. 2018 Jan;154(1):211-223.e8. doi: 10.1053/j.gastro.2017.09.020. Epub 2017 Sep 25. [access_to_detailed_offer] => /wp-content/uploads/BIO17006-D1_COCQUEREL-DEPROY.pdf [rare_disease] => false [second_indication] => false [inventors] => COCQUEREL-DEPROY Laurence,GOFFARD Anne,MONTPELLIER Claire,DUBUISSON Jean [number_application] => European Procedure (Patents) (EPA) - 30 Janv. 2017 - 17 305 097.2 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Infectious DiseasesTherapy Area:
• ProductType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 622 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Human POC, Immunoassay, Infectious Diseases, Product [taxonomieurl] => Biomarker, Human POC, Immunoassay, Infectious Diseases, Product ) [623] => stdClass Object ( [post] => stdClass Object ( [post_title] => Prognosis of patients suffering from cirrhosis [guid] => https://technology-offers.inserm-transfert.com/offer/prognosis-of-patients-suffering-from-cirrhosis/ [post_content] => Following a prospective clinical study that includes 242 patients, the inventors show that hepatocyte-derived MV levels predicted transplantation-free survival at 6 months in univariate analysis. In multivariate analysis, this association was shown to be independent of Child-Pugh and of MELD score. Thus the present invention relates to a method of predicting the transplantation-free survival time of a patient suffering from cirrhosis comprising determining the level of hepatocyte-derived microvesicles (e.g. by an ELISA assay) in a blood sample obtained from the patient. [post_date] => 2017-03-21 13:54:49 [post_modified] => 2024-09-11 15:52:05 [ID] => 3596 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 642ae015-5c20-4e29-95d2-8a6421155610 [etat_fiche_online] => en_ligne [date_application] => 21-03-2017 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO16371-D1 [keywords] => ELISA, Immunoassay, Treatment Response, Prognosis in Cirrhosis [pub_scient_inv_dispo] => [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => RAUTOU Pierre-Emmanuel,BOULANGER-ROBERT Chantal [number_application] => European Procedure (Patents) (EPA) - 21 Mars 2017 - 17 305 315.8 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 623 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Cirrhosis, Gastrointestinal Diseases, Immunoassay, Liver cirrhosis, Pre-Analytic Validation [taxonomieurl] => Biomarker, Biomarker, Cirrhosis, Gastrointestinal Diseases, Immunoassay, Liver cirrhosis, Pre-Analytic Validation ) [624] => stdClass Object ( [post] => stdClass Object ( [post_title] => Specific T cell subpopulation for diagnosis, prognosis, risk prediction and treatment of IBD [guid] => https://technology-offers.inserm-transfert.com/offer/specific-t-cell-subpopulation-for-diagnosis-prognosis-risk-prediction-and-treatment-of-ibd/ [post_content] => The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4+ CD8??low phenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of F. prau. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes.The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of F. prau-specific cells among CD4+ CD8??low T lymphocytes, from a blood sample and without needing to assess their F. prau specificity. T lymphocytes with a CD4+ CD8??low CCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients.The disease related to a decrease of F. prau is particularly an inflammatory bowel disease (IBD), such as Crohn’s disease. [post_date] => 2018-06-01 13:54:48 [post_modified] => 2024-09-11 15:53:45 [ID] => 3594 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 2b6cd460-d5e9-3489-a08a-5b7eb11ff99b [etat_fiche_online] => en_ligne [date_application] => 01-06-2018 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO17114-D1 [keywords] => Flow Cytometry, Immunoassay, Diagnostic, Risk Prediction, Treatment Response, Prognosis in IBD, Inflamatory Bowel Disease, Crohn’s Disease [pub_scient_inv_dispo] => Gastroenterology. 2018 Jul 5. pii: S0016-5085(18)34720-6. doi: 10.1053/j.gastro.2018.06.078. [access_to_detailed_offer] => http:/ [rare_disease] => false [second_indication] => false [inventors] => JOTEREAU Francine,GODEFROY Emmanuelle,SARRABAYROUSE Guillaume,SOKOL Harry,ALTARE Frédéric [number_application] => European Procedure (Patents) (EPA) - 01 Juin 2018 - 18305677.9 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 624 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Gastrointestinal Diseases, Immunoassay, Inflammatory Bowel Disease / Crohn's Disease, Pre-Analytic Validation [taxonomieurl] => Biomarker, Biomarker, Gastrointestinal Diseases, Immunoassay, Inflammatory Bowel Disease / Crohn's Disease, Pre-Analytic Validation ) [625] => stdClass Object ( [post] => stdClass Object ( [post_title] => An 8 gene signature to predict survival time of patients with decompensated alcoholic cirrhosis [guid] => https://technology-offers.inserm-transfert.com/offer/an-8-gene-signature-to-predict-survival-time-of-patients-with-decompensated-alcoholic-cirrhosis/ [post_content] => Cirrhosis is a chronic disease of the liver whose prevalence will dramatically increase during the next decade. Cirrhosis can result from a number of chronic liver diseases such as alcoholic liver disease, chronic viral hepatitis, non-alcoholic steatohepatitis, autoimmune diseases of the liver (primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis). The occurrence of complications indicates the transition to the phase called decompensated (approximately 100,000 patients per year in France); These complications include ascites (30 000 patients per year in France), gastrointestinal bleeding (10,000 episodes / year in France), renal failure and bacterial infections which is very common and often due to the translocation of Gram-negative intestinal bacteria. Mortality in cirrhosis is thus usually a consequence of decompensation or its ensuing complications. The treatment of choice for decompensated cirrhosis is liver transplantation and many such patients are placed on transplant waiting lists. Therefore predicting the survival time of patients with decompensated alcoholic cirrhosis is highly desirable for determining whether the patient shall be eligible to transplantation. The MELD (Model for End Stage Liver Disease) score is currently used for organ allocation. Although the MELD score predicts 90-day mortality based on bilirubin, INR (international normalized ratio) and serum creatinine, the predisposing factors for death and final events leading to mortality need to be improved.Thus, the present invention relates to methods for predicting the survival time of patients with decompensated alcoholic cirrhosis, using an 8 gene transcriptional signature as a biomarker.Scientific publication(s):J Hepatol., 2016 Dec 28, Weiss E. et al., Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome, doi: 10.1016/j.jhep.2016.12.008. [post_date] => 2015-11-10 13:54:47 [post_modified] => 2024-08-28 12:17:35 [ID] => 3590 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 0dafefc9-8a5e-49dc-b28d-6fd77a1cf991 [etat_fiche_online] => en_ligne [date_application] => 10-11-2015 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO15324-D1 [keywords] => Biomarker, Diagnostic, Method, RT-PCR, Transcriptomics, Liver Disease, Alcoholic Cirrhosis, Prognosis [pub_scient_inv_dispo] => [access_to_detailed_offer] => [rare_disease] => false [second_indication] => false [inventors] => RAUTOU Pierre-Emmanuel,WEISS Emmanuel [number_application] => European Procedure (Patents) (EPA) - 10 Nov. 2015 - 15 306 785.5 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => transcriptomics [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gastrointestinal DiseasesTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 625 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Biomarker, Biomarker, Gastrointestinal Diseases, Human POC, Liver Disease, Method, Transcriptomics [taxonomieurl] => Biomarker, Biomarker, Gastrointestinal Diseases, Human POC, Liver Disease, Method, Transcriptomics ) [626] => stdClass Object ( [post] => stdClass Object ( [post_title] => A progression model that estimates a normative scenario of the progressive impairments of neurodegenerative diseases [guid] => https://technology-offers.inserm-transfert.com/offer/a-progression-model-that-estimates-a-normative-scenario-of-the-progressive-impairments-of-neurodegenerative-diseases/ [post_content] => The invention relates to age-related brain diseases, such as Parkinson’s or Alzheimer’s disease. Statistical models based on the regression of measurements with age are inadequate to model the progression of such diseases. As a consequence, the inventors worked on a numerical model to determine a temporal progression for such biological phenomenon, the numerical model being a function in a Riemann manifold.Such model enables to obtain a method for determining the temporal progression of a biological phenomenon which can be implemented on computer and provides better results than statistical models based on the regression of measurements. This determining method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine. [post_date] => 2016-05-11 13:54:45 [post_modified] => 2024-09-11 15:51:01 [ID] => 3585 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 06a608c4-4fba-495f-ae95-523fa5a24f37 [etat_fiche_online] => en_ligne [date_application] => 11-05-2016 [date] => [bd_referent] => Anne COCHI [bd_referent_id] => [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 [reference_online] => MECA16023-D1 [keywords] => Disease Progression model - Neurodegenerative Diseases - Patient Segmentation- Data Mining
[pub_scient_inv_dispo] => Front Neurol. 2018 May 4;9:235. doi: 10.3389/fneur.2018.00235. eCollection 2018. [access_to_detailed_offer] => /wp-content/uploads/MECA16023-D1_DURRLEMAN.pdf [rare_disease] => false [second_indication] => false [inventors] => SCHIRATTI Jean-Baptiste,ALLASSONNIERE Stéphanie,COLLIOT Olivier [number_application] => International Procedure (PCT) - 11 Mai 2016 - PCT/IB2016/052699 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Alzheimer’s diseaseTherapy Area:
• MethodType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => anne.cochi@inserm-transfert.fr [first_name] => Anne [last_name] => COCHI [wp_capabilities] => stdClass Object ( [um_admin-inserm-transfert] => 1 ) [wp_user_level] => 0 [dismissed_wp_pointers] => [role] => admin-inserm-transfert [bd_referent] => Anne COCHI [contact_description] => Business Development Manager [contact_email] => anne.cochi@inserm-transfert.fr [contact_phone] => +33 1 80 05 86 41 ) [comteur] => 626 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Alzheimer’s disease, Biomarker, Central Nervous System, Method, Others [taxonomieurl] => Alzheimer’s disease, Biomarker, Central Nervous System, Method, Others ) [627] => stdClass Object ( [post] => stdClass Object ( [post_title] => Methods and kits for the rapid detection of the Escherichia coli O25b-ST131 clone [guid] => https://technology-offers.inserm-transfert.com/offer/methods-and-kits-for-the-rapid-detection-of-the-escherichia-coli-o25b-st131-clone/ [post_content] => Escherichia coli O25b-ST131 clone is a worldwide pandemic clone, causing predominantly community-onset antimicrobial-resistant infection. A high prevalence of the clone (30%u201360%) has been identified amongst fluoroquinolone-resistant E. coli. In addition, it potentially harbours a variety of ?-lactamase genes. A broad distribution has been demonstrated amongst antimicrobial-resistant E. coli from human infection in Europe, North America, Canada, Japan and Korea. The clinical spectrum of disease described is similar to that for other E. coli, with urinary tract infection predominant. Description ranges from uncomplicated cystitis to severe infection complicated by bacteraemia, renal abscess and emphysematous pyelonephritis. Other sites of infection have included the respiratory tract, ascitic fluid, intra-abdominal abscess, bones/joints and bacteraemia without a clinically apparent focus. The O25b-ST131 clone has also been reported as a prominent cause of E. coli neonatal sepsis. The clone thus constitutes a major public health concern and there is an unmet need for the development of new method for detecting it. Phenotypic detection of the ST131 clone is not possible and DNA-based techniques, including MLST and PCR, remains time consuming.The present invention relates to methods and kits for the rapid detection of the E. coli O25b-ST131 clone. The inventors have isolated a podoviridae bacteriophage (LM33_P1) infecting the E. coli strain LM33 isolated from ventilator associated pneumonia and which belongs to clone STI31-025b. By testing different strains of E coli belonging to 129 others various distinct serotypes (including twelve O25a) they show that LM33_P1 is able to infect exclusively O25b strains (none of non-O25b strains could be infected by LM33_P1). The specificity displayed by LM33_P1 to infect only O25b serotype strains is based on a very specific polypeptide (Gp17) used by LM33_P1 to attach the bacterial cell via LPS molecule.Scientific publication(s):J Antimicrob Chemother., 2016 Nov, Dufour N. et al., Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex, doi: 10.1093/jac/dkw253 [post_date] => 2016-04-13 13:54:45 [post_modified] => 2024-09-11 15:52:08 [ID] => 3584 ) [post_meta] => stdClass Object ( [object] => [application] => Diagnostic [idSugar] => 036ba56c-ae35-4d93-a770-f1a35f77649c [etat_fiche_online] => en_ligne [date_application] => 13-04-2016 [date] => [bd_referent] => Pierre MAZOT [bd_referent_id] => [contact_email] => pierre.mazot@inserm-transfert.fr [contact_phone] => +33 (0) 155030136 [reference_online] => BIO15218-D1 [keywords] => Escherichia coli O25b-ST131 clone, polypeptide, diagnostic, lateral flow device, Immunoassay [pub_scient_inv_dispo] => J Antimicrob Chemother. 2016 Nov;71(11):3072-3080. Epub 2016 Jul 7. [access_to_detailed_offer] => /wp-content/uploads/BIO15218-D1_RICARD.pdf [rare_disease] => false [second_indication] => false [inventors] => Jean-Damien RICARD,Laurent DEBARBIEUX,Olivier CLERMONT,Nicolas DUFOUR,Erick DENAMUR [number_application] => EP16 305 433.1 [technology_engineering] => [multidisciplinary_field] => [technological_platform] => immunoassay [post_categoryname] => Diagnostic [parent_category] => 195 [inserm_tags_to_put] =>

• BiomarkerField of development:
• Gram-Negative Bacterial InfectionsTherapy Area:
• BiomarkerType of patent:

[tags_order_view] => stdClass Object ( [field_of_development] => Field of development [thera_area] => Therapy Area [type_of_patent] => Type of patent ) ) [user] => stdClass Object ( [nickname] => Inserm Transfert [first_name] => Inserm [last_name] => Transfert [wp_capabilities] => stdClass Object ( [author] => 1 [um_member] => 1 ) [wp_user_level] => 2 [dismissed_wp_pointers] => pll_lgt [role] => member [bd_referent] => Inserm Transfert [contact_description] => [contact_email] => contact@inserm-transfert.fr [contact_phone] => +33 1 55 03 01 00 ) [comteur] => 627 [terms] => Array ( [0] => Diagnostic ) [taxonomie] => Animal POC, Biologic, Biomarker, Biomarker, Escherichia Coli Infections, Gram-Negative Bacterial Infections, Immunoassay, Infectious Diseases, Peptide, Product, Recombinant Peptide [taxonomieurl] => Animal POC, Biologic, Biomarker, Biomarker, Escherichia Coli Infections, Gram-Negative Bacterial Infections, Immunoassay, Infectious Diseases, Peptide, Product, Recombinant Peptide ) )